PT J
AU Brown, ML
   Rojas, E
   Gouda, S
AF Brown, Melanie L
   Rojas, Enrique
   Gouda, Suzanne
TI A Mind-Body Approach to Pediatric Pain Management.
SO Children (Basel, Switzerland)
LA English
DT Review
DE acupuncture; hypnosis; meditation; mind–body medicine; pain management; pediatrics; yoga
AB Pain is a significant public health problem that affects all populations and has  significant financial, physical and psychological impact. Opioid medications,  once the mainstay of pain therapy across the spectrum, can be associated with  significant morbidity and mortality. Centers for Disease and Control (CDC)  guidelines recommend that non-opioid pain medications are preferred for chronic  pain outside of certain indications (cancer, palliative and end of life care).  Mindfulness, hypnosis, acupuncture and yoga are four examples of mind-body  techniques that are often used in the adult population for pain and symptom  management. In addition to providing significant pain relief, several studies  have reported reduced use of opioid medications when mind-body therapies are  implemented. Mind-body medicine is another approach that can be used in children  with both acute and chronic pain to improve pain management and quality of life.
C1 Department of Pediatrics, The University of Chicago, Chicago, IL 60637, USA erojas@peds.bsd.uchicago.edu (E.R.). melanie.brown@childrensmn.org.
   Department of Pain, Palliative Care and Integrative Medicine, Children's 
   Department of Pediatrics, The University of Chicago, Chicago, IL 60637, USA erojas@peds.bsd.uchicago.edu (E.R.). erojas@peds.bsd.uchicago.edu.
   Department of Pediatrics, The University of Chicago, Chicago, IL 60637, USA erojas@peds.bsd.uchicago.edu (E.R.). Suzanne.Gouda@uchospitals.edu.
NR 0
TC 0
SN 2227-906
EI 2227-906
J9 Children (Basel)
PD JUN 21
PY 2017
VL 4
IS 6
BP 
EP 
DI 10.3390/children4060050
PG 0
UT PubMed:28632194
PM 28632194
DA 2017-06-21
ER

PT J
AU Zhang, SQ
   Wu, TT
   Zhang, HH
   Yang, Y
   Jiang, HY
   Cao, SC
   Xie, F
   Xia, XT
   Lu, JQ
   Zhong, Y
AF Zhang Shiqiang
   Wu Tingting
   Zhang Haisheng
   Yang Yun
   Jiang Haiyan
   Cao Shengcheng
   Xie Fang
   Xia Xiaoting
   Lu Junqiang
   Zhong Yi
TI Effect of electroacupuncture on chemotherapy-induced peripheral neuropathy in patients with malignant tumor: a single-blinded, randomized controlled trial
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE Electroacupuncture; Quality of life; Chemotherapy-induced peripheral neuropathy; Randomized controlled trial
ID acupuncture; cancer; pain
AB OBJECTIVE: To evaluate the effect of electroacupuncture on chemotherapy-induced peripheral neuropathy (CIPN), quality of life and immune status of patients with malignant tumors. METHODS: From Jan, 2013 to May, 2014, 37 patients with malignant tumors were included in this prospective single-blinded study, and randomized to receive either electroacupuncture or acupuncture treatment on basis of chemotherapy. The chemotherapy was continued for 2 courses as previous before the treatments, with 21 days as a course of treatment. Patients received acupuncture and electroacupuncture once per day starting at the day before chemotherapy for consecutive 7 days followed by 14 days off, with 21 days as a course of treatment, and continued for two courses of treatment. Then CIPN, traditional Chinese clinical symptoms,quality of life and immune status were all evaluated for each patient prior treatment and after two courses of treatment. RESULTS: The gender, age, cancer species as well as incidence (83.3% vs 84.2%) and grades of CIPN before treatments were all similar in patients receiving acupuncture or electroacupuncture (all P > 0.05). After treatments, most patients with peripheral neuropathy were cured by two courses of electroacupuncture (84.2% vs 21.1%), whereas the other group of patients had similar incidences of peripheral neuropathy compared with prior-acupuncture (83.3% vs 72.2%). Besides, patients receiving electroacupuncture had lower incidence of peripheral neuropathy than those receiving acupuncture treatment (x(2) = 9.745, P = 0.002). The grades of peripheral neuropathy were significantly different in the two groups post-treatment (x(2) = 13.983, P = 0.007). The total effective rates for traditional Chinese clinical symptoms were 16.7% and 84.2% in acupuncture and electroacupuncture groups, respectively (Z = - 4.239, P < 0.001). The electroacupuncture treatment provided a more satisfactory life for patients compared with acupuncture (Z = - 4.76, P < 0.001). Both electroacupuncture and acupuncture had no effects on immune function. CONCLUSION: Electroacupuncture could alleviate CIPN, and improve traditional Chinese clinical symptoms and quality of life, but did not affect immune function. (C) 2017 JTCM. All rights reserved.
C1 [Zhang Shiqiang; Wu Tingting; Yang Yun; Jiang Haiyan; Xia Xiaoting; Lu Junqiang; Zhong Yi] Shanghai Univ Tradit Chinese Med, Shanghai Tradit Chinese Med Integrated Hosp, Oncol Dept, Shanghai 200082, Peoples R China.
   [Zhang Haisheng; Cao Shengcheng] Fangta Tradit Chinese Med Hosp of Songjiang Dist, Oncol Dept, Shanghai 201600, Peoples R China.
   [Xie Fang] Jingan Dist Ctr Hosp Shanghai, Oncol Dept, Shanghai 200040, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine
RP Zhong, Y (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai Tradit Chinese Med Integrated Hosp, Oncol Dept, Shanghai 200082, Peoples R China.
EM zhyimed@163.com
FU Comprehensive and Integrative Medicine Institute, Korea; Shanghai TCM-integrated Hospital; Effect of Bushen-Jianpi Decoction on Postoperative Recurrence and Vasculogenic Mimicry Formation after Recurrence in Liver Cancer Tissues of Nude Mice with Transplanted Liver Cancer [2012J003A]; Mechanism Study of Fuzheng Jianpi Decoction on Tumor Metastasis Inhibition by Protecting Intestinal Barrier and Regulating PI3K/AKT Signaling Pathway Expression in Colorectal Tumor Microenvironment [15ZR1438700]; Effect of Jianpi-Guchang Decoction on the Gut Barrier Function and Immune Function in Lung or Colorectal Cancer Patients Treated by Chemotherapy Based on the Thought of "Same Treatment for Different Diseases" [15401930300]; Effect of Jianpi-Guben Decoction on the Gut Barrier Function in Postoperative Colorectal Cancer Patients Treated by Chemotherapy to Balance the Gut Enviroment [Hongkou 1502-01]
CR Bao T, 2012, MED ACUPUNCT, V24, P181, DOI 10.1089/acu.2011.0868
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Brunelli B, 2004, J NEUROL SCI, V218, P59, DOI 10.1016/j.jns.2003.10.013
   Cao P, 2012, TANG, V2, P1
   Chan KKL, 2011, ANN ONCOL, V22, P2241, DOI 10.1093/annonc/mdq749
   Department of Medical Administration in Ministry of Health China, 1991, DIAGN TREATM COMM MA, V0, P2725
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Grober J, 1960, KLIN LEHRBUCH PHYS T, V1960, P378
   Hsiao E, 2013, APHA, V2013, P0
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   LEVI F, 1992, CANCER, V69, P893, DOI 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Minton O, 2007, J PAIN SYMPTOM MANAG, V33, P115, DOI 10.1016/j.jpainsymman.2006.09.011
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Sumera FC, 2013, 28 PHIL CHEM C 2013, V45, P0
   Tian YP, 2011, TIANJIN J TCM, V28, P212
   Ullah MF, 2008, ASIAN PAC J CANCER P, V9, P1
   White AR, 2014, COCHRANE LIB, V1, P162
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
NR 21
TC 19
Z9 19
U1 0
U2 32
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD APR 15
PY 2017
VL 37
IS 2
BP 179
EP 184
DI 
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA EU7HS
UT WOS:000401206500005
PM 29960289
DA 2026-01-16
ER

PT J
AU Miladinia, M
   Baraz, S
   Shariati, A
   Malehi, AS
AF Miladinia, Mojtaba
   Baraz, Shahram
   Shariati, Abdolali
   Malehi, Amal Saki
TI Effects of Slow-Stroke Back Massage on Symptom Cluster in Adult Patients With Acute Leukemia Supportive Care in Cancer Nursing
SO CANCER NURSING
LA English
DT Article
DE Acute leukemia; Chemotherapy; Complementary medicine; Fatigue; Massage therapy; Nursing; Pain; Randomized controlled trial; Sleep; Slow-stroke back massage
ID randomized controlled-trial; sleep disturbance; therapy; fatigue; complementary; intervention; acupuncture; management; distress; pain
AB Background: Patients with acute leukemia usually experience pain, fatigue, and sleep disorders, which affect their quality of life. Massage therapy, as a nondrug approach, can be useful in controlling such problems. However, very few studies have been conducted on the effects of massage therapy on the complications of leukemia. Objective: The aim of this study was to examine the effects of slow-stroke back massage (SSBM) on the symptom cluster in acute leukemia adult patients undergoing chemotherapy. Methods: In this randomized controlled trial, 60 patients with acute leukemia were allocated randomly to either the intervention or control group. The intervention group received SSBM 3 times a week (every other day for 10 minutes) for 4 weeks. The pain, fatigue, and sleep disorder intensities were measured using the numeric rating scale. The sleep quality was measured using the Pittsburgh Sleep Quality Index. Statistical tests of chi(,) t test, and the repeated-measure analysis of variance were used for data analysis. Results: Results showed that the SSBM intervention significantly reduced the progressive sleep disorder, pain, fatigue, and improved sleep quality over time. Conclusions: Slow-stroke back massage, as a simple, noninvasive, and cost-effective approach, along with routine nursing care, can be used to improve the symptom cluster of pain, fatigue, and sleep disorders in leukemia patients. Implications for Practice: Oncology nurses can increase their knowledge regarding this symptom cluster and work to diminish the cluster components by using SSBM in adult leukemia patients.
C1 [Miladinia, Mojtaba; Baraz, Shahram; Shariati, Abdolali] Ahvaz Jundishapur Univ Med Sci, Nursing Care Res Ctr Chron Dis, Sch Nursing & Midwifery, Golestan St, Ahvaz 6135715794, Iran.
   [Malehi, Amal Saki] Ahvaz Jundishapur Univ Med Sci, Dept Biostat & Epidemil, Sch Publ Hlth, Ahvaz, Iran.
C3 Ahvaz Jundishapur University of Medical Sciences (AJUMS); Ahvaz Jundishapur University of Medical Sciences (AJUMS)
RP Baraz, S (corresponding author), Ahvaz Jundishapur Univ Med Sci, Nursing Care Res Ctr Chron Dis, Sch Nursing & Midwifery, Golestan St, Ahvaz 6135715794, Iran.
EM shahrambaraz@ajums.ac.ir
CR Bao T, 2011, J PAIN SYMPTOM MANAG, V41, P995, DOI 10.1016/j.jpainsymman.2010.08.012
   Barsevick Andrea M, 2007, SEMIN ONCOL NURS, V23, P89, DOI 10.1016/j.soncn.2007.01.009
   Battaglini CL, 2009, INTEGR CANCER THER, V8, P130, DOI 10.1177/1534735409334266
   Beck SL, 2004, J PAIN SYMPTOM MANAG, V27, P140, DOI 10.1016/j.jpainsymman.2003.12.002
   Bower JE, 2012, J CLIN ONCOL, V30, P4449, DOI 10.1200/JCO.2012.46.0436
   Buysse D J, 1989, PSYCHIATRY RES, V28, P193
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Clevenger L, 2013, CANCER-AM CANCER SOC, V119, P3234, DOI 10.1002/cncr.28188
   Currin J, 2008, CANCER NURS, V31, P214, DOI 10.1097/01.NCC.0000305725.65345.f3
   Dodd M J, 2001, ONCOL NURS FORUM, V28, P465
   Edwards H E, 2001, NURS HEALTH SCI, V3, P35, DOI 10.1046/j.1442-2018.2001.00069.x
   Erickson JM, 2013, INT J NURS STUD, V50, P847, DOI 10.1016/j.ijnurstu.2012.10.011
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Falkensteiner Maria, 2011, ISRN NURS, V2011, P929868, DOI 10.5402/2011/929868
   Hajbaghery MA, 2005, BMC HEALTH SERV RES, V5, P0, DOI 10.1186/1472-6963-5-24
   Hasankhani H, 2013, INT RES J APPL BASIC, V4, P3004, DOI 10.1515/jcim-2017-0183
   Holland B, 2001, REHABIL NURS, V26, P182
   Huang ST, 2010, INT J NURS STUD, V47, P1354, DOI 10.1016/j.ijnurstu.2010.03.008
   Humphreys J, 2008, MIDDLE RANGE THEORY FOR NURSING, V2nd, P145
   Karagozoglu S, 2013, APPL NURS RES, V26, P210, DOI 10.1016/j.apnr.2013.07.002
   Kashani Fahimeh, 2014, IRAN J NURS MIDWIFERY RES, V19, P113
   Kim HJ, 2005, CANCER NURS, V28, P270
   Kwekkeboom KL, 2012, J PAIN SYMPTOM MANAG, V44, P810, DOI 10.1016/j.jpainsymman.2011.12.281
   Kwekkeboom Kristine L, 2010, ONCOL NURS FORUM, V37, PE151, DOI 10.1188/10.ONF.E151-E159
   Lee JS, 2003, ACAD EMERG MED, V10, P1128, DOI 10.1197/S1069-6563(03)00372-5
   Meek S S, 1993, IMAGE J NURS SCH, V25, P17
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Mok Esther, 2004, COMPLEMENT THER NURS MIDWIFERY, V10, P209, DOI 10.1016/j.ctnm.2004.05.006
   Morrow GR, 2007, ONCOLOGIST, V12, P1, DOI 10.1634/theoncologist.12-S1-1
   Musarezaie Amir, 2014, J EDUC HEALTH PROMOT, V3, P64, DOI 10.4103/2277-9531.134778
   Niggemann B, 2003, ALLERGY, V58, P707, DOI 10.1034/j.1398-9995.2003.00219.x
   Otte JL, 2015, CANCER MED-US, V4, P183, DOI 10.1002/cam4.356
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   Romito F, 2014, EUR J CANCER CARE, V23, P385, DOI 10.1111/ecc.12106
   Rosen G, 2015, SLEEP MED, V16, P503, DOI 10.1016/j.sleep.2014.11.002
   Shinde MB, 2014, INTERNATIONAL JOURNAL OF SCIENCE AND RESEARCH, V3, P292
   Soltow D, 2010, CANCER NURS, V33, P296, DOI 10.1097/NCC.0b013e3181ce5a1a
   Sudarshan M, 2013, COMPLEMENT THER CLIN, V19, P227, DOI 10.1016/j.ctcp.2013.06.004
   Tas D, 2014, ASIAN PAC J CANCER P, V15, P3139, DOI 10.7314/APJCP.2014.15.7.3139
   Taylor AG, 2009, BRAIN BEHAV IMMUN, V0, P0
   Valeberg BT, 2013, CANCER NURS, V36, P429, DOI 10.1097/NCC.0b013e3182747bcf
   Walters SJ, 2010, J AUST TRADIT-MED SO, V16, P141
   Wesa KM, 2009, EXPERT REV ANTICANC, V9, P1241, DOI 10.1586/ERA.09.100
   Zarea K, 2009, NURS HEALTH SCI, V11, P326, DOI 10.1111/j.1442-2018.2009.00466.x
   Zhou KN, 2015, EUR J ONCOL NURS, V19, P54, DOI 10.1016/j.ejon.2014.07.010
NR 45
TC 43
Z9 50
U1 1
U2 62
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD JAN-FEB 15
PY 2017
VL 40
IS 1
BP 31
EP 38
DI 10.1097/NCC.0000000000000353
PG 8
WC Oncology; Nursing
SC Oncology; Nursing
GA EG0AH
UT WOS:000390692300010
PM 26925992
DA 2026-01-16
ER

PT J
AU Shalom-Sharabi, I
   Samuels, N
   Lev, E
   Lavie, O
   Keinan-Boker, L
   Schiff, E
   Ben-Arye, E
AF Shalom-Sharabi, Ilanit
   Samuels, Noah
   Lev, Efraim
   Lavie, Ofer
   Keinan-Boker, Lital
   Schiff, Elad
   Ben-Arye, Eran
TI Impact of a complementary/integrative medicine program on the need for supportive cancer care-related medications
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Integrative medicine; Supportive care; Medication use; Complementary medicine; Chemotherapy
ID randomized controlled-trial; chemotherapy-induced nausea; breast-cancer; oncology; pain; electroacupuncture; acupuncture; arthralgia; prevention; adherence
AB Despite the growing evidence supporting the use of complementary/integrative medicine (CIM) in the treatment of chemotherapy-induced toxicities, little is known on CIM impact of these therapies regarding the use of medications for supportive cancer care. In this study, we examined the impact of CIM on the need for supportive cancer care-related medications. Patients with breast or gynecological cancer referred to and attending an integrative physician (IP) consultation for gastrointestinal (GI) concerns were designated as the treatment group; those not attending as controls. Adherence to the integrative care program (AIC) was defined as attending >= 4 CIM interventions. The need for conventional supportive care-related medications and doses was determined from patients' medical files, as well as the implications on the potential for cost reduction. Of the 205 patients diagnosed with GI concerns, 116 attended the IP consultation and weekly CIM treatments (56.6%; treatment group), of which 85 (73.3%) were adherent to the program (AIC subgroup); 89 did not undergo an IP consultation (43.4%; controls). Within-group analysis found a greater decrease in the use of non-opioid analgesics (NOAs) at 6 weeks in the treatment group (P = 0.01), more so in the AIC subgroup (P = 0.02). A cost analysis suggests that reduced NOA use in the treatment group reduced the cost of supportive care, covering 27.1% of the overall expense of CIM treatments. Controls were less likely to require anti-emetics (P = 0.007). Between-group analysis showed a trend for reduced use of anxiolytics (P = 0.06) and NOAs (P = 0.08) among treated patients, with lower dose equivalents for NOAs than controls (P < 0.001). CIM treatments may reduce the need for NOAs among patients with breast or gynecological cancer.
C1 [Shalom-Sharabi, Ilanit; Samuels, Noah; Ben-Arye, Eran] Clalit Hlth Serv, Lin Med Ctr, Oncol Serv, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.
   [Shalom-Sharabi, Ilanit] Univ Haifa, Grad Studies Author, Haifa, Israel.
   [Samuels, Noah] Sheba Med Ctr, Inst Oncol, Tal Ctr Integrat Med, Tel Hashomer, Israel.
   [Lev, Efraim] Univ Haifa, Dept Israel Studies, Haifa, Israel.
   [Lavie, Ofer] Carmel Hosp, Dept Obstet & Gynecol, Gynecol Oncol Serv, Haifa, Israel.
   [Keinan-Boker, Lital] Univ Haifa, Sch Publ Hlth, Fac Social Welf & Hlth Sci, Haifa, Israel.
   [Keinan-Boker, Lital] Israel Minist Hlth, Israel Ctr Dis Control, Jerusalem, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Dept Internal Med, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Integrat Med Serv, Haifa, Israel.
   [Ben-Arye, Eran] Technion Israel Inst Technol, Dept Family Med, Complementary & Tradit Med Unit, Fac Med, Haifa, Israel.
C3 Clalit Health Services; University of Haifa; Tel Aviv University; Chaim Sheba Medical Center; University of Haifa; Clalit Health Services; Carmel Medical Center; University of Haifa; Ministry of Health - Israel; Bnai Zion Medical Center; Bnai Zion Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Lin Med Ctr, Oncol Serv, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Dept Family Med, Complementary & Tradit Med Unit, Fac Med, Haifa, Israel.
EM eranben@netvision.net.il
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Ben-Arye E, 2015, CLIN NUTR, V34, P1215, DOI 10.1016/j.clnu.2014.12.011
   Ben-Arye E, 2015, SUPPORT CARE CANCER, V23, P3411, DOI 10.1007/s00520-015-2690-0
   Ben-Arye E, 2014, SUPPORT CARE CANCER, V22, P627, DOI 10.1007/s00520-013-2016-z
   Ben-Arye E, 2013, MED ONCOL, V30, P0, DOI 10.1007/s12032-013-0511-1
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Binkhorst L, 2013, BREAST CANCER RES TR, V139, P923, DOI 10.1007/s10549-013-2585-z
   Briesacher BA, 2007, J GEN INTERN MED, V22, P864, DOI 10.1007/s11606-007-0180-x
   Bruera E, 1991, J PALLIAT CARE, V7, P6
   Butler LD, 2009, HEALTH PSYCHOL, V28, P579, DOI 10.1037/a0016124
   Chan Alexandre, 2012, J MANAG CARE PHARM, V18, P385
   Charalambous A, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0156911
   Kligler B, 2011, AM J MANAG CARE, V17, P779
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Levine ME, 2008, J ALTERN COMPLEM MED, V14, P545, DOI 10.1089/acm.2007.0817
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mardby AC, 2007, PATIENT EDUC COUNS, V69, P158, DOI 10.1016/j.pec.2007.08.011
   Mir O, 2012, SUPPORT CARE CANCER, V20, P2235, DOI 10.1007/s00520-012-1503-y
   Molassiotis A, 2002, SUPPORT CARE CANCER, V10, P237, DOI 10.1007/s00520-001-0329-9
   Montgomery GH, 2007, JNCI-J NATL CANCER I, V99, P1304, DOI 10.1093/jnci/djm106
   Oldenmenger WH, 2013, J PAIN SYMPTOM MANAG, V45, P1083, DOI 10.1016/j.jpainsymman.2012.06.007
   Park JW, 2016, J CANCER RES CLIN, V142, P1031, DOI 10.1007/s00432-015-2108-x
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Roila F, 2010, ANN ONCOL, V21, Pv232, DOI 10.1093/annonc/mdq194
   Ryan JL, 2012, SUPPORT CARE CANCER, V20, P1479, DOI 10.1007/s00520-011-1236-3
   Sharabi IS, 2016, SUPPORT CARE CANCER, V24, P4345, DOI 10.1007/s00520-016-3274-3
   Song QH, 2013, INT J CLIN EXP MED, V6, P979
   Van Gool AR, 2010, PHARM WORLD SCI, V32, P704, DOI 10.1007/s11096-010-9444-3
   Wilkinson SM, 2007, J CLIN ONCOL, V25, P532, DOI 10.1200/JCO.2006.08.9987
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zhao J, 2013, PHARMAZIE, V68, P421, DOI 10.1691/ph.2013.2876
NR 34
TC 16
Z9 16
U1 3
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD OCT 15
PY 2017
VL 25
IS 10
BP 3181
EP 3190
DI 10.1007/s00520-017-3726-4
PG 10
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA FF2KZ
UT WOS:000408727600024
PM 28434097
DA 2026-01-16
ER

PT J
AU Nagraj, SK
   George, RP
   Shetty, N
   Levenson, D
   Ferraiolo, DM
   Shrestha, A
AF Nagraj, Sumanth Kumbargere
   George, Renjith P.
   Shetty, Naresh
   Levenson, David
   Ferraiolo, Debra M.
   Shrestha, Ashish
TI Interventions for managing taste disturbances
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE *Acupuncture Therapy; Quality of Life; Randomized ControlledTrials as Topic; TasteDisorders [diagnosis; *therapy]; Taste Perception; Zinc Compounds [adverse effects; *therapeutic use]; Adolescent; Adult; Child; Humans
ID placebo-controlled trial; double-blind; zinc supplementation; cancer-patients; pilocarpine treatment; gustatory function; smell dysfunction; uremic hypogeusia; oral zinc; acuity
AB Background The sense of taste is very much essential to the overall health of an individual. It is a necessary component to enjoy one's food, which in turn provides nutrition to an individual. Any disturbance in taste perception can hamper quality of life in such patients by influencing their appetite, body weight and psychological well-being. Taste disorders have been treated using different modalities of treatment and there is no consensus for the best intervention. Hence this Cochrane Review was undertaken. This is an update of the Cochrane Review first published in November 2014. Objective To assess the effects of interventions for the management of patients with taste disturbances. S e a r c h m e t h o d s Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 4 July 2017); the Cochrane Central Register of Controlled Trials (CENTRAL; 2017 Issue 6) in the Cochrane Library (searched 4 July 2017); MEDLINE Ovid (1946 to 4 July 2017); Embase Ovid (1980 to 4 July 2017); CINAHL EBSCO (1937 to 4 July 2017); and AMED Ovid (1985 to 4 July 2017). The US National Institutes of Health Ongoing Trials Register ClinicalTrials. gov (www. clinicaltrials. gov) and the World Health Organization International Clinical Trials Registry Platform were searched for trials. Abstracts from scientific meetings and conferences were searched on 25 September 2017. No restrictions were placed on the language or date of publication when searching the electronic databases. Selection criteria We included all randomised controlled trials (RCTs) comparing any pharmacological agent with a control intervention or any nonpharmacological agent with a control intervention. We also included cross-over trials in the review. Data collection and analysis Two pairs of review authors independently, and in duplicate, assessed the quality of trials and extracted data. Wherever possible, we contacted trial authors for additional information. We collected adverse events information from the trials. Main results We included 10 trials (581 participants), nine of which we were able to include in the quantitative analyses (566 participants). We assessed three trials (30%) as having a low risk of bias, four trials (40%) at high risk of bias and three trials (30%) as having an unclear risk of bias. We only included studies on taste disorders in this review that were either idiopathic, or resulting from zinc deficiency or chronic renal failure. Of these, nine trials with 544 people compared zinc supplements to placebo for patients with taste disorders. The participants in two trials were children and adolescents with respective mean ages of 10 and 11.2 years and the other seven trials had adult participants. Out of these nine, two trials assessed the patient-reported outcome for improvement in taste acuity using zinc supplements (risk ratio (RR) 1.40, 95% confidence interval (CI) 0.94 to 2.09; 119 participants, very low-quality evidence). We meta-analysed for taste acuity improvement using objective outcome (continuous data) in idiopathic and zinc-deficient taste disorder patients (standardised mean difference (SMD) 0.44, 95% CI 0.23 to 0.65; 366 participants, three trials, very low-quality evidence). We also analysed one cross-over trial separately using the first half of the results for taste detection (mean difference (MD) 2.50, 95% CI 0.93 to 4.07; 14 participants, very low-quality evidence), and taste recognition (MD3.00, 95% CI 0.66 to 5.34; 14 participants, very low-quality evidence). Wemetaanalysed taste acuity improvement using objective outcome (dichotomous data) in idiopathic and zinc-deficient taste disorder patients (RR 1.42, 95% 1.09 to 1.84; 292 participants, two trials, very low-quality evidence). Out of the nine trials using zinc supplementation, four reported adverse events like eczema, nausea, abdominal pain, diarrhoea, constipation, decrease in blood iron, increase in blood alkaline phosphatase, and minor increase in blood triglycerides. One trial tested taste discrimination using acupuncture (MD 2.80, 95% CI -1.18 to 6.78; 37 participants, very low-quality evidence). No adverse events were reported in the acupuncture trial. None of the included trials could be included in the meta-analysis for health-related quality of life in taste disorder patients. Authors' conclusions We found very low-quality evidence that was insufficient to conclude on the role of zinc supplements to improve taste acuity reported by patients and very low-quality evidence that zinc supplements improve taste acuity in patients with zinc deficiency/ idiopathic taste disorders. We did not find any evidence to conclude the role of zinc supplements for improving taste discrimination, or any evidence addressing health-related quality of life due to taste disorders. We found very low-quality evidence that is not sufficient to conclude on the role of acupuncture for improving taste discrimination in cases of idiopathic dysgeusia (distortion of taste) and hypogeusia (reduced ability to taste). We were unable to draw any conclusions regarding the superiority of zinc supplements or acupuncture as none of the trials compared these interventions.
C1 [Nagraj, Sumanth Kumbargere] Melaka Manipal Med Coll, Dept Oral Med & Oral Radiol, Fac Dent, Jalan Batu Hampar, Bukit Baru 75150, Melaka, Malaysia.
   [George, Renjith P.] Melaka Manipal Med Coll, Dept Oral Pathol, Fac Dent, Melaka, Malaysia.
   [Shetty, Naresh] IMU, Sch Dent Oral & Maxillofacial Surg, Bukit Jalil, Malaysia.
   [Levenson, David; Ferraiolo, Debra M.] NYU, Coll Dent, Dept Oral & Maxillofacial Pathol Radiol & Med, New York, NY USA.
   [Shrestha, Ashish] BP Koirala Inst Hlth Sci, Coll Dent, Community Dent, Dharan, Nepal.
C3 Manipal Academy of Higher Education (MAHE); Manipal University College Malaysia; Manipal Academy of Higher Education (MAHE); Manipal University College Malaysia; New York University; B.P. Koirala Institute of Health Sciences
RP Nagraj, SK (corresponding author), Melaka Manipal Med Coll, Dept Oral Med & Oral Radiol, Fac Dent, Jalan Batu Hampar, Bukit Baru 75150, Melaka, Malaysia.
EM sumikn@rediffmail.com
FU Faculty of Dentistry, Melaka-Manipal Medical College, Manipal University, Melaka Campus, Malaysia; Faculty of Dentistry, International Medical University, Kuala Lumpur, Malaysia; National Institute for Health Research (NIHR), UK; NIHR, via Cochrane Infrastructure funding; Cochrane Oral Health Global Alliance; Global Alliance; Professor BV Moses Centre for Research & Training in Evidence-Informed Healthcare, ICMR Advanced Centre for Evidence-Based Medicine, Cochrane South Asia, Christian Medical College, Vellore, India
CR Aframian DJ, 2007, ORAL DIS, V13, P88, DOI 10.1111/j.1601-0825.2006.01252.x
   Unknown -, 2011, COCHRANE HDB SYSTEMA, V0, P0
   ATKINTHOR E, 1978, AM J CLIN NUTR, V31, P1948, DOI 10.1093/ajcn/31.10.1948
   BARRIE SA, 1987, AGENTS ACTIONS, V21, P222, DOI 10.1007/BF01974946
   BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1
   BICKNELL JM, 1988, WESTERN J MED, V149, P457
   Birks J, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/l4651858.CD003120.pub3
   Brandt H, 2008, DTSCH Z AKUPUNKT, V51, P24, DOI 10.1016/j.dza.2008.01.003
   Brandt H HB, 2008, REV INT ACUPUNTURA, V2, P155
   Brisbois TD, 2011, ANN ONCOL, V22, P2086, DOI 10.1093/annonc/mdq727
   Bromley SM, 2000, AM FAM PHYSICIAN, V61, P427
   DAHL H, 1984, ACTA OPHTHALMOL, V62, P739
   de Moraes M, 2012, J ORAL PATHOL MED, V41, P281, DOI 10.1111/j.1600-0714.2011.01100.x
   DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519
   Deniz F, 2016, EXP CLIN ENDOCR DIAB, V124, P562, DOI 10.1055/s-0042-108446
   EGGERT JV, 1982, INT J PED NEPHROL, V3, P21
   Femiano F, 2002, INT J ORAL MAX SURG, V31, P625, DOI 10.1054/ijom.2002.0276
   FIKENTSCHER R, 1987, LARYNGO RHINO OTOL, V66, P355, DOI 10.1055/s-2007-998675
   Fujiyama R, 2010, ODONTOLOGY, V98, P82, DOI 10.1007/s10266-009-0110-y
   Gardiner J, 2008, BIOSCIENCE HYPOTHESE, V1, P251
   Gondivkar SM, 2009, ORAL SURG ORAL MED O, V108, P876, DOI 10.1016/j.tripleo.2009.08.015
   Green A, 2013, J PSYCHOPHARMACOL, V27, P265, DOI 10.1177/0269881112472567
   Greenway FL, 2011, J AM COLL NUTR, V30, P178, DOI 10.1080/07315724.2011.10719958
   Halyard MY, 2007, INT J RADIAT ONCOL, V67, P1318, DOI 10.1016/j.ijrobp.2006.10.046
   Hartman-Petrycka M, 2016, APPETITE, V107, P159, DOI 10.1016/j.appet.2016.08.004
   Hawkes CH, 2002, THE MOST COMMON COMPLAINTS: SMELL AND TASTE COMPLAINTS, V2nd ed, P0
   Heckmann SM, 2005, J DENT RES, V84, P35, DOI 10.1177/154405910508400105
   Henkin RI, 2000, J COMPUT ASSIST TOMO, V24, P106, DOI 10.1097/00004728-200001000-00022
   HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006
   HENKIN RI, 1963, J CLIN INVEST, V42, P727, DOI 10.1172/JCI104765
   Henkin RI, 1999, AM J MED SCI, V318, P392, DOI 10.1097/00000441-199912000-00006
   Henkin RI, 2007, AM J MED SCI, V334, P431, DOI 10.1097/MAJ.0b013e3180de4d97
   Henkin RI, 2014, NUTRITION, V30, P690, DOI 10.1016/j.nut.2013.11.003
   Henkin RI, 2013, AM J OTOLARYNG, V34, P477, DOI 10.1016/j.amjoto.2013.04.006
   Henkin RI, 2012, ARCH OTOLARYNGOL, V138, P1064, DOI 10.1001/2013.jamaoto.342
   Henkin RI, 2011, AM J OTOLARYNG, V32, P38, DOI 10.1016/j.amjoto.2009.10.001
   Henkin RI, 2011, AM J OTOLARYNG, V32, P178, DOI 10.1016/j.amjoto.2010.05.005
   Henkin RI, 2010, AM J MED SCI, V339, P249, DOI 10.1097/MAJ.0b013e3181cda0e3
   Henkin RI, 2009, METABOLISM, V58, P1717, DOI 10.1016/j.metabol.2009.05.027
   Higgins J, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000049
   Hovan AJ, 2010, SUPPORT CARE CANCER, V18, P1081, DOI 10.1007/s00520-010-0902-1
   Ikeda M, 2005, ACTA OTO-LARYNGOL, V125, P1203, DOI 10.1080/00016480510040173
   Ikeda Minoru, 2013, NIHON JIBIINKOKA GAKKAI KAIHO, V116, P17
   Imoscopi A, 2012, AGING CLIN EXP RES, V24, P570, DOI 10.3275/8520
   Ishimaru T, 2001, CHEM SENSES, V26, P91, DOI 10.1093/chemse/26.1.91
   Iwatsuki K, 2012, J PHARMACOL SCI, V118, P123, DOI 10.1254/jphs.11R08CP
   Jham Bruno C, 2009, J ORAL SCI, V51, P565
   Kamphuis MMJW, 2003, BRIT J NUTR, V90, P199, DOI 10.1079/BJN2003858
   Kashihara K, 2011, INTERNAL MED, V50, P2311, DOI 10.2169/internalmedicine.50.5935
   Kinnamon SC, 2012, ACTA PHYSIOL, V204, P158, DOI 10.1111/j.1748-1716.2011.02308.x
   Leek H, 2002, MICRON, V33, P153, DOI 10.1016/S0968-4328(01)00004-X
   Lyckholm Laurel, 2012, J PAIN PALLIAT CARE PHARMACOTHER, V26, P111, DOI 10.3109/15360288.2012.676618
   MAHAJAN S K, 1992, JOURNAL OF TRACE ELEMENTS IN EXPERIMENTAL MEDICINE, V5, P33
   MAHAJAN SK, 1980, AM J CLIN NUTR, V33, P1517, DOI 10.1093/ajcn/33.7.1517
   MAHAJAN SK, 1982, AM J CLIN NUTR, V36, P1177, DOI 10.1093/ajcn/36.6.1177
   MAHAJAN SK, 1979, T AM SOC ART INT ORG, V25, P443
   Matson A, 2003, J RENAL NUTR, V13, P224, DOI 10.1016/S1051-2276(03)00072-4
   Mattes RD, 2004, HUM PSYCHOPHARM CLIN, V19, P81, DOI 10.1002/hup.562
   Mattes RD, 2009, ANNU REV NUTR, V29, P305, DOI 10.1146/annurev-nutr-080508-141108
   McLaughlin L, 2014, ONCOL NURS FORUM, V41, PE194, DOI 10.1188/14.ONF.E194-E202
   Miller IJ, 1995, NEUROL DIS, V0, P521
   MISTRETTA CM, 1984, J ANAT, V138, P323
   MOSSMAN KL, 1978, INT J RADIAT ONCOL, V4, P663, DOI 10.1016/0360-3016(78)90190-6
   Mueller C, 2003, RHINOLOGY, V41, P2
   Nagao Y, 2010, MED SCI MONITOR, V16, P0
   Nagraj SK, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010470.pub2
   Najafizade N, 2013, J RES MED SCI, V18, P123
   Ohno Tomohisa, 2003, JOURNAL OF MEDICAL AND DENTAL SCIENCES, V50, P101
   Ohnuki M, 2014, BMC ORAL HEALTH, V14, P0, DOI 10.1186/1472-6831-14-36
   Padala Kalpana P, 2006, PRIM CARE COMPANION J CLIN PSYCHIATRY, V8, P178
   Porter SR, 2010, ORAL ONCOL, V46, P457, DOI 10.1016/j.oraloncology.2010.03.011
   Rawal S, 2016, CHEM SENSES, V41, P69, DOI 10.1093/chemse/bjv057
   Ripamonti C, 1998, CANCER-AM CANCER SOC, V82, P1938, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1938::AID-CNCR18>3.0.CO;2-U
   RUSSELL RM, 1980, AM J CLIN NUTR, V33, P2741, DOI 10.1093/ajcn/33.12.2741
   Sakagami M, 2009, ACTA OTO-LARYNGOL, V129, P1115, DOI 10.1080/00016480802552550
   Sakai C, 2017, 77 SCI SESS AM DIAB, V0, P0
   Sakai F, 2002, ACTA OTO-LARYNGOL, V122, P129, DOI 10.1080/00016480260046517
   Sakai F, 1995, NIHON JIBIINKOKA GAKKAI KAIHO, V98, P1135
   Sanchez Nebra J, 1993, NUTR HOSP, V8, P561
   Sasano T, 2010, BIOL PHARM BULL, V33, P1791, DOI 10.1248/bpb.33.1791
   Sergi G, 2017, CRIT REV FOOD SCI, V57, P3684, DOI 10.1080/10408398.2016.1160208
   Silverman J E, 1983, J ORAL MED, V38, P14
   Smutzer G, 2008, LARYNGOSCOPE, V118, P1411, DOI 10.1097/MLG.0b013e31817709a0
   SOLOMONS N, 1974, CLIN RES, V22, P582
   Soter A, 2008, LARYNGOSCOPE, V118, P611, DOI 10.1097/MLG.0b013e318161e53a
   SPIELMAN AI, 1992, CHEM SENSES, V17, P451, DOI 10.1093/chemse/17.4.451
   Sprenger K B, 1983, KIDNEY INT SUPPL, V16, P0
   Stewart-Knox BJ, 2008, BRIT J NUTR, V99, P129, DOI 10.1017/S0007114507781485
   Strasser F, 2008, ONCOLOGIST, V13, P337, DOI 10.1634/theoncologist.2007-0217
   Sturniolo GC, 1985, J HEPATOL S1, V1, P0
   Tomita H, 1986, AURIS NASUS LARYNX, V13 Suppl 1, P0
   Treldal C, 2016, ORAL DIS, V22, P123, DOI 10.1111/odi.12386
   Tupe RP, 2009, J AM COLL NUTR, V28, P388, DOI 10.1080/07315724.2009.10718101
   Vent J, 2010, OTOLARYNG HEAD NECK, V142, P505, DOI 10.1016/j.otohns.2010.01.012
   WATSON AR, 1983, HUM NUTR-CLIN NUTR, V37, P219
   Wickham R S, 1999, ONCOL NURS FORUM, V26, P697
   Wilken Marlene K, 2012, CLIN J ONCOL NURS, V16, P0
   Winkler S, 1999, J AM DENT ASSOC, V130, P1759, DOI 10.14219/jada.archive.1999.0133
   YOSHIDA S, 1991, AURIS NASUS LARYNX, V18, P153
NR 103
TC 41
Z9 53
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PD JUN 15
PY 2017
VL 0
IS 12
BP 
EP 
DI 10.1002/14651858.CD010470.pub3
PG 79
WC Medicine, General & Internal
SC General & Internal Medicine
GA FR5JG
UT WOS:000419102200040
PM 29260510
DA 2026-01-16
ER

PT J
AU Soós, SA
   Jeszenoi, N
   Darvas, K
   Harsányi, L
AF Soos Sandor Arpad
   Jeszenoi Norbert
   Darvas Katalin
   Harsanyi Laszlo
TI Attitudes, knowledge and use of complementary and alternative medicine among perioperative healthcare professionals
SO ORVOSI HETILAP
LA Hungarian
DT Article
DE nurses; surgery; integrative medicine
ID postoperative pain; nurses attitudes; herbal medicines; national-survey; united-states; double-blind; acupuncture; surgery; therapy; cancer
AB Introduction: Perioperative healthcare professionals' attitudes towards non- conventional treatments have not been explored in Hungary yet. Aim: Our goal was to survey healthcare professionals' attitude and knowledge towards naturopathy in six clinics of the Semmelweis University that provide perioperative care. Method: An anonymous, paper-based questionnaire was used. With an 82% response rate, the data was gained from 119 questionnaires and was processed using statistical analysis and chi-squared test. Results: Only 25.2% of those surveyed considered themselves to be well- informed in this field. 68.1% of the participants had an interest in naturopathy and 60.5% would have liked to learn about naturopathy. 70.6% would be willing to use non-conventional treatments in their daily work, predominantly those who have used these methods in the case of their own illness, p = 0.0027. The most popular treatment methods included homeopathy, alternative massage and movement therapy, acupuncture and manual therapy. Conclusion: As anticipated based on international literature in this field, those Hungarian healthcare professionals who took part in our survey showed openness and interest towards naturopathy.
C1 [Soos Sandor Arpad; Darvas Katalin; Harsanyi Laszlo] Semmelweis Egyet, Altalanos Orvostud Kar, Sebeszeti Klin 1, Budapest, Hungary.
   [Darvas Katalin] Semmelweis Egyet, Altalanos Orvostud Kar, Aneszteziol & Intenziv Terapias Klin, Budapest, Hungary.
   [Jeszenoi Norbert] Eotvos Lorand Univ, Genet Tanszek, Budapest, Hungary.
   [Jeszenoi Norbert] MTA NAP B Mol Neuroendokrinol Kutatocsoport, Elettani Intezet, Szentagothai Kutatokozpont, Idegtud Kozpont Pecsi Tud Egyet, Pecs, Hungary.
C3 Semmelweis University; Semmelweis University; Eotvos Lorand University; University of Pecs
RP Soós, SA (corresponding author), Ulloi Ut 78, H-1082 Budapest, Hungary.
EM soossandormd@gmail.com
CR Almeida JC, 1996, ANN INTERN MED, V125, P940, DOI 10.7326/0003-4819-125-11-199612010-00023
   Bahall M, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0610-y
   Barlow T, 2013, COMPLEMENT THER MED, V21, P529, DOI 10.1016/j.ctim.2013.06.008
   Bjerså K, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-42
   Boitor M, 2015, PAIN MANAG NURS, V16, P354, DOI 10.1016/j.pmn.2014.08.014
   Booth-Laforce C, 2010, J PROF NURS, V26, P293, DOI 10.1016/j.profnurs.2010.03.003
   Brown Janis, 2007, COMPLEMENT THER CLIN PRACT, V13, P194, DOI 10.1016/j.ctcp.2007.03.003
   Buchan S, 2012, BR J NURS, V21, P676
   Buchan Shonagh, 2012, BR J NURS, V21, P672
   Christina J, 2016, ASIA-PAC J ONCOL NUR, V3, P241, DOI 10.4103/2347-5625.189816
   Chu FY, 2007, INT J NURS STUD, V44, P1371, DOI 10.1016/j.ijnurstu.2006.07.001
   Cooke M, 2012, AUST CRIT CARE, V25, P213, DOI 10.1016/j.aucc.2011.12.055
   Damkier A, 1998, SCAND J CARING SCI, V12, P119, DOI 10.1080/02839319850163057
   DeKeyser FG, 2001, J ADV NURS, V36, P41, DOI 10.1046/j.1365-2648.2001.01941.x
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Ernst E, 2000, B WORLD HEALTH ORGAN, V78, P252
   Giannelli M, 2007, BMC FAM PRACT, V8, P0, DOI 10.1186/1471-2296-8-30
   Hill C F, 1993, INTENSIVE CRIT CARE NURS, V9, P116, DOI 10.1016/0964-3397(93)90052-Y
   Holroyd E, 2008, INT J NURS STUD, V45, P1660, DOI 10.1016/j.ijnurstu.2008.04.003
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Jalili J, 2013, PLAST RECONSTR SURG, V131, P168, DOI 10.1097/PRS.0b013e318272f1bb
   Kaye AD, 2000, J CLIN ANESTH, V12, P468, DOI 10.1016/S0952-8180(00)00195-1
   장은희, 2003, KOREAN JOURNAL OF ADULT NURSING 성인간호학회지, V15, P402
   Leach Matthew J, 2004, COMPLEMENT THER NURS MIDWIFERY, V10, P13, DOI 10.1016/S1353-6117(03)00082-9
   Leung JM, 2001, ANESTH ANALG, V93, P1062, DOI 10.1097/00000539-200110000-00053
   Lindquist Ruth, 2005, CRIT CARE NURSE, V25, P63
   Lucenteforte E, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/527238
   Malicka I, 2014, MENOPAUSE REV, V13, P221, DOI 10.5114/pm.2014.44997
   Marx W, 2015, CURR OPIN SUPPORT PA, V9, P189, DOI 10.1097/SPC.0000000000000135
   Medical Sciences Section Hungarian Academy of Sciences, 2011, ORV HETIL, V152, P1197, DOI 10.1556/OH.2011.29171
   Mei-Ying Chang, 2004, J NURS RES, V12, P103
   Melland H I, 2000, NURSE EDUC, V25, P247
   Miller J, 2015, ORTHOP NURS, V34, P227, DOI 10.1097/NOR.0000000000000163
   Miller LG, 1998, ARCH INTERN MED, V158, P2200, DOI 10.1001/archinte.158.20.2200
   Noll DR, 2008, J AM OSTEOPATH ASSOC, V108, P508
   Pettersson PH, 2012, J CLIN NURS, V21, P1799, DOI 10.1111/j.1365-2702.2012.04114.x
   Roncada G, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1468-3
   Shorofi Seyed Afshin, 2010, COMPLEMENT THER CLIN PRACT, V16, P229, DOI 10.1016/j.ctcp.2010.05.008
   Shuval J, 2006, SOC SCI MED, V63, P1784, DOI 10.1016/j.socscimed.2006.05.009
   Singer Shepherd R, 2010, BMC CLIN PHARMACOL, V10, P9, DOI 10.1186/1472-6904-10-9
   Skinner CM, 2002, BRIT J ANAESTH, V89, P792, DOI 10.1093/bja/aef256
   Son HM, 2001, J KOREAN ACAD FUNDAM, V8, P314
   Soós SA, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1426-0
   Soós SA, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0890-2
   Soós SA, 2015, ORVOSI HETILAP, V156, P1133, DOI 10.1556/650.2015.30132
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Taghavi R, 2013, KOREAN J PAIN, V26, P46, DOI 10.3344/kjp.2013.26.1.46
   Tracy MF, 2005, AM J CRIT CARE, V14, P404
   Tracy MF, 2003, HEART LUNG, V32, P197, DOI 10.1016/S0147-9563(03)00040-2
   Trail-Mahan T, 2013, PAIN MANAG NURS, V14, P277, DOI 10.1016/j.pmn.2011.06.001
   Tsao GJ, 2015, LARYNGOSCOPE, V125, P1972, DOI 10.1002/lary.25252
   Tsen LC, 2000, ANESTHESIOLOGY, V93, P148, DOI 10.1097/00000542-200007000-00025
   Wang Hsiao-Lan, 2004, PAIN MANAG NURS, V5, P59, DOI 10.1016/j.pmn.2004.01.002
   Wang SM, 2001, ANESTH ANALG, V93, P1178, DOI 10.1097/00000539-200111000-00024
   Waterbrook AL, 2010, J EMERG MED, V39, P569, DOI 10.1016/j.jemermed.2008.01.007
   Wilkinson J M, 2002, COMPLEMENT THER NURS MIDWIFERY, V8, P142, DOI 10.1054/ctnm.2002.0632
   Yang B, 2014, AFR J TRADIT COMPLEM, V11, P101, DOI 10.4314/ajtcam.v11i4.17
   Yildirim Y, 2010, J CLIN NURS, V19, P1157, DOI 10.1111/j.1365-2702.2009.03188.x
   Yom YH, 2008, J CLIN NURS, V17, P2565, DOI 10.1111/j.1365-2702.2007.02065.x
   Yoshikawa K, 2015, J AM COLL SURGEONS, V221, P571, DOI 10.1016/j.jamcollsurg.2015.03.004
NR 62
TC 1
Z9 1
U1 0
U2 14
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD MAR 15
PY 2017
VL 158
IS 10
BP 368
EP 375
DI 10.1556/650.2017.30676
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA EP3NV
UT WOS:000397289900002
PM 28270001
DA 2026-01-16
ER

PT J
AU Schlaeger, JM
   Cai, HY
   Xu, NG
   Steffens, AD
   Wang, L
   Wilkie, DJ
AF Schlaeger, Judith M.
   Cai, Hui Yan
   Xu Nenggui
   Steffens, Alana D.
   Wang Lin
   Wilkie, Diana J.
TI Do Vulvodynia TCM Patterns Differ by Pain Types? Beginning Evidence Supporting the Concept
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE vulvodynia; acupuncture; Traditional Chinese Medicine; pain
ID vulvar vestibulitis syndrome; chronic pelvic pain; neuropathic pain; lung-cancer; women; questionnaire; classification; descriptors; thresholds; diagnosis
AB Introduction: Vulvodynia affects a maximum of 14 million U.S. women; however, it has not been adequately characterized. Traditional Chinese Medicine (TCM) offers pattern diagnoses that may be considered vulvodynia phenotypes and may guide the development of more targeted treatments. Objectives: In women with vulvodynia, to explore relationships between the TCM patterns and pain. Design/Methods: In an exploratory study, 36 women diagnosed with vulvodynia had a TCM assessment and completed the Short Form McGill Pain Questionnaire (SF-MPQ). Results: All 36 women were diagnosed with one of the two TCM patterns (excess heat [n = 28] or excess cold [n = 8]). Although not statistically significant, (1) the excess heat pattern group had a higher mean sensory score (14.4 +/- 6.0) and mean affective pain score (4.1 +/- 2.8) (more pain) compared with the mean sensory score (13.3 +/- 5.9) and mean affective score (3.3 +/- 1.8) of the excess cold pattern group; (2) there was a higher mean score for neuropathic sensory descriptors in the excess heat pattern group (1.55 +/-.58) compared with the excess cold pattern group (1.16 +/- 0.72); and (3) there was a higher mean score for nociceptive sensory descriptors in the excess cold pattern group (1.23 +/- 0.45) compared with the excess heat pattern group (1.14 +/- 0.62). The difference in the hotburning mean score between the two TCM pattern groups was statistically significant (t [34] = 6.55, p < 0.0001). Conclusion: Intriguing trends were observed in the pain scores for the two TCM pattern groups. The possibility that TCM pattern groups have different types of pain (neuropathic vs. nociceptive) deserves further research in larger samples. If these exploratory findings are confirmed, the characterization of TCM patterns could lead to new treatments for vulvodynia.
C1 [Schlaeger, Judith M.] Univ Illinois, Coll Nursing, Dept Women Children & Family Hlth Sci, 840 S Damen Ave, Chicago, IL 60612 USA.
   [Cai, Hui Yan] Natl Univ Hlth Sci, Dept Acupuncture & Oriental Med, Lombard, IL USA.
   [Xu Nenggui; Wang Lin] Guangzhou Univ Chinese Med, Dept Acupuncture, Guangzhou, Guangdong, Peoples R China.
   [Steffens, Alana D.] Univ Illinois, Coll Nursing, Off Res Facilitat, Chicago, IL USA.
   [Wilkie, Diana J.] Univ Florida, Coll Nursing, Dept Biobehav Nursing Sci, Gainesville, FL 32611 USA.
C3 University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Guangzhou University of Chinese Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University System of Florida; University of Florida
RP Schlaeger, JM (corresponding author), Univ Illinois, Coll Nursing, Dept Women Children & Family Hlth Sci, 840 S Damen Ave, Chicago, IL 60612 USA.
EM jschlaeg@uic.edu
CR Bohm-Starke N, 1999, GYNECOL OBSTET INVES, V48, P270, DOI 10.1159/000010198
   Bornstein J, 2016, J SEX MED, V13, P607, DOI 10.1016/j.jsxm.2016.02.167
   BOUREAU F, 1990, PAIN, V42, P145, DOI 10.1016/0304-3959(90)91158-F
   Chen JK, 2009, CHINES HERBAL FORMUL, V0, P0
   Cherny NI, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P139
   Deadman P, 2007, US J CHINESE MED PUB, V0, P0
   Dobratz MC, 2008, AM J HOSP PALLIAT ME, V25, P469, DOI 10.1177/1049909108322293
   Epstein JB, 2009, HEAD NECK ONCOL, V1, P0, DOI 10.1186/1758-3284-1-26
   Farmer MA, 2013, PAIN, V154, P2277, DOI 10.1016/j.pain.2013.05.028
   Fitzgerald CM, 2011, J REPROD MED, V56, P117
   Giesecke J, 2004, OBSTET GYNECOL, V104, P126, DOI 10.1097/01.AOG.0000129238.49397.4e
   Granot M, 2002, BJOG-INT J OBSTET GY, V109, P863, DOI 10.1111/j.1471-0528.2002.01416.x
   Haefner Hope K, 2005, J LOW GENIT TRACT DIS, V9, P40, DOI 10.1097/00128360-200501000-00009
   Loving S, 2014, EUR J PAIN, V18, P1259, DOI 10.1002/j.1532-2149.2014.485.x
   Lowenstein L, 2004, PAIN, V107, P47, DOI 10.1016/j.pain.2003.09.012
   Martin LA, 1997, J PAIN SYMPTOM MANAG, V14, P99, DOI 10.1016/S0885-3924(97)00009-2
   MASSON EA, 1989, PAIN, V38, P25, DOI 10.1016/0304-3959(89)90068-7
   MELZACK R, 1986, PAIN, V27, P297, DOI 10.1016/0304-3959(86)90157-0
   MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5
   MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8
   Neville CE, 2012, J BODYW MOV THER, V16, P50, DOI 10.1016/j.jbmt.2011.06.002
   PAYNE R, 1989, CANCER, V63, P2266, DOI 10.1002/1097-0142(19890601)63:11<2266::AID-CNCR2820631135>3.0.CO;2-5
   Portenoy R K, 1997, SEMIN ONCOL NURS, V13, P25, DOI 10.1016/S0749-2081(97)80046-0
   Pukall CF, 2002, PAIN, V96, P163, DOI 10.1016/S0304-3959(01)00442-0
   Schlaeger JM, 2015, J SEX MED, V12, P1019, DOI 10.1111/jsm.12830
   Stockdale CK, 2014, J LOW GENIT TRACT DI, V18, P93, DOI 10.1097/LGT.0000000000000021
   Tu FF, 2008, CLIN J PAIN, V24, P45, DOI 10.1097/AJP.0b013e318156db13
   Tu FF, 2008, AM J OBSTET GYNECOL, V198, P0, DOI 10.1016/j.ajog.2007.09.002
   Twycross R, 1997, ACTA ANAESTH SCAND, V41, P141, DOI 10.1111/j.1399-6576.1997.tb04628.x
   Wilkie DJ, 2010, J NATL MED ASSOC, V102, P18, DOI 10.1016/S0027-9684(15)30471-5
   WILKIE DJ, 1991, CLIN J PAIN, V7, P292, DOI 10.1097/00002508-199112000-00007
   Wilkie DJ, 2001, J PAIN SYMPTOM MANAG, V22, P899, DOI 10.1016/S0885-3924(01)00351-7
   Zhang Z, 2011, CLIN J PAIN, V27, P755, DOI 10.1097/AJP.0b013e31821c98ec
NR 33
TC 1
Z9 2
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAY 15
PY 2017
VL 23
IS 5
BP 380
EP 384
DI 10.1089/acm.2015.0353
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA EV0UM
UT WOS:000401460900012
PM 28294632
DA 2026-01-16
ER

PT J
AU Mate, A
   Molnar, I
   Szoke, H
   Hegyi, G
AF Mate, Agnes
   Molnar, Istvan
   Szoke, Henrik
   Hegyi, Gabriella
TI Newer application of Oncothermia to non-malignant diseases such as Dupuytren's contracture of the hand and chronic lower back pain lasting more than 4 weeks
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article
DE Physiotherapy; Oncothermia; Dupuytren's contracture; Non-specific low back pain
ID cancer
AB Oncothermia (OTM) is based on electromagnetic interactions with the living matter. Its nano-targeting approach establishes a new paradigm. OTM could be applied not only to treat malignancies but it is feasible to apply for other diseases too. OTH is well proven method from the laboratory level to the clinical applications, promoting the natural processes, re-establishing of the synchronization between the cells. This approach allows therapy of some nonmalignant diseases too. Our objective is to use OTM for the irregularities of tissue-growth and for pain syndromes as well. OTM uses precisely tuned radiofrequency (RF) current flowing through the treated part of the body. We made extensive study, proving in details the applicability of the OTM for Dupuytren's contracture and chronic low back pain, in conjunction with permanent acupuncture method, a modified process of traditional Chinese Medicine (TCM). The synergy of the ancient and the state-of-art medical knowledges is the basic method of the present research. Our results with application of OTM for chronic low back pain and Dupuytren's contracture shows definite improvements of the patients involved in the study. We measured the success with the Visual Analog Scale (VAS), with anecdotic quality of life (QoL), and the shortening of the of-work period due to the disease. We measured that VAS decreased significantly, the hand contracture became less rigid and less contracted. The QoL of patients improved and their complaints which blocked their regular activity has significantly reduced. OTM method was safe & no adverse effects were observed. Recognition of the distortions in the healthy tissue have some common principles and possibilities in TCM and OTM: both the methods recognize the loss of complexity of the living organization. Data of our recent study verified the relevant end-points of our present study: the safety, the quality of life (QoL), the prolonged painless status of the patient.
C1 [Mate, Agnes; Molnar, Istvan] Pecs Univ, Hlth Sci Fac, Pecs, Hungary.
   [Szoke, Henrik; Hegyi, Gabriella] Pecs Univ, Hlth Sci Dept, CAM Div, Pecs, Hungary.
C3 University of Pecs; University of Pecs
RP Hegyi, G (corresponding author), Petofi U 79, H-1196 Budapest, Hungary.
EM drhegyi@hu.inter.net
CR Andocs G, 2009, ELECTROMAGN BIOL MED, V28, P148, DOI 10.1080/15368370902724633
   Andocs G, 2009, STRAHLENTHER ONKOL, V185, P120, DOI 10.1007/s00066-009-1903-1
   Ballerini M, 2013, C PAPERS MED, V2013, P0
   Beachy SH, 2011, INT J HYPERTHER, V27, P344, DOI 10.3109/02656736.2011.562873
   Hegyi G, 2013, C PAPERS MED, V2013, P0
   Hegyi G, 2012, J ALTERN COMPLEM MED, V18, P1
   Hegyi G, 2013, 32 ANN C ICHS 2013 P, V0, P0
   Hegyi G, 2012, OPEN JOURNAL OF BIOPHYSICS, V02, P60, DOI 10.4236/OJBIPHY.2012.23009
   Hegyi G, 2013, ACUPUNCTURE ELECTRO, V38, P161, DOI 10.3727/036012913X13831832269243
   Kanodia AK, 2010, J AM BOARD FAM MED, V23, P354, DOI 10.3122/jabfm.2010.03.080252
   Szasz A, 2013, ELECTROMAGNETIC EFFE, V0, P0
   Szasz A, 2013, THERM. MED, V29, P1, DOI 10.3191/THERMALMED.29.1
   Szasz A, 2013, HYPERTHERMIA, V0, P0
   Szasz A, 2011, ONCOTHERMIA: PRINCIPLES AND PRACTICES, V0, PP1, DOI 10.1007/978-90-481-9498-8
   Szasz O, 2014, J CANCER SCI THER, V6, P117
   Yang KL, 2016, ONCOTARGET, V7, P84082, DOI 10.18632/oncotarget.11444
   Zais O, 2013, C PAPERS MED, V2013, P0
NR 17
TC 1
Z9 1
U1 0
U2 12
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PD JUN 15
PY 2017
VL 42
IS 2
BP 121
EP 133
DI 10.3727/036012917X15004036818267
PG 13
WC Integrative & Complementary Medicine; Neurosciences
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA FD9WH
UT WOS:000407872300004
DA 2026-01-16
ER

PT J
AU Zhou, M
   Li, Y
   Han, X
   Xing, Q
   Wang, Y
   Dong, X
   Chang, J
AF Zhou, Mintao
   Li, Yu
   Han, Xuechang
   Xing, Qunzhi
   Wang, Yiyao
   Dong, Xu
   Chang, Junxiao
TI [Clinical research of electroacupuncture on the analgesic effect of thoracic
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Neimadian; Point, PC 6 (Neiguan); analgesia; electroacupuncture; thoracic surgery
AB OBJECTIVE: To discuss the clinical therapeutic effects of electroacupuncture at  Neimadian (Extra) and Neiguan (PC 6) on the analgesic effect of thoracic  perioperative stage and its effect mechanism. METHODS: Sixty cases of esophageal  cancer with elective radical resection under general anesthesia were divided into  an observation group and a control group according to the operation sequence, 30  cases in each one. In the control group, the general anesthesia was simply  applied and sufentanil was administered for patient controlled intravenous  analgesia (PCIA) after operation. In the observation group, on the basis of the  scheme as the control group, the electroacupuncture was used at Neimadian (Extra)  and Neiguan (PC 6) 30 min before anesthesia induction and after operation, with  continuous wave, tolerable intensity, lasting for 30 min. Separately, before  acupuncture (T1) and 2h (T2), 12h (T3), 24h (T4) and 48h (T5) after operation,  the plasma β-endorphin (β-EP), 5-hydroxytryptamine (5-HT) and prostaglandin E(2)  (PGE(2)) were determined. During operation, under the same state (from 50 to 60)  of bispectrum of EEG (BIS), the intraoperative anesthetic dose was recorded.  Using visual analogue scale (VAS), the pain degree was evaluated at T2, T3, T4  and T5 separately and the grade assessment of the therapeutic effects and safety  were recorded at each time point. RESULTS: ①The total dosage of sufentanil in the  observation group was less than that in the control group[(1.83±0.56) mg vs  (2.54±0.62) mg, P<0.05]. ②VAS scores at T2, T3 and T4 in the patients of the  observation group were all lower than those in the control group (all P<0.05).  ③The levels of plasma β-EP at T3, T4 and T5 in the observation group were  increased significantly as compared with those in the control group (all P<0.05)  and the levels of plasma 5-HT and PGE(2) at T2, T3 and T4 were reduced  significantly as compared with those in the control group (all P<0.05). ④ The  excellent analgesia rates 2h、12h and 24h after operation in the observation group  were better than those in the control group (all P<0.05). ⑤The rate of the A  grade safety in the observation group was higher than that in the control group  (P<0.05). CONCLUSIONS: Electroacupuncture at Neimadian (Extra) and Neiguan (PC 6)  provides the safe and effective postoperative anesthesia of thoracic surgery and  reduces the dosage of analgesics during the operation, which is possibly related  to the increase of endogenous β-EP and the inhibition on the release of 5-HT and  PGE(2).
C1 Clinical Medical School of Henan University of Science and Technology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang471003, China.
   Clinical Medical School of Henan University of Science and Technology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang471003, China.
   Clinical Medical School of Henan University of Science and Technology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang471003, China.
   Clinical Medical School of Henan University of Science and Technology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang471003, China.
   Clinical Medical School of Henan University of Science and Technology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang471003, China.
   Clinical Medical School of Henan University of Science and Technology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang471003, China.
   Clinical Medical School of Henan University of Science and Technology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang471003, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD DEC 13
PY 2017
VL 37
IS 7
BP 705
EP 709
DI 10.13703/j.0255-2930.2017.07.006
PG 4
WC Acupuncture Analgesia; Acupuncture Points; Anesthesia, General; Anesthetics, Intravenous; administration & dosage; Biomedical Research; Case-Control Studies; Dinoprostone; blood; Electroacupuncture; methods; Esophageal Neoplasms; surgery; Humans; Pain Management; Pain Measurement; Serotonin; blood; Sufentanil; administration & dosage; beta-Endorphin; blood
UT PubMed:29231542
PM 29231542
DA 2017-12-13
ER

PT J
AU Ondrejkovicova, A
   Petrovics, G
   Svitkova, K
   Balogh, V
AF Ondrejkovicova, Alena
   Petrovics, Gabriel
   Svitkova, Katarína
   Balogh, Vladimír
TI Is non-pharmacological treatment an effective option for chronic low back pain?
SO Neuro endocrinology letters
LA English
DT Journal Article
AB OBJECTIVE: Despite of pain being important warning signal for body ability to  respond to internal or external threats, chronic pain is perceived as a  discomfort by patients, leading to somatic, emotional and social negative  changes. Lifestyle, wrong seating habits and some occupations may contribute to  chronic back pain. Therapy for chronic back pain should include not only  pharmacological or invasive interventions, but mostly change of lifestyle,  physiotherapy and non-pharmacological methods. METHODS: The main objective of the  paper was to compare subjective perception of the effectiveness of various  methods for treatment of low back pain. In total, 100 patients were asked to fill  the questionnaire after completing the treatment, whether conventional or  non-pharmacological. We have aimed to analyze not only the perception of the  patients, but also indicators of the patient's lifestyle, their nutrition and  physical activity. RESULTS: Oral drugs was the most effective option perceived by  the patients, followed by non-pharmacological methods, such as massages, heat  application and acupuncture. At the same time, all patients who changed their  lifestyle, for example reduced smoking and alcohol and increased physical  activity, achieved better results in non-pharmacological treatment and  experienced higher pain alleviation compared to the patients treated by  medications only. CONCLUSION: Non-pharmacological therapy of chronic  non-malignant low back pain could be an effective option offered in combination  with medicaments and change of lifestyle.
C1 Department of Acupuncture, Institute of Traditional Chinese Medicine, Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.
   Department of Acupuncture, Institute of Traditional Chinese Medicine, Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.
   Department of Acupuncture, Institute of Traditional Chinese Medicine, Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.
   Department of Acupuncture, Institute of Traditional Chinese Medicine, Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.
NR 0
TC 0
SN 
EI 0172-780
J9 Neuro Endocrinol Lett
PD AUG 2
PY 2017
VL 38
IS 3
BP 169
EP 172
DI 
PG 3
WC Acupuncture Therapy; Analgesics; therapeutic use; Chronic Pain; drug therapy; Exercise; physiology; Female; Health Behavior; physiology; Hot Temperature; therapeutic use; Humans; Life Style; Low Back Pain; drug therapy; Male; Massage; Pain Management; methods; Pain Measurement; Pain Perception; physiology; Physical Therapy Modalities; Treatment Outcome
UT PubMed:28759184
PM 28759184
DA 2017-08-02
ER

PT J
AU Qu, F
   Li, R
   Sun, W
   Lin, G
   Zhang, R
   Yang, J
   Tian, L
   Xing, GG
   Jiang, H
   Gong, F
   Liang, XY
   Meng, Y
   Liu, JY
   Zhou, LY
   Wang, SY
   Wu, Y
   He, YJ
   Ye, JY
   Han, SP
   Han, JS
AF Qu, Fan
   Li, Rong
   Sun, Wei
   Lin, Ge
   Zhang, Rong
   Yang, Jing
   Tian, Li
   Xing, Guo-Gang
   Jiang, Hui
   Gong, Fei
   Liang, Xiao-Yan
   Meng, Yan
   Liu, Jia-Yin
   Zhou, Li-Ying
   Wang, Shu-Yu
   Wu, Yan
   He, Yi-Jing
   Ye, Jia-Yu
   Han, Song-Ping
   Han, Ji-Sheng
TI Use of electroacupuncture and transcutaneous electrical acupoint stimulation in
SO Journal of Zhejiang University. Science. B
LA English
DT Review
DE Electroacupuncture (EA); Group consensus; Reproductive medicine; Transcutaneous electrical acupoint stimulation (TEAS)
AB With the rapid development of assisted reproductive technology, various  reproductive disorders have been effectively addressed. Acupuncture-like  therapies, including electroacupuncture (EA) and transcutaneous electrical  acupoint stimulation (TEAS), become more popular world-wide. Increasing evidence  has demonstrated that EA and TEAS are effective in treating gynecological  disorders, especially infertility. This present paper describes how to select  acupoints for the treatment of infertility from the view of theories of  traditional Chinese medicine and how to determine critical parameters of electric  pulses of EA/TEAS based on results from animal and clinical studies. It  summarizes the principles of clinical application of EA/TEAS in treating various  kinds of reproductive disorders, such as polycystic ovary syndrome (PCOS), pain  induced by oocyte retrieval, diminished ovarian reserve, embryo transfer, and  oligospermia/ asthenospermia. The possible underlying mechanisms mediating the  therapeutic effects of EA/TEAS in reproductive medicine are also examined.
C1 Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
   Center of Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, 
   Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Wuxi HANS Therapy Medical Technology Co., Ltd., Wuxi 214092, China.
   Center of Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital / Key Laboratory of Assisted Reproduction, Ministry ofEducation / Beijing Key Laboratory of Reproductive Endocrinology and AssistedReproductive Technology, Beijing 100191, China.
   Center of Reproductive Medicine, the Second Hospital Affiliated to Shandong University of Traditional Chinese Medicine, Jinan 250001, China.
   Center of Reproductive Medicine, CITIC Xiangya Reproductive and Genetic Hospital, Changsha 410008, China.
   Neuroscience Research Institute, Peking University / Department of Neurobiology, School of Basic Medical Sciences / Peking University Health Science Center / KeyLab for Neuroscience, Ministry of Education/Ministry of Health, Beijing 100083,China.
   Center of Reproductive Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.
   Center of Reproductive Medicine, Peking University People's Hospital, Beijing 100044, China.
   Neuroscience Research Institute, Peking University / Department of Neurobiology, School of Basic Medical Sciences / Peking University Health Science Center / KeyLab for Neuroscience, Ministry of Education/Ministry of Health, Beijing 100083,China.
   Center of Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital / Key Laboratory of Assisted Reproduction, Ministry ofEducation / Beijing Key Laboratory of Reproductive Endocrinology and AssistedReproductive Technology, Beijing 100191, China.
   Center of Reproductive Medicine, CITIC Xiangya Reproductive and Genetic Hospital, Changsha 410008, China.
   Center of Reproductive Medicine, the Sixth Affiliated Hospital of Zhongshan University, Guangzhou 510655, China.
   Center of Reproductive Medicine, Jiangsu Province Hospital, Nanjing 210029, China.
   Center of Reproductive Medicine, Jiangsu Province Hospital, Nanjing 210029, China.
   Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
   Center of Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, 
   Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Wuxi HANS Therapy Medical Technology Co., Ltd., Wuxi 214092, China.
   Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
   Center of Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, 
   Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Wuxi HANS Therapy Medical Technology Co., Ltd., Wuxi 214092, China.
   Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
   Center of Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, 
   Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Wuxi HANS Therapy Medical Technology Co., Ltd., Wuxi 214092, China.
   Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
   Center of Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, 
   Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Wuxi HANS Therapy Medical Technology Co., Ltd., Wuxi 214092, China.
   Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
   Center of Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, 
   Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Wuxi HANS Therapy Medical Technology Co., Ltd., Wuxi 214092, China.
   Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
   Center of Reproductive Medicine, Department of Obstetrics and Gynecology, Peking 
   Neuroscience Research Institute, Peking University / Department of Neurobiology, School of Basic Medical Sciences / Peking University Health Science Center / KeyLab for Neuroscience, Ministry of Education/Ministry of Health, Beijing 100083,China.
   Center of Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, 
   Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Wuxi HANS Therapy Medical Technology Co., Ltd., Wuxi 214092, China.
   Neuroscience Research Institute, Peking University / Department of Neurobiology, School of Basic Medical Sciences / Peking University Health Science Center / KeyLab for Neuroscience, Ministry of Education/Ministry of Health, Beijing 100083,China.
NR 0
TC 0
SN 1862-178
EI 1673-158
J9 J Zhejiang Univ Sci B
PD MAR 9
PY 2017
VL 18
IS 3
BP 186
EP 193
DI 10.1631/jzus.B1600437
PG 7
WC Acupuncture Points; Analgesia; Animals; Asthenozoospermia; therapy; Clinical Trials as Topic; Electroacupuncture; methods; Embryo Transfer; Female; Genital Diseases, Female; therapy; Humans; Infertility, Female; therapy; Infertility, Male; therapy; Kidney; Male; Medicine, Chinese Traditional; Oligospermia; therapy; Oocyte Retrieval; Oocytes; cytology; Ovarian Reserve; Polycystic Ovary Syndrome; therapy; Pregnancy; Pregnancy Rate; Reproductive Medicine; Transcutaneous Electric Nerve Stimulation; methods; Uterus
UT PubMed:28271655
PM 28271655
DA 2017-03-09
ER

PT J
AU Nia, HS
   Sharif, SP
   Yaghoobzadeh, A
   Yeoh, KK
   Goudarzian, AH
   Soleimani, MA
   Jamali, S
AF Nia, Hamid Sharif
   Sharif, Saeed Pahlevan
   Yaghoobzadeh, Ameneh
   Yeoh, Ken Kyid
   Goudarzian, Amir Hossein
   Soleimani, Mohammad Ali
   Jamali, Saman
TI Effect of acupressure on pain in Iranian leukemia patients: A randomized controlled trial study
SO INTERNATIONAL JOURNAL OF NURSING PRACTICE
LA English
DT Article
DE acupressure; cancer; Iran; leukemia; nursing; pain
ID symptom management; postoperative pain; cancer pain; acupuncture; therapy; anxiety; nausea
AB Nonpharmacological methods of pain relief such as acupressure are becoming increasingly popular worldwide. Practitioners often claim that such methods are highly effective and less invasive than analgesic drugs, but available empirical evidence is largely inconclusive. This study aimed to test the hypothesis that, postacupressure intervention, the amount of pain experienced by sampled leukemia patients, who received acupressure in addition to standard care, will reduce substantially compared to patients who received only routine treatment. This controlled trial was undertaken with hospitalized leukemia patients between February and June 2015. Our primary sample consisted of 100 participants who were randomly allocated to 2 groups. One (intervention) group underwent 12 acupressure sessions in addition to standard treatment while the control group received no intervention apart from being given the standard treatment for leukemia. The visual analogue scale was used to measure the levels of pain experienced. No significant differences were found between the 2 groups across 12 interventions. However, each group reported significantly different pain level changes before and after each intervention, suggested that the acupressure method was effective in reducing pain in the short term. Nurses are able to apply this complementary therapy alongside other procedures to manage these patients' pain. It is recommended that further studies be conducted to better understand the specific conditions under which acupressure can provide effective pain relief.
C1 [Nia, Hamid Sharif] Mazandaran Univ Med Sci, Sch Nursing & Midwifery Amol, Sari, Iran.
   [Sharif, Saeed Pahlevan] Taylors Business Sch, Subang Jaya, Malaysia.
   [Yaghoobzadeh, Ameneh] Univ Tehran Med Sci, Tehran, Iran.
   [Yeoh, Ken Kyid] Univ Nottingham, Sch Business, Semenyih Selangor Darul Ehsan, Univ Nottingham Malaysia Campus, Semenyih, Selangor Darul, Malaysia.
   [Goudarzian, Amir Hossein; Jamali, Saman] Mazandaran Univ Med Sci, Student Res Comm, Sari, Iran.
   [Soleimani, Mohammad Ali] Qazvin Univ Med Sci, Social Determinants Hlth Res Ctr, Qazvin, Iran.
C3 Mazandaran University of Medical Sciences; Tehran University of Medical Sciences; University of Nottingham Malaysia; Mazandaran University of Medical Sciences; Qazvin University of Medical Sciences (QUMS)
RP Goudarzian, AH (corresponding author), Mazandaran Univ Med Sci, Student Res Comm, Nursing, Sari, Iran.
EM amir_sari@yahoo.com
FU Mazandaran University of Medical Sciences [360]
CR Aghamiri Z, 2005, HAYAT, V11, P19
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Anderson JG, 2015, EXPLORE-NY, V11, P208, DOI 10.1016/j.explore.2015.02.006
   Bao T, 2011, J PAIN SYMPTOM MANAG, V41, P995, DOI 10.1016/j.jpainsymman.2010.08.012
   Belfer I, 2014, PAIN MED, V15, P1590, DOI 10.1111/pme.12487
   Büyükyilmaz F, 2013, PAIN MANAG NURS, V14, P143, DOI 10.1016/j.pmn.2010.11.001
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   de Beer J, 2012, J ARTHROPLASTY, V27, P865, DOI 10.1016/j.arth.2011.12.031
   DeLisa JA, 2005, PHYS MED REHABILITAT, V0, P0
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Faircloth Amanda, 2015, AANA J, V83, P289
   Gagliese L, 1997, PAIN, V70, P3, DOI 10.1016/0304-3959(77)90032-X
   Gasperini G, 2014, INT J ORAL MAX SURG, V43, P868, DOI 10.1016/j.ijom.2014.02.015
   Golbin A KH, 2004, SLEEP PSYCHIATRY, V1st, P0
   Hauck M, 2013, PAIN, V154, P539, DOI 10.1016/j.pain.2012.12.016
   Herr K, 2011, J PAIN, V12, PS3, DOI 10.1016/j.jpain.2010.11.011
   Hjelmstedt A, 2010, ACTA OBSTET GYN SCAN, V89, P1453, DOI 10.3109/00016349.2010.514323
   Hsieh LLC, 2004, PREV MED, V39, P168, DOI 10.1016/j.ypmed.2004.01.036
   Karimipour F, 2012, EFFECT ACUPRESSURE S, V0, P0
   Kermanshahi S, 2010, J KERMANSHAH U MED S, V13, P0
   King J, 2004, BREAST CANC ANSWERS, V0, P0
   Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015
   Kwekkeboom KL, 2010, J PAIN SYMPTOM MANAG, V39, P126, DOI 10.1016/j.jpainsymman.2009.05.022
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Mahmodzadeh Ardakani H, 2012, J URMIA NURSING MIDW, V10, P0
   Moore DJ, 2013, PAIN, V154, P190, DOI 10.1016/j.pain.2012.07.016
   PALEY CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.PUB3
   RICHARDSON PH, 1986, PAIN, V24, P15, DOI 10.1016/0304-3959(86)90023-0
   Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233
   Rose L, 2012, AM J CRIT CARE, V21, P251, DOI 10.4037/ajcc2012611
   Song HJ, 2015, COMPLEMENT THER MED, V23, P68, DOI 10.1016/j.ctim.2014.11.002
   Wong C L, 2010, COMPLEMENT THER CLIN PRACT, V16, P64, DOI 10.1016/j.ctcp.2009.10.002
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Yuan C-S, 2003, TEXTBOOK OF COMPLEMENTARY AND ALTERNATIVE MEDICINES, V0, P0
NR 34
TC 18
Z9 22
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1322-7114
EI 1440-172X
J9 INT J NURS PRACT
JI Int. J. Nurs. Pract.
PD APR 15
PY 2017
VL 23
IS 2
BP 
EP 
DI 10.1111/ijn.12513
PG 7
WC Nursing
SC Nursing
GA ER1IT
UT WOS:000398544300003
PM 28058748
DA 2026-01-16
ER

PT J
AU Roberts, K
   Rickett, K
   Greer, R
   Woodward, N
AF Roberts, Kate
   Rickett, Kirsty
   Greer, Ristan
   Woodward, Natasha
TI Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis
SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
LA English
DT Review
DE Aromatase inhibitors; Letrozole; Exemestane; Anastrozole; AIMSS; Musculoskeletal symptoms; Arthralgias; Breast cancer
ID adjuvant anastrozole therapy; randomized clinical-trial; quality-of-life; induced arthralgia; joint symptoms; double-blind; risk-factors; bone pain; follow-up; phase-ii
AB Aromatase Inhibitors (Al) are widely used for the adjuvant treatment of hormone receptor positive breast cancers in the post-menopausal population. AI are often associated with significant joint and muscular symptoms; symptoms that are commonly referred to as aromatase inhibitor-associated musculoskeletal syndrome (AIMSS). AIMSS adversely impacts health-related quality of life of many patients, and reduces Al compliance. Although there are informal practice recommendations, the limited current level of evidence for management of AIMSS for breast cancer patients on aromatase inhibitors has made development of formal guidelines challenging, and remains an unmet need. This is the first systematic review to consider the evidence for all pharmacological and non-pharmacological interventions in the treatment of AIMSS, including physical therapy, acupuncture and complementary therapies. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Roberts, Kate; Woodward, Natasha] Mater Hlth Serv, Dept Med Oncol, Brisbane, Qld, Australia.
   [Rickett, Kirsty; Greer, Ristan; Woodward, Natasha] Univ Queensland, Brisbane, Qld, Australia.
   [Greer, Ristan; Woodward, Natasha] Mater Med Res Inst Mater Hlth Serv, Brisbane, Qld, Australia.
C3 Mater Health Services; University of Queensland; Mater Health Services; University of Queensland; Mater Research
RP Roberts, K (corresponding author), Mater Hlth Serv, Dept Med Oncol, Brisbane, Qld, Australia.
EM Kate.Roberts@health.q1d.gov.au
CR Unknown -, 2016, NATURAL MED COMPREHE, V0, P0
   Aydiner A, 2013, BREAST, V22, P121, DOI 10.1016/j.breast.2013.01.014
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Birrell S, 2010, TESTOSTERONE UNDECAN, V69, P0
   Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Burstein HJ, 2007, BREAST, V16, P223, DOI 10.1016/j.breast.2007.01.011
   Cantarero-Villanueva I, 2013, CLIN REHABIL, V27, P123, DOI 10.1177/0269215512448256
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Coates AS, 2007, J CLIN ONCOL, V25, P486, DOI 10.1200/JCO.2006.08.8617
   Coleman RE, 2008, CANCER TREAT REV, V34, P275, DOI 10.1016/j.ctrv.2007.10.004
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6
   DeNysschen CA, 2014, EUR J CANCER CARE, V23, P493, DOI 10.1111/ecc.12155
   Deshpande Prasanna R, 2011, PERSPECT CLIN RES, V2, P137, DOI 10.4103/2229-3485.86879
   Fields J, 2015, A FEASIBILITY STUDY OF A NORDIC WALKING INTERVENTION FOR WOMEN EXPERIENCING AROMATASE INHIBITOR ASSOCIATED ARTHRALGIA, V0, P0
   Galantino ML, 2013, ALTERN THER HEALTH M, V19, P38
   Galantino ML, 2012, INTEGR CANCER THER, V11, P313, DOI 10.1177/1534735411413270
   Goss PE, 2016, NEW ENGL J MED, V375, P209, DOI 10.1056/NEJMoa1604700
   Greenlee H, 2013, SUPPORT CARE CANCER, V21, P1077, DOI 10.1007/s00520-012-1628-z
   Hadji P, 2014, ANN ONCOL, V25, P372, DOI 10.1093/annonc/mdt513
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Henry NL, 2011, CANCER-AM CANCER SOC, V117, P5469, DOI 10.1002/cncr.26230
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6
   Ingle JN, 2006, BREAST CANCER RES TR, V99, P295, DOI 10.1007/s10549-006-9207-y
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Jacobsen PB, 2015, PSYCHO-ONCOLOGY, V24, P1578, DOI 10.1002/pon.3756
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kadakia KC, 2016, ASCO ANN M P, V0, P0
   Khan QJ, 2012, J CLIN ONCOL, V30, P0
   Khan QJ, 2010, BREAST CANCER RES TR, V119, P111, DOI 10.1007/s10549-009-0495-x
   Kiyomi A, 2015, J CANCER, V6, P367, DOI 10.7150/jca.10695
   Kubo M, 2012, ANTICANCER RES, V32, P2331
   Laroche F, 2014, J PAIN, V15, P293, DOI 10.1016/j.jpain.2013.11.004
   Lash BW, 2011, J CLIN ONCOL, V29, P0, DOI 10.1200/jco.2011.29.15_suppl.e19725
   Lintermans A, 2013, ANN ONCOL, V24, P350, DOI 10.1093/annonc/mds290
   Liu P, 2014, GENET MOL RES, V13, P5285, DOI 10.4238/2014.July.24.7
   Lohrisch CA, 2011, J CLIN ONCOL, V29, P0, DOI 10.1200/jco.2011.29.15_suppl.636
   Lustberg MB, 2015, CANC RES, V75, P0
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Massimino K, 2011, J CLIN ONCOL, V29, P0, DOI 10.1200/jco.2011.29.27_suppl.170
   Menas Pamela, 2012, J ONCOL PHARM PRACT, V18, P387, DOI 10.1177/1078155211434853
   Miller WR, 2003, J STEROID BIOCHEM, V86, P413, DOI 10.1016/S0960-0760(03)00352-2
   Muslimani AA, 2009, CLIN BREAST CANCER, V9, P34, DOI 10.3816/CBC.2009.n.006
   Muss HB, 2008, J CLIN ONCOL, V26, P1956, DOI 10.1200/JCO.2007.12.6334
   Nyrop KA, 2014, J GERIATR ONCOL, V5, P148, DOI 10.1016/j.jgo.2013.12.002
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Olivo SA, 2008, PHYS THER, V88, P156, DOI 10.2522/ptj.20070147
   Partridge AH, 2008, J CLIN ONCOL, V26, P556, DOI 10.1200/JCO.2007.11.5451
   Pavuluri MN, 2004, J AM ACAD CHILD PSY, V43, P528, DOI 10.1097/00004583-200405000-00006
   Presant CA, 2007, CLIN BREAST CANCER, V7, P775, DOI 10.3816/CBC.2007.n.038
   Prieto-Alhambra D, 2011, BREAST CANCER RES TR, V125, P869, DOI 10.1007/s10549-010-1075-9
   Rastelli AL, 2011, BREAST CANCER RES TR, V129, P107, DOI 10.1007/s10549-011-1644-6
   Regan MM, 2011, LANCET ONCOL, V12, P1101, DOI 10.1016/S1470-2045(11)70270-4
   Rosati MS, 2011, J CLIN ONCOL, V29, P0, DOI 10.1200/jco.2011.29.15_suppl.533
   Santa-Maria CA, 2014, J CLIN ONCOL, V32, P0, DOI 10.1200/jco.2014.32.15_suppl.9615
   Schwarzer G, 2016, METAL GEN PACKAGE ME, V0, P0
   Sestak I, 2009, J CLIN ONCOL, V27, P4961, DOI 10.1200/JCO.2009.22.0236
   Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Spathis A, 2014, J CLIN ONCOL, V32, P1882, DOI 10.1200/JCO.2013.54.4346
   The Cochrane Collaboration, 2011, COCHRANE HDB SYSTEMA, V0, P0
   Xepapadakis G, 2010, EJC SUPPL, V8, P164, DOI 10.1016/S1359-6349(10)70393-1
   Zhang QY, 2010, AM J CLIN ONCOL-CANC, V33, P557, DOI 10.1097/COC.0b013e3181cae782
NR 69
TC 51
Z9 62
U1 1
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1040-8428
EI 1879-0461
J9 CRIT REV ONCOL HEMAT
JI Crit. Rev. Oncol./Hematol.
PD MAR 15
PY 2017
VL 111
IS 
BP 66
EP 80
DI 10.1016/j.critrevonc.2017.01.010
PG 15
WC Oncology; Hematology
SC Oncology; Hematology
GA EO8RR
UT WOS:000396958100008
PM 28259297
DA 2026-01-16
ER

PT J
AU Brown, ML
   Rojas, E
   Gouda, S
AF Brown, Melanie L.
   Rojas, Enrique
   Gouda, Suzanne
TI A Mind-Body Approach to Pediatric Pain Management
SO CHILDREN-BASEL
LA English
DT Review
DE mind-body medicine; pain management; pediatrics; acupuncture; yoga; meditation; hypnosis
ID mindfulness meditation; stress reduction; opioid prescriptions; acupuncture stimulation; behavioral medicine; cost-effectiveness; abdominal-pain; limbic system; young-adults; back-pain
AB Pain is a significant public health problem that affects all populations and has significant financial, physical and psychological impact. Opioid medications, once the mainstay of pain therapy across the spectrum, can be associated with significant morbidity and mortality. Centers for Disease and Control (CDC) guidelines recommend that non-opioid pain medications are preferred for chronic pain outside of certain indications (cancer, palliative and end of life care). Mindfulness, hypnosis, acupuncture and yoga are four examples of mind-body techniques that are often used in the adult population for pain and symptom management. In addition to providing significant pain relief, several studies have reported reduced use of opioid medications when mind-body therapies are implemented. Mind-body medicine is another approach that can be used in children with both acute and chronic pain to improve pain management and quality of life.
C1 [Brown, Melanie L.; Rojas, Enrique; Gouda, Suzanne] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA.
   [Brown, Melanie L.] Childrens Hosp & Clin Minnesota, Dept Pain Palliat Care & Integrat Med, Minneapolis, MN 55404 USA.
C3 University of Chicago; Children's Hospitals & Clinics of Minnesota
RP Brown, ML (corresponding author), Univ Chicago, Dept Pediat, Chicago, IL 60637 USA.; Brown, ML (corresponding author), Childrens Hosp & Clin Minnesota, Dept Pain Palliat Care & Integrat Med, Minneapolis, MN 55404 USA.
EM melanie.brown@childrensmn.org; erojas@peds.bsd.uchicago.edu; Suzanne.Gouda@uchospitals.edu
FU Coleman Foundation; Oberweiler Foundation; Patient-Centered Outcomes Research Institute (PCORI); PCORI
CR Adams D, 2011, PEDIATRICS, V128, PE1575, DOI 10.1542/peds.2011-1091
   Anand KJS, 2010, PEDIATRICS, V125, PE1208, DOI 10.1542/peds.2009-0489
   ANAND KJS, 1994, CRIT CARE MED, V22, P334, DOI 10.1097/00003246-199402000-00027
   ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   Unknown -, 2015, NHPCOS FACTS FIG HOS, V0, P0
   Asmundson GJG, 2012, PAIN RES MANAG, V17, P397, DOI 10.1155/2012/908061
   Ball TM, 2003, CLIN PEDIATR, V42, P527, DOI 10.1177/000992280304200607
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Biella G, 2001, NEUROIMAGE, V14, P60, DOI 10.1006/nimg.2001.0798
   Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370
   Brands MMMG, 2011, COMPLEMENT THER MED, V19, P109, DOI 10.1016/j.ctim.2011.05.004
   Britton WB, 2014, J SCHOOL PSYCHOL, V52, P263, DOI 10.1016/j.jsp.2014.03.002
   Burke CA, 2010, J CHILD FAM STUD, V19, P133, DOI 10.1007/s10826-009-9282-x
   Carlson LE, 2008, CURR TREAT OPTION ON, V9, P127, DOI 10.1007/s11864-008-0064-2
   Carlsson Christer, 2002, ACUPUNCT MED, V20, P82
   Chaves J, 1993, HDB CLIN HYPNOSIS, V0, PP511, DOI 10.1037/10274-023
   CHAVES JF, 1994, AM J CLIN HYPN, V37, P117, DOI 10.1080/00029157.1994.10403124
   Cho HK, 2016, LARYNGOSCOPE, V126, P608, DOI 10.1002/lary.25721
   Collins J, 1976, AANA J, V44, P62
   de Freitas GRM, 2014, PAIN MED, V15, P807, DOI 10.1111/pme.12332
   Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784
   Dhond RP, 2008, PAIN, V136, P407, DOI 10.1016/j.pain.2008.01.011
   Dhond RP, 2007, PAIN, V128, P8, DOI 10.1016/j.pain.2007.01.001
   Dillworth T, 2012, TRANSL BEHAV MED, V2, P65, DOI 10.1007/s13142-011-0084-5
   Dumas EO, 2008, AAPS J, V10, P537, DOI 10.1208/s12248-008-9056-1
   Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006
   Edenfield TM, 2012, PSYCHOL RES BEHAV MA, V5, P131, DOI 10.2147/PRBM.S34937
   Elvey R L, 1997, J HAND THER, V10, P122
   Evans S, 2010, J PAIN SYMPTOM MANAG, V39, P904, DOI 10.1016/j.jpainsymman.2009.09.018
   Favara-Scacco C, 2001, MED PEDIATR ONCOL, V36, P474, DOI 10.1002/mpo.1112
   FRIEDMAN R, 1995, HEALTH PSYCHOL, V14, P509, DOI 10.1037/0278-6133.14.6.509
   Friedrichsdorf SJ, 2016, CHILDREN-BASEL, V3, P0, DOI 10.3390/children3040042
   Friedrichsdorf Stefan J, 2013, J OPIOID MANAG, V9, P151, DOI 10.5055/jom.2013.0156
   Galantino Mary Lou, 2008, PEDIATR PHYS THER, V20, P66, DOI 10.1097/PEP.0b013e31815f1208
   Gerik SM, 2005, SOUTH MED J, V98, P295, DOI 10.1097/01.SMJ.0000154772.49481.53
   Goldberg DS, 2011, BMC PUBLIC HEALTH, V11, P0, DOI 10.1186/1471-2458-11-770
   Golianu B, 2007, SEMIN PERINATOL, V31, P318, DOI 10.1053/j.semperi.2007.07.007
   Grant JA, 2011, PAIN, V152, P150, DOI 10.1016/j.pain.2010.10.006
   Grant JA, 2010, EMOTION, V10, P43, DOI 10.1037/a0018334
   Grant JA, 2009, PSYCHOSOM MED, V71, P106, DOI 10.1097/PSY.0b013e31818f52ee
   Groenewald CB, 2014, J PAIN, V15, P925, DOI 10.1016/j.jpain.2014.06.002
   Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7
   Han B, 2015, JAMA-J AM MED ASSOC, V314, P1468, DOI 10.1001/jama.2015.11859
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Hashmi JA, 2013, BRAIN, V136, P2751, DOI 10.1093/brain/awt211
   Hassett AL, 2013, J PAIN, V14, P1390, DOI 10.1016/j.jpain.2013.06.010
   Hermesdorf M, 2016, J PAIN, V17, P606, DOI 10.1016/j.jpain.2016.01.474
   Hölzel BK, 2008, SOC COGN AFFECT NEUR, V3, P55, DOI 10.1093/scan/nsm038
   Hölzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671
   Hoffart C, 2014, ARTHRITIS RHEUMATOL, V66, PS201, DOI 10.1002/art.38581
   Hooker KE, 2008, GESTALT REVIEW, V12, P75, DOI 10.5325/GESTALTREVIEW.12.1.0075
   Hsieh JC, 2001, NEUROSCI LETT, V307, P105, DOI 10.1016/S0304-3940(01)01952-8
   Hui KKS, 2010, AUTON NEUROSCI-BASIC, V157, P81, DOI 10.1016/j.autneu.2010.03.022
   Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F
   Jain G, 2014, PAIN PHYSICIAN, V17, P109
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Joyce A, 2010, ADV SCH MENT HEALTH, V3, P17, DOI 10.1080/1754730X.2010.9715677
   KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3
   KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519
   KABATZINN J, 1992, AM J PSYCHIAT, V149, P936
   Kelly KM, 2004, EUR J CANCER, V40, P2041, DOI 10.1016/j.ejca.2004.05.012
   Kemper KJ, 2000, PEDIATRICS, V105, P941
   King S, 2011, PAIN, V152, P2729, DOI 10.1016/j.pain.2011.07.016
   Kohen DP, 2014, CHILDREN-BASEL, V1, P74, DOI 10.3390/children1020074
   Kraag G, 2006, J SCHOOL PSYCHOL, V44, P449, DOI 10.1016/j.jsp.2006.07.001
   Kuehn BM, 2007, JAMA-J AM MED ASSOC, V297, P249, DOI 10.1001/jama.297.3.249
   Laengler A, 2008, EUR J CANCER, V44, P2233, DOI 10.1016/j.ejca.2008.07.020
   Lafferty WE, 2006, COMPLEMENT THER MED, V14, P100, DOI 10.1016/j.ctim.2006.01.009
   Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19
   Lee AA, 2006, JOURNAL OF CHINESE MEDICINE, V0, P21
   Lee MS, 2011, CHIN J INTEGR MED, V17, P187, DOI 10.1007/s11655-011-0665-7
   Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0
   Lu DP, 2013, MED ACUPUNCT, V25, P311, DOI 10.1089/acu.2012.0921
   Ludwig DS, 2008, JAMA-J AM MED ASSOC, V300, P1350, DOI 10.1001/jama.300.11.1350
   Lund I, 2016, J PAIN RES, V9, P157, DOI 10.2147/JPR.S55580
   Lundeberg T, 2002, INT CONGR SER, V1238, P3, DOI 10.1016/S0531-5131(02)00416-8
   Manchikanti Kavita N, 2008, J OPIOID MANAG, V4, P271, DOI 10.5055/jom.2008.0031
   Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014
   Mano KEJ, 2013, ALTERN THER HEALTH M, V19, P8
   Mathews L, 2011, INDIAN J PALLIAT CAR, V17, P70, DOI 10.4103/0973-1075.76247
   McCracken LM, 2007, PAIN, V131, P63, DOI 10.1016/j.pain.2006.12.013
   McGeown WJ, 2015, PSYCHIAT RES-NEUROIM, V231, P151, DOI 10.1016/j.pscychresns.2014.11.015
   McLellan AT, 2008, JAMA-J AM MED ASSOC, V300, P2672, DOI 10.1001/jama.2008.793
   MELZACK R, 1977, PAIN, V3, P3, DOI 10.1016/0304-3959(77)90032-X
   MILLER JJ, 1995, GEN HOSP PSYCHIAT, V17, P192, DOI 10.1016/0163-8343(95)00025-M
   Molassiotis Alexander, 2004, EUR J ONCOL NURS, V8, P50, DOI 10.1016/S1462-3889(03)00054-1
   Montgomery GH, 2000, INT J CLIN EXP HYP, V48, P138, DOI 10.1080/00207140008410045
   Morgan D, 2003, PSYCHOTHER RES, V13, P123, DOI 10.1080/713869628
   Morone NE, 2008, PAIN, V134, P310, DOI 10.1016/j.pain.2007.04.038
   Nahin RL, 2016, MAYO CLIN PROC, V91, P1292, DOI 10.1016/j.mayocp.2016.06.007
   Napadow V, 2007, PAIN, V130, P254, DOI 10.1016/j.pain.2006.12.003
   Niemtzow RC, 2015, MED ACUPUNCT, V27, P344, DOI 10.1089/acu.2014.1055
   Niemtzow RC, 2007, MED ACUPUNCT, V19, P225, DOI 10.1089/acu.2007.0603
   Ochi JW, 2013, INT J PEDIATR OTORHI, V77, P2058, DOI 10.1016/j.ijporl.2013.10.008
   Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512
   Post-White Janice, 2005, SEMIN ONCOL NURS, V21, P107
   Rainville P, 1999, J COGNITIVE NEUROSCI, V11, P110, DOI 10.1162/089892999563175
   Rainville P, 2002, J COGNITIVE NEUROSCI, V14, P887, DOI 10.1162/089892902760191117
   Robbins CJ, 2002, COGN BEHAV PRACT, V9, P50, DOI 10.1016/S1077-7229(02)80040-2
   Rogovik AL, 2007, CAN FAM PHYSICIAN, V53, P823
   Rosenzweig S, 2010, J PSYCHOSOM RES, V68, P29, DOI 10.1016/j.jpsychores.2009.03.010
   Sibinga EMS, 2013, PREV MED, V57, P799, DOI 10.1016/j.ypmed.2013.08.027
   Simons LE, 2015, PAIN, V156, P1511, DOI 10.1097/j.pain.0000000000000199
   Slover Robin, 2010, ADV PEDIATR, V57, P141, DOI 10.1016/j.yapd.2010.08.009
   Sobel DS, 2000, PROG BRAIN RES, V122, P393
   Sobel DS, 2000, JAMA-J AM MED ASSOC, V284, P1705, DOI 10.1001/jama.284.13.1705
   Stevens BJ, 2011, CAN MED ASSOC J, V183, PE403, DOI 10.1503/cmaj.101341
   Taylor EM, 2008, PAIN RES MANAG, V13, P25, DOI 10.1155/2008/478102
   Terhune DB, 2015, NEUROPHYSIOL CLIN, V45, P177, DOI 10.1016/j.neucli.2014.10.003
   TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P
   Thera N, 1962, HEART BUDDHIST MEDIT, V0, P0
   THOMAS M, 1991, AM J CHINESE MED, V19, P95, DOI 10.1142/S0192415X91000156
   Tsai SL, 2016, MED ACUPUNCT, V28, P293, DOI 10.1089/acu.2016.29027.slt.correx
   Tsai SL, 2016, ANN EMERG MED, V68, P583, DOI 10.1016/j.annemergmed.2016.05.006
   Vallath N, 2010, INDIAN J PALLIAT CAR, V16, P1, DOI 10.4103/0973-1075.63127
   Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478
   Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401
   Wang BG, 1997, ANESTH ANALG, V85, P406, DOI 10.1097/00000539-199708000-00029
   Woolery A, 2004, ALTERN THER HEALTH M, V10, P60
   Woolf CJ, 2010, J CLIN INVEST, V120, P3742, DOI 10.1172/JCI45178
   Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133
   Wu MT, 2002, NEUROIMAGE, V16, P1028, DOI 10.1006/nimg.2002.1145
   Yaster M, 1996, PEDIATRICS, V98, P135
   Zeidan F, 2012, NEUROSCI LETT, V520, P165, DOI 10.1016/j.neulet.2012.03.082
   Zeidan F, 2010, J PAIN, V11, P199, DOI 10.1016/j.jpain.2009.07.015
   ZELTZER L, 1982, J PEDIATR-US, V101, P1032
   Zeltzer LK, 2002, J PAIN SYMPTOM MANAG, V24, P437, DOI 10.1016/S0885-3924(02)00506-7
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zheng Z, 2008, EUR J PAIN, V12, P671, DOI 10.1016/j.ejpain.2007.10.003
NR 136
TC 34
Z9 41
U1 1
U2 28
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9067
J9 CHILDREN-BASEL
JI Children-Basel
PD JUN 15
PY 2017
VL 4
IS 6
BP 
EP 
DI 10.3390/children4060050
PG 13
WC Pediatrics
SC Pediatrics
GA EZ0TW
UT WOS:000404419400008
PM 28632194
DA 2026-01-16
ER

PT J
AU He, YH
   Liu, YH
   May, BH
   Zhang, AL
   Zhang, HB
   Lu, CJ
   Yang, LH
   Guo, XF
   Xue, CC
AF He, Yihan
   Liu, Yihong
   May, Brian H.
   Zhang, Anthony Lin
   Zhang, Haibo
   Lu, ChuanJian
   Yang, Lihong
   Guo, Xinfeng
   Xue, Charlie Changli
TI Effectiveness of acupuncture for cancer pain: protocol for an umbrella review and meta-analyses of controlled trials
SO BMJ OPEN
LA English
DT Review
ID quality-of-life; traditional chinese medicine; randomized controlled-trial; breast-cancer; symptom management; systematic reviews; clinical-research; palliative care; arthralgia; guidelines
AB Introduction The National Comprehensive Cancer Network guidelines for adult cancer pain indicate that acupuncture and related therapies may be valuable additions to pharmacological interventions for pain management. Of the systematic reviews related to this topic, some concluded that acupuncture was promising for alleviating cancer pain, while others argued that the evidence was insufficient to support its effectiveness. Methods and analysis This review will consist of three components: (1) synthesis of findings from existing systematic reviews; (2) updated meta-analyses of randomised clinical trials and (3) analyses of results of other types of clinical studies. We will search six English and four Chinese biomedical databases, dissertations and grey literature to identify systematic reviews and primary clinical studies. Two reviewers will screen results of the literature searches independently to identify included reviews and studies. Data from included articles will be abstracted for assessment, analysis and summary. Two assessors will appraise the quality of systematic reviews using Assessment of Multiple Systematic Reviews; assess the randomised controlled trials using the Cochrane Collaboration's risk of bias tool and other types of studies according to the Newcastle-Ottawa Scale. We will use 'summary of evidence' tables to present evidence from existing systematic reviews and meta-analyses. Using the primary clinical studies, we will conduct meta-analysis for each outcome, by grouping studies based on the type of acupuncture, the comparator and the specific type of pain. Sensitivity analyses are planned according to clinical factors, acupuncture method, methodological characteristics and presence of statistical heterogeneity as applicable. For the non-randomised studies, we will tabulate the characteristics, outcome measures and the reported results of each study. Consistencies and inconsistencies in evidence will be investigated and discussed. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluation approach to evaluate the quality of the overall evidence. Ethics and dissemination There are no ethical considerations associated with this review. The findings will be disseminated in peer-reviewed journals or conference presentations.
C1 [He, Yihan; Liu, Yihong; May, Brian H.; Zhang, Anthony Lin; Zhang, Haibo; Lu, ChuanJian; Yang, Lihong; Guo, Xinfeng; Xue, Charlie Changli] RMIT Univ, China Australia Int Res Ctr Chinese Med, Melbourne, Vic, Australia.
   [He, Yihan; Liu, Yihong; Zhang, Haibo; Lu, ChuanJian; Yang, Lihong; Guo, Xinfeng; Xue, Charlie Changli] Guangdong Prov Hosp Chinese Med, Guangdong Prov Acad Chinese Med Sci, Guangzhou, Guangdong, Peoples R China.
   [He, Yihan; Liu, Yihong; Zhang, Haibo; Lu, ChuanJian; Yang, Lihong; Guo, Xinfeng; Xue, Charlie Changli] Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Guangdong, Peoples R China.
C3 Royal Melbourne Institute of Technology (RMIT); Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Guo, XF; Xue, CC (corresponding author), RMIT Univ, China Australia Int Res Ctr Chinese Med, Melbourne, Vic, Australia.; Guo, XF; Xue, CC (corresponding author), Guangdong Prov Hosp Chinese Med, Guangdong Prov Acad Chinese Med Sci, Guangzhou, Guangdong, Peoples R China.; Guo, XF; Xue, CC (corresponding author), Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Guangdong, Peoples R China.
EM drguoxinfeng@163.com; charlie.xue@rmit.edu.au
FU Guangdong Provincial Academy of Chinese Medical Sciences, China; RMIT University through China-Australia International Research Centre for Chinese Medicine; School of Health and Biomedical Sciences, RMIT University
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Aromataris E, 2015, INT J EVID-BASED HEA, V13, P132, DOI 10.1097/XEB.0000000000000055
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Ballard M, 2017, RES SYNTH METHODS, V8, P92, DOI 10.1002/jrsm.1229
   Bian ZX, 2014, CHIN J INTEGR MED, V20, P326, DOI 10.1007/s11655-014-1808-4
   Bian ZX, 2011, ANN INTERN MED, V154, P290, DOI 10.7326/0003-4819-154-4-201102150-00016
   Bian ZX, 2011, J ALTERN COMPLEM MED, V17, P97, DOI 10.1089/acm.2010.0353
   Birch S, 2004, J ALTERN COMPLEM MED, V10, P481, DOI 10.1089/1075553041323911
   Birch S, 2008, ACUPUNCTURE RES STRA, V0, P15
   Bruera E, 1991, J PALLIAT CARE, V7, P6
   Burton AW, 2014, CURR OPIN SUPPORT PA, V8, P112, DOI 10.1097/SPC.0000000000000047
   Candido KD, 2017, CURR PAIN HEADACHE R, V21, P0, DOI 10.1007/s11916-017-0613-0
   Carlson CL, 2016, J PAIN RES, V9, P515, DOI 10.2147/JPR.S97759
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Chambers D, 2010, EUR J VASC ENDOVASC, V39, P26, DOI 10.1016/j.ejvs.2009.09.010
   Cheng CW, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/739642
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Cox E, 2009, VALUE HEALTH, V12, P1053, DOI 10.1111/j.1524-4733.2009.00601.x
   Cramer H, 2016, MEDICINE, V95, P2901
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   Deeks JJ, 2003, HEALTH TECHNOL ASSES, V7, Piii, DOI 10.3310/HTA7270
   Fang J, 2013, EVID-BASED COMPL ALT, V2013, P1
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Garcia MK, 2014, INTEGR CANCER THER, V13, P133, DOI 10.1177/1534735413510558
   GRAHAM C, 1980, PAIN, V8, P377, DOI 10.1016/0304-3959(80)90081-0
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA, V0, P0
   Hopewell S, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.MR000010.pub3
   Hsiung WT, 2015, COMPLEMENT THER MED, V23, P339, DOI 10.1016/j.ctim.2015.03.010
   Hu C, 2016, J EVID-BASED INTEGR, V2016, P1, DOI 10.1155/2016/1720239
   Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821
   Jacobsen PB, 2002, ONCOLOGY-NY, V16, P133
   Jefferson T, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000975.pub2
   Johnstone PAS, 2011, J ACUPUNCT MERIDIAN, V4, P209, DOI 10.1016/j.jams.2011.09.011
   Ju Lu, 2016, ZHONGGUO ZHEN JIU, V36, P203
   Kim YC, 2015, CANCER MED-US, V4, P1196, DOI 10.1002/cam4.471
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Lam TY, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1838-5
   Leppert W, 2016, J PHYSIOL PHARMACOL, V67, P787
   Lu A, 2015, EVID-BASED COMPL ALT, V2015, P1
   Lu AP, 2004, WORLD J GASTROENTERO, V10, P1854
   Lu Aiping, 2013, EVID BASED COMPLEMENT ALTERNAT MED, V2013, P723659, DOI 10.1155/2013/723659
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Luckett T, 2013, J PAIN SYMPTOM MANAG, V46, P229, DOI 10.1016/j.jpainsymman.2012.07.021
   Lundeberg T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep049
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Mercadante S, 2015, CURR OPIN ANESTHESIO, V28, P559, DOI 10.1097/ACO.0000000000000224
   NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines, 2017, ADULT CANC PAIN VERS, V0, P0
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Pachman DR, 2012, J CLIN ONCOL, V30, P3687, DOI 10.1200/JCO.2012.41.7238
   Paley CA, 2017, PAIN MANAG, V7, P345, DOI 10.2217/pmt-2017-0018
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Paley CA, 2011, BMJ SUPPORT PALLIAT, V1, P51, DOI 10.1136/bmjspcare-2011-000022
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq020
   Paley CA, 2011, ACUPUNCT MED, V29, P0, DOI 10.1136/aim.2010.003087
   Paul M, 2014, CLIN MICROBIOL INFEC, V20, P97, DOI 10.1111/1469-0691.12489
   Peinemann F, 2014, BMJ OPEN, V4, P0, DOI 10.1136/bmjopen-2013-004720
   Peinemann F, 2011, EUR UROL, V60, P881, DOI 10.1016/j.eururo.2011.06.044
   Peng LH, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009389.pub3
   Petrisor Ba, 2007, INDIAN J ORTHOP, V41, P11, DOI 10.4103/0019-5413.30519
   Phillips JL, 2010, COLLEGIAN, V17, P47, DOI 10.1016/j.colegn.2010.04.007
   Reeves S, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002213.pub2
   Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233
   Schmoor C, 2011, BIOMETRICAL J, V53, P369, DOI 10.1002/bimj.201000154
   Schreiber JA, 2013, ONCOL NURS FORUM, V40, P106, DOI 10.1188/13.ONF.106-108
   Schünemann HJ, 2013, RES SYNTH METHODS, V4, P49, DOI 10.1002/jrsm.1078
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Shea BJ, 2007, BMC MED RES METHODOL, V7, P0, DOI 10.1186/1471-2288-7-10
   Sherman K, 2008, ACUPUNCTURE RES, V0, P0
   Simone CB II, 2012, CLIN J PAIN, V28, P157, DOI 10.1097/AJP.0b013e318223be30
   Song TJ, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-015-0769-z
   Sterne J, 2008, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, V0, P0, DOI DOI 10.1002/9780470712184.CH10
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Tao WW, 2015, ONCOTARGET, V6, P39725, DOI 10.18632/oncotarget.5388
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   VENTAFRIDDA V, 1987, CANCER-AM CANCER SOC, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120
   Wang Cheng-Hsu, 2015, ACTA ANAESTHESIOL TAIWAN, V53, P58, DOI 10.1016/j.aat.2015.05.005
   Wells GA, 2013, RES SYNTH METHODS, V4, P63, DOI 10.1002/jrsm.1077
   Witt CM, 2011, CHIN J INTEGR MED, V17, P166, DOI 10.1007/s11655-011-0662-x
   Wu XL, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep11728
   Yang GS, 2017, CANCER NURS, V40, PE26, DOI 10.1097/NCC.0000000000000409
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zaslawski CJ, 2003, COMPLEMENT THER MED, V11, P11, DOI 10.1016/S0965-2299(02)00116-4
   Zhang CS, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0140825
   Zhong LLD, 2016, CHIN MED-UK, V11, P0, DOI 10.1186/s13020-016-0099-4
NR 94
TC 14
Z9 16
U1 0
U2 34
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD DEC 15
PY 2017
VL 7
IS 12
BP 
EP 
DI 10.1136/bmjopen-2017-018494
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA FU4MH
UT WOS:000423826700141
PM 29229658
DA 2026-01-16
ER

PT J
AU Greenlee, H
   DuPont-Reyes, MJ
   Balneaves, LG
   Carlson, LE
   Cohen, MR
   Deng, G
   Johnson, JA
   Mumber, M
   Seely, D
   Zick, SM
   Boyce, LM
   Tripathy, D
AF Greenlee, Heather
   DuPont-Reyes, Melissa J
   Balneaves, Lynda G
   Carlson, Linda E
   Cohen, Misha R
   Deng, Gary
   Johnson, Jillian A
   Mumber, Matthew
   Seely, Dugald
   Zick, Suzanna M
   Boyce, Lindsay M
   Tripathy, Debu
TI Clinical practice guidelines on the evidence-based use of integrative therapies
SO CA: a cancer journal for clinicians
LA English
DT Journal Article
DE acupressure; acupuncture; breast cancer; complementary therapies; integrative medicine; integrative oncology; massage; meditation; music therapy; stress management; yoga
AB Answer questions and earn CME/CNE Patients with breast cancer commonly use  complementary and integrative therapies as supportive care during cancer  treatment and to manage treatment-related side effects. However, evidence  supporting the use of such therapies in the oncology setting is limited. This  report provides updated clinical practice guidelines from the Society for  Integrative Oncology on the use of integrative therapies for specific clinical  indications during and after breast cancer treatment, including anxiety/stress,  depression/mood disorders, fatigue, quality of life/physical functioning,  chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced  peripheral neuropathy, pain, and sleep disturbance. Clinical practice guidelines  are based on a systematic literature review from 1990 through 2015. Music  therapy, meditation, stress management, and yoga are recommended for  anxiety/stress reduction. Meditation, relaxation, yoga, massage, and music  therapy are recommended for depression/mood disorders. Meditation and yoga are  recommended to improve quality of life. Acupressure and acupuncture are  recommended for reducing chemotherapy-induced nausea and vomiting.  Acetyl-L-carnitine is not recommended to prevent chemotherapy-induced peripheral  neuropathy due to a possibility of harm. No strong evidence supports the use of  ingested dietary supplements to manage breast cancer treatment-related side  effects. In summary, there is a growing body of evidence supporting the use of  integrative therapies, especially mind-body therapies, as effective supportive  care strategies during breast cancer treatment. Many integrative practices,  however, remain understudied, with insufficient evidence to be definitively  recommended or avoided. CA Cancer J Clin 2017;67:194-232. © 2017 American Cancer  Society.
C1 Assistant Professor, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
   Member, Herbert Irving Comprehensive Cancer Center, Columbia University, New 
   Doctoral Fellow, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
   Associate Professor, College of Nursing, Rady Faculty of Health Sciences, Winnipeg, MB, Canada.
   Professor, Department of Oncology, University of Calgary, Calgary, AB, Canada.
   Adjunct Professor, American College of Traditional Chinese Medicine at California Institute of Integral Studies, San Francisco, CA.
   Clinic Director, Chicken Soup Chinese Medicine, San Francisco, CA.
   Medical Director, Integrative Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
   Post-Doctoral Scholar, Department of Biobehavioral Health, The Pennsylvania State University, University Park, PA.
   Radiation Oncologist, Harbin Clinic, Rome, GA.
   Executive Director, Ottawa Integrative Cancer Center, Ottawa, ON, Canada.
   Executive Director of Research, Canadian College of Naturopathic Medicine, 
   Research Associate Professor, Department of Family Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI.
   Research Associate Professor, Department of Nutritional Sciences, School of 
   Research Informationist, Memorial Sloan Kettering Library, Memorial Sloan Kettering Cancer Center, New York, NY.
   Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
NR 0
TC 0
SN 1542-486
EI 0007-923
J9 CA Cancer J Clin
PD APR 25
PY 2017
VL 67
IS 3
BP 194
EP 232
DI 10.3322/caac.21397
PG 38
WC Anxiety; therapy; Breast Neoplasms; complications; Complementary Therapies; Depression; therapy; Fatigue; therapy; Female; Humans; Lymphedema; therapy; Mood Disorders; therapy; Nausea; therapy; Peripheral Nervous System Diseases; therapy; Quality of Life; Sleep Wake Disorders; therapy; Stress, Psychological; therapy; Vomiting; therapy
UT PubMed:28436999
PM 28436999
DA 2017-04-25
ER

PT J
AU Liu, YH
   Ye, Y
   Zheng, JB
   Wang, XQ
   Zhang, Y
   Lin, HS
AF Liu, Yi-Hua
   Ye, Yang
   Zheng, Jia-Bin
   Wang, Xue-Qian
   Zhang, Ying
   Lin, Hong-Sheng
TI Acupuncture for enhancing early recovery of bowel function in cancer: Protocol
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Cancer patients undergoing surgical procedure often suffer from bowel  dysfunction and postoperative ileus (POI). Cancer management for early recovery  of bowel function is still a challenging topic. Acupuncture has been commonly  used in a variety of gastrointestinal diseases. The aim of this study is to  evaluate the effects of acupuncture therapy to reduce the duration of POI and  enhance bowel function in cancer patients. METHODS: We will systematically screen  all randomized controlled trials (RCTs) published through electronically and hand  searching. The following search engines including Medline, EMBASE, Cochrane  CENTRAL, the Cumulative Index to Nursing and Allied Health Literature, Allied and  Complementary Medicine Database, the Chinese Biomedical Literature Database, the  China National Knowledge Infrastructure, VIP Information, Wanfang Data, one  Japanese database (Japan Science and Technology Information Aggregator,  Electronic) and 2 Korean Medical Databases (Korean Studies Information, and Data  Base Periodical Information Academic) will be retrieved. Supplementary sources  will be searched including gray literature, conference proceedings, and potential  identified publications. Two reviewers will independently conduct the trial  inclusion, data extraction and assess the quality of studies. The time to first  passing flatus and time to first bowel motion will be assessed as the primary  outcomes. Adverse effects, time to first bowel sound, visual analog scale (VAS)  pain score, hospital stay, and postoperative analgesic requirement will be  measured as secondary outcomes. Methodological quality will be evaluated  according to the Cochrane risk of bias. Details of interventions will be assessed  by the Standards for Reporting Interventions in Controlled Trials of Acupuncture  (STRICTA) checklist. All analyses will be applied by RevMan (version 5.3) and  StataSE (version 12). ETHICS AND DISSEMINATION: This systematic review will  provide up-to-date information on acupuncture therapy for early recovery of bowel  function in cancer patients. This review does not require ethical approval and  will be reported in a peer-reviewed journal and presented at a relevant  conference. TRIAL REGISTRATION NUMBER: PROSPERO CRD42016049633.
C1 Graduate School of Beijing University of Chinese Medicine Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD APR 27
PY 2017
VL 96
IS 17
BP e6644
EP e6644
DI 10.1097/MD.0000000000006644
PG 1
WC Acupuncture Therapy; Humans; Ileus; etiology; Neoplasms; complications; Postoperative Complications; therapy; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic
UT PubMed:28445263
PM 28445263
DA 2017-04-27
ER

PT J
AU Moran, JM
   Fernández, AS
   Pedrera-Zamorano, JD
AF Moran, Jose M
   Fernández, Antonio S
   Pedrera-Zamorano, Juan D
TI Response to "Assessing the Impact of Acupuncture on Pain, Nausea, Anxiety, and
SO Oncology nursing forum
LA English
DT Journal Article
DE acupuncture ; mastectomy; nausea; pain
AB We read with interest the pilot randomized, controlled trial by Quinlan-Woodward  et al. (2016) published in Oncology Nursing Forum about the impact of acupuncture  on pain, nausea, anxiety, and coping in women undergoing a mastectomy. We think  that there are both theoretical and methodologic issues that do not allow the  authors to conclude that their study demonstrated that acupuncture delivered  postoperatively in the hospital after mastectomy can reduce the severity of  symptoms experienced and increase the patient's ability to cope with her  symptoms. .
C1 University of Extremadura.
   Hospital San Pedro de Alcántara.
   University of Extremadura.
NR 0
TC 0
SN 1538-068
EI 
J9 Oncol Nurs Forum
PD AUG 19
PY 2017
VL 44
IS 5
BP 522
EP 524
DI 10.1188/17.ONF.522-524
PG 2
WC Acupuncture Therapy; Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Analgesics; therapeutic use; Anti-Anxiety Agents; therapeutic use; Antiemetics; therapeutic use; Anxiety; therapy; Breast Neoplasms; surgery; Female; Humans; Mastectomy; adverse effects; Middle Aged; Nausea; therapy; Pain, Postoperative; etiology
UT PubMed:28820520
PM 28820520
DA 2017-08-19
ER

PT J
AU Zhou, K
   Jia, P
   Bhargava, S
   Zhang, Y
   Reza, T
   Peng, YB
   Wang, GG
AF Zhou, Kehua
   Jia, Peng
   Bhargava, Swati
   Zhang, Yong
   Reza, Taslima
   Peng, Yuan Bo
   Wang, Gary G
TI Opioid tapering in patients with prescription opioid use disorder: A
SO Scandinavian journal of pain
LA English
DT Journal Article
DE Chronic non-cancer pain; Medication assisted treatment; Methadone; Opioid use disorder
AB BACKGROUND AND AIMS: Opioid use disorder (OUD) refers to a maladaptive pattern of  opioid use leading to clinically significant impairment or distress. OUD causes,  and vice versa, misuses and abuse of opioid medications. Clinicians face daily  challenges to treat patients with prescription opioid use disorder. An  evidence-based management for people who are already addicted to opioids has been  identified as the national priority in the US; however, options are limited in  clinical practices. In this study, we aimed to explore the success rate and  important adjuvant medications in the medication assisted treatment with  temporary use of methadone for opioid discontinuation in patients with  prescription OUD. METHODS: This is a retrospective chart review performed at a  private physician office for physical medicine and rehabilitation. We reviewed  all medical records dated between December 1st, 2011 and August 30th, 2016. The  initial evaluation of the included patients (N=140) was completed between  December 1st, 2011 and December 31st, 2014. They all have concumittant  prescription OUD and chronic non-cancer pain. The patients (87 female and 53  male) were 46.7±12.7 years old, and had a history of opioid use of 7.7±6.1 years.  All patients received the comprehensive opioid taper treatments (including  interventional pain management techniques, psychotherapy, acupuncture, physical  modalities and exercises, and adjuvant medications) on top of the medication  assisted treatment using methadone (transient use). Opioid tapering was  considered successful when no opioid medication was used in the last patient  visit. RESULTS: The 140 patients had pain of 9.6±8.4 years with 8/10 intensity  before treatment which decreased after treatment in all comparisons (p<0.001 for  all). Opioids were successfully tapered off in 39 (27.9%) patients after 6.6±6.7  visits over 8.8±7.2 months; these patients maintained opioid abstinence over  14.3±13.0 months with regular office visits. Among the 101 patients with  unsuccessful opioid tapering, 13 patients only visited the outpatient clinic  once. Significant differences were found between patients with and without  successful opioid tapering in treatment duration, number of clinic visits, the  use of mirtazepine, bupropion, topiramate, and trigger point injections with the  univariate analyses. The use of mirtazepine (OR, 3.75; 95% CI, 1.48-9.49),  topiramate (OR, 5.61; 95% CI, 1.91-16.48), or bupropion (OR, 2.5; 95% CI,  1.08-5.81) was significantly associated with successful opioid tapering. The  associations remain significant for mirtazepine and topiramate (not bupropion) in  different adjusted models. CONCLUSIONS: With comprehensive treatments, 27.9% of  patients had successful opioid tapering with opioid abstinence for over a year.  The use of mirtazepine, topiramate, or likely bupropion was associated with  successful opioid tapering in the medication assisted treatment with temporary  use of methadone. Opioid tapering may be a practical option and should be  considered for managing prescription OUD. IMPLICATIONS: For patients with OUD,  indefinite opioid maintenance treatment may not be necessary. Considering the  ethical values of autonomy, nonmaleficence, and beneficence, clinicians should  provide patients with OUD the option of opioid tapering.
C1 Catholic Health System Internal Medicine Training Program, Sisters of Charity Hospital, University at Buffalo, 2157 Main Street, Buffalo, NY 14214, UnitedStates. 
   Faculty of Geo-information Science and Earth Observation (ITC), University of Twente, Enschede 7500, The Netherlands. 
   Catholic Health System Internal Medicine Training Program, Sisters of Charity Hospital, University at Buffalo, 2157 Main Street, Buffalo, NY 14214, UnitedStates. 
   School of Public Health and Health Management, Chongqing Medical University, Chongqing 400016, China. 
   Academic Buffalonias in Physical Medicine and Rehabilitation, 2121 Main St #210, Buffalo, NY 14214, United States
   Avalon University School of Medicine,Youngstown, OH, United States. 
   Department of Psychology, University of Texas at Arlington, 501 S Nedderman Dr., Arlington, TX 76019-0528, United States. 
   Catholic Health System Internal Medicine Training Program, Sisters of Charity Hospital, University at Buffalo, 2157 Main Street, Buffalo, NY 14214, UnitedStates
   Academic Buffalonias in Physical Medicine and Rehabilitation, 2121 MainSt #210, Buffalo, NY 14214, United States.
EM angwang2017@gmail.com
NR 0
TC 0
SN 1877-887
EI 
J9 Scand J Pain
PD OCT 11
PY 2017
VL 17
IS 
BP 167
EP 173
DI 10.1016/j.sjpain.2017.09.005
PG 6
WC Analgesics, Opioid; administration & dosage; Chronic Pain; drug therapy; Drug Prescriptions; Female; Humans; Male; Methadone; administration & dosage; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; drug therapy; Pain; drug therapy; Pain Management; methods; Retrospective Studies
UT PubMed:28988103
PM 28988103
DA 2017-10-11
ER

PT J
AU Liang, Y
   Du, JY
   Fang, JF
   Fang, RY
   Zhou, J
   Shao, XM
   Jiang, YL
   Chen, YT
   Fang, JQ
AF Liang, Yi
   Du, Jun-Ying
   Fang, Jun-Fan
   Fang, Ruo-Yi
   Zhou, Jie
   Shao, Xiao-Mei
   Jiang, Yong-Liang
   Chen, Yi-Tian
   Fang, Jian-Qiao
TI Alleviating Mechanical Allodynia and Modulating Cellular Immunity Contribute to
SO Integrative cancer therapies
LA English
DT Journal Article
DE analgesia; bone cancer pain; cellular immunity; electroacupuncture; mechanical allodynia; morphine; naloxone
AB HYPOTHESIS: Electroacupuncture (EA) has been used as an alternative analgesic  therapy for hundreds of years, yet its analgesic potency and therapeutic  advantage against bone cancer pain (BCP) in comparison with morphine remains  unclear. This study aimed to investigate the effects of EA on mechanical  allodynia and cellular immunity of BCP rats, and to further explore the potential  mechanism. METHODS: The BCP model was established by implanting Walker 256  mammary gland carcinoma cells into the left tibia of adult female Sprague-Dawley  rats. EA (dilatational wave, 2/100 Hz, 0.5 mA-1mA-1.5 mA for 10 minutes each  intensity) was applied bilaterally to Zusanli (ST 36) and Kunlun (BL 60) for 30  minutes. Both EA stimulation and morphine (10 mg/kg, intraperitoneally) was given  once every other day. Naloxone (0.3 mg/kg, intraperitoneally) was injected at 30  minutes prior to EA. Mechanical allodynia were demonstrated by paw withdrawal  thresholds (PWTs) which measured by dynamic plantar aesthesiometer. T cell  proliferation, percentage of CD3(+), CD4(+) and CD8(+) T lymphocytes in spleen as  well as expression of interleukin-2 (IL-2) in plasma were detected by WST-8, flow  cytometry, and enzyme-linked immunosorbent assay technique, respectively.  RESULTS: An intratibial inoculation of Walker 256 mammary gland carcinoma cells  significantly decreased PWTs to mechanical stimuli. EA stimulation alleviated  mechanical allodynia in BCP rats, and the analgesic potency of EA was weaker than  that of morphine. In contrast to morphine, EA stimulation of BCP rats increased  splenic concanavalin A (Con A)-induced T cell proliferation and plasma IL-2  content, as well as increased the percentages of splenic CD(3)(+)CD(4)(+) and  CD(3)(+)CD(8)(+) T cell subsets. Moreover, both the analgesic effect and the  partial immunomodulation of EA were suppressed by an intraperitoneal injection of  naloxone. CONCLUSION: EA could significantly alleviate BCP-induced mechanical  allodynia. Although the analgesic effect of EA was weaker than that of morphine,  EA had an immunomodulation effect on cellular immunity. Both analgesic and  immunomodulatory effect of EA might share the same mechanism via the  opioid-mediated pathway, which needs further investigation.
C1 1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   2 The Third Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 
   1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   2 The Third Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
   1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD SEP 6
PY 2017
VL 17
IS 2
BP 401
EP 410
DI 10.1177/1534735417728335
PG 9
WC Animals; Bone Neoplasms; immunology; CD3 Complex; immunology; CD4-Positive T-Lymphocytes; immunology; CD8-Positive T-Lymphocytes; immunology; Cancer Pain; immunology; Cell Proliferation; physiology; Electroacupuncture; methods; Female; Humans; Hyperalgesia; immunology; Immunity, Cellular; immunology; Rats; Rats, Sprague-Dawley
UT PubMed:28870114
PM 28870114
DA 2017-09-06
ER

PT J
AU Rossi, E
   Di, Stefano M
   Firenzuoli, F
   Monechi, MV
   Baccetti, S
AF Rossi, Elio
   Di Stefano, Mariella
   Firenzuoli, Fabio
   Monechi, Maria Valeria
   Baccetti, Sonia
TI Add-On Complementary Medicine in Cancer Care: Evidence in Literature and
SO Medicines (Basel, Switzerland)
LA English
DT Review
DE cancer care; complementary medicines (CM); evidence in literature; integration in public health service
AB Background: According to the literature an increasing number of cancer patients  demand for complementary therapies during their disease. Research has  demonstrated that some of these therapies are effective and safe as adjunctive  treatments in specific symptoms of these patients. Methods: The aims of the paper  are to review the main and recent papers of international literature on the  effectiveness of complementary medicine (CM) therapies on side effects of  anti-cancer protocols and improvement in the quality of life of oncological  patients, and to describe the integration of evidence-based acupuncture, herbal  medicine and homeopathy treatments in Public Cancer Network of the region of  Tuscany. Results: After the review of literature and the approval of a Regional  Resolution, some CM will be introduced in Cancer Departments in Tuscany to  additionally treat cancer-related symptoms and side effects of conventional  cancer therapy: acupuncture for nausea and post-chemotherapy and post-surgery  vomiting, pain, hot flashes of iatrogenic menopause, xerostomia; homeopathy for  hot flashes of iatrogenic menopause and the side effects of radiotherapy; herbal  medicine for cancer-related fatigue, nausea and vomiting, pain, mucositis,  anxiety, and depression. Conclusions: The integration of evidence-based  complementary treatments allows for an effective response to the demand coming  from cancer patients and combines safety and equity of access in public health  systems.
C1 Tuscan Network of Integrative Medicine (TNIM), Regione Toscana, Assessorato al Diritto alla Salute, al Welfare e all'Integrazione socio-sanitaria, DirezioneDiritti di cittadinanza e coesione sociale, Via Taddeo Alderotti 26/N, Firenze50139, Italy. e.rossi@mednat.it.
   Tuscan Network of Integrative Medicine (TNIM), Regione Toscana, Assessorato al Diritto alla Salute, al Welfare e all'Integrazione socio-sanitaria, DirezioneDiritti di cittadinanza e coesione sociale, Via Taddeo Alderotti 26/N, Firenze50139, Italy. m.distefano@mednat.it.
   Tuscan Network of Integrative Medicine (TNIM), Regione Toscana, Assessorato al Diritto alla Salute, al Welfare e all'Integrazione socio-sanitaria, DirezioneDiritti di cittadinanza e coesione sociale, Via Taddeo Alderotti 26/N, Firenze50139, Italy. fabio.firenzuoli@unifi.it.
   Tuscan Network of Integrative Medicine (TNIM), Regione Toscana, Assessorato al Diritto alla Salute, al Welfare e all'Integrazione socio-sanitaria, DirezioneDiritti di cittadinanza e coesione sociale, Via Taddeo Alderotti 26/N, Firenze50139, Italy. valeriamonechi@gmail.com.
   Tuscan Network of Integrative Medicine (TNIM), Regione Toscana, Assessorato al Diritto alla Salute, al Welfare e all'Integrazione socio-sanitaria, DirezioneDiritti di cittadinanza e coesione sociale, Via Taddeo Alderotti 26/N, Firenze50139, Italy. sonia.baccetti@uslcentro.toscana.it.
NR 0
TC 0
SN 2305-632
EI 2305-632
J9 Medicines (Basel)
PD SEP 21
PY 2017
VL 4
IS 1
BP 
EP 
DI 10.3390/medicines4010005
PG 0
UT PubMed:28930222
PM 28930222
DA 2017-09-21
ER

PT J
AU Viscuse, PV
   Price, K
   Millstine, D
   Bhagra, A
   Bauer, B
   Ruddy, KJ
AF Viscuse, Paul V
   Price, Katharine
   Millstine, Denise
   Bhagra, Anjali
   Bauer, Brent
   Ruddy, Kathryn J
TI Integrative medicine in cancer survivors.
SO Current opinion in oncology
LA English
DT Review
AB PURPOSE OF REVIEW: Due to medical advances and an aging population, the number of  cancer survivors continues to rise. Survivors often experience late and long-term  sequelae of cancer and its treatment (e.g., fatigue, pain, fear of recurrence,  and stress). As a result, some patients have utilized or expressed interest in  integrative medicine (IM) modalities for prevention of recurrence, optimizing  health, enhancing quality of life, and managing symptoms. The purpose of this  review is to focus on research published during the past year that informs our  understanding of the utility of IM for cancer survivors. RECENT FINDINGS:  Physical activity, diet, dietary supplements, mind-body modalities, acupuncture,  and massage therapy all may play a role in the management of the physical (e.g.,  fatigue and pain) and emotional (e.g., anxiety and fear) issues faced by cancer  survivors. SUMMARY: IM therapies are appealing to and utilized by many cancer  survivors and may reduce symptom burden. Clinicians who provide cancer  survivorship care may improve patient care by understanding the evidence for and  against their use.
C1 aDepartment of Medicine bDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota cDivision of Women's Health Internal Medicine, Mayo Clinic, Scottsdale,Arizona, USA.
NR 0
TC 0
SN 1531-703
EI 1040-874
J9 Curr Opin Oncol
PD MAY 2
PY 2017
VL 29
IS 4
BP 235
EP 242
DI 10.1097/CCO.0000000000000376
PG 7
WC Acupuncture Therapy; Diet; Dietary Supplements; Exercise; Humans; Massage; Mind-Body Therapies; Neoplasms; mortality; Survivors
UT PubMed:28459738
PM 28459738
DA 2017-05-02
ER

PT J
AU Mazzei, LG
   Bergamaschi, CC
   Silva, MT
   Lopes, LC
AF Mazzei, Lauren Giustti
   Bergamaschi, Cristiane de Cássia
   Silva, Marcus Tolentino
   Lopes, Luciane Cruz
TI Use of IMMPACT domains in clinical trials of acupuncture for chronic pain: a
SO BMJ open
LA English
DT Review
DE acupuncture; chronic pain; methodological survey
AB INTRODUCTION: Pain is one of the most common and most debilitating complaints  among patients. It affects the individual, their relationship with friends and  family, their ability to function at work, and their sociability. Acupuncture is  one of the therapeutic resources for managing chronic pain. Given the variability  of outcome measures in controlled randomised clinical trials on  non-oncologicchronic pain (CRCT-NOCP), the Initiative in Methods, Measurements  and Pain Assessment in Clinical Trials (IMMPACT) recommends six domains to be  covered in evaluating the effectiveness of treatments for chronic pain.  OBJECTIVE: To check whether the methodological quality of outcome reporting in  published trials has used IMMPACT recommendations in measuring CRCT-NOCP outcomes  when acupuncture was used as a treatment. METHOD: This is a methodological study.  We will systematically search for eligible studies in specific databases with a  defined strategy. We will use the MeSHterms of 'acupuncture', 'chronic pain' and  similar terms, without restrictions on idiom. Eligible studies will include those  which are randomised and chose NOCP patients to be treated with acupuncture or  control (sham acupuncture or no acupuncture), recruited after September 2004,  with ≥100 patients. The measured outcomes are to be the presence of outcome  domains recommended by IMMPACT, domains reported by the patient or clinician,  tools used to measure such domains, as well as other features of the studies. We  shall conduct a regression analysis to explore factors which can be associated  with the presence of outcome domains according to IMMPACT recommendations. ETHICS  AND DISSEMINATION: This survey will be submitted for presentation at congresses  and for publication in a scientific journal. The findings obtained in this study  will allow us to measure the quality of the evidence and provide greater  transparency in decisions regarding the use of acupuncture as a viable  alternative to managing chronic pain.
C1 Department of Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, São Paulo, Brazil.
   Department of Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, São Paulo, Brazil.
   Department of Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, São Paulo, Brazil.
   Department of Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, São Paulo, Brazil.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD OCT 1
PY 2017
VL 7
IS 9
BP e014904
EP e014904
DI 10.1136/bmjopen-2016-014904
PG 1
WC Acupuncture Therapy; Chronic Pain; therapy; Humans; Pain Management; methods; Pain Measurement; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome
UT PubMed:28963280
PM 28963280
DA 2017-10-01
ER

PT J
AU Tsaousi, GG
   Pourzitaki, C
   Bilotta, F
AF Tsaousi, Georgia G.
   Pourzitaki, Chryssa
   Bilotta, Federico
TI Prophylaxis of postoperative complications after craniotomy
SO CURRENT OPINION IN ANESTHESIOLOGY
LA English
DT Review
DE craniotomy; postoperative complications; postoperative nausea and vomiting; seizures; thromboprophylaxis
ID venous thromboembolism prophylaxis; brain-tumor surgery; double-blind; intraoperative dexmedetomidine; nausea; management; pain; chemotherapy; acupuncture; anesthesia
AB Purpose of review This review reports an update of the evidence on practices applied for the prevention and management of the most common complications after craniotomy surgery. Recent findings Latest guidelines support the combined thromboprophylaxis with the use of both mechanical and chemical modalities, preferably applied within 24 h after craniotomy. Nevertheless, a heightened risk of minor hemorrhagic events remains an issue of concern. Postoperative nausea and vomiting (PONV) and pain constitute the complications most commonly encountered during the first 24 h postcraniotomy. Recently, neurokinin type-1 receptor antagonists have been tested as adjuncts for PONV prophylaxis with encouraging results, whereas dexmedetomidine and gabapentinoids emerge as promising alternatives for postcraniotomy pain management. The available data for seizure prophylaxis following craniotomy lacks scientific quality; thus, this remains still a debatable issue. Significantly, a growing body of evidence supports the superiority of levetiracetam over the older antiepileptic drugs (AEDs), in terms of efficacy and safety. Summary Optimum management of postoperative complications is incorporated as an integral part of the augmented quality of care in patients undergoing craniotomy surgery, aiming to improve outcomes. This review may serve as a benchmark for neuroanesthetists for heightened clinical awareness and prompt institution of well-documented practices.
C1 [Tsaousi, Georgia G.] Aristotle Univ Thessaloniki, Sch Med, Dept Anesthesiol & ICU, Maiandrou 32, GR-56224 Thessaloniki, Greece.
   [Pourzitaki, Chryssa] Aristotle Univ Thessaloniki, Sch Med, Dept Pharmacol, Thessaloniki, Greece.
   [Bilotta, Federico] Univ Roma La Sapienza, Dept Anesthesiol, Rome, Italy.
C3 Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; Sapienza University Rome
RP Tsaousi, GG (corresponding author), Aristotle Univ Thessaloniki, Sch Med, Dept Anesthesiol & ICU, Maiandrou 32, GR-56224 Thessaloniki, Greece.
EM tsaousig@otenet.gr
CR Alshehri N, 2016, J NEURO-ONCOL, V130, P561, DOI 10.1007/s11060-016-2259-x
   An LX, 2014, AM J CHINESE MED, V42, P1099, DOI 10.1142/S0192415X14500682
   Ansari SF, 2014, J NEURO-ONCOL, V118, P117, DOI 10.1007/s11060-014-1402-9
   Asmussen S, 2017, J NEUROSURG ANESTH, V29, P219, DOI 10.1097/ANA.0000000000000290
   Atsuta J, 2017, J ANESTH, V31, P82, DOI 10.1007/s00540-016-2267-1
   Bergese SD, 2016, FRONT MED-LAUSANNE, V3, P0, DOI 10.3389/fmed.2016.00001
   Bergese SD, 2015, FRONT MED, V2, P0, DOI 10.3389/fmed.2015.00040
   Bergese SD, 2016, FRONT MED-LAUSANNE, V3, P0, DOI 10.3389/fmed.2016.00029
   Bilotta F, 2013, CURR OPIN ANESTHESIO, V26, P517, DOI 10.1097/01.aco.0000432513.92822.c2
   Cote DJ, 2016, J CLIN NEUROSCI, V25, P13, DOI 10.1016/j.jocn.2015.05.053
   Dasenbrock HH, 2015, NEUROSURG FOCUS, V39, P0, DOI 10.3171/2015.10.FOCUS15386
   Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002
   Gruenbaum SE, 2016, CURR OPIN ANESTHESIO, V29, P552, DOI 10.1097/ACO.0000000000000365
   Gupta Priyanka, 2014, ANESTH ESSAYS RES, V8, P72, DOI 10.4103/0259-1162.128914
   Kimmell KT, 2015, J NEUROSURG, V122, P1004, DOI 10.3171/2014.10.JNS14632
   Kong XY, 2015, CLIN NEUROL NEUROSUR, V134, P98, DOI 10.1016/j.clineuro.2015.04.010
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Lockney DT, 2017, WORLD NEUROSURG, V98, P28, DOI 10.1016/j.wneu.2016.10.079
   Nyquist P, 2016, NEUROCRIT CARE, V24, P47, DOI 10.1007/s12028-015-0221-y
   Peng K, 2015, CLIN THER, V37, P1114, DOI 10.1016/j.clinthera.2015.02.011
   Peng YM, 2016, J NEUROSURG ANESTH, V28, P309, DOI 10.1097/ANA.0000000000000230
   Pergolizzi JV, 2012, J CLIN ANESTH, V24, P334, DOI 10.1016/j.jclinane.2011.07.019
   Pourzitaki C, 2016, BRIT J CLIN PHARMACO, V82, P315, DOI 10.1111/bcp.12926
   Rajan S, 2016, J NEUROSURG ANESTH, V28, P282, DOI 10.1097/ANA.0000000000000221
   Rapoport BL, 2010, SUPPORT CARE CANCER, V18, P423, DOI 10.1007/s00520-009-0680-9
   Riva M, 2005, NEUROL SCI, V26, PS40, DOI 10.1007/s10072-005-0404-y
   Ryu JH, 2014, BMC ANESTHESIOL, V14, P0, DOI 10.1186/1471-2253-14-63
   Rocha PAS, 2015, HEADACHE, V55, P733, DOI 10.1111/head.12563
   Sayegh ET, 2014, J NEUROSURG, V121, P1139, DOI 10.3171/2014.7.JNS132829
   Shimony N, 2016, J NEUROSURG, V125, P1513, DOI 10.3171/2015.10.JNS151516
   Sjåvik K, 2016, WORLD NEUROSURG, V88, P320, DOI 10.1016/j.wneu.2015.12.077
   Song J, 2016, J NEUROSURG ANESTH, V28, P14, DOI 10.1097/ANA.0000000000000190
   Titsworth WL, 2016, J NEUROSURG, V125, P1523, DOI 10.3171/2015.10.JNS15698
   Tricco AC, 2015, BMC PHARMACOL TOXICO, V16, P0, DOI 10.1186/2050-6511-16-1
   Tsaousi G, 2016, PAIN PRACTICE, V0, P1
   Vadivelu N, 2016, J PAIN RES, V9, P37, DOI 10.2147/JPR.S85782
   Weston J, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007286.pub3
   Yang Y, 2015, J CLIN NEUROSCI, V22, P1227, DOI 10.1016/j.jocn.2015.01.025
NR 39
TC 9
Z9 14
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0952-7907
EI 1473-6500
J9 CURR OPIN ANESTHESIO
JI Curr. Opin. Anesthesiol.
PD OCT 15
PY 2017
VL 30
IS 5
BP 534
EP 539
DI 10.1097/ACO.0000000000000493
PG 6
WC Anesthesiology
SC Anesthesiology
GA FJ5MG
UT WOS:000412795000003
PM 28692438
DA 2026-01-16
ER

PT J
AU Viscuse, PV
   Price, K
   Millstine, D
   Bhagra, A
   Bauer, B
   Ruddy, KJ
AF Viscuse, Paul V.
   Price, Katharine
   Millstine, Denise
   Bhagra, Anjali
   Bauer, Brent
   Ruddy, Kathryn J.
TI Integrative medicine in cancer survivors
SO CURRENT OPINION IN ONCOLOGY
LA English
DT Review
DE cancer; complementary alternative medicine; integrative medicine; survivorship
ID vitamin-d supplementation; quality-of-life; breast-cancer; physical-activity; stress reduction; massage therapy; pilot trial; follow-up; risk; intervention
AB Purpose of reviewDue to medical advances and an aging population, the number of cancer survivors continues to rise. Survivors often experience late and long-term sequelae of cancer and its treatment (e.g., fatigue, pain, fear of recurrence, and stress). As a result, some patients have utilized or expressed interest in integrative medicine (IM) modalities for prevention of recurrence, optimizing health, enhancing quality of life, and managing symptoms. The purpose of this review is to focus on research published during the past year that informs our understanding of the utility of IM for cancer survivors.Recent findingsPhysical activity, diet, dietary supplements, mind-body modalities, acupuncture, and massage therapy all may play a role in the management of the physical (e.g., fatigue and pain) and emotional (e.g., anxiety and fear) issues faced by cancer survivors.SummaryIM therapies are appealing to and utilized by many cancer survivors and may reduce symptom burden. Clinicians who provide cancer survivorship care may improve patient care by understanding the evidence for and against their use.
C1 [Viscuse, Paul V.; Bhagra, Anjali; Bauer, Brent] Mayo Clin, Dept Med, Rochester, MN USA.
   [Price, Katharine; Ruddy, Kathryn J.] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA.
   [Millstine, Denise] Mayo Clin, Div Womens Hlth Internal Med, Scottsdale, AZ USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix
RP Ruddy, KJ (corresponding author), Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA.
EM ruddy.kathryn@mayo.edu
FU CTSA Grant Program from National Center for Advancing Translational Sciences (NCATS) of the NIH [UL1 TR000135, KL2TR000136-09]
CR American Cancer Society, 2014, CANC TREAT SURV FACT, V0, P0
   Arthur AE, 2016, J CANCER SURVIV, V10, P981, DOI 10.1007/s11764-016-0544-5
   Arthur AE, 2014, CANCER-AM CANCER SOC, V120, P2704, DOI 10.1002/cncr.28778
   Barak-Nahum A, 2016, SOC SCI MED, V166, P1, DOI 10.1016/j.socscimed.2016.07.046
   Blair CK, 2016, J CANCER SURVIV, V10, P103, DOI 10.1007/s11764-015-0456-9
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Braden BB, 2016, BRAIN BEHAV, V6, P0, DOI 10.1002/brb3.443
   Byrd D, 2017, J RACIAL ETHN HLTH D, V0, P0
   Carpenter J, 2015, MENOPAUSE, V22, P1155, DOI 10.1097/GME.0000000000000546
   Choi T, 2016, INTEGR CANC THER, V0, P0
   Cutshall SM, 2015, SUPPORT CARE CANCER, V23, P2989, DOI 10.1007/s00520-015-2666-0
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Deng Gary E, 2009, J SOC INTEGR ONCOL, V7, P85
   Denlinger CS, 2014, J NATL COMPR CANC NE, V12, P1396, DOI 10.6004/jnccn.2014.0137
   Donoyama N, 2016, GYNECOL ONCOL, V142, P531, DOI 10.1016/j.ygyno.2016.06.022
   Elkins G, 2008, J CLIN ONCOL, V26, P5022, DOI 10.1200/JCO.2008.16.6389
   Elkins G, 2010, CURR TREAT OPTION ON, V11, P128, DOI 10.1007/s11864-010-0129-x
   Gaskin CJ, 2016, CANCER CAUSE CONTROL, V27, P1093, DOI 10.1007/s10552-016-0787-5
   Hagstrom AD, 2016, EUR J CANCER CARE, V25, P784, DOI 10.1111/ecc.12422
   Hall AE, 2016, SUPPORT CARE CANCER, V24, P4413, DOI 10.1007/s00520-016-3282-3
   Hu C, 2016, J EVID-BASED INTEGR, V2016, P1, DOI 10.1155/2016/1720239
   Irwin M, 2016, CANCER, V123, P1249
   Irwin ML, 2008, J CLIN ONCOL, V26, P3958, DOI 10.1200/JCO.2007.15.9822
   Jahnke Roger, 2010, AM J HEALTH PROMOT, V24, Pe1, DOI 10.4278/ajhp.081013-LIT-248
   Janelsins MC, 2016, INTEGR CANCER THER, V15, P263, DOI 10.1177/1534735415617021
   Johns SA, 2016, SUPPORT CARE CANCER, V24, P4085, DOI 10.1007/s00520-016-3220-4
   Kampshoff CS, 2016, SUPPORT CARE CANCER, V24, P3333, DOI 10.1007/s00520-016-3148-8
   Kelley GA, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0129181
   Kenfield SA, 2014, EUR UROL, V65, P887, DOI 10.1016/j.eururo.2013.08.009
   Kimman ML, 2017, BMC MED, V15, P0, DOI 10.1186/s12916-016-0768-2
   Kroenke CH, 2005, J CLIN ONCOL, V23, P9295, DOI 10.1200/JCO.2005.02.0198
   Kushi LH, 2012, CA-CANCER J CLIN, V62, P30, DOI 10.3322/caac.20140
   Larkey LK, 2016, COMPLEMENT THER MED, V29, P196, DOI 10.1016/j.ctim.2016.10.006
   Lee PLT, 2016, COMPLEMENT THER MED, V27, P87, DOI 10.1016/j.ctim.2016.06.003
   Lengacher CA, 2016, J CLIN ONCOL, V34, P2827, DOI 10.1200/JCO.2015.65.7874
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Lewis C, 2016, SUPPORT CARE CANCER, V24, P1655, DOI 10.1007/s00520-015-2945-9
   Ligibel JA, 2008, J CLIN ONCOL, V26, P907, DOI 10.1200/JCO.2007.12.7357
   McCullough ML, 2011, CANCER EPIDEM BIOMAR, V20, P1089, DOI 10.1158/1055-9965.EPI-10-1173
   Mendoza ME, 2016, PSYCHOONCOLOGY, V0, P0
   Merckaert I, 2016, PSYCHOONCOLOGY, V0, P0
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Ornish D, 2013, LANCET ONCOL, V14, P1112, DOI 10.1016/S1470-2045(13)70366-8
   Rock CL, 2012, CA-CANCER J CLIN, V62, P243, DOI 10.3322/caac.21142
   Rogers LQ, 2016, BREAST CANCER RES TR, V159, P283, DOI 10.1007/s10549-016-3945-2
   Salehi A, 2016, SUPPORT CARE CANCER, V24, P4895, DOI 10.1007/s00520-016-3345-5
   Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754, DOI 10.1093/ajcn/83.4.754
   Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6
   Simonavice E, 2017, SUPPORT CARE CANCER, V25, P9, DOI 10.1007/s00520-016-3374-0
   Spees CK, 2016, CANCER CONTROL, V23, P302, DOI 10.1177/107327481602300314
   Stan DL, 2016, SUPPORT CARE CANCER, V24, P4005, DOI 10.1007/s00520-016-3233-z
   Stanton AL, 2015, ADV EXP MED BIOL, V862, P231, DOI 10.1007/978-3-319-16366-6_15
   Strasser B, 2013, MED SCI SPORT EXER, V45, P2080, DOI 10.1249/MSS.0b013e31829a3b63
   Ulitsky A, 2011, JPEN-PARENTER ENTER, V35, P308, DOI 10.1177/0148607110381267
   van Roekel Eline H, 2016, PREV MED REP, V4, P262, DOI 10.1016/j.pmedr.2016.06.022
   van Roekel EH, 2016, CANCER CAUSE CONTROL, V27, P513, DOI 10.1007/s10552-016-0725-6
   Wang L, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep38962
   Watson E, 2016, BJU INT, V117, PE10, DOI 10.1111/bju.13122
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Zeng YC, 2014, COMPLEMENT THER MED, V22, P173, DOI 10.1016/j.ctim.2013.11.010
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2017, BREAST CANCER RES TR, V161, P299, DOI 10.1007/s10549-016-4070-y
NR 63
TC 32
Z9 39
U1 0
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8746
EI 1531-703X
J9 CURR OPIN ONCOL
JI Curr. Opin. Oncol.
PD JUL 15
PY 2017
VL 29
IS 4
BP 235
EP 242
DI 10.1097/CCO.0000000000000376
PG 8
WC Oncology
SC Oncology
GA EX2WM
UT WOS:000403091400003
PM 28459738
DA 2026-01-16
ER

PT J
AU Eustachi, A
   Melchart, D
AF Eustachi, Axel
   Melchart, Dieter
TI [Complementary and Alternative Medicine in Oncology - What Makes Sense?].
SO Deutsche medizinische Wochenschrift (1946)
LA ger
DT Review
AB The basis of any complementary therapy should be the recommendation of a healthy  lifestyle (diet, nutrition, exercise, stress-reduction), and appropriate  self-help techniques (e. g. thermotherapy, herbal OTC-products) aimed at  releasing the patients' most debilitating symptoms. For therapy-resistant or  strong symptoms, more invasive interventions or medical treatments with an  acceptable evidence base can be used (e. g. acupuncture for cancer pain, herbal  prescriptions). The effects of any complementary intervention should be  controlled for a period of six weeks after its administration. Patients should be  advised not to use products or methods with possibly harmful side effects or  negative interactions with conventional medications.
NR 0
TC 0
SN 1439-441
EI 
J9 Dtsch Med Wochenschr
PD JUN 22
PY 2017
VL 142
IS 12
BP 882
EP 888
DI 10.1055/s-0042-121882
PG 6
WC Acupuncture Therapy; adverse effects; Complementary Therapies; adverse effects; Evidence-Based Medicine; Exercise; Feeding Behavior; Humans; Life Style; Neoplasms; complications; Phytotherapy; adverse effects; Quality of Life; psychology; Risk Factors; Self Care; Stress, Psychological; complications
UT PubMed:28637073
PM 28637073
DA 2017-06-22
ER

PT J
AU Chen, L
   Lin, CC
   Huang, TW
   Kuan, YC
   Huang, YH
   Chen, HC
   Kao, CY
   Su, CM
   Tam, KW
AF Chen, Lawrence
   Lin, Chao-Chun
   Huang, Tsai-Wei
   Kuan, Yi-Chun
   Huang, Yao-Hsien
   Chen, Hung-Chou
   Kao, Chun-Yu
   Su, Chih-Ming
   Tam, Ka-Wai
TI Effect of acupuncture on arornatase inhibitor-induced arthralgia in patients with breast cancer: A meta-analysis of randomized controlled trials
SO BREAST
LA English
DT Article
DE Acupuncture; Aromatase inhibitor-induced arthralgia; Meta-analysis; Breast cancer
ID joint symptoms; aromatase; women; electroacupuncture
AB Purpose: Aromatase inhibitor (AI)-induced arthralgia (AIA) is a common side effect that may lead to premature discontinuation of effective hormonal therapy in patients with breast cancer. Acupuncture may relieve joint pain in patients with AIA. We conducted a meta-analysis of randomized controlled trials (RCTs) to evaluate the effectiveness of acupuncture in pain relief in AIA. Methods: The PubMed, Embase, Cochrane Library, and Scopus databases and the ClinicalTrials.gov registry were searched for studies published before February 2017. Individual effect sizes were standardized, and a meta-analysis was conducted to calculate the pooled effect size by using a random effect model. Pain was assessed using the Brief Pain Inventory (BPI) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 3-4, 6-8, and 12 weeks. Secondary outcomes included disability level, upper extremity function, physical performance, and quality of life. Results: Five trials involving 181 patients were reviewed. Significant pain reduction was observed after 6 8 weeks of acupuncture treatment. Patients receiving acupuncture showed a significant decrease in the BPI worst pain score (weighted mean difference [WMD]: -3.81, 95% confidence interval [CI]: -5.15 to -2.47) and the WOMAC pain score (WMD: -130.77, 95% CI: -230.31 to -31.22) after 6-8 weeks of treatment. One of the 4 trials reported 18 minor adverse events in 8 patients during 398 intervention episodes. Conclusion: Acupuncture is a safe and viable nonpharmacologic treatment that may relieve joint pain in patients with AIA. Additional studies involving a higher number of RCTs are warranted. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Chen, Lawrence; Lin, Chao-Chun; Chen, Hung-Chou; Tam, Ka-Wai] Taipei Med Univ, Shuang Ho Hosp, Ctr Evidence Based Hlth Care, 291 Zhongzheng Rd, New Taipei 23561, Taiwan.
   [Huang, Tsai-Wei] HungKuang Univ, Dept Nursing, Coll Med & Nursing, Taichung, Taiwan.
   [Kuan, Yi-Chun; Huang, Yao-Hsien] Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, New Taipei, Taiwan.
   [Kuan, Yi-Chun] Taipei Med Univ, Sch Med, Dept Neurol, Taipei, Taiwan.
   [Chen, Hung-Chou] Taipei Med Univ, Shuang Ho Hosp, Dept Phys Med & Rehabil, New Taipei, Taiwan.
   [Kao, Chun-Yu] Taipei Med Univ, Dept Surg, Shuang Ho Hosp, Div Pediat Surg, Taipei, Taiwan.
   [Su, Chih-Ming; Tam, Ka-Wai] Taipei Med Univ, Shuang Ho Hosp, Div Gen Surg, Dept Surg, New Taipei, Taiwan.
   [Su, Chih-Ming; Tam, Ka-Wai] Taipei Med Univ, Sch Med, Dept Surg, Coll Med, Taipei, Taiwan.
   [Tam, Ka-Wai] Taipei Med Univ, Cochrane Taiwan, Taipei, Taiwan.
C3 Taipei Medical University; Shuang Ho Hospital; Hungkuang University; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University; Taipei Medical University
RP Tam, KW (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Ctr Evidence Based Hlth Care, 291 Zhongzheng Rd, New Taipei 23561, Taiwan.
EM kelvintam@h.tmu.edu.tw
CR AIHW, 2012, AIHW CANC SER, V74, P0
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Burstein HJ, 2007, BREAST, V16, P223, DOI 10.1016/j.breast.2007.01.011
   Center for Disease Control and Prevention, 2012, BREAST CANC STAT, V0, P0
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.3.CO;2-G
   Galantino ML, 2012, INTEGR CANCER THER, V11, P313, DOI 10.1177/1534735411413270
   Harrell JC, 2007, CANCER RES, V67, P10582, DOI 10.1158/0008-5472.CAN-07-1655
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Kawakita K, 2006, J PHARMACOL SCI, V100, P443, DOI 10.1254/jphs.CRJ06004X
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   Liberati A, 2009, ANN INTERN MED, V151, PW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   SJOLUND B, 1977, ACTA PHYSIOL SCAND, V100, P382, DOI 10.1111/j.1748-1716.1977.tb05964.x
   Xepapadakis G, 2010, BREAST, V19, P249, DOI 10.1016/j.breast.2010.03.031
NR 24
TC 48
Z9 56
U1 0
U2 13
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD JUN 15
PY 2017
VL 33
IS 
BP 132
EP 138
DI 10.1016/j.breast.2017.03.015
PG 7
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA EW0WB
UT WOS:000402210800020
PM 28384564
DA 2026-01-16
ER

PT J
AU Bishop, FL
   Coghlan, B
   Geraghty, AWA
   Everitt, H
   Little, P
   Holmes, MM
   Seretis, D
   Lewith, G
AF Bishop, Felicity L.
   Coghlan, Beverly
   Geraghty, Adam W. A.
   Everitt, Hazel
   Little, Paul
   Holmes, Michelle M.
   Seretis, Dionysis
   Lewith, George
TI What techniques might be used to harness placebo effects in non-malignant pain? A literature review and survey to develop a taxonomy
SO BMJ OPEN
LA English
DT Review
ID randomized controlled-trial; open-label use; clinical-practice; interventions; nocebo; metaanalysis; expectancy; osteoarthritis; communication; acupuncture
AB Objectives Placebo effects can be clinically meaningful but are seldom fully exploited in clinical practice. This review aimed to facilitate translational research by producing a taxonomy of techniques that could augment placebo analgesia in clinical practice. Design Literature review and survey. Methods We systematically analysed methods which could plausibly be used to elicit placebo effects in 169 clinical and laboratory-based studies involving nonmalignant pain, drawn from seven systematic reviews. In a validation exercise, we surveyed 33 leading placebo researchers (mean 12 year sa  pound (TM) research experience, SD 9.8), who were asked to comment on and add to the draft taxonomy derived from the literature. Results The final taxonomy defines 30 procedures that may contribute to placebo effects in clinical and experimental research, proposes 60 possible clinical applications and classifies procedures into five domains: the patienta  pound (TM) s characteristics and belief (5 procedures and 11 clinical applications), the practitionera  pound (TM) s characteristics and beliefs (2 procedures and 4 clinical applications), the healthcare setting (8 procedures and 13 clinical applications), treatment characteristics (8 procedures and 14 clinical applications) and the patienta " pound practitioner interaction (7 procedures and 18 clinical applications). Conclusion The taxonomy provides a preliminary and novel tool with potential to guide translational research aiming to harness placebo effects for patient benefit in practice.
C1 [Bishop, Felicity L.; Holmes, Michelle M.; Seretis, Dionysis] Univ Southampton, Fac Social Human & Math Sci, Dept Psychol, Southampton, Hants, England.
   [Coghlan, Beverly; Geraghty, Adam W. A.; Everitt, Hazel; Little, Paul; Lewith, George] Univ Southampton, Aldermoor Hlth Ctr, Primary Care & Populat Sci, Southampton, Hants, England.
C3 University of Southampton; University of Southampton
RP Bishop, FL (corresponding author), Univ Southampton, Fac Social Human & Math Sci, Dept Psychol, Southampton, Hants, England.
EM F.L.Bishop@southampton.ac.uk
FU National Institute of Health Research (NIHR) School for Primary Care Research (SPCR) [161]; NIHR; Solent NHS Trust
CR Barnhill A, 2015, J MED ETHICS, V41, P673, DOI 10.1136/medethics-2014-102651
   Bélanger L, 2007, J SLEEP RES, V16, P77, DOI 10.1111/j.1365-2869.2007.00566.x
   Benedetti F, 2003, J NEUROSCI, V23, P4315
   Benedetti F, 2003, PREVENTION TREATMENT, V6, P0
   Benedetti F, 2016, LANCET NEUROL, V15, P736, DOI 10.1016/S1474-4422(16)00066-1
   Benedetti F, 2013, PHYSIOL REV, V93, P1207, DOI 10.1152/physrev.00043.2012
   Benedetti F, 2011, PATIENT EDUC COUNS, V84, P413, DOI 10.1016/j.pec.2011.04.034
   Bensing JM, 2010, PATIENT EDUC COUNS, V80, P293, DOI 10.1016/j.pec.2010.05.033
   Bingel U, 2011, SCI TRANSL MED, V3, P0, DOI 10.1126/scitranslmed.3001244
   Bishop FL, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0101822
   Bishop FL, 2014, FAM PRACT, V31, P357, DOI 10.1093/fampra/cmu016
   Blease C, 2016, BIOETHICS, V30, P407, DOI 10.1111/bioe.12245
   Brody H, 2000, J FAM PRACTICE, V49, P649
   Colloca L, 2013, PAIN, V154, P511, DOI 10.1016/j.pain.2013.02.002
   Colloca L, 2012, JAMA-J AM MED ASSOC, V307, P567, DOI 10.1001/jama.2012.115
   Colloca L, 2011, PHILOS T R SOC B, V366, P1922, DOI 10.1098/rstb.2010.0399
   Colloca L, 2011, PHILOS T R SOC B, V366, P1859, DOI 10.1098/rstb.2010.0398
   Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6
   Dijkstra K, 2006, J ADV NURS, V56, P166, DOI 10.1111/j.1365-2648.2006.03990.x
   Doherty M, 2009, OSTEOARTHR CARTILAGE, V17, P1255, DOI 10.1016/j.joca.2009.03.023
   Dowell Deborah, 2016, JAMA, V315, P1624, DOI 10.15585/mmwr.rr6501e1
   Drahota A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005315.pub2
   Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923
   Fässler M, 2009, BMC HEALTH SERV RES, V9, P0, DOI 10.1186/1472-6963-9-144
   Faria V, 2008, EUR NEUROPSYCHOPHARM, V18, P473, DOI 10.1016/j.euroneuro.2008.03.002
   Feffer K, 2016, GEN HOSP PSYCHIAT, V41, P53, DOI 10.1016/j.genhosppsych.2016.05.004
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Ford AC, 2010, ALIMENT PHARM THER, V32, P144, DOI 10.1111/j.1365-2036.2010.04328.x
   Greville-Harris M, 2015, AM J MED, V128, P126, DOI 10.1016/j.amjmed.2014.08.031
   Howick J, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0062599
   Howick J, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0058247
   Hróbjartsson A, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003974.pub3
   Hyland ME, 2008, J PSYCHOSOM RES, V65, P405, DOI 10.1016/j.jpsychores.2008.02.006
   Jubb J, 2013, NEUROSCI BIOBEHAV R, V37, P2709, DOI 10.1016/j.neubiorev.2013.09.006
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Kaptchuk TJ, 2015, NEW ENGL J MED, V373, P8, DOI 10.1056/NEJMp1504023
   Kaptchuk TJ, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0015591
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   Kelley JM, 2012, PSYCHOTHER PSYCHOSOM, V81, P312, DOI 10.1159/000337053
   Kirsch I, 2005, J CLIN PSYCHOL, V61, P791, DOI 10.1002/jclp.20126
   Kirsch I, 2004, PSYCHOL BULL, V130, P341, DOI 10.1037/0033-2909.130.2.341
   Kirsch I, 1997, APPL PREV PSYCHOL, V6, P69, DOI 10.1016/S0962-1849(05)80012-5
   Kirsch I, 1998, PREVENTION TREATMENT, V1, P0, DOI 10.1037/1522-3736.1.1.12A
   Klinger R, 2014, PAIN, V155, P1055, DOI 10.1016/j.pain.2013.12.007
   Lichtenberg P, 2004, J MED ETHICS, V30, P551, DOI 10.1136/jme.2002.002832
   Linde K, 2011, PHILOS T R SOC B, V366, P1905, DOI 10.1098/rstb.2010.0383
   Manchikanti L, 2011, PAIN PHYSICIAN, V14, P0
   Meissner K, 2011, PHILOS T R SOC B, V366, P1783, DOI 10.1098/rstb.2010.0414
   Michie S, 2009, HEALTH PSYCHOL, V28, P690, DOI 10.1037/a0016136
   Mistiaen P, 2016, EUR J PAIN, V20, P675, DOI 10.1002/ejp.797
   Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011
   Ortiz R, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2015-011012
   Patel SM, 2005, NEUROGASTROENT MOTIL, V17, P332, DOI 10.1111/j.1365-2982.2005.00650.x
   Peerdeman KJ, 2016, PAIN, V157, P1179, DOI 10.1097/j.pain.0000000000000540
   Planès S, 2016, PHARMACOL RES PERSPE, V4, P0, DOI 10.1002/prp2.208
   Price DD, 2005, SEMINARS PAIN MED, V3, P15
   Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941
   Puhl AA, 2011, PAIN RES MANAG, V16, P45, DOI 10.1155/2011/625315
   Rice T, 2010, J MAT CULT, V15, P287, DOI 10.1177/1359183510373985
   Sandler A, 2008, CHILD CARE HLTH DEV, V34, P111, DOI 10.1111/j.1365-2214.2007.00743.x
   Sandler AD, 2008, CHILD CARE HLTH DEV, V34, P104, DOI 10.1111/j.1365-2214.2007.00797.x
   Snyder CF, 2012, QUAL LIFE RES, V21, P1305, DOI 10.1007/s11136-011-0054-x
   Stewart-Williams S, 2004, PSYCHOL BULL, V130, P324, DOI 10.1037/0033-2909.130.2.324
   Strauss E, 1998, CLIN ORTHOP RELAT R, V0, P2
   Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015
   Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225
   Vase L, 2002, PAIN, V99, P443, DOI 10.1016/S0304-3959(02)00205-1
   Vase L, 2013, PAIN, V154, P1659, DOI 10.1016/j.pain.2013.05.008
   Vase L, 2009, PAIN, V145, P36, DOI 10.1016/j.pain.2009.04.008
   White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007
   Witt CM, 2012, EUR J PAIN, V16, P1455, DOI 10.1002/j.1532-2149.2012.00152.x
   Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015
NR 73
TC 31
Z9 35
U1 1
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD JUN 15
PY 2017
VL 7
IS 6
BP 
EP 
DI 10.1136/bmjopen-2016-015516
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA FB8LT
UT WOS:000406391200163
PM 28667217
DA 2026-01-16
ER

PT J
AU Sarradon-Eck, A
   Bouhnik, AD
   Rey, D
   Bendiane, MK
   Huiart, L
   Peretti-Watel, P
AF Sarradon-Eck, Aline
   Bouhnik, Anne-Déborah
   Rey, Dominique
   Bendiane, Marc-Karim
   Huiart, Laetitia
   Peretti-Watel, Patrick
TI Use of non-conventional medicine two years after cancer diagnosis in France:
SO Journal of cancer survivorship : research and practice
LA English
DT Journal Article
DE Cancer survivors; Cohort study; Complementary and alternative medicine; Coping; France; Integrative medicine
AB PURPOSE: The purpose of this study was to assess the use of non-conventional  medicine (NCM) in a representative sample of French patients 2 years after cancer  diagnosis. METHODS: The study was based on data obtained in the VICAN survey  (2012) on a representative sample of 4349 patients 2 years after cancer  diagnosis. Self-reported data were collected at telephone interviews with  patients. The questionnaire addressed the various types of non-conventional  treatments used at the time of the survey. RESULTS: Among the participants, 16.4%  reported that they used NCM, and 45.3% of this group had not used NCM before  cancer diagnosis (new NCM users). Commonly, NCMs used were homeopathy (64.0%),  acupuncture (22.1%), osteopathy (15.1%), herbal medicine (8.1%), diets (7.3%) and  energy therapies (5.8%). NCM use was found to be significantly associated with  younger age, female gender and a higher education level. Previous NCM use was  significantly associated with having a managerial occupation and an expected  5-year survival rate ≥80% at diagnosis; recent NCM use was associated with cancer  progression since diagnosis, impaired quality of life and higher pain reports.  CONCLUSION: This is the first study on NCM use 2 years after cancer diagnosis in  France. In nearly half of the NCM users, cancer diagnosis was one of the main  factors which incited patients to use NCM. Apart from the NCM users'  socioeconomic profile, the present results show that impaired health was a  decisive factor: opting for unconventional approaches was therefore a pragmatic  response to needs which conventional medicine fails to meet during the course of  the disease. IMPLICATIONS FOR CANCER SURVIVORS: Better information of patients  and caregivers is needed to allow access to these therapies to a larger  population of survivors.
C1 Aix Marseille Univ, INSERM, IRD, SESSTIM, "Economics & Social Sciences Applied to Health & Analysis of Medical Information", Marseille, France.aline.sarradon@inserm.fr.
   Inst Paoli Calmettes, SESSTIM, Marseille, France. aline.sarradon@inserm.fr.
   Aix Marseille Univ, INSERM, IRD, SESSTIM, "Economics & Social Sciences Applied to Health & Analysis of Medical Information", Marseille, France.
   Aix Marseille Univ, INSERM, IRD, SESSTIM, "Economics & Social Sciences Applied to Health & Analysis of Medical Information", Marseille, France.
   ORS PACA, Southeastern Health Regional Observatory, Marseille, France.
   Aix Marseille Univ, INSERM, IRD, SESSTIM, "Economics & Social Sciences Applied to Health & Analysis of Medical Information", Marseille, France.
   ORS PACA, Southeastern Health Regional Observatory, Marseille, France.
   Aix Marseille Univ, INSERM, IRD, SESSTIM, "Economics & Social Sciences Applied to Health & Analysis of Medical Information", Marseille, France.
   CHU de la Réunion, Unité de Soutien Méthodologique, Saint Denis, France.
   CHU de la Réunion, INSERM, CIC 1410, Saint-Pierre, France.
   Aix Marseille Univ, INSERM, IRD, SESSTIM, "Economics & Social Sciences Applied to Health & Analysis of Medical Information", Marseille, France.
   ORS PACA, Southeastern Health Regional Observatory, Marseille, France.
NR 0
TC 0
SN 1932-226
EI 
J9 J Cancer Surviv
PD FEB 6
PY 2017
VL 11
IS 4
BP 421
EP 430
DI 10.1007/s11764-017-0599-y
PG 9
WC Adolescent; Adult; Aged; Aged, 80 and over; Complementary Therapies; methods; Female; France; Humans; Male; Middle Aged; Neoplasms; therapy; Quality of Life; Self Report; Surveys and Questionnaires; Survivors; psychology; Time Factors; Young Adult
UT PubMed:28150122
PM 28150122
DA 2017-02-06
ER

PT J
AU Satija, A
   Bhatnagar, S
AF Satija, Aanchal
   Bhatnagar, Sushma
TI Complementary Therapies for Symptom Management in Cancer Patients.
SO Indian journal of palliative care
LA English
DT Journal Article
DE Cancer; complementary therapies; mind-body therapies; pain; quality of life
AB Cancer patients are often poly-symptomatic which distressingly affects their  quality of lives (QOLs). Alhough, conventional management provides adequate  symptom control, yet is coupled with some limitations. Complementary therapies  (CTs) have shown beneficial effects in cancer patients for symptomatic relief.  The aim of this article is to provide evidence-based review of commonly used CTs  for symptom management in cancer care. Hypnosis has promising evidence to be used  for managing symptoms such as pain, chemotherapy-induced nausea/vomiting,  distress, fatigue, and hot flashes. Guided imagery increases comfort and can be  used as a psycho-supportive therapy. Meditation substantially improves  psychological function, mental health, and QOL. Cognitive behavioral therapies  effectively reduce pain, distress, fatigue, anxiety, and depression; and improve  subjective sleep outcomes along with mood and QOL. Yoga has short term beneficial  effects for anxiety, depression, fatigue, perceived stress, QOL, and well-being.  T'ai Chi and qigong are beneficial adjunctive therapies for supportive cancer  care, but their role in reducing cancer pain is not well proven. Acupuncture is  effective for reducing treatment related side-effects, pain and fatigue. Other  therapies such as massage techniques, energy therapies, and spiritual  interventions have also demonstrated positive role in managing cancer-related  symptoms and improve overall well-being. However, the clinical effectiveness of  these therapies for symptom management in cancer patients cannot be concluded due  to poor strength of evidence. Nonetheless, these are relatively free from risks  and hence can be given along with conventional treatments. Only by tailoring  these therapies as per patient's beliefs and preferences, optimal  patient-centered holistic care can be provided.
C1 Department of Onco-Anaesthesia and Palliative Medicine, Dr. BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
   Department of Onco-Anaesthesia and Palliative Medicine, Dr. BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
NR 0
TC 0
SN 1998-373
EI 0973-107
J9 Indian J Palliat Care
PD NOV 11
PY 2017
VL 23
IS 4
BP 468
EP 479
DI 10.4103/IJPC.IJPC_100_17
PG 11
UT PubMed:29123357
PM 29123357
DA 2017-11-11
ER

PT J
AU Ondrejkovicová, A
   Petrovics, G
   Svitková, K
   Balogh, V
AF Ondrejkovicova, Alena
   Petrovics, Gabriel
   Svitkova, Katarina
   Balogh, Vladimir
TI Is non-pharmacological treatment an effective option for chronic low back pain?
SO NEUROENDOCRINOLOGY LETTERS
LA English
DT Article
DE chronic low back pain; acupuncture; pain treatment
ID acupuncture; cost; trial
AB OBJECTIVE: Despite of pain being important warning signal for body ability to respond to internal or external threats, chronic pain is perceived as a discomfort by patients, leading to somatic, emotional and social negative changes. Lifestyle, wrong seating habits and some occupations may contribute to chronic back pain. Therapy for chronic back pain should include not only pharmacological or invasive interventions, but mostly change of lifestyle, physiotherapy and non-pharmacological methods. METHODS: The main objective of the paper was to compare subjective perception of the effectiveness of various methods for treatment of low back pain. In total, 100 patients were asked to fill the questionnaire after completing the treatment, whether conventional or non-pharmacological. We have aimed to analyze not only the perception of the patients, but also indicators of the patient's lifestyle, their nutrition and physical activity. RESULTS: Oral drugs was the most effective option perceived by the patients, followed by non-pharmacological methods, such as massages, heat application and acupuncture. At the same time, all patients who changed their lifestyle, for example reduced smoking and alcohol and increased physical activity, achieved better results in non-pharmacological treatment and experienced higher pain alleviation compared to the patients treated by medications only. CONCLUSION: Non-pharmacological therapy of chronic non-malignant low back pain could be an effective option offered in combination with medicaments and change of lifestyle.
C1 [Ondrejkovicova, Alena; Petrovics, Gabriel; Svitkova, Katarina; Balogh, Vladimir] Slovak Med Univ Bratislava, Fac Med, Inst Tradit Chinese Med, Dept Acupuncture, Bratislava, Slovakia.
C3 Slovak Medical University Bratislava; Comenius University Bratislava
RP Ondrejkovicová, A (corresponding author), Slovak Med Univ Bratislava, Fak Med, Inst Tradit Med, Dept Acupuncture, Limbova 12, Bratislava 83303, Slovakia.
EM aondrejk@hotmail.com
CR Balogh V, 2001, 21 CONGR AC SLOV BOH, V0, P5
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011
   Dagenais S, 2008, SPINE J, V8, P8, DOI 10.1016/j.spinee.2007.10.005
   Enthoven WTM, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012087
   Fiala P, 2016, AKUPUNKTURA VE 21 ST, V0, P0
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Hoy D, 2012, ARTHRITIS RHEUM-US, V64, P2028, DOI 10.1002/art.34347
   HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8
   Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656
   Masar O, 2013, ANALGEZA SEDACIA URG, V0, P0
   Ondrejkovicová A, 2016, NEUROENDOCRINOL LETT, V37, P163
   Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443
   Thomas KJ, 2005, HEALTH TECHNOL ASSES, V9, P0
   Torp S, 2001, J OCCUP ENVIRON MED, V43, P120, DOI 10.1097/00043764-200102000-00010
NR 15
TC 5
Z9 5
U1 0
U2 10
PU MAGHIRA & MAAS PUBLICATIONS
PI MUNSBACH
PA MAGHIRA & MAAS S A R L, 6C, RUE GABRIEL LIPPMANN, L-5365 MUNSBACH, LUXEMBOURG
SN 0172-780X
EI 2354-4716
J9 NEUROENDOCRINOL LETT
JI Neuroendocrinol. Lett.
PD JUN 15
PY 2017
VL 38
IS 3
BP 169
EP 172
DI 
PG 4
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA FC2TB
UT WOS:000406690100007
PM 28759184
DA 2026-01-16
ER

PT J
AU Rizi, MS
   Shamsalinia, A
   Ghaffari, F
   Keyhanian, S
   Nabi, BN
AF Rizi, Moloud Sharifi
   Shamsalinia, Abbas
   Ghaffari, Fatemeh
   Keyhanian, Shahrbanoo
   Nabi, Bahram Naderi
TI The effect of acupressure on pain, anxiety, and the physiological indexes of patients with cancer undergoing bone marrow biopsy
SO COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
LA English
DT Article
DE Acupressure; Pain; Anxiety; Physiological indexes; Bone marrow; Biopsy; Aspiration
ID auricular acupressure; preoperative anxiety; aspiration; fatigue; blind
AB Objectives: This study aimed to determine the effect of acupressure on pain intensity, anxiety, and physiological indexes of patients with cancer undergoing bone marrow biopsy and aspiration. Methods: The study was designed as a randomized, double-blinded, controlled trial. Ninety samples was selected using the convenience sampling method, then for allocation groups random block sampling was used (30 for each group). The three groups were similar by age and gender. LI4 and HT7 (Shen Men) acupressure points were examined for the intervention. Sham pressure was used in the placebo group while no intervention was applied in the control group. Results: The results showed that the lowest average anxiety score (1.5 +/- 0.5; P = 0.01) and the lowest average pain score (4.9 +/- 0.8) after the intervention were related to the acupressure method (P = 0.001). Conclusion: Cost effectiveness and short-term simple education make acupressure method useful in clinical settings for different illnesses. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Rizi, Moloud Sharifi; Shamsalinia, Abbas; Ghaffari, Fatemeh] Babol Univ Med Sci, Ramsar Nursing Care Res Ctr, Babol Sar 4691714141, Mazandaran, Iran.
   [Keyhanian, Shahrbanoo] Azad Univ Tonekabon, Dept Oncol, Tonekabon, Mazandaran, Iran.
   [Nabi, Bahram Naderi] Guilan Univ Med Sci, Anesthesiol Res Ctr, Anesthesiol Dept, Rasht, Iran.
C3 Babol University of Medical Sciences; Guilan University of Medical Sciences
RP Ghaffari, F (corresponding author), Babol Univ Med Sci, Ramsar Nursing Care Res Ctr, Babol Sar 4691714141, Mazandaran, Iran.
EM sharifi.molod@gmail.com; abbasshamsalinia@yahoo.com; ghafarifateme@yahoo.com; Keyhani_333@yahoo.com; naderi_bahram@gums.ac.ir
CR Agarwal A, 2005, ANAESTHESIA, V60, P978, DOI 10.1111/j.1365-2044.2005.04332.x
   Unknown -, 2012, DANESHVAR, V0, P0
   Bao T, 2011, J PAIN SYMPTOM MANAG, V41, P995, DOI 10.1016/j.jpainsymman.2010.08.012
   Barker R, 2006, ACAD EMERG MED, V13, P19, DOI 10.1197/j.aem.2005.07.014
   Barnes LLB, 2002, EDUC PSYCHOL MEAS, V62, P603, DOI 10.1177/001316402128775049
   Evans D, 2005, PEDIATR ANESTH, V15, P131, DOI 10.1111/j.1460-9592.2005.01407.x
   Farajollahi M, 2004, IRAN J NURS, V16, P47
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688
   Hosseinabadi R, 2015, J INFUS MURS, V38, P397, DOI 10.1097/NAN.0000000000000065
   Jaddini Emil, 2016, ACTA HAEMATOLOGICA POLONICA, V47, P226, DOI 10.1016/j.achaem.2016.04.003
   Kober A, 2003, ANESTHESIOLOGY, V98, P1328, DOI 10.1097/00000542-200306000-00005
   Kuo SY, 2016, INT J NURS STUD, V53, P17, DOI 10.1016/j.ijnurstu.2015.10.006
   Lang T, 2007, AM J EMERG MED, V25, P887, DOI 10.1016/j.ajem.2007.01.016
   Lechtzin N, 2010, J ALTERN COMPLEM MED, V16, P965, DOI 10.1089/acm.2009.0531
   Lidén Y, 2012, EUR J ONCOL NURS, V16, P323, DOI 10.1016/j.ejon.2011.07.009
   Mora B, 2007, J UROLOGY, V178, P160, DOI 10.1016/j.juro.2007.03.019
   Myers Cynthia D, 2008, J SOC INTEGR ONCOL, V6, P19
   NikbakhtNasrabadi A, 2012, IRAN J NURS IJN, V27, P54
   Padmanabhan R, 2005, ANAESTHESIA, V60, P874, DOI 10.1111/j.1365-2044.2005.04287.x
   Portnow Jana, 2003, J NATL COMPR CANC NETW, V1, P435
   Rajaee N, 2015, V2, V0, P6
   Shabanloei Reza, 2010, AORN J, V91, P746, DOI 10.1016/j.aorn.2010.04.001
   Sharif F, 2011, ARCH REHABIL, V12, P8
   Taghadosi M, 2014, LIFE SCI J, V11, P153
   Valiee S, 2012, J PERIANESTH NURS, V27, P259, DOI 10.1016/j.jopan.2012.05.003
   Wang SM, 2005, ANESTH ANALG, V101, P666, DOI 10.1213/01.ANE.0000175212.17642.45
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
NR 34
TC 47
Z9 53
U1 1
U2 30
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1744-3881
EI 1873-6947
J9 COMPLEMENT THER CLIN
JI Complement. Ther. Clin. Pract.
PD NOV 15
PY 2017
VL 29
IS 
BP 136
EP 141
DI 10.1016/j.ctcp.2017.09.002
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA FN6ZM
UT WOS:000416166000015
PM 29122251
DA 2026-01-16
ER

PT J
AU Fu, T
   Wang, L
   Du, J
   Chen, F
   Fang, J
   Liang, Y
   Fang, J
AF Fu, Taofang
   Wang, Lingling
   Du, Junying
   Chen, Feng
   Fang, Junfan
   Liang, Yi
   Fang, Jianqiao
TI [Effects of electroacupuncture on expression of μ-opioid receptor in nucleus
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE bone cancer pain; electroacupuncture (EA); morphine tolerance; μ-opioid receptor
AB OBJECTIVE: To observe the effects of electroacupuncture (EA) on pain behavior in  rats with bone cancer pain and morphine tolerance, and to explore partial action  mechanism. METHODS: Forty-two SD healthy female rats were randomly divided into a  sham operation group (7 rats), a bone cancer pain group (8 rats), a morphine  tolerance group (9 rats), an EA group (9 rats) and a sham EA group (9 rats). The  rats in the sham operation group were treated with injection of phosphate buffer  saline at medullary cavity of left-side tibia, and the rats in the remaining  groups were injected with MRMT-1 breast cancer cells. After operation, no  treatment was given to rats in the sham operation group and bone cancer pain  group. 11 days after operation, rats in the morphine tole-rance group, EA group  and sham EA group were treated with intraperitoneal injection of morphine  hydrochloride, once every 12 hours, for 11 days to establish the model of bone  cancer pain and morphine tolerance. One day after the establishment of this bone  cancer pain model, the rats in the morphine tolerance group were injected with  morphine, once every 12 hours (9:00 a.m. and 9:00 p.m.) for 7 days; the rats in  the EA group and sham EA group were injected with morphine at 9:00 a.m., and  treated with EA (2 Hz/100 Hz) and sham EA (only injected into the subcutaneous  tissue) at bilateral "Zusanli" (ST 36) and "Kunlun" (BL 60), 30 min per  treatment, once a day for 7 days. One day before cancer cell injection, 6 days, 8  days, 10 days after operation, after 30 min on 1 days, 5 days, 9 days, 11 days of  morphine injection, and after 30 min on 1 days, 3 days, 5 days, 7 days of EA  treatment, the paw withdrawal threshold (PWT) was measured in each group. On 11  day of morphine injection, HE staining was applied to observe the morphology and  structure change of tibia in the sham operation group, bone cancer pain group and  morphine tolerance group, random 2 rats in each group. On 7 days of EA treatment,  fluorescent immunohistochemical method was applied to observe the expression of  μ-opioid receptor positive cells in nucleus ceruleus in each group, random 4 rats  in each one. RESULTS: After 10 days of the cancer cells injection, the PWT of 28  rats of bone cancer pain model (8 rats in the bone cancer pain group, 8 rats in  the morphine tolerance group, 6 rats in the EA group and 6 rats in the sham EA  group) was significantly lower than that of 7 rats in the sham operation group  (P<0.01). After one day of morphine injection, the PWT of the morphine tolerance  group, EA group and sham EA group was higher than that of the bone cancer pain  group (all P<0.01); on 11 d of morphine injection, the PWT of the morphine  tolerance group, EA group and sham EA group was not significantly different from  that of the bone cancer pain group (all P>0.05). On 11 d of morphine injection,  the tumor induced by cancer cells was observed in upper 1/3 tibia in the bone  cancer pain group and morphine tolerance group, and the marrow cavity was filled  with MRMT-1 cancer cells; no abnormal change was observed in the sham operation  group. On 1 d, 3 d, 5 d and 7 d of EA treatment, the PWT of the cancer pain  group, morphine tolerance group and sham EA group was lower than that of the EA  group (all P<0.01). On 7 d of EA treatment, the positive expression of MOR in  nucleus ceruleus in the cancer pain group, morphine tolerance group, EA group and  sham EA group was lower than that in the sham operation group (P<0.01, P<0.05),  and that in the cancer pain group, morphine tolerance group and sham EA group was  lower than that in the EA group (all P<0.01). CONCLUSIONS: EA can improve  mechanical pain threshold in rats with bone cancer pain-morphine tolerance, and  improve the abnormal pain, which is likely to be involved with improvement of the  MOR positive cells expression in nucleus ceruleus by EA.
C1 Laboratory of Acupuncture and Neurobiology, the Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Laboratory of Acupuncture and Neurobiology, the Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Laboratory of Acupuncture and Neurobiology, the Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Department of Acupuncture and Moxibustion, the First Affiliated Hospital of Jiaxing University.
   Laboratory of Acupuncture and Neurobiology, the Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Laboratory of Acupuncture and Neurobiology, the Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Laboratory of Acupuncture and Neurobiology, the Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD DEC 13
PY 2017
VL 37
IS 5
BP 513
EP 520
DI 10.13703/j.0255-2930.2017.05.017
PG 7
WC Analgesics, Opioid; therapeutic use; Animals; Cancer Pain; metabolism; Electroacupuncture; Female; Locus Coeruleus; metabolism; Morphine; therapeutic use; Pain Threshold; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; metabolism
UT PubMed:29231613
PM 29231613
DA 2017-12-13
ER

PT J
AU Pugh, SL
   Wyatt, G
   Wong, RKW
   Sagar, SM
   Yueh, B
   Singh, AK
   Yao, M
   Nguyen-Tan, PF
   Yom, SS
   Cardinale, FS
   Sultanem, K
   Hodson, DI
   Krempl, GA
   Chavez, A
   Yeh, AM
   Bruner, DW
AF Pugh, Stephanie L.
   Wyatt, Gwen
   Wong, Raimond K. W.
   Sagar, Stephen M.
   Yueh, Bevan
   Singh, Anurag K.
   Yao, Min
   Nguyen-Tan, Phuc Felix
   Yom, Sue S.
   Cardinale, Francis S.
   Sultanem, Khalil
   Hodson, D. Ian
   Krempl, Greg A.
   Chavez, Ariel
   Yeh, Alexander M.
   Bruner, Deborah W.
TI Exploratory Factor Analysis of NRG Oncology's University of Washington Quality of Life Questionnaire-RTOG Modification
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Quality of life; factor analysis; xerostomia
ID neck-cancer patients; radiation-induced xerostomia; colony-stimulating factor; oral complications; phase-iii; uw-qol; head; patient; impact; radiotherapy
AB Context. The 15-item University of Washington Quality of Life questionnaire-Radiation Therapy Oncology Group (RTOG) modification (UW-QOL-RTOG modification) has been used in several trials of head and neck cancer conducted by NRG Oncology such as RTOG 9709, RTOG 9901, RTOG 0244, and RTOG 0537. Objectives. This study is an exploratory factor analysis (EFA) to establish validity and reliability of the instrument subscales. Methods. EFA on the UW-QOL-RTOG modification was conducted using baseline data from NRG Oncology's RTOG 0537, a trial of acupuncture-like transcutaneous electrical nerve stimulation in treating radiation-induced xerostomia. Cronbach alpha coefficient was calculated to measure reliability; correlation with the University of Michigan Xerostomia Related Quality of Life Scale was used to evaluate concurrent validity; and correlations between consecutive time points were used to assess test-retest reliability. Results. The 15-item EFA of the modified tool resulted in 11 items split into four factors: mucus, eating, pain, and activities. Cronbach alpha ranged from 0.71 to 0.93 for the factors and total score, consisting of all 11 items. There were strong correlations (rho >= 0.60) between consecutive time points and between total score and the Xerostomia Related Quality of Life Scale total score (rho > 0.65). Conclusion. The UW-QOLeRTOG modification is a valid tool that can be used to assess symptom burden of head and neck cancer patients receiving radiation therapy or those who have recently completed radiation. The modified tool has acceptable reliability, concurrent validity, and test-retest reliability in this patient population, as well as the advantage of having being shortened from 15 to 11 items. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Pugh, Stephanie L.] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA.
   [Wyatt, Gwen] Michigan State Univ, E Lansing, MI 48824 USA.
   [Wong, Raimond K. W.; Sagar, Stephen M.; Hodson, D. Ian] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada.
   [Yueh, Bevan] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
   [Singh, Anurag K.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
   [Yao, Min] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Nguyen-Tan, Phuc Felix] Hop Notre Dame De Bon Secours, CHUM, Montreal, PQ, Canada.
   [Yom, Sue S.] UCSF Med Ctr, San Francisco, CA USA.
   [Cardinale, Francis S.] Yale Univ, New Haven, CT USA.
   [Sultanem, Khalil] McGill Univ, Montreal, PQ, Canada.
   [Krempl, Greg A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
   [Chavez, Ariel] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA.
   [Yeh, Alexander M.] Indiana Univ Hosp, Melvin & Bren Simon Canc Ctr, 550 N Univ Blvd, Indianapolis, IN 46202 USA.
   [Bruner, Deborah W.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
C3 Michigan State University; McMaster University; University of Minnesota System; University of Minnesota Twin Cities; Roswell Park Comprehensive Cancer Center; University System of Ohio; Case Western Reserve University; Universite de Montreal; University of California System; University of California San Francisco; UCSF Medical Center; Yale University; McGill University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County; Indiana University Health; IU Health University Hospital; Emory University
RP Pugh, SL (corresponding author), 1818 Market St,Suite 1720, Philadelphia, PA 19103 USA.
EM pughs@nrgoncology.org
FU National Cancer Institute (NCI) [U10CA21661, U10CA180868, U10CA180822, U10CA37422, UG1CA189867]; National Cancer Institute [U10CA180868, U10CA180822, UG1CA190000, UG1CA189867] Funding Source: NIH RePORTER
CR Basch E, 2006, LANCET ONCOL, V7, P903, DOI 10.1016/S1470-2045(06)70910-X
   Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006
   Cohen J, 1988, STAT POWER ANAL BEHA, V0, P0, DOI DOI 10.4324/9780203771587
   Di Maio M, 2015, J CLIN ONCOL, V33, P910, DOI 10.1200/JCO.2014.57.9334
   Dirix P, 2006, CANCER-AM CANCER SOC, V107, P2525, DOI 10.1002/cncr.22302
   Elting LS, 2008, CANCER-AM CANCER SOC, V113, P2704, DOI 10.1002/cncr.23898
   Epstein JB, 2010, SUPPORT CARE CANCER, V18, P1023, DOI 10.1007/s00520-010-0897-7
   Fisher J, 2003, INT J RADIAT ONCOL, V56, P832, DOI 10.1016/S0360-3016(03)00121-4
   Germano F, 2015, MINERVA STOMATOL, V64, P189
   Goepfert RP, 2015, LARYNGOSCOPE, V125, P869, DOI 10.1002/lary.25023
   HASSAN SJ, 1993, HEAD NECK-J SCI SPEC, V15, P485, DOI 10.1002/hed.2880150603
   Henson BS, 2001, ORAL ONCOL, V37, P84, DOI 10.1016/S1368-8375(00)00063-4
   Hoffman KE, 2014, QUAL LIFE RES, V23, P1841, DOI 10.1007/s11136-014-0628-5
   Hovan AJ, 2010, SUPPORT CARE CANCER, V18, P1081, DOI 10.1007/s00520-010-0902-1
   Jensen SB, 2010, SUPPORT CARE CANCER, V18, P1039, DOI 10.1007/s00520-010-0827-8
   Jha N, 2012, INT J RADIAT ONCOL, V84, P437, DOI 10.1016/j.ijrobp.2012.02.034
   Laraway DC, 2012, BRIT J ORAL MAX SURG, V50, P122, DOI 10.1016/j.bjoms.2010.12.005
   List MA, 2000, CURR OPIN ONCOL, V12, P215, DOI 10.1097/00001622-200005000-00006
   MORTON RP, 1995, J LARYNGOL OTOL, V109, P1029, DOI 10.1017/S0022215100131962
   Movsas B, 2003, SEMIN RADIAT ONCOL, V13, P235, DOI 10.1016/S1053-4296(03)00029-8
   Murphy BA, 2015, J CLIN ONCOL, V33, P3314, DOI 10.1200/JCO.2015.61.3836
   Nunnally JC, 1978, PSYCHOMETRIC THEORY, V0, P0
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Onakoya PA, 2006, J NATL MED ASSOC, V98, P765
   Osborne JW, 2005, PRACTICAL ASSESSMENT, V10, P1, DOI 10.7275/jyj1-4868
   Parker PA, 2003, PSYCHO-ONCOLOGY, V12, P183, DOI 10.1002/pon.635
   Petersen MA, 2006, EUR J CANCER, V42, P1159, DOI 10.1016/j.ejca.2006.01.032
   Reeve BB, 2013, HEAD NECK-J SCI SPEC, V35, P1255, DOI 10.1002/hed.23115
   Rogers SN, 2010, ARCH OTOLARYNGOL, V136, P352, DOI 10.1001/archoto.2010.32
   Rogers SN, 2009, ARCH OTOLARYNGOL, V135, P369, DOI 10.1001/archoto.2009.7
   Rogers SN, 2006, ORAL ONCOL, V42, P281, DOI 10.1016/j.oraloncology.2005.08.002
   Rogers SN, 2002, HEAD NECK-J SCI SPEC, V24, P521, DOI 10.1002/hed.10106
   Rogers SN, 2012, J CRANIOMAXILLOFAC S, V30, P125
   Ryu JK, 2007, INT J RADIAT ONCOL, V67, P643, DOI 10.1016/j.ijrobp.2006.09.043
   Scarantino Charles, 2006, J SUPPORT ONCOL, V4, P252
   Sonis ST, 2002, ONCOLOGY-NY, V16, P680
   Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8
   US Department of Health and Human Services (USDHHS); Guidance for industry, 2009, GUID IND PAT REP OUT, V0, P0
   Weymuller EA, 2001, ARCH OTOLARYNGOL, V127, P489
   Wong RKW, 2015, INT J RADIAT ONCOL, V92, P220, DOI 10.1016/j.ijrobp.2015.01.050
   Wyatt G, 2016, QUAL LIFE RES, V25, P2323, DOI 10.1007/s11136-016-1255-0
   Xiao CH, 2013, CANCER NURS, V36, PE1, DOI 10.1097/NCC.0b013e318269040f
NR 42
TC 5
Z9 8
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JAN 15
PY 2017
VL 53
IS 1
BP 139
EP U180
DI 10.1016/j.jpainsymman.2016.11.002
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA EO2BW
UT WOS:000396502600018
PM 27899312
DA 2026-01-16
ER

PT J
AU Han, X
   Wang, L
   Shi, H
   Zheng, G
   He, J
   Wu, W
   Shi, J
   Wei, G
   Zheng, W
   Sun, J
   Huang, H
   Cai, Z
AF Han, Xiaoyan
   Wang, Lijuan
   Shi, Hongfei
   Zheng, Gaofeng
   He, Jingsong
   Wu, Wenjun
   Shi, Jimin
   Wei, Guoqing
   Zheng, Weiyan
   Sun, Jie
   Huang, He
   Cai, Zhen
TI Acupuncture combined with methylcobalamin for the treatment of
SO BMC cancer
LA English
DT Journal Article
DE Acupuncture; CIPN; Methylcobalamin; Multiple myeloma
AB BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) seriously affects  the quality of life of patients with multiple myeloma (MM) as well as the  response rate to chemotherapy. Acupuncture has a potential role in the treatment  of CIPN, but at present there have been no randomized clinical research studies  to analyze the effectiveness of acupuncture for the treatment of CIPN,  particularly in MM patients. METHODS: The MM patients (104 individuals) who met  the inclusion criteria were randomly assigned into a solely methylcobalamin  therapy group (500 μg intramuscular methylcobalamin injections every other day  for 20 days; ten injections) followed by 2 months of 500 μg oral methylcobalamin  administration, three times per day) and an acupuncture combined with  methylcobalamin (Met + Acu) group (methylcobalamin used the same way as above  accompanied by three cycles of acupuncture). Of the patients, 98 out of 104  completed the treatment and follow-ups. There were 49 patients in each group. The  evaluating parameters included the visual analogue scale (VAS) pain score,  Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity  (Fact/GOG-Ntx) questionnaire scores, and electromyographic (EMG) nerve conduction  velocity (NCV) determinations. We evaluated the changes of the parameters in each  group before and after the therapies and made a comparison between the two  groups. RESULTS: After 84 days (three cycles) of therapy, the pain was  significantly alleviated in both groups, with a significantly higher decrease in  the acupuncture treated group (P < 0.01). The patients' daily activity evaluated  by Fact/GOG-Ntx questionnaires significantly improved in the Met + Acu group  (P < 0.001). The NCV in the Met + Acu group improved significantly while  amelioration in the control group was not observed. CONCLUSIONS: The present  study suggests that acupuncture combined with methylcobalamin in the treatment of  CIPN showed a better outcome than methylcobalamin administration alone. TRIAL  REGISTRATION: China Clinical Trials Register (registration no.  ChiCTR-INR-16009079 , registration date August 24, 2016).
C1 Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Present Address: Department of Hematology, Hematology Laboratory, Linyi People's 
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China.
   Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, ZhejiangUniversity, No. 79 Qingchun Road, Hangzhou, 310003, China. caiz@zju.edu.cn.
NR 0
TC 0
SN 1471-240
EI 
J9 BMC Cancer
PD JAN 11
PY 2017
VL 17
IS 1
BP 40
EP 40
DI 10.1186/s12885-016-3037-z
PG 0
WC Acupuncture Therapy; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; China; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Multiple Myeloma; drug therapy; Neoplasm Staging; Peripheral Nervous System Diseases; chemically induced; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate; Vitamin B 12; analogs & derivatives
UT PubMed:28068938
PM 28068938
DA 2017-01-11
ER

PT J
AU He, Y
   Liu, Y
   May, BH
   Zhang, AL
   Zhang, H
   Lu, C
   Yang, L
   Guo, X
   Xue, CC
AF He, Yihan
   Liu, Yihong
   May, Brian H
   Zhang, Anthony Lin
   Zhang, Haibo
   Lu, ChuanJian
   Yang, Lihong
   Guo, Xinfeng
   Xue, Charlie Changli
TI Effectiveness of acupuncture for cancer pain: protocol for an umbrella review and
SO BMJ open
LA English
DT Journal Article
DE acupuncture; cancer pain; meta-analyses; umbrella review
AB INTRODUCTION: The National Comprehensive Cancer Network guidelines for adult  cancer pain indicate that acupuncture and related therapies may be valuable  additions to pharmacological interventions for pain management. Of the systematic  reviews related to this topic, some concluded that acupuncture was promising for  alleviating cancer pain, while others argued that the evidence was insufficient  to support its effectiveness. METHODS AND ANALYSIS: This review will consist of  three components: (1) synthesis of findings from existing systematic reviews; (2)  updated meta-analyses of randomised clinical trials and (3) analyses of results  of other types of clinical studies. We will search six English and four Chinese  biomedical databases, dissertations and grey literature to identify systematic  reviews and primary clinical studies. Two reviewers will screen results of the  literature searches independently to identify included reviews and studies. Data  from included articles will be abstracted for assessment, analysis and summary.  Two assessors will appraise the quality of systematic reviews using Assessment of  Multiple Systematic Reviews; assess the randomised controlled trials using the  Cochrane Collaboration's risk of bias tool and other types of studies according  to the Newcastle-Ottawa Scale. We will use 'summary of evidence' tables to  present evidence from existing systematic reviews and meta-analyses. Using the  primary clinical studies, we will conduct meta-analysis for each outcome, by  grouping studies based on the type of acupuncture, the comparator and the  specific type of pain. Sensitivity analyses are planned according to clinical  factors, acupuncture method, methodological characteristics and presence of  statistical heterogeneity as applicable. For the non-randomised studies, we will  tabulate the characteristics, outcome measures and the reported results of each  study. Consistencies and inconsistencies in evidence will be investigated and  discussed. Finally, we will use the Grading of Recommendations Assessment,  Development and Evaluation approach to evaluate the quality of the overall  evidence. ETHICS AND DISSEMINATION: There are no ethical considerations  associated with this review. The findings will be disseminated in peer-reviewed  journals or conference presentations. PROSPERO REGISTRATION NUMBER:  CRD42017064113.
C1 China-Australia International Research Center for Chinese Medicine, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial 
   China-Australia International Research Center for Chinese Medicine, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial 
   China-Australia International Research Center for Chinese Medicine, RMIT University, Melbourne, Victoria, Australia.
   China-Australia International Research Center for Chinese Medicine, RMIT University, Melbourne, Victoria, Australia.
   China-Australia International Research Center for Chinese Medicine, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial 
   China-Australia International Research Center for Chinese Medicine, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial 
   China-Australia International Research Center for Chinese Medicine, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial 
   China-Australia International Research Center for Chinese Medicine, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial 
   China-Australia International Research Center for Chinese Medicine, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD DEC 13
PY 2017
VL 7
IS 12
BP e018494
EP e018494
DI 10.1136/bmjopen-2017-018494
PG 1
WC Humans; Acupuncture Therapy; Cancer Pain; therapy; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic; Meta-Analysis as Topic
UT PubMed:29229658
PM 29229658
DA 2017-12-13
ER

PT J
AU Enblom, A
   Johnsson, A
AF Enblom, Anna
   Johnsson, Anna
TI Type and frequency of side effects during PC6 acupuncture: observations from therapists and patients participating in clinical efficacy trials of acupuncture
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE Complementary Medicine; Physiotherapy; Adverse Events; Clinical Trials; Acupuncture
ID chemotherapy-induced nausea; postoperative nausea; placebo-acupuncture; manual acupuncture; single-blind; cancer; electroacupuncture; prophylaxis; acupressure; prevention
AB Background Many therapists practise PC6 acupuncture for emesis (nausea and vomiting) during pregnancy, different cancer therapies, palliative care, after surgery, or to induce relaxing effects in general. Knowledge of side effects is central to shared decision-making. Aim To describe the type and frequency of side effects and the level of needle-induced pain during PC6 acupuncture. Methods We included 1298 PC6 acupuncture treatments, delivered to 221 participants (77% women, mean age 52.5, range 18-91 years). The subjects had received genuine PC6 acupuncture, in one of two previous randomised controlled trials, aimed at inducing antiemetic (n=100, with 100 providing data on side effects and 94 on needle-induced pain, respectively) or relaxing (n=121, with 120 providing data) effects. Side effects during and after the acupuncture treatments were registered in structured treatment protocols and study diaries. Results No serious complications occurred. Side effects during the acupuncture sessions included minor bleeding in 5.0%, tiredness in 4.9%, numbness in 4.5% and dizziness in 1.4% of the 1298 treatments. After treatment, the mean proportions of participants reporting side effects each week were: tiredness 25.8%; feeling cold 17.8%; dizziness 9.7%; sweating 9.3%; haematoma 8.8%; and soreness at the needling sites 4.3%. Participants perceived the needling to be not painful (47.4% of participants), or mildly (39.1%), moderately (11.6%) or very painful (1.4%). Conclusions Few side effects occurred and those that did were mild. Nearly 90% found PC6 acupuncture to be not painful or only mildly painful. Healthcare professionals may consider the observed levels of side effects when informing patients about side effects of PC6 acupuncture.
C1 [Enblom, Anna] Linkoping Univ, Reg Ostergotland, Linkoping, Sweden.
   [Enblom, Anna] Linkoping Univ, Dept Med & Hlth Sci, Div Physiotherapy, S-58183 Linkoping, Sweden.
   [Johnsson, Anna] Skane Univ Hosp, Dept Oncol, Lund, Sweden.
   [Johnsson, Anna] Lund Univ, Dept Clin Sci, Div Oncol & Pathol, Lund, Sweden.
C3 Linkoping University; Linkoping University; Lund University; Skane University Hospital; Lund University
RP Enblom, A (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, Div Physiotherapy, S-58183 Linkoping, Sweden.
EM anna.enblom@liu.se
FU Swedish Cancer Society [04 0483]; Vardal Institute; Region of Ostergotland [LIO-345691, LIO-613331, LIO-426011]; University of Linkoping [LIO-345691, LIO-613331, LIO-426011]; Cancer Rehabilitation Foundation [C 40111]; Osher Centrum for Integrative Medicine, Karolinska Institute
CR AGLIETTI L, 1990, CANCER CHEMOTH PHARM, V26, P239, DOI 10.1007/BF02897209
   Anna E, 2008, COMPLEMENT THER MED, V16, P288, DOI 10.1016/j.ctim.2008.02.012
   Boelig RC, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010607.pub2
   Carlsson CPO, 2000, J PAIN SYMPTOM MANAG, V20, P273, DOI 10.1016/S0885-3924(00)00185-8
   Chen YD, 2015, ACUPUNCT MED, V33, P103, DOI 10.1136/acupmed-2014-010594
   Clarkson CE, 2015, ACTA OBSTET GYN SCAN, V94, P453, DOI 10.1111/aogs.12587
   DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508
   DUNDEE JW, 1986, BMJ-BRIT MED J, V293, P583, DOI 10.1136/bmj.293.6547.583
   DUNDEE JW, 1990, J ROY SOC MED, V83, P360, DOI 10.1177/014107689008300608
   El-Deeb AM, 2011, J ANESTH, V25, P698, DOI 10.1007/s00540-011-1198-0
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Enblom A, 2011, ACUPUNCT MED, V29, P94, DOI 10.1136/aim.2010.003384
   Ernst G, 2003, COMPLEMENT THER MED, V11, P93, DOI 10.1016/S0965-2299(03)00004-9
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Habek D, 2004, FORSCH KOMP KLAS NAT, V11, P20, DOI 10.1159/000077192
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   HO RT, 1990, ANAESTHESIA, V45, P327, DOI 10.1111/j.1365-2044.1990.tb14744.x
   Hoffmann TC, 2015, JAMA INTERN MED, V175, P274, DOI 10.1001/jamainternmed.2014.6016
   Knight B, 2001, OBSTET GYNECOL, V97, P184, DOI 10.1016/S0029-7844(00)01152-2
   Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Liodden I, 2015, ACUPUNCT MED, V33, P196, DOI 10.1136/acupmed-2014-010738
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   MacPherson Hugh, 2005, ACUPUNCT MED, V23, P112
   Matthews A, 2015, COCHRANE DB SYST REV, V8, P0
   McKeon C, 2015, ACUPUNCT MED, V33, P277, DOI 10.1136/acupmed-2015-010781
   Melchart D, 2006, SUPPORT CARE CANCER, V14, P878, DOI 10.1007/s00520-006-0028-7
   Neri I, 2005, MINERVA GINECOL, V57, P471
   Nystrom E, 2008, ACUPUNCT MED, V26, P27, DOI 10.1136/aim.26.1.27
   Odsberg A, 2001, COMPLEMENT THER MED, V9, P17, DOI 10.1054/ctim.2000.0418
   Peuker Elmar, 2004, ACUPUNCT MED, V22, P40
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Rosen A, 2014, STOCKH STR CTR ANN W, V1, P0
   Sharma S, 2007, J ANAESTHESIOL CLIN PHARMACOL, V23, P401
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Smith C, 2002, BIRTH-ISS PERINAT C, V29, P1, DOI 10.1046/j.1523-536X.2002.00149.x
   Smith K, 2016, BIOETHICS, V30, P60, DOI 10.1111/bioe.12243
   SOUTHWORTH SR, 1990, J HAND SURG-BRIT EUR, V15B, P111, DOI 10.1016/0266-7681(90)90063-A
   Streitberger K, 2004, ANAESTHESIA, V59, P142, DOI 10.1111/j.1365-2044.2004.03577.x
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Streitberger K, 2007, J ALTERN COMPLEM MED, V13, P585, DOI 10.1089/acm.2007.6247
   Streitberger K, 2006, AUTON NEUROSCI-BASIC, V129, P107, DOI 10.1016/j.autneu.2006.07.015
   Usichenko TI, 2016, ACUPUNCT MED, V34, P70, DOI 10.1136/acupmed-2015-010926
   White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485
   White Adrian, 2004, ACUPUNCT MED, V22, P122
   Wu JY, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/432467
NR 48
TC 7
Z9 11
U1 0
U2 23
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD DEC 15
PY 2017
VL 35
IS 6
BP 421
EP 429
DI 10.1136/acupmed-2016-011270
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA FR4QA
UT WOS:000419049100004
PM 29222203
DA 2026-01-16
ER

PT J
AU Deng, G
   Giralt, S
   Chung, DJ
   Landau, H
   Siman, J
   Search, B
   Coleton, M
   Vertosick, E
   Shapiro, N
   Chien, C
   Wang, XS
   Cassileth, B
   Mao, JJ
AF Deng, Gary
   Giralt, Sergio
   Chung, David J
   Landau, Heather
   Siman, Jonathan
   Search, Benjamin
   Coleton, Marci
   Vertosick, Emily
   Shapiro, Nathan
   Chien, Christine
   Wang, Xin S
   Cassileth, Barrie
   Mao, Jun J
TI Acupuncture for reduction of symptom burden in multiple myeloma patients
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture; Complementary therapies; Hematopoietic stem cell transplantation; Integrative medicine; Multiple myeloma; Symptom management
AB PURPOSE: Hematopoietic stem cell transplantation (HCT) is potentially curative  for a number of hematologic malignancies, but is associated with high symptom  burden. We conducted a randomized sham-controlled trial (RCT) to evaluate  efficacy and safety of acupuncture as an integrative treatment for managing  common symptoms during HCT. METHODS: Adult patients with multiple myeloma  undergoing high-dose melphalan followed by autologous HCT (AHCT) were randomized  to receive either true or sham acupuncture once daily for 5 days starting the day  after chemotherapy. Patients and clinical evaluators, but not acupuncturists,  were blinded to group assignment. Symptom burden, the primary outcome was  assessed with the MD Anderson Symptom Inventory (MDASI) at baseline, during  transplantation, and at 15 and 30 days post transplantation. RESULTS: Among 60  participants, true acupuncture produced nonsignificant reductions in overall  MDASI core symptom scores and symptom interference scores during transplantation  (P = .4 and .3, respectively), at 15 days (P = .10 and .3), and at 30 days  posttransplantation (P = .2 and .4) relative to sham. However, true acupuncture  was significantly more efficacious in reducing nausea, lack of appetite, and  drowsiness at 15 days (P = .042, .025, and .010, respectively). Patients  receiving sham acupuncture were more likely to increase pain medication use  posttransplantation (odds ratio 5.31, P = .017). CONCLUSIONS: Acupuncture was  well tolerated with few attributable adverse events. True acupuncture may prevent  escalation of symptoms including nausea, lack of appetite, and drowsiness  experienced by patients undergoing AHCT, and reduce the use of pain medications.  These findings need to be confirmed in a future definitive study. TRIAL  REGISTRATION: NCT01811862.
C1 Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA. dengg@mskcc.org.
   Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Health Outcomes Research Group, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Health Outcomes Research Group, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Health Outcomes Research Group, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
NR 0
TC 0
SN 1433-733
EI 0941-435
J9 Support Care Cancer
PD SEP 19
PY 2017
VL 26
IS 2
BP 657
EP 665
DI 10.1007/s00520-017-3881-7
PG 8
WC Acupuncture Therapy; methods; Female; Hematopoietic Stem Cell Transplantation; methods; Humans; Male; Multiple Myeloma; therapy; Prospective Studies; Transplantation, Autologous; methods
UT PubMed:28920142
PM 28920142
DA 2017-09-19
ER

PT J
AU Lu, Z
   Moody, J
   Marx, BL
   Hammerstrom, T
AF Lu, Zhaoxue
   Moody, Jennifer
   Marx, Benjamin L
   Hammerstrom, Tracy
TI Treatment of Chemotherapy-Induced Peripheral Neuropathy in Integrative Oncology:
SO Journal of alternative and complementary medicine (New York, N.Y.)
LA English
DT Journal Article
DE acupuncture; chemotherapy-induced peripheral neuropathy; integrative oncology; neurological pain; neuropathic pain
AB OBJECTIVES: Complementary and alternative medicine is increasingly integrated  into cancer care. We sought detail on the treatment of chemotherapy-induced  peripheral neuropathy (CIPN) with acupuncture and oriental medicine (AOM) by  surveying practitioners at integrative oncology (IO) sites across the United  States. DESIGN: Online survey of licensed acupuncturists. SETTING/LOCATION: IO  sites in the United States. SUBJECTS: Fifteen licensed acupuncturists who  completed the survey between February 2014 and June 2014. OUTCOME MEASURES:  Demographics, IO setting characteristics, AOM treatment characteristics, and  practitioner-reported outcomes. RESULTS: Respondents reported an average of  31.3 ± 17.2 patients per week, and one-third (10.1 mean; 7.2 standard deviation  [SD]) were treated for CIPN. Medical doctors (86.7%) were the most common  providers with whom respondents worked. Traditional Chinese medicine style  acupuncture was utilized by a majority of respondents (86.7%), and the most  commonly used points were local, typically in the hands and feet, such as Ba  Feng, Ba Xie, LV3, and LI4. In addition to acupuncture, nutritional advice was  the most frequent auxiliary modality provided by respondents (85.7%). On average,  respondents provided 12.75 ± 4.17 treatments for CIPN patients, and a majority  (53%) reported treating patients once per week. Timing of the treatments relative  to chemotherapy infusion was evenly distributed between "1-2 days after infusion"  (60%), "at time of infusion" (53.3%), and "1-2 days before infusion" (46.7%).  Sixty percent of respondents rated outcomes as "moderately successful with  moderate improvement seen." CONCLUSION: This survey provides detail regarding IO  sites using acupuncture for CIPN as well as real-world treatment patterns,  including common point combinations, visit characteristics, and  practitioner-reported outcomes. This information contributes to the emerging  evidence on the use of acupuncture to address unmet needs of CIPN patients, and  supports the development of best practice guidelines for the treatment of CIPN  with acupuncture in the IO setting.
C1 Oregon College of Oriental Medicine , Portland, OR.
   Oregon College of Oriental Medicine , Portland, OR.
   Oregon College of Oriental Medicine , Portland, OR.
   Oregon College of Oriental Medicine , Portland, OR.
NR 0
TC 0
SN 1557-770
EI 
J9 J Altern Complement Med
PD JUL 1
PY 2017
VL 23
IS 12
BP 964
EP 970
DI 10.1089/acm.2017.0052
PG 6
WC Acupuncture; organization & administration; Acupuncture Therapy; statistics & numerical data; Adult; Cross-Sectional Studies; Female; Health Personnel; Humans; Integrative Oncology; Male; Medicine, Chinese Traditional; Middle Aged; Peripheral Nervous System Diseases; chemically induced; Surveys and Questionnaires
UT PubMed:28661695
PM 28661695
DA 2017-07-01
ER

PT J
AU Zhu, HD
   Gong, Z
   Hu, BW
   Wei, QL
   Kong, J
   Peng, CB
AF Zhu, Hua-Dong
   Gong, Zhen
   Hu, Bing-Wei
   Wei, Qiao-Ling
   Kong, Jun
   Peng, Cong-Bin
TI The Efficacy and Safety of Transcutaneous Acupoint Interferential Current
SO Integrative cancer therapies
LA English
DT Journal Article
DE cancer pain; lactulose; opioid-induced constipation; quality of life; transcutaneous acupoint interferential current therapy
AB INTRODUCTION: Opioid-induced constipation (OIC) is a principal complication  secondary to analgesic therapy for cancer pain patients who suffer moderate to  severe pain. In this study, we observe the efficacy and safety of transcutaneous  acupoint interferential current (IFC) stimulation in those patients with OIC.  METHODS: A total of 198 patients were randomly allocated to the IFC group and  control group in a 1:1 ratio. Finally, 98 patients in the IFC group received 14  sessions administered over 2 weeks, whereas 100 patients in the control group  took lactulose orally during the same period. Observation items were documented  at management stage and at follow-up stage according to Cleveland Constipation  Scales (CCS), pain Numeric Rating Scales (NRS) and Patient Assessment of  Constipation Quality of Life (PAC-QoL). RESULTS: The total curative effects of  the IFC group and the control group were indistinguishable (76.5% vs 70.0%, P =  .299). Regarding CCS and PAC-QoL scores, no significant difference was observed  between the 2 groups during the management time and at the follow-up stage of  week 3 ( P > .05, respectively), but groups were distinguished at the follow-up  stage of week 4 ( P < .001 and P = .031, respectively). The pain NRS decreased  significantly at management stage week 2 and follow-up stage week 3 and week 4 (  P = .013, P = .041, P = .011, respectively). CONCLUSIONS: Transcutaneous acupoint  IFC therapy over acupoints of Tianshu (ST25) and Zhongwan (RN12) may improve  constipation and quality of life in cancer patients receiving opiates; further  studies are worthwhile.
C1 1 Tongde Hospital of Zhejiang Province, Hangzhou, China.
   1 Tongde Hospital of Zhejiang Province, Hangzhou, China.
   1 Tongde Hospital of Zhejiang Province, Hangzhou, China.
   1 Tongde Hospital of Zhejiang Province, Hangzhou, China.
   1 Tongde Hospital of Zhejiang Province, Hangzhou, China.
   1 Tongde Hospital of Zhejiang Province, Hangzhou, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD OCT 28
PY 2017
VL 17
IS 2
BP 437
EP 443
DI 10.1177/1534735417734910
PG 6
WC Acupuncture Points; Analgesics, Opioid; adverse effects; Cancer Pain; therapy; Constipation; chemically induced; Female; Humans; Male; Middle Aged; Pain Management; methods; Prospective Studies; Quality of Life; Treatment Outcome
UT PubMed:29076387
PM 29076387
DA 2017-10-28
ER

PT J
AU Lee, I
   Garland, SN
   DeMichele, A
   Farrar, JT
   Im, EO
   Mao, JJ
AF Lee, Iris
   Garland, Sheila N.
   DeMichele, Angela
   Farrar, John T.
   Im, Eun-Ok
   Mao, Jun J.
TI A cross-sectional survey of pain catastrophising and acupuncture use among breast cancer survivors
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
ID inhibitor-induced arthralgia; musculoskeletal pain; fear-avoidance; trial; arthritis; scale; depression; symptoms; anxiety; women
AB Introduction Treatment-related joint pain affects almost half of all women with breast cancer using aromatase inhibitors and is a major reason for terminating treatment. Although acupuncture is becoming an increasingly popular, evidence-based option for treating pain, little is known about the potential influence of psychological factors on acupuncture use. Objective We aimed to evaluate the association between pain catastrophising and use of acupuncture in breast cancer survivors experiencing arthralgia. Methods We conducted a cross-sectional survey of arthralgic breast cancer patients. Patients were asked if they had used acupuncture since their cancer diagnosis. The Pain Catastrophising Scale (PCS) was used to measure negative coping styles related to the experience of pain. We performed multiple logistic regression analysis to evaluate the relationship between pain catastrophising and acupuncture use, adjusting for covariates. Results Of the 424 participants, 69 (16%) reported use of acupuncture since their breast cancer diagnosis. In multivariate analyses, compared to those in the lowest PCS score tertile, patients with the highest PCS scores were more likely to have used acupuncture (p=0.03). In particular, patients with high levels of rumination (p=0.005) and magnification (p=0.008) were more likely to have used acupuncture. Helplessness was not associated with acupuncture use (p=0.23). Conclusions High levels of pain catastrophising, and specifically the processes of rumination and magnification, were associated with greater acupuncture use. We believe this could have important implications for understanding which population is more likely to seek acupuncture treatment and how this alternative therapy could be better targeted to these patients.
C1 [Lee, Iris; Garland, Sheila N.; Mao, Jun J.] Univ Pennsylvania, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
   [Lee, Iris; DeMichele, Angela; Farrar, John T.; Mao, Jun J.] Univ Pennsylvania, Perelman Sch Med, Dept Biostatist & Epidemiol, Philadelphia, PA 19104 USA.
   [Garland, Sheila N.] Mem Univ Newfoundland, Dept Psychol, St John, NF, Canada.
   [DeMichele, Angela; Farrar, John T.; Im, Eun-Ok; Mao, Jun J.] Univ Pennsylvania, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA USA.
   [Im, Eun-Ok] Univ Pennsylvania, Sch Nursing, Philadelphia, PA USA.
   [Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Bendheim Ctr Integrat Med, 1429 First Ave, New York, NY 10021 USA.
C3 University of Pennsylvania; University of Pennsylvania; Memorial University Newfoundland; University of Pennsylvania; University of Pennsylvania; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Univ Pennsylvania, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.; Mao, JJ (corresponding author), Univ Pennsylvania, Perelman Sch Med, Dept Biostatist & Epidemiol, Philadelphia, PA 19104 USA.; Mao, JJ (corresponding author), Univ Pennsylvania, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA USA.; Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Bendheim Ctr Integrat Med, 1429 First Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU National Center for Complementary and Alternative Medicine [K23 AT004112]; National Cancer Institute [R01 CA158243]; National Institutes of Health/National Cancer Institute Cancer Center [P30 CA008748]
CR Unknown -, 2015, BRIEF PAIN INV, V0, P0
   Asmundson GJG, 2004, UNDERSTANDING AND TREATING FEAR OF PAIN, V0, P3
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Barnes PM, 2008, NATL HLTH STAT REPOR, V12, P0
   Bishop FL, 2015, CLIN J PAIN, V31, P254, DOI 10.1097/AJP.0000000000000108
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Chlebowski RT, 2009, J CLIN ONCOL, V27, P4032, DOI 10.1200/JCO.2009.23.3270
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Coleman RE, 2008, CANCER TREAT REV, V34, P275, DOI 10.1016/j.ctrv.2007.10.004
   Craner JR, 2015, CLIN J PAIN, V0, P0
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Eccleston C, 2007, PAIN, V132, P233, DOI 10.1016/j.pain.2007.09.014
   Edwards RR, 2013, J PAIN SYMPTOM MANAG, V46, P30, DOI 10.1016/j.jpainsymman.2012.06.016
   Edwards RR, 2006, ARTHRIT RHEUM-ARTHR, V55, P325, DOI 10.1002/art.21865
   Flink IK, 2012, BRIT J HEALTH PSYCH, V17, P408, DOI 10.1111/j.2044-8287.2011.02044.x
   Fontaine C, 2008, BREAST, V17, P376, DOI 10.1016/j.breast.2008.02.006
   Gatchel RJ, 2000, OCCUPATIONAL MUSCULO, V0, P3
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Johannes CB, 2010, J PAIN, V11, P1230, DOI 10.1016/j.jpain.2010.07.002
   KEEFE FJ, 1989, PAIN, V37, P51, DOI 10.1016/0304-3959(89)90152-8
   Lamé IE, 2005, EUR J PAIN, V9, P15, DOI 10.1016/j.ejpain.2004.02.006
   Leeuw M, 2007, J BEHAV MED, V30, P77, DOI 10.1007/s10865-006-9085-0
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Presant CA, 2007, CLIN BREAST CANCER, V7, P775, DOI 10.3816/CBC.2007.n.038
   Röschke J, 2000, J AFFECT DISORDERS, V57, P73, DOI 10.1016/S0165-0327(99)00061-0
   Schappert SM, 2006, VITAL HLTH STAT, V13, P1
   Soeken KL, 2004, CLIN J PAIN, V20, P13, DOI 10.1097/00002508-200401000-00004
   Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19
   Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524
   Van Damme S, 2002, PAIN, V96, P319, DOI 10.1016/S0304-3959(01)00463-8
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 35
TC 6
Z9 7
U1 0
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD FEB 15
PY 2017
VL 35
IS 1
BP 
EP 
DI 10.1136/acupmed-2016-011056
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA EP3BQ
UT WOS:000397257900006
PM 27177930
DA 2026-01-16
ER

PT J
AU Butkovic, D
   Tot, OK
AF Butkovic, D.
   Tot, O. K.
TI Laser acupuncture treatment of neuropathic pain in a boy with brain tumour
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Laser acupuncture; Neuropathic pain; Paediatric; Brain tumour; Linezolid
ID induced peripheral neuropathy; therapy
AB Neuropathic pain occurrence is associated with some cytostatic and antibiotics use. Pharmacological therapy for the treatment of neuropathic pain is sometimes unsuccessful, and complementary methods like acupuncture are included. In this case report, a 14-year-old boy with cerebral tumour and neuropathic pain in his feet after chemotherapy and linezolid use is presented. A complete cessation of neuropathic pain symptoms like hyperalgesia and allodynia was accomplished after laser acupuncture application.
C1 [Butkovic, D.; Tot, O. K.] Univ Osijek, Sch Med, Osijek, Croatia.
   [Butkovic, D.] Childrens Hosp Zagreb, Paediat Pain Clin, Zagreb, Croatia.
   [Tot, O. K.] Clin Hosp Ctr Osijek, Dept Pain Therapy, Osijek, Croatia.
C3 University of JJ Strossmayer Osijek; University of Zagreb; University of Zagreb Hospital
RP Butkovic, D (corresponding author), Childrens Hosp Zagreb, Dept Anaesthesiol Reanimat & Intens Care, Klaiceva 16, Zagreb 10000, Croatia.
EM diana.butkovic1@gmail.com
CR Abramowski MC, 2010, J ADV PRACTIT ONCOL, V1, P279
   Bressler AM, 2004, LANCET INFECT DIS, V4, P528, DOI 10.1016/S1473-3099(04)01109-0
   Chokshi SK, 2017, PEDIATR BLOOD CANCER, V64, P0, DOI 10.1002/pbc.26424
   Ferkovid M, 1998, ALCUPUNKTURA, V0, P0
   Golianu B, 2014, CHILDREN-BASEL, V1, P134, DOI 10.3390/children1020134
   Jung M, 2016, KLIN PADIATR, V228, P313, DOI 10.1055/s-0042-111692
   Kaley TJ, 2009, BRIT J HAEMATOL, V145, P3, DOI 10.1111/j.1365-2141.2008.07558.x
   Lin K, 2016, MED ACUPUNCT, V28, P156, DOI 10.1089/acu.2016.1173
   Linam WM, 2009, PEDIATR INFECT DIS J, V28, P149, DOI 10.1097/INF.0b013e3181945999
   Navratil L, 2002, J CLIN LASER MED SUR, V20, P341, DOI 10.1089/104454702320901134
   Ogundipe O, 2013, INTERNET J INTERNAL, V10, P1
   Piccolo J, 2014, AM J HEALTH-SYST PH, V71, P19, DOI 10.2146/ajhp130126
   Rapson LM, 2003, J SPINAL CORD MED, V26, P21, DOI 10.1080/10790268.2003.11753655
   Schröder S, 2007, EUR J NEUROL, V14, P276, DOI 10.1111/j.1468-1331.2006.01632.x
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Whittaker P, 2004, LASER MED SCI, V19, P69, DOI 10.1007/s10103-004-0296-8
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
NR 17
TC 3
Z9 4
U1 0
U2 14
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD DEC 15
PY 2017
VL 35
IS 
BP 53
EP 56
DI 10.1016/j.ctim.2017.09.006
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA FQ2XR
UT WOS:000418221800010
PM 29154067
DA 2026-01-16
ER

PT J
AU Frączek, P
   Kilian-Kita, A
   Püsküllüoglu, M
   Krzemieniecki, K
AF Frączek, Paulina
   Kilian-Kita, Aneta
   Püsküllüoglu, Mirosława
   Krzemieniecki, Krzysztof
TI Acupuncture as anticancer treatment?
SO Contemporary oncology (Poznan, Poland)
LA English
DT Review
DE acupuncture; anticancer treatment; cancer; complementary treatment; therapy
AB The mystery of Traditional Chinese Medicine has been attracting people for years.  Acupuncture, ranked among the most common services of Complementary and  Alternative Medicine, has recently gained a lot of interest in the scientific  world. Contemporary researchers have been continuously trying to shed light on  its possible mechanism of action in human organism. Numerous studies pertaining  to acupuncture's application in cancer symptoms or treatment-related side effects  management have already been published. Moreover, since the modern idea of  acupuncture's immunomodulating effect seems to be promising, scientists have  propounded a concept of its potential application as part of direct anti-tumor  therapy. In our previous study we summarized possible use of acupuncture in  management of cancer symptoms and treatment-related ailments, such as  chemotherapy-induced nausea and vomiting, pain, xerostomia, vasomotor symptoms,  neutropenia, fatigue, anxiety, insomnia, lymphoedema after mastectomy and  peripheral neuropathy. This article reviews the studies concerning acupuncture as  a possible tool in modern anticancer treatment.
C1 Department of Oncology Jagiellonian University, Krakow, Poland.
   Department of Oncology Jagiellonian University, Krakow, Poland.
   Department of Oncology Jagiellonian University, Krakow, Poland.
   Department of Oncology Jagiellonian University, Krakow, Poland.
NR 0
TC 0
SN 1897-430
EI 1428-252
J9 Contemp Oncol (Pozn)
PD FEB 28
PY 2017
VL 20
IS 6
BP 453
EP 457
DI 10.5114/wo.2016.65604
PG 4
UT PubMed:28239282
PM 28239282
DA 2017-02-28
ER

PT J
AU Ji, D
   Zhou, YL
   Li, SS
   Li, D
   Chen, H
   Xiong, YC
   Zhang, YQ
   Xu, H
AF Ji, Dong
   Zhou, Yalan
   Li, Shuangshuang
   Li, Dai
   Chen, Hui
   Xiong, Yuanchang
   Zhang, Yuqiu
   Xu, Hua
TI Anti-nociceptive effect of dexmedetomidine in a rat model of monoarthritis via suppression of the TLR4/NF-κB p65 pathway
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE dexmedetomidine; anti-nociceptive; inflammatory cytokine; signaling pathway
ID spinal glial activation; nf-kappa-b; peripheral-nerve injury; neuropathic pain; pathological pain; receptor; electroacupuncture; microglia; agonist; phosphorylation
AB As a therapeutic target for neuropathic pain, the anti-nociceptive effects of alpha 2-adrenoceptors (alpha 2AR) have attracted attention. Dexmedetomidine (DEX), a potent and highly selective alpha 2AR agonist, has exhibited significant analgesic effects in neuropathic pain, but the underlying mechanism has remained elusive. The present study investigated the effect of DEX on Toll-like receptor (TLR) 4 and nuclear factor (NF)-kappa B p65 expression, as well as the production of pro-inflammatory cytokines. The rat monoarthritis (MA) model was induced by intra-articular injection of complete Freund's adjuvant (CFA) at the ankle joint. After induction of MA, the rats were intrathecally treated with normal saline or DEX (2.5 mu g) for 3 consecutive days. The concentration of interleukin-1 beta and -6 as well as tumor necrosis factor-alpha was examined by ELISA. The expression levels of TLR4 and NF-kappa B p65 were determined by western blot analysis and immunohistochemistry. The results indicated that the pro-inflammatory cytokines TLR4 and NF-kappa B p65 were significantly upregulated in MA rats. DEX treatment markedly reduced mechanical and thermal hyperalgesia, suppressed MA-induced elevation of the pro-inflammatory cytokines and inhibited the TLR4/NF-kappa B p65 pathway, while these effects were blocked by pre-treatment with the selective alpha 2AR antagonist BRL44408 (15 mu g) at 30 min prior to CFA injection. These results suggested that DEX has an antinoci-ceptive effect via suppressing the TLR4/NF-kappa B p65 pathway.
C1 [Ji, Dong; Zhou, Yalan; Li, Shuangshuang; Li, Dai; Chen, Hui; Xiong, Yuanchang; Xu, Hua] Second Mil Med Univ, Changhai Hosp, Dept Anesthesiol, 168 Changhai Rd, Shanghai 200433, Peoples R China.
   [Zhang, Yuqiu] Fudan Univ, Inst Neurobiol, Inst Brain Sci, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.
   [Zhang, Yuqiu] Fudan Univ, State Key Lab Med Neurobiol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.
C3 Naval Medical University; Fudan University; Fudan University
RP Xu, H (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Anesthesiol, 168 Changhai Rd, Shanghai 200433, Peoples R China.; Zhang, YQ (corresponding author), Fudan Univ, Inst Neurobiol, Inst Brain Sci, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.; Zhang, YQ (corresponding author), Fudan Univ, State Key Lab Med Neurobiol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.
EM yuqiuzhang@fudan.edu.cn; pshhuaxu@163.com
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041
   BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380
   Bettoni I, 2008, GLIA, V56, P1312, DOI 10.1002/glia.20699
   Buerkle H, 1998, BRIT J ANAESTH, V81, P208, DOI 10.1093/bja/81.2.208
   Cao H, 2008, NEUROSCI BIOBEHAV R, V32, P972, DOI 10.1016/j.neubiorev.2008.03.009
   Chu YX, 2012, NEUROSCI BULL, V28, P49, DOI 10.1007/s12264-012-1058-4
   Conway EL, 1998, NEUROSCIENCE, V82, P805
   Feng YF, 2005, MOL CELL BIOL, V25, P4010, DOI 10.1128/MCB.25.10.4010-4022.2005
   GRILLI M, 1993, INT REV CYTOL, V143, P1
   Gwak YS, 2012, EXP NEUROL, V234, P362, DOI 10.1016/j.expneurol.2011.10.010
   HEAL DJ, 1993, EUR J PHARMACOL, V249, P37, DOI 10.1016/0014-2999(93)90659-6
   Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009
   Lee HG, 2013, NEUROSCI LETT, V557, P118, DOI 10.1016/j.neulet.2013.10.002
   Li SS, 2014, NEUROSCI LETT, V560, P21, DOI 10.1016/j.neulet.2013.12.012
   Liu L, 2012, BRAIN RES, V1427, P1, DOI 10.1016/j.brainres.2011.08.019
   Malmberg AB, 2001, BRIT J PHARMACOL, V132, P1827, DOI 10.1038/sj.bjp.0704032
   Milligan ED, 2003, J NEUROSCI, V23, P1026
   Mori K, 2002, NEUROPHARMACOLOGY, V43, P1026, DOI 10.1016/S0028-3908(02)00211-3
   ONeill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557
   Paqueron X, 2003, ANESTHESIOLOGY, V99, P199, DOI 10.1097/00000542-200307000-00030
   Peng L, 2003, BRAIN RES, V978, P65, DOI 10.1016/S0006-8993(03)02766-5
   Pertovaara A, 2000, ANESTHESIOLOGY, V92, P1082, DOI 10.1097/00000542-200004000-00027
   Saito O, 2010, BRIT J PHARMACOL, V160, P1754, DOI 10.1111/j.1476-5381.2010.00811.x
   Schaible HG, 2002, ANN NY ACAD SCI, V966, P343, DOI 10.1111/j.1749-6632.2002.tb04234.x
   Shan S, 2007, NEUROBIOL DIS, V26, P558, DOI 10.1016/j.nbd.2007.02.007
   Shan S, 2007, PAIN, V129, P64, DOI 10.1016/j.pain.2006.09.035
   Shimode N, 2003, NEUROSCI LETT, V343, P45, DOI 10.1016/S0304-3940(03)00309-4
   Sun S, 2008, BRAIN RES BULL, V75, P83, DOI 10.1016/j.brainresbull.2007.07.027
   Sun S, 2006, EXP NEUROL, V198, P294, DOI 10.1016/j.expneurol.2005.11.011
   Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002
   UNNERSTALL JR, 1984, BRAIN RES REV, V7, P69, DOI 10.1016/0165-0173(84)90030-4
   VIRTANEN R, 1988, EUR J PHARMACOL, V150, P9, DOI 10.1016/0014-2999(88)90744-3
   Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3
   Wright Jeffrey G, 2003, AM J RESPIR MED, V2, P211
   Wu GJ, 2008, TOXICOL APPL PHARM, V228, P105, DOI 10.1016/j.taap.2007.11.027
   Wu YQ, 2013, MEDIAT INFLAMM, V2013, P0, DOI 10.1155/2013/562154
   Wu YQ, 2012, CELL PHYSIOL BIOCHEM, V30, P609, DOI 10.1159/000341442
   Xu B, 2010, CLIN EXP PHARMACOL P, V37, Pe158, DOI 10.1111/j.1440-1681.2010.05426.x
   Xu B, 2010, ACTA PHARMACOL SIN, V31, P523, DOI 10.1038/aps.2010.32
   Xu JJ, 2006, ANESTH ANALG, V103, P714, DOI 10.1213/01.ane.0000226100.46866.ea
   Xu M, 2000, ANESTHESIOLOGY, V93, P473, DOI 10.1097/00000542-200008000-00027
   Yang JL, 2012, MOL BRAIN, V5, P0, DOI 10.1186/1756-6606-5-18
NR 43
TC 16
Z9 17
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD NOV 15
PY 2017
VL 14
IS 5
BP 4910
EP 4918
DI 10.3892/etm.2017.5196
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA FM4GS
UT WOS:000414973100132
PM 29201195
DA 2026-01-16
ER

PT J
AU Paley, CA
   Johnson, MI
AF Paley, Carole A
   Johnson, Mark I
TI Acupuncture for the management of cancer-related pain?
SO Pain management
LA English
DT Journal Article
DE acupuncture; cancer; pain
C1 Centre for Pain Research, School of Clinical & Applied Sciences, Leeds Beckett University, City Campus, Leeds LS1 3HE, UK.
   Research & Development Department, Airedale NHS Foundation Trust, Skipton Road, 
   Centre for Pain Research, School of Clinical & Applied Sciences, Leeds Beckett University, City Campus, Leeds LS1 3HE, UK.
NR 0
TC 0
SN 1758-187
EI 
J9 Pain Manag
PD SEP 25
PY 2017
VL 7
IS 5
BP 345
EP 349
DI 10.2217/pmt-2017-0018
PG 4
WC Acupuncture Therapy; Cancer Pain; therapy; Humans; Pain Management; methods; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:28936907
PM 28936907
DA 2017-09-25
ER

PT J
AU Garcia, JBS
   Lech, O
   Kraychete, DC
   Rico, MA
   Hernández-Castro, JJ
   Colimon, F
   Guerrero, C
   Gallegos, MS
   Lara-Solares, A
   Cantisani, JAF
   Amescua-Garcia, C
   Núñez, MDG
   Cook, MDB
   Iskandar, AJ
   Sierra, PB
AF Santos Garcia, Joao Batista
   Lech, Osvandre
   Kraychete, Durval Campos
   Antonieta Rico, Maria
   Hernandez-Castro, John Jairo
   Colimon, Frantz
   Guerrero, Carlos
   Sempertegui Gallegos, Manuel
   Lara-Solares, Argelia
   Flores Cantisani, Jose Alberto
   Amescua-Garcia, Cesar
   Guillen Nunez, Maria del Rocio
   Berenguel Cook, Maria del Rosario
   Jreige Iskandar, Aziza
   Bonilla Sierra, Patricia
TI The role of tramadol in pain management in Latin America: a report by the Change Pain Latin America Advisory Panel
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Review
DE Pain management; tramadol; Latin America; abuse; prescription control
ID prescription opioid analgesics; low-back-pain; pharmacological-treatment; postoperative pain; neuropathic pain; abuse liability; efns guidelines; drug-abuse; osteoarthritis; children
AB Objective: Change Pain Latin America (CPLA) was created to enhance chronic pain understanding and develop pain management improving strategies in this region. During its seventh meeting (August 2016), the main objective was to discuss tramadol's role in treating pain in Latin America. Furthermore, potential pain management consequences were considered, if tramadol was to become more stringently controlled. Methods: Key topics discussed were: main indications for prescribing tramadol, its pharmacological characteristics, safety and tolerability, effects of restrictions on its availability and use, and consequent impact on pain care quality. Results: The experts agreed that tramadol is used to treat a wide spectrum of non-oncological pain conditions (e.g. post-surgical, musculoskeletal, post-traumatic, neuropathic, fibromyalgia), as well as cancer pain. Its relevance when treating special patient groups (e.g. the elderly) is recognized. The main reasons for tramadol's high significance as a treatment option are: its broad efficacy, an inconspicuous safety profile and its availability, considering that access to strong analgesics - mainly controlled drugs (classical opioids) - is highly restricted in some countries. The CPLA also agreed that tramadol is well tolerated, without the safety issues associated with long-term nonsteroidal anti-inflammatory drug (NSAID) use, with fewer opioid-like side effects than classical opioids and lower abuse risk. Conclusions: In Latin America, tramadol is a valuable and frequently used medication for treating moderate to severe pain. More stringent regulations would have significant impact on its availability, especially for outpatients. This could cause regression to older and frequently inadequate pain management methods, resulting in unnecessary suffering for many Latin American patients.
C1 [Santos Garcia, Joao Batista] Univ Fed Maranhao, Pain & Palliat Care, Sao Luis, MA, Brazil.
   [Lech, Osvandre] UFFS HSVP IOT, Shoulder & Elbow Serv, Passo Fundo, Brazil.
   [Kraychete, Durval Campos] Univ Fed Bahia, Pain Outpatient Clin, Salvador, BA, Brazil.
   [Antonieta Rico, Maria] Univ Desarrollo, Clin Alemana, Santiago, Chile.
   [Hernandez-Castro, John Jairo] Univ Rosario MEDERI, Pain Med & Palliat Care, Bogota, Colombia.
   [Colimon, Frantz] Ctr Oncol Antioquia, Intervent Pain Management & Palliat Care Unit, Medellin, Antioquia, Colombia.
   [Guerrero, Carlos] Univ Los Andes, Hosp Univ Fdn Santa Fe, Bogota, Colombia.
   [Sempertegui Gallegos, Manuel] Hosp Metropolitano, Pain Clin, Quito, Ecuador.
   [Lara-Solares, Argelia] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Pain Med & Palliat Care, Mexico City, DF, Mexico.
   [Flores Cantisani, Jose Alberto] IMSS, Programa Reg Cuidados Paliat, Unidad Med Alta Especialidad 25, Monterrey, NL, Mexico.
   [Amescua-Garcia, Cesar] Hosp Angeles, Tijuana, Mexico.
   [Guillen Nunez, Maria del Rocio] Hosp Med Sur, Med Dolor & Cuidados Paliat, Mexico City, DF, Mexico.
   [Berenguel Cook, Maria del Rosario] Totalcare Oncosalud Auna, Dept Med Paliat & Tratamiento Dolor, Lima, Peru.
   [Jreige Iskandar, Aziza] UCV, Unidad Rehabil DM, Rehabil Residency Program, Maracay, Venezuela.
   [Bonilla Sierra, Patricia] Inst Med Floresta, Inst Oncol Luis Razetti Pain Clin & Palliat Care, Caracas, Venezuela.
C3 Universidade Federal do Maranhao; Universidade Federal da Bahia; Universidad del Desarrollo; Clinica Alemana; Universidad del Rosario; Universidad de los Andes (Colombia); Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; University of Central Venezuela
RP Garcia, JBS (corresponding author), Univ Fed Maranhao, Pain & Palliat Care, Sao Luis, MA, Brazil.
EM jbgarcia@uol.com.br
FU Grunenthal
CR Adams EH, 2006, J PAIN SYMPTOM MANAG, V31, P465, DOI 10.1016/j.jpainsymman.2005.10.006
   Allegaert K, 2015, CLIN PHARMACOKINET, V54, P167, DOI 10.1007/s40262-014-0191-9
   Unknown -, 2011, WORLD MED SITUATION, V0, P0
   Rico MA, 2016, PAIN MED, V17, P704, DOI 10.1111/pme.12905
   Attal N, 2006, EUR J NEUROL, V13, P1153, DOI 10.1111/j.1468-1331.2006.01511.x
   Attal N, 2010, EUR J NEUROL, V17, P1113, DOI 10.1111/j.1468-1331.2010.02999.x
   Bamigbade TA, 1998, PAIN REV, V5, P155, DOI 10.1191/096813098668122984
   Benzon HT, 2014, PRACTICAL MANAGEMENT OF PAIN, V5th, P0
   Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6
   Bösenberg AT, 1998, ANAESTHESIA, V53, P960, DOI 10.1046/j.1365-2044.1998.00526.x
   Cavalieri TA, 2007, J AM OSTEOPATH ASSOC, V107, P0
   Cepeda MS, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005522.pub2
   Chaparro LE, 2014, SPINE, V39, P556, DOI 10.1097/BRS.0000000000000249
   Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006
   Cicero TJ, 2007, PAIN MED, V8, P157, DOI 10.1111/j.1526-4637.2006.00259.x
   Cicero TJ, 2005, PHARMACOEPIDEM DR S, V14, P851, DOI 10.1002/pds.1113
   COLLART L, 1993, SCHWEIZ MED WSCHR, V123, P2241
   Commission on Narcotic Drugs, 2011, ECN72011CRP3 COMM NA, V0, P0
   Cousins MJ, 2011, PAIN, V152, P2673, DOI 10.1016/j.pain.2011.09.012
   Desmeules JA, 1996, BRIT J CLIN PHARMACO, V41, P7, DOI 10.1111/j.1365-2125.1996.tb00152.x
   Duhmke RM, 2006, COCHRANE DB SYST REV, V3, P0
   Epstein DH, 2006, BIOL PSYCHOL, V73, P90, DOI 10.1016/j.biopsycho.2006.01.010
   Gillen C, 2000, N-S ARCH PHARMACOL, V362, P116, DOI 10.1007/s002100000266
   Grond S, 2004, CLIN PHARMACOKINET, V43, P879, DOI 10.2165/00003088-200443130-00004
   GROND S, 1995, PAIN, V62, P313, DOI 10.1016/0304-3959(94)00274-I
   Gupta A, 2013, PAIN MANAG, V3, P315, DOI 10.2217/pmt.13.23
   Harbin M, 2014, CAN FAM PHYSICIAN, V60, P0
   Haslam C, 2008, CLIN INTERV AGING, V3, P111
   Hassanian-Moghaddam H, 2015, RES PHARM SCI, V10, P544
   Hernandez JJ, 2011, MED DEL DOLOR, V0, P19
   HOUMES RJM, 1992, ANESTH ANALG, V74, P510
   Hsu Shao-Keh, 2012, ACTA ANAESTHESIOL TAIWAN, V50, P101, DOI 10.1016/j.aat.2012.08.008
   *INCB, 2006, EINCB20051 UN, V0, P0
   International Pain Summit Of The International Association For The Study Of Pain, 2011, J PAIN PALLIAT CARE PHARMACOTHER, V25, P29, DOI 10.3109/15360288.2010.547560
   Jorge LF, 1999, PHARMACOGENETICS, V9, P217
   Kirchheiner J, 2008, J CLIN PSYCHOPHARM, V28, P78, DOI 10.1097/JCP.0b013e318160f827
   Knisely JS, 2002, DRUG ALCOHOL DEPEN, V68, P15, DOI 10.1016/S0376-8716(02)00107-2
   Langford RM, 1998, ACUTE PAIN, V1, P7
   Lara-Solares A, 2017, PAIN MANAG, V7, P287, DOI 10.2217/pmt-2017-0006
   Lara-Solares A, 2017, PAIN MANAG, V7, P207, DOI 10.2217/pmt-2016-0065
   Lassen D, 2015, CLIN PHARMACOKINET, V54, P825, DOI 10.1007/s40262-015-0268-0
   Leppert W, 2005, SUPPORT CARE CANCER, V13, P5, DOI 10.1007/s00520-004-0720-4
   Mamdani M, 2004, BRIT MED J, V328, P1415, DOI 10.1136/bmj.38068.716262.F7
   Martins RO, 2015, J BRAS PNEUMOL, V41, P238, DOI 10.1590/S1806-37132015000004415
   Mildh LH, 1999, J CLIN ANESTH, V11, P310, DOI 10.1016/S0952-8180(99)00047-1
   NICE, 2015, NONST ANT DRUGS KEY, V0, P0
   Petrone D, 1999, J CLIN PHARM THER, V24, P115, DOI 10.1046/j.1365-2710.1999.00203.x
   Raffa RB, 2008, J CLIN PHARM THER, V33, P101, DOI 10.1111/j.1365-2710.2008.00897.x
   Raffa RB, 2013, ENCY PAIN, V0, P1071
   Rosenthal NR, 2004, J AM GERIATR SOC, V52, P374, DOI 10.1111/j.1532-5415.2004.52108.x
   Sacerdote P, 1997, PAIN, V72, P325, DOI 10.1016/S0304-3959(97)00055-9
   Sacerdote Paola, 2008, CURR OPIN SUPPORT PALLIAT CARE, V2, P14, DOI 10.1097/SPC.0b013e3282f5272e
   Garcia JBS, 2014, REV BRAS ANESTESIOL, V64, P140, DOI 10.1016/j.bjane.2013.03.004
   SCHAFFER J, 1986, ANAESTHESIST, V35, P408
   Schneider MF, 2009, PHARMACOEPIDEM DR S, V18, P778, DOI 10.1002/pds.1780
   Schnitzer TJ, 2002, J PAIN SYMPTOM MANAG, V23, PS24, DOI 10.1016/S0885-3924(02)00372-X
   Scott LJ, 2000, DRUGS, V60, P139, DOI 10.2165/00003495-200060010-00008
   Single Convention on Narcotic Drugs, 1961, SINGL CONV NARC DRUG, V0, P0
   Stassinos GL, 2017, CLIN TOXICOL PHILA P, V53, P707
   Tarkkila P, 1997, J CLIN ANESTH, V9, P582, DOI 10.1016/S0952-8180(97)00147-5
   Tarkkila P, 1998, EUR J ANAESTH, V15, P64, DOI 10.1097/00003643-199801000-00013
   van Amsterdam Jan, 2015, CURR DRUG ABUSE REV, V8, P3, DOI 10.2174/187447370801150611184218
   Vazzana M, 2015, BIOMED PHARMACOTHER, V70, P234, DOI 10.1016/j.biopha.2015.01.022
   VICKERS MD, 1995, EUR J ANAESTH, V12, P265
   Walton Betancourth SB, 2014, ARCH DIS CHILD S, V99, P0
   Whelton A, 1999, AM J MED, V106, P13S, DOI 10.1016/S0002-9343(99)00113-8
   Whittle SL, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003113.pub3
   WHO, 2014, WHO TECH REP SER, V986, P1
   Zhou SF, 2009, CLIN PHARMACOKINET, V48, P689, DOI 10.2165/11318030-000000000-00000
NR 71
TC 11
Z9 12
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JUN 15
PY 2017
VL 33
IS 9
BP 1615
EP 1621
DI 10.1080/03007995.2017.1354821
PG 7
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA FE1DZ
UT WOS:000407959900009
PM 28696784
DA 2026-01-16
ER

PT J
AU Zeng, YJ
   Lin, YH
   Wang, YC
   Chang, JH
   Wu, JH
   Hsu, SF
   Tsai, SY
   Lin, CH
   Wen, YR
AF Zeng, Yen-Jing
   Lin, Yu-Hsiang
   Wang, You-Cheng
   Chang, Ju-Hsin
   Wu, Jih-Huah
   Hsu, Sheng-Feng
   Tsai, Shih-Ying
   Lin, Ching-Huang
   Wen, Yeong-Ray
TI Laser acupuncture-induced analgesic effect and molecular alterations in an
SO Lasers in medical science
LA English
DT Journal Article
DE Laser acupuncture; MAPK; Postoperative pain; TNF; iNOS
AB Low-level laser acupuncture (LLLA) produces photobiomodulation through  acupuncture point and is an alternative to low-level laser therapy. Although the  analgesic effect of LLLA on chronic pain has been proven, its effect on acute  postincisional pain has yet to be investigated. A plantar incision (PI) model was  used to mimic human postsurgical pain. Male adult rats received GaAlAs laser  irradiation at the right ST36 acupoint immediately after operation and on the  following 4 days. Three laser treatment groups (two red laser groups with a 30-  or 15-min treatment duration and one 30-min near-infrared laser group) were  compared with sham LLLA and naive groups and an electroacupuncture (EA) group  (separate study). Behavioral withdrawal thresholds of both hind paws were  measured before and after incision. Expression of mitogen-activated protein  kinases (p-ERK and p-p38), inducible nitric oxide synthase (iNOS), and tumor  necrosis factor (TNF) in the spinal cord was analyzed. All three LLLA treatments  attenuated post-PI tactile allodynia in the ipsilateral paw, but only the 30-min  red laser treatment affected the contralateral paw and had similar efficacy to  that of EA. All laser treatments barely reduced heat hyperalgesia in both hind  paws. At 3 days after PI, the 30-min red laser group showed reversed increases of  PI-induced p-ERK, p-p38, and iNOS but not TNF expression in the spinal cord.  Repetitive LLLA treatments ameliorated PI-induced mechanical pain. The inhibition  of multiple sensitization signals highlights the unique clinical role of LLLA.  Thus, LLLA is an alternative to EA as an adjuvant for postoperative pain control.
C1 Graduate Institute of Clinical Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
   Microelectronic and Optoelectronic Engineering Department of Electronic Engineering, National Yunlin University of Science and Technology, Yunlin,Taiwan.
   Department of Electronic Engineering, National Yunlin University of Science and Technology, Yunlin, Taiwan.
   Graduate Institute of Clinical Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
   Department of Anesthesiology, China Medical University Hospital, No. 2, Yuh-Der 
   Department of Biomedical Engineering, Ming Chuan University, Taipei City, Taiwan.
   Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
   Department of Acupuncture, China Medical University Hospital Taipei Branch, 
   Acupuncture Research Center, China Medical University, Taichung, Taiwan.
   Department of Anesthesiology, China Medical University Hospital, No. 2, Yuh-Der Rd, North District, 40447, Taichung, Taiwan.
   Microelectronic and Optoelectronic Engineering Department of Electronic Engineering, National Yunlin University of Science and Technology, Yunlin,Taiwan.
   Department of Electronic Engineering, National Yunlin University of Science and 
   Department of Anesthesiology, China Medical University Hospital, No. 2, Yuh-Der Rd, North District, 40447, Taichung, Taiwan. yr.wen@yahoo.com.tw.
   Graduate Institute of Acupuncture Science, College of Chinese Medicine, China 
   Acupuncture Research Center, China Medical University, Taichung, Taiwan. yr.wen@yahoo.com.tw.
   Department of Anesthesiology, School of Medicine, China Medical University, 
   Center for Pain Research and Management, Department of Anesthesiology, School of Medicine, China Medical University, Taichung, Taiwan. yr.wen@yahoo.com.tw.
NR 0
TC 0
SN 1435-604
EI 0268-892
J9 Lasers Med Sci
PD NOV 6
PY 2017
VL 33
IS 2
BP 295
EP 304
DI 10.1007/s10103-017-2367-7
PG 9
WC Acupuncture Points; Analgesics; pharmacology; Animals; Disease Models, Animal; Dose-Response Relationship, Radiation; Electroacupuncture; Extracellular Signal-Regulated MAP Kinases; metabolism; Humans; Hyperalgesia; therapy; Laser Therapy; Male; Nitric Oxide Synthase Type II; metabolism; Pain; enzymology; Pain Management; Rats, Sprague-Dawley; p38 Mitogen-Activated Protein Kinases; metabolism
UT PubMed:29103083
PM 29103083
DA 2017-11-06
ER

PT J
AU Gregory, R
   Gilles, C
   Aude, A
   Laurie, L
   Leila, B
   Jean-Cyr, Y
   Jean-Christophe, M
AF Gregory, Reychler
   Gilles, Caty
   Aude, Arcq
   Laurie, Lebrun
   Leila, Belkhir
   Jean-Cyr, Yombi
   Jean-Christophe, Marot
TI Effects of massage therapy on anxiety, depression, hyperventilation and quality of life in HIV infected patients: A randomized controlled trial
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Massage; Anxiety; Depression; HIV
ID antiretroviral therapy; cancer-patients; health; acupuncture; management; disorders; adherence; symptoms; services; sample
AB Introduction: HIV infection is often preceded or accompanied by psychiatric comorbidities. These disorders improve with complementary therapies. The aim of this study was to measure the effect of massage therapy on anxiety, depression, hyperventilation and quality of life in HIV infected patients. Method: Adult HIV-infected patients were randomized (n = 29) in massage therapy group (one hour a week during four weeks) and control group. Anxiety and depression (HADS-A and HADS-D), hyperventilation (Nijmegen questionnaire) and quality of life (WHOQOL-HIV) were evaluated at inclusion and after 4 weeks. Results: At inclusion, 51% and 17% of the patients had a positive HADS-A and HADS-D score respectively. Two facets from WHOQOL-HIV ("Home environment" and "Death and dying" (p = 0.04)) were different between groups. After the four week massage therapy, a significant improvement was observed only for Nijmegen questionnaire (p = 0.01) and HADS-A (p = 0.04) contrarily to WHOQOL-HIV and HADS-D. Domains of the WHOQOL-HIV did not improve following the massage therapy. Only "Pain and discomfort" facet improved after massage therapy (p = 0.04). Conclusion: This study highlights the positive impact of a four week massage therapy on anxiety and hyperventilation in HIV infected patients. However, neither benefit of this program was observed on depression and quality of life.
C1 [Gregory, Reychler] Catholic Univ Louvain, Pole Pneumol ORL &Dermatol, IREC, Brussels, Belgium.
   [Gregory, Reychler; Gilles, Caty] Clin Univ St Luc, Serv Med Phys & Readaptat, Brussels, Belgium.
   [Gregory, Reychler; Aude, Arcq; Laurie, Lebrun] Clin Univ St Luc, Serv Pneumol, Brussels, Belgium.
   [Leila, Belkhir; Jean-Cyr, Yombi] Clin Univ St Luc, Serv Med Interne, AIDS Reference Ctr, Brussels, Belgium.
   [Jean-Christophe, Marot] Clin St Pierre, Serv Infectiol, Ottignies, Belgium.
C3 Universite Catholique Louvain; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc
RP Gregory, R (corresponding author), Clin Univ St Luc UCL, Serv Pneumol, Ave Hippocrate 10, B-1200 Brussels, Belgium.
EM Gregory.reychler@uclouvain.be; gilles.caty@uclouvain.be; aude.arcq@student.uclouvain.be; laurie.lebrun@student.uclouvain.be; leila.belkhir@uclouvain.be; jean.yombi@uclouvain.be; Jean-Christophe.MAROT@cspo.be
CR Andrinopoulos K, 2011, AIDS EDUC PREV, V23, P367, DOI 10.1521/aeap.2011.23.4.367
   Babaee Sima, 2012, IRAN J NURS MIDWIFERY RES, V17, P0
   Bauer Brent A, 2010, COMPLEMENT THER CLIN PRACT, V16, P70, DOI 10.1016/j.ctcp.2009.06.012
   Blom EH, 2014, PSYCHOPHYSIOLOGY, V51, P412, DOI 10.1111/psyp.12188
   Campsmith Michael L, 2003, HEALTH QUAL LIFE OUTCOMES, V1, P12, DOI 10.1186/1477-7525-1-12
   Canavarro MC, 2011, AIDS CARE, V23, P187, DOI 10.1080/09540121.2010.498870
   Chauhan V S, 2013, IND PSYCHIATRY J, V22, P125, DOI 10.4103/0972-6748.132925
   Chin JJ, 2009, AIDS CARE, V21, P1289, DOI 10.1080/09540120902732019
   Ciesla JA, 2001, AM J PSYCHIAT, V158, P725, DOI 10.1176/appi.ajp.158.5.725
   Crane JD, 2012, SCI TRANSL MED, V4, P0, DOI 10.1126/scitranslmed.3002882
   Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544
   DeLorenze GN, 2010, AIDS PATIENT CARE ST, V24, P705, DOI 10.1089/apc.2010.0139
   Diego MA, 2001, INT J NEUROSCI, V106, P35, DOI 10.3109/00207450109149736
   Falkensteiner Maria, 2011, ISRN NURS, V2011, P929868, DOI 10.5402/2011/929868
   Ford N, 2015, LANCET HIV, V2, PE438, DOI 10.1016/S2352-3018(15)00137-X
   Gibson D, 2007, J ALTERN COMPLEM MED, V13, P39, DOI 10.1089/acm.2006.5283
   Hays RD, 2000, AM J MED, V108, P714, DOI 10.1016/S0002-9343(00)00387-9
   Hernandez-Reif M, 2008, EVID-BASED COMPL ALT, V5, P345, DOI 10.1093/ecam/nem032
   Hillier SL, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007502.pub2
   Hinz A, 2010, EUR J CANCER CARE, V19, P522, DOI 10.1111/j.1365-2354.2009.01088.x
   Hou WH, 2010, J CLIN PSYCHIAT, V71, P894, DOI 10.4088/JCP.09r05009blu
   Hsiung PC, 2005, QUAL LIFE RES, V14, P141, DOI 10.1007/s11136-004-6252-z
   Institut scientifique de Sante publique, 2014, EPIDEMIOLOGIE SID IN, V0, P0
   Jörngården A, 2007, EUR J CANCER, V43, P1952, DOI 10.1016/j.ejca.2007.05.031
   Kagee A, 2010, AIDS CARE, V22, P159, DOI 10.1080/09540120903111445
   Kemppainen JK, 2006, AIDS CARE, V18, P597, DOI 10.1080/09540120500275726
   Li YG, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0111707
   Liu CL, 2006, QUAL LIFE RES, V15, P941, DOI 10.1007/s11136-005-5913-x
   Liu SL, 2015, EUR REV MED PHARMACO, V19, P3843
   Mills E, 2005, INT J STD AIDS, V16, P395, DOI 10.1258/0956462054093962
   Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528
   Morrison MF, 2002, AM J PSYCHIAT, V159, P789, DOI 10.1176/appi.ajp.159.5.789
   Mrus JM, 2006, QUAL LIFE RES, V15, P503, DOI 10.1007/s11136-005-1946-4
   Naoroibam Rosy, 2016, INT J YOGA, V9, P57, DOI 10.4103/0973-6131.171723
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Paxton RJ, 2007, J SCHOOL HEALTH, V77, P180, DOI 10.1111/j.1746-1561.2007.00189.x
   Poland RE, 2013, J ALTERN COMPLEM MED, V19, P334, DOI 10.1089/acm.2012.0058
   Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, P0, DOI 10.1186/1477-7525-6-46
   Razavi P, 2012, AIDS RES TREAT, V2012, P0, DOI 10.1155/2012/849406
   Reda AA, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0016049
   Reychler G, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0073180
   Robertson K, 2014, AIDS CARE, V26, P1555, DOI 10.1080/09540121.2014.936813
   Roux P, 2009, J CLIN PSYCHIAT, V70, P1328, DOI 10.4088/JCP.08l04885
   Shacham Enbal, 2016, J INT ASSOC PROVID AIDS CARE, V15, P126, DOI 10.1177/2325957414553846
   Sherbourne CD, 2000, AM J PSYCHIAT, V157, P248, DOI 10.1176/appi.ajp.157.2.248
   Sin NL, 2014, ANN BEHAV MED, V47, P259, DOI 10.1007/s12160-013-9559-6
   Slot M, 2015, HIV MED, V16, P393, DOI 10.1111/hiv.12223
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Thomas Mike, 2005, PRIM CARE RESPIR J, V14, P78, DOI 10.1016/j.pcrj.2004.10.007
   UNAIDS, 2015, AIDS CHANG EV UNAIDS, V0, P0
   VANDIXHOORN J, 1985, J PSYCHOSOM RES, V29, P199, DOI 10.1016/0022-3999(85)90042-X
   VANSTEENKISTE J, 1991, EUR RESPIR J, V4, P393
   Wong V T C, 2013, EAST ASIAN ARCH PSYCHIATRY, V23, P6
   Wouters E, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0034881
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 55
TC 6
Z9 14
U1 0
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD JUN 15
PY 2017
VL 32
IS 
BP 109
EP 114
DI 10.1016/j.ctim.2017.05.002
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA EZ4RQ
UT WOS:000404700600017
PM 28619295
DA 2026-01-16
ER

PT J
AU Sovak, G
   Budgell, B
AF Sovak, Guy
   Budgell, Brian
TI TENS-like Stimulation Downregulates Inflammatory Cytokines in a PC-12 Cell Line
SO JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS
LA English
DT Article
DE Transcutaneous Electrical Nerve Stimulation; Cytokines
ID electrical nerve-stimulation; nf-kappa-b; low-back-pain; signaling pathways; spinal stenosis; acupuncture; activation; survival
AB Objectives: The purpose of this study was to evaluate the effects of transcutaneous electrical nerve stimulation (TENS)-like stimulation on the expression of the proinflammatory cytokines tumor necrosis factor a (TNF-alpha), interleukin 1 beta (IL-1 beta), and IL-6 in PC-12 cells, which are commonly used as neuronal cell models. Methods: Nerve growth factor-differentiated PC-12 cells were exposed to electrical stimulation for 15 minutes at 1 mA, 200 mu s, and 100 Hz. Cell lysate from stimulated and control cells was assayed for TNF-alpha, IL-1 beta, and IL-6. In 6 trials, cells were preincubated with the L-type ion channel blocker nicardipine. Cultured cells were also incubated with Alexa Fluor 488 and visualized by fluorescence microscopy to determine the nuclear vs cytoplasmic distribution of the p65 sub-unit of NF-kappa B Results: Compared with control (unstimulated) cells, the stimulated cells had a downregulation of the assayed cytokines. However, preincubation with the L-type ion channel blocker nicardipine blocked this effect of stimulation. Additionally, it was noted that TENS-like stimulation promoted a relative sequestration of the p65 subunit of NF-kappa B in the cytoplasm vs the nucleus. Conclusions: It appears that in this cell line and with these stimulation parameters, TENS-like stimulation attenuated the expression of the assayed proinflammatory cytokines, in part by promoting the relative sequestration of the p65 subunit of NF-kappa B in the cytoplasm, and that voltage-dependent calcium channels have a role in the cascade of events initiated by the TENS-like stimulation.
C1 [Sovak, Guy; Budgell, Brian] Canadian Mem Chiropract Coll, 6100 Leslie St, Toronto, ON M2H 3J1, Canada.
RP Sovak, G (corresponding author), Canadian Mem Chiropract Coll, 6100 Leslie St, Toronto, ON M2H 3J1, Canada.
EM gsovak@cmcc.ca
FU Canadian Memorial Chiropractic College
CR Ammendolia C, 2015, SELF MANAGEMENT IMPR, V0, P0
   Buchmuller A, 2012, EUR J PAIN, V16, P656, DOI 10.1002/j.1532-2149.2011.00061.x
   Budgell BS, 2014, SPINAL CORD, V52, P744, DOI 10.1038/sc.2014.120
   Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753
   Cha MH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/792765
   Chen YW, 2015, PHYS THER, V95, P76, DOI 10.2522/ptj.20130306
   DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0
   Fang JF, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-134
   Grant DJ, 1999, PAIN, V82, P9, DOI 10.1016/S0304-3959(99)00027-5
   GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424
   Kalra A, 2001, J PHARMACOL EXP THER, V298, P257
   Kaltschmidt B, 2005, BBA-MOL CELL RES, V1745, P287, DOI 10.1016/j.bbamcr.2005.05.009
   Keskin EA, 2012, GYNECOL OBSTET INVES, V74, P76, DOI 10.1159/000337720
   Khadilkar A, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003008.pub3
   Kroeling P, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004251.pub5
   Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003
   Magis Delphine, 2013, J HEADACHE PAIN, V14, P95, DOI 10.1186/1129-2377-14-95
   Matsuo H, 2014, PAIN, V155, P1888, DOI 10.1016/j.pain.2014.06.022
   Ohtori S, 2012, SPINE, V37, P439, DOI 10.1097/BRS.0b013e318238af83
   Ohtori S, 2011, EUR SPINE J, V20, P942, DOI 10.1007/s00586-010-1595-3
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Sekiguchi M, 2004, SPINE, V29, P1105, DOI 10.1097/00007632-200405150-00011
   Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000
   Yates CC, 2013, MED ACUPUNCT, V25, P285, DOI 10.1089/acu.2012.0952
NR 26
TC 3
Z9 3
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-4754
EI 
J9 J MANIP PHYSIOL THER
JI J. Manip. Physiol. Ther.
PD JUL-AUG 15
PY 2017
VL 40
IS 6
BP 381
EP 386
DI 10.1016/j.jmpt.2017.03.008
PG 6
WC Health Care Sciences & Services; Integrative & Complementary Medicine; Rehabilitation
SC Health Care Sciences & Services; Integrative & Complementary Medicine; Rehabilitation
GA FM2JH
UT WOS:000414810500002
PM 28822472
DA 2026-01-16
ER

PT J
AU Montross-Thomas, LP
   Meier, EA
   Reynolds-Norolahi, K
   Raskin, EE
   Slater, D
   Mills, PJ
   MacElhern, L
   Kallenberg, G
AF Montross-Thomas, Lori P.
   Meier, Emily A.
   Reynolds-Norolahi, Kimberly
   Raskin, Erin E.
   Slater, Daniel
   Mills, Paul J.
   MacElhern, Lauray
   Kallenberg, Gene
TI Inpatients' Preferences, Beliefs, and Stated Willingness to Pay for Complementary and Alternative Medicine Treatments
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE complementary and alternative medicine; inpatients; holistic care; integrative medicine; patient satisfaction; patient preferences
ID integrative medicine; patient satisfaction; massage therapy; pain; anxiety; care; oncology
AB Objectives: Research demonstrates the benefits of complementary and alternative medicine (CAM) in myriad environments. Yet, the majority of CAM services are offered in outpatient settings. Incorporating CAM into hospital settings may lead to increased patient comfort, well-being, and overall satisfaction with hospital admissions. Few studies have examined CAM services among inpatients. Therefore, this study assessed inpatients' preferences and beliefs regarding CAM, as well as their stated willingness to pay for these services. Design: Adult patients (n=100), ranging in age from 19-95 years (M=53 years; SD=19.2 years), were recruited during their hospitalization in the University of California, San Diego, Healthcare System. The inpatients completed a brief individual interview to gather their perspectives on common CAM services, including acupuncture, aromatherapy, art therapy, guided imagery, healthy food, humor therapy, massage therapy, music therapy, pet therapy, Reiki, and stress management. Inpatients were asked which CAM therapies they perceived as being potentially the most helpful, their willingness to pay for those therapies, and their perceived beliefs regarding the use of those therapies. Results: Inpatients most commonly perceived healthy food (85%), massage therapy (82%), and humor therapy (70%) to be the most helpful, and were most willing to pay for healthy food (71%), massage therapy (70%), and stress management (48%). Inpatients most commonly believed CAM treatments would provide relaxation (88%), increase well-being (86%), and increase their overall satisfaction with the hospitalization (85%). Conclusions: This study suggests that CAM services may be a beneficial addition to hospitals, as demonstrated by inpatients' interest and stated willingness to pay for these services. These findings may help organizational leaders when making choices regarding the development of CAM services within hospitals, particularly since a significant percentage of inpatients reported that CAM services would increase their overall satisfaction with the hospitalization. These results merit further attention given the need to increase cost savings while enhancing the overall patient experience in today's medical marketplace.
C1 [Montross-Thomas, Lori P.; Meier, Emily A.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
   [Montross-Thomas, Lori P.; Meier, Emily A.] Univ Calif San Diego, Moores Canc Ctr, Patient & Family Support Serv, Psychiat & Psychosocial Serv, San Diego, CA 92103 USA.
   [Montross-Thomas, Lori P.; Reynolds-Norolahi, Kimberly; Raskin, Erin E.; Slater, Daniel; Mills, Paul J.; Kallenberg, Gene] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA.
   [Raskin, Erin E.; Mills, Paul J.; MacElhern, Lauray; Kallenberg, Gene] Univ Calif San Diego, Ctr Integrat Med, San Diego, CA 92103 USA.
   [Reynolds-Norolahi, Kimberly] True Wellness Acupuncture, San Diego, CA USA.
C3 University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego
RP Montross-Thomas, LP (corresponding author), Univ Calif San Diego, 9500 Gilman Dr 0664, La Jolla, CA 92093 USA.
EM lpmontross@ucsd.edu
FU Westreich Foundation
CR Ahles TA, 1999, J PAIN SYMPTOM MANAG, V18, P157, DOI 10.1016/S0885-3924(99)00061-5
   Unknown -, 2010, 2010 COMPLEMENTARY A, V0, P0
   Boulding W, 2011, AM J MANAG CARE, V17, P41
   Dreyer NE, 2015, COMPLEMENT THER CLIN, V21, P154, DOI 10.1016/j.ctcp.2015.06.004
   Dusek Jeffery A, 2010, J PATIENT SAF, V6, P48, DOI 10.1097/PTS.0b013e3181d10ad5
   Gardiner P, 2013, J HEALTH COMMUN, V18, P290, DOI 10.1080/10810730.2013.830663
   Horrigan B, 2012, INTEGRATIVE MEDICINE IN AMERICA: HOW INTEGRATIVE MEDICINE IS BEING PRACTICED IN CLINICAL SETTINGS ACROSS THE UNITED STATES, V0, P0
   Johnson JR, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-486
   Johnson Jill R, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP330, DOI 10.1093/jncimonographs/lgu030
   Kligler B, 2011, AM J MANAG CARE, V17, P779
   Kutner M, 2006, HLTH LITERACY AM ADU, V0, P0
   Lewis Charles R, 2003, AM J HOSP PALLIAT CARE, V20, P221, DOI 10.1177/104990910302000312
   Li L, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0156076
   Maizes V, 2009, EXPLORE-NY, V5, P277, DOI 10.1016/j.explore.2009.06.008
   Mandel Susan E, 2014, HOSP TOP, V92, P28, DOI 10.1080/00185868.2014.906830
   Mann JD, 2004, INTEGRATING COMPLEMENTARY ALTERNATIVE THERAPIES WITH CONVENTIONAL CARE THE CONVERGENCE OF COMPLEMENTARY, V0, P0
   Newshan Gayle, 2004, COMPLEMENT THER NURS MIDWIFERY, V10, P168, DOI 10.1016/j.ctnm.2004.01.003
   Rhee TG, 2016, COMPLEMENT THER MED, V24, P7, DOI 10.1016/j.ctim.2015.11.002
NR 18
TC 14
Z9 19
U1 1
U2 20
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD APR 15
PY 2017
VL 23
IS 4
BP 259
EP 263
DI 10.1089/acm.2016.0288
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA ER7ZB
UT WOS:000399033400006
PM 28112554
DA 2026-01-16
ER

PT J
AU Enblom, A
AF Enblom, Anna
TI Patients' and physiotherapists' belief in and use of acupuncture for
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE ACUPUNCTURE; COMPLEMENTARY MEDICINE; ONCOLOGY; PAIN MANAGEMENT; PHYSIOTHERAPY; REHABILITATION MEDICINE
AB BACKGROUND: It is important to investigate attitudes to acupuncture, because  therapists' and patients' expectations may affect the treatment outcome. AIM: To  explore the use of and belief in acupuncture among oncological physiotherapists  and to explore patients' interest in receiving acupuncture during cancer therapy  and their belief in its effectiveness. METHODS: 522 patients (80% female, mean  age 67 years) reported on their interest in receiving acupuncture for nausea  during radiotherapy treatment; a subgroup (n=198) additionally disclosed their  belief in the effectiveness of acupuncture. 117 Swedish oncological  physiotherapists (96% female, mean age 48 years) answered a questionnaire  regarding their use of and belief in acupuncture. RESULTS: Of the patients  initiating cancer therapy, 359 (69%) were interested in receiving acupuncture.  The patients believed acupuncture to be effective for pain (79%), nausea (79%)  and vasomotor symptoms (48%). Of the 117 physiotherapists, 66 (56%) practised  acupuncture. Physiotherapists generally believed in the effectiveness of  acupuncture. For pain, 89% believed that acupuncture was effective and 42% of  them practised it. Similar responses were noted for chemotherapy-induced nausea  (86% and 38%, respectively) and vasomotor symptoms (80% and 28%, respectively).  Younger physiotherapists and patients were more likely to believe in the  effectiveness of acupuncture compared with older ones. CONCLUSIONS: More than two  thirds of patients with cancer were interested in receiving acupuncture during  therapy. Patients and oncological physiotherapists believed that acupuncture was  effective for cancer pain, nausea and vasomotor symptoms. Further studies of  acupuncture for cancer-related symptoms and of the effect of patients' and  clinicians' therapeutic relationships, including treatment expectations, would be  welcome.
C1 Department of Medical and Health Sciences, Division of Physiotherapy, Linköping University, Linköping, Sweden.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD APR 27
PY 2017
VL 35
IS 4
BP 251
EP 258
DI 10.1136/acupmed-2015-011007
PG 7
WC Acupuncture Therapy; psychology; Adult; Aged; Antineoplastic Agents; adverse effects; Cancer Pain; etiology; Cross-Sectional Studies; Culture; Drug Therapy; Female; Humans; Male; Middle Aged; Nausea; etiology; Neoplasms; drug therapy; Oncologists; psychology; Patients; psychology; Radiotherapy; adverse effects; Surveys and Questionnaires; Treatment Outcome
UT PubMed:28442462
PM 28442462
DA 2017-04-27
ER

PT J
AU Marchant, J
AF Marchant, Jo
TI Acupuncture in cancer study reignites debate about controversial technique.
SO Nature
LA English
DT News
NR 0
TC 0
SN 1476-468
EI 
J9 Nature
PD DEC 15
PY 2017
VL 552
IS 7684
BP 157
EP 158
DI 10.1038/d41586-017-08309-y
PG 1
WC Acupuncture; Antidepressive Agents; therapeutic use; Aromatase Inhibitors; adverse effects; Breast Neoplasms; complications; Cancer Pain; etiology; Duloxetine Hydrochloride; therapeutic use; Female; Humans; Medication Adherence; psychology; Placebo Effect; Reproducibility of Results
UT PubMed:29239361
PM 29239361
DA 2017-12-15
ER

PT J
AU Sharifi, Rizi M
   Shamsalinia, A
   Ghaffari, F
   Keyhanian, S
   Naderi, Nabi B
AF Sharifi Rizi, Moloud
   Shamsalinia, Abbas
   Ghaffari, Fatemeh
   Keyhanian, Shahrbanoo
   Naderi Nabi, Bahram
TI The effect of acupressure on pain, anxiety, and the physiological indexes of
SO Complementary therapies in clinical practice
LA English
DT Journal Article
DE Acupressure; Anxiety; Aspiration; Biopsy; Bone marrow; Pain; Physiological indexes
AB OBJECTIVES: This study aimed to determine the effect of acupressure on pain  intensity, anxiety, and physiological indexes of patients with cancer undergoing  bone marrow biopsy and aspiration. METHODS: The study was designed as a  randomized, double-blinded, controlled trial. Ninety samples was selected using  the convenience sampling method, then for allocation groups random block sampling  was used (30 for each group). The three groups were similar by age and gender.  LI4 and HT7 (Shen Men) acupressure points were examined for the intervention.  Sham pressure was used in the placebo group while no intervention was applied in  the control group. RESULTS: The results showed that the lowest average anxiety  score (1.5 ± 0.5; P = 0.01) and the lowest average pain score (4.9 ± 0.8) after  the intervention were related to the acupressure method (P = 0.001). CONCLUSION:  Cost effectiveness and short-term simple education make acupressure method useful  in clinical settings for different illnesses.
C1 Ramsar Nursing Care Research Center, Babol University of Medical Sciences, Babol, Mazandaran, Iran. 
   Ramsar Nursing Care Research Center, Babol University of Medical Sciences, Babol, Mazandaran, Iran. 
   Ramsar Nursing Care Research Center, Babol University of Medical Sciences, Babol, Mazandaran, Iran. 
   Department of Oncology, Azad University of Tonekabon, Tonekabon, Mazandaran, Iran. 
   Anesthesiology Department, Anesthesiology Research Center, Guilan University of Medical Sciences, Rasht, Iran.
EM naderi_bahram@gums.ac.ir
NR 0
TC 0
SN 1873-694
EI 
J9 Complement Ther Clin Pract
PD NOV 11
PY 2017
VL 29
IS 
BP 136
EP 141
DI 10.1016/j.ctcp.2017.09.002
PG 5
WC Acupressure; methods; Adult; Aged; Anxiety; prevention & control; Biopsy, Needle; Bone Marrow; Female; Humans; Male; Middle Aged; Neoplasms; pathology; Pain; prevention & control; Pain Management; methods
UT PubMed:29122251
PM 29122251
DA 2017-11-11
ER

PT J
AU Yeh, CH
   Lin, WC
   Suen, LKP
   Park, NJ
   Wood, LJ
   van Londen, GJ
   Bovbjerg, DH
AF Yeh, Chao Hsing
   Lin, Wei-Chun
   Suen, Lorna Kwai-Ping
   Park, Na-Jin
   Wood, Lisa J.
   van Londen, G. J.
   Bovbjerg, Dana Howard
TI Auricular Point Acupressure to Manage Aromatase Inhibitor-Induced Arthralgia in Postmenopausal Breast Cancer Survivors: A Pilot Study
SO ONCOLOGY NURSING FORUM
LA English
DT Article
DE acupressure; aromatase inhibitor-induced arthralgia; breast cancer survivors
ID self-efficacy questionnaire; adjuvant hormonal-therapy; clinical-practice; pain; osteoarthritis; acupuncture; symptoms; outcm; women; trial
AB Purpose/Objectives: To assess the feasibility of auricular point acupressure to manage aromatase inhibitor-induced arthralgia. Design: Wait list control design. Setting: Outpatient clinics and oncology center. Sample: 20 women with aromatase inhibitor-induced arthralgia. Methods: After baseline data were collected, participants waited one month before they received acupressure once per week for four weeks at a convenient time. The baseline data served as the control comparison. Self-reported measures and blood samples were obtained at baseline, at preintervention, weekly during the intervention, and at post intervention. Main Research Variables: The primary outcomes included pain intensity, pain interference, stiffness, and physical function. Inflammatory cytokines and chemokines were tested. Findings: After the four-week intervention, participants reported decreases in worst pain and pain interference, and improvements in physical function, cancer-related symptom severity, and interference. The proinflammatory cytokines and chemokines displayed a trend of a mean percentage reduction. The anti-inflammatory cytokine interieukin-13 increased from pre- to postintervention. Conclusions: Auricular point acupressure is feasible and may be effective in managing arthralgia in breast cancer survivors. Implications for Nursing: Nurses can administer acupressure in clinical settings, which could enhance the management of aromatase inhibitor-induced arthraigia and contribute to a shift from traditional disease-based biomedical models to a broader, integrative, medical paradigm for managing aromatase inhibitor-induced arthraigia.
C1 [Yeh, Chao Hsing] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA.
   [Lin, Wei-Chun; Park, Na-Jin] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA.
   [Suen, Lorna Kwai-Ping] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R China.
   [Wood, Lisa J.] MGH Inst Hlth Profess, Nursing Res, Charlestown, MA USA.
   [van Londen, G. J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
   [van Londen, G. J.] Univ Pittsburgh, Inst Canc, Biobehav Oncol Program, Pittsburgh, PA 15260 USA.
   [Bovbjerg, Dana Howard] Hillman Canc Ctr, Pittsburgh, PA USA.
C3 Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hong Kong Polytechnic University; Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh
RP Yeh, CH (corresponding author), Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA.
EM cyeh13@jhu.edu
FU American Cancer Society [124638-PEP-13-237-01-PCSM]
CR Alimi D, 2002, MED ACUPUNCT, V13, P18
   Unknown -, 2005, AURICULAR MEDICINE: A COMPLETE MANUAL OF AURICULAR DIAGNOSIS AND TREATMENT, V0, P0
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Beaton DE, 2005, J BONE JOINT SURG AM, V87A, P1038, DOI 10.2106/JBJS.D.02060
   Bellamy N, 2002, WOMAC OSTEOARTHRITIS, V0, P0, DOI DOI 10.1016/j.breast.2007.01.011
   Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Broderick JE, 2013, ARTHRIT CARE RES, V65, P1625, DOI 10.1002/acr.22025
   Burstein HJ, 2007, BREAST, V16, P223, DOI 10.1016/j.breast.2007.01.011
   Burstein HJ, 2014, J CLIN ONCOL, V32, P2255, DOI 10.1200/JCO.2013.54.2258
   Chinese Association of Acupuncture-Moxibustion, 2008, NOM LOC AUR AC POINT, V0, P0, DOI DOI 10.1016/Hval.2014.09.005
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Cleeland CS, 2000, CANCER-AM CANCER SOC, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V
   Craig BM, 2014, VALUE HEALTH, V17, P846, DOI 10.1016/j.jval.2014.09.005
   Dawson-Basoa M, 1998, BRAIN RES, V794, P61, DOI 10.1016/S0006-8993(98)00192-9
   Din OS, 2010, BREAST CANCER RES TR, V120, P525, DOI 10.1007/s10549-010-0757-7
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Furlan AD, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/953139
   Glare PA, 2014, J CLIN ONCOL, V32, P1739, DOI 10.1200/JCO.2013.52.4629
   HANNAN MT, 1990, ARTHRITIS RHEUM-US, V33, P525, DOI 10.1002/art.1780330410
   Henry NL, 2008, BREAST CANCER RES TR, V111, P365, DOI 10.1007/s10549-007-9774-6
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2015, ADV EXP MED BIOL, V862, P89, DOI 10.1007/978-3-319-16366-6_7
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Hershman DL, 2010, J CLIN ONCOL, V28, P4120, DOI 10.1200/JCO.2009.25.9655
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6
   Hsu C, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-276
   Hu W, 2015, INT J CLIN EXP MED, V8, P1956
   Huang LC, 2006, AURICULAR DIAGNOSIS, V0, P0, DOI DOI 10.1200/jco.2014.57.1547
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Islander U, 2011, MOL CELL ENDOCRINOL, V335, P14, DOI 10.1016/j.mce.2010.05.018
   Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x
   Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q
   Kinne RW, 2000, ARTHRITIS RES, V2, P189, DOI 10.1186/ar86
   Kramer PR, 2004, ARTHRITIS RHEUM, V50, P1967, DOI 10.1002/art.20309
   Lind BK, 2005, SPINE, V30, P1454, DOI 10.1097/01.brs.0000166527.18442.10
   Linkov F, 2007, CANCER EPIDEM BIOMAR, V16, P102, DOI 10.1158/1055-9965.EPI-06-0602
   Lundeberg Thomas, 2007, ACUPUNCT MED, V25, P87
   Lundeberg T, 2008, ACUPUNCT MED, V26, P234, DOI 10.1136/aim.26.4.234
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Mao JJ, 2011, BREAST CANCER RES, V13, P0, DOI 10.1186/bcr2813
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Murphy CC, 2012, BREAST CANCER RES TR, V134, P459, DOI 10.1007/s10549-012-2114-5
   National Cancer Institute, 2013, JOINP REGR PROGR, V0, P0, DOI DOI 10.1016/j.ejpain.2005.12.008
   Nevitt MC, 1996, ARCH INTERN MED, V156, P2073, DOI 10.1001/archinte.156.18.2073
   Nicholas MK, 2007, EUR J PAIN, V11, P153, DOI 10.1016/j.ejpain.2005.12.008
   Nicholas MK, 2015, J PAIN, V16, P153, DOI 10.1016/j.jpain.2014.11.002
   Nogier P, 1987, POINTS REFLEXES AURI, V0, P0
   Nogier P, 1981, HDB AURICULOTHERAPY, V0, P0
   Nogier R, 2014, MED ACUPUNCT, V26, P76, DOI 10.1089/acu.2014.1035
   Oleson T, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   OLESON TD, 1980, PAIN, V8, P217, DOI 10.1016/0304-3959(88)90009-7
   Presant CA, 2007, CLIN BREAST CANCER, V7, P775, DOI 10.3816/CBC.2007.n.038
   Prieto-Alhambra D, 2015, ANN RHEUM DIS, V74, P557, DOI 10.1136/annrheumdis-2013-204043
   PROMIS Health Organization and PROMIS Cooperative Group, 2016, PROMIS 29 PROF V2 0, V0, P0
   Romoli M, 2014, NEUROL SCI, V35, PS189, DOI 10.1007/s10072-014-1768-7
   SAKU K, 1993, CLIN CARDIOL, V16, P415, DOI 10.1002/clc.4960160509
   Schafer LM, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-234
   Schnur JB, 2007, PERS INDIV DIFFER, V42, P419, DOI 10.1016/j.paid.2006.07.009
   Shelton RC, 2013, BREAST CANCER RES TR, V137, P817, DOI 10.1007/s10549-012-2370-4
   Szopinski JZ, 2006, J TRADIT CHIN MED, V26, P260
   Szopinski JZ, 2003, MED ACUPUNCTURE, V15, P31
   Vickers AJ, 2010, TRIALS, V11, P0, DOI 10.1186/1745-6215-11-90
   World Health Organization, 1990, REP WORK GROUP ARR A, V0, P0
   Yeh CH, 2014, J PAIN RELIEF, V0, P0, DOI DOI 10.4172/2167-0846.1000139
   Yeh CH, 2013, MED ACUPUNCT, V25, P423, DOI 10.1089/acu.2013.1006
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/934670
   Zhang CS, 2014, J ALTERN COMPLEM MED, V20, P147, DOI 10.1089/acm.2013.0238
   Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154
NR 70
TC 22
Z9 25
U1 2
U2 17
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD JUL 15
PY 2017
VL 44
IS 4
BP 476
EP 487
DI 10.1188/17.ONF.476-487
PG 12
WC Oncology; Nursing
SC Oncology; Nursing
GA FX9GK
UT WOS:000426406400010
PM 28632237
DA 2026-01-16
ER

PT J
AU Ismail, NFF
   Neoh, CF
   Lim, SM
   Abdullah, AH
   Mastuki, MF
   Ramasamy, K
   Zainuddin, N
   Saim, L
   Ming, LC
AF Ismail, Nor Faizatul Fatikah
   Neoh, Chin Fen
   Lim, Siong Meng
   Abdullah, Amir Heberd
   Mastuki, Mohd Fahmi
   Ramasamy, Kalavathy
   Zainuddin, Nazli
   Saim, Lokman
   Ming, Long Chiau
TI The immediate effect of facial candling on inflammatory mediators, substance P, symptoms severity, and quality of life in allergic rhinitis patients Study protocol for a randomized controlled trial
SO MEDICINE
LA English
DT Article
DE complementary therapies; ethnomedicine; folk medicine; immune system diseases; otorhinolaryngologic diseases; respiratory hypersensitivity; traditional medicine
ID dna microarray analysis; asthma; population; management; pain; acupuncture; diagnosis; massage; disease; impact
AB Introduction: Asian countries have a variety of ethnic groups and culture that provide their own traditional treatment in health care. Facial candling appears to be one of the popular traditional treatments in Southeast Asian. The complementary medicine practitioners promote that the facial candling treatment would help in reducing the symptoms of allergic rhinitis and other problems related to sinus. Due to the lack of evidence available, the effectiveness of this treatment method and its mechanism, however, remains unknown. The objective of this research is therefore to study impact of facial candling on inflammatory mediators, substance P (SP), symptoms severity, and quality of life (QoL) in allergic rhinitis patients. Method and analysis: A randomized, nonblinded, controlled trial will be carried out by recruiting a total of 66 eligible allergic rhinitis patients who fulfill the inclusion criteria from a university health center. The subjects will be randomly assigned into 2 groups: intervention group receiving facial candling treatment and control group (no treatment given). Samples of blood and nasal mucus will be collected right before and after intervention. Samples collected will be analyzed. The primary outcomes are the changes in the level of SP in both blood and mucus samples between both groups. The secondary outcomes include the levels of inflammatory mediators (ie, tumor necrosis factor alpha, interleukin (IL)-3, IL-5, IL-6, IL-10, and IL-13) and the severity of allergic rhinitis symptoms as measured by a visual analogous scale and QoL using the Rhinitis Quality of Life Questionnaire (RQLQ). Ethical and trial registration: The study protocols are approved from the Ethical and Research Committee of the Universiti Teknologi MARA (REC/113/15). The trial is registered under the Australia New Zealand Clinical Trial Registry (ACTRN12616000299404). The trial was registered on 03/07/2016 and the first patient was enrolled on 10/12/2016. Conclusion: Facial candling is one of the unique treatments using candles to reduce the severity of symptoms and inflammation. This is the first ever study conducted on facial candling that will give rise to new knowledge underlying the effects of facial candling on severity of symptoms and inflammation relief mechanism mediated by substance P and inflammatory mediators.
C1 [Ismail, Nor Faizatul Fatikah; Neoh, Chin Fen; Lim, Siong Meng; Ramasamy, Kalavathy; Ming, Long Chiau] Univ Teknol MARA UiTM, Fac Pharm, Puncak Alam, Malaysia.
   [Neoh, Chin Fen; Lim, Siong Meng; Ramasamy, Kalavathy] Univ Teknol MARA, Collaborat Drug Discovery Res CDDR Grp, Pharmaceut & Life Sci CoRe, Shah Alam, Selangor, Malaysia.
   [Abdullah, Amir Heberd] Univ Teknol MARA, Fac Hlth Sci, Environmetal Hlth Dept, Bertam, Penang, Malaysia.
   [Abdullah, Amir Heberd] Univ Teknol MARA, Pharmaceut & Life Sci CoRe, Vector Borne Dis Res Grp VERDI, Shah Alam, Selangor, Malaysia.
   [Mastuki, Mohd Fahmi] Univ Teknol MARA, Fac Hlth Sci, Med Lab Dept, Puncak Alam, Johor, Malaysia.
   [Zainuddin, Nazli] Univ Teknol MARA, Fac Med, Puncak Alam, Selangor, Malaysia.
   [Saim, Lokman; Ming, Long Chiau] KPJ Healthcare Univ Coll, Sch Pharm, Lot PT 17010 Persiaran Seriemas, Nilai 71800, Negeri Sembilan, Malaysia.
C3 Universiti Teknologi MARA; Universiti Teknologi MARA; Universiti Teknologi MARA; Universiti Teknologi MARA; Universiti Teknologi MARA
RP Ming, LC (corresponding author), KPJ Healthcare Univ Coll, Sch Pharm, Lot PT 17010 Persiaran Seriemas, Nilai 71800, Negeri Sembilan, Malaysia.
EM longchiauming@gmail.com
FU Research Entity Initiative: UiTM, Ministry of Higher Education [600-IRMI/DANA5/3/REI (0004/2016)]; KPJ Healthcare University College
CR Accordini S, 2015, BMC PULM MED, V15, P0, DOI 10.1186/s12890-015-0008-0
   Amadesi S, 2012, CIRCULATION, V125, P1774, DOI 10.1161/CIRCULATIONAHA.111.089763
   Ashaari ZA, 2010, ANN ACAD MED SINGAP, V39, P619
   Benson M, 2002, CYTOKINE, V18, P20, DOI 10.1006/cyto.2002.1012
   Benson M, 2001, CLIN EXP ALLERGY, V31, P361, DOI 10.1046/j.1365-2222.2001.01045.x
   Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x
   Callebaut I, 2014, AM J RHINOL ALLERGY, V28, P290, DOI 10.2500/ajra.2014.28.4052
   Cardell LO, 2016, NPJ PRIM CARE RESP M, V26, P0, DOI 10.1038/npjpcrm.2015.82
   Choi SM, 2013, ALLERGY, V68, P365, DOI 10.1111/all.12053
   CHUNG KF, 1990, EUR RESPIR J, V3, P329
   Crossley KM, 2004, ARCH PHYS MED REHAB, V85, P815, DOI 10.1016/S0003-9993(03)00613-0
   Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755
   Gould HJ, 2012, ESSENTIALS OF REGIONAL ANESTHESIA, V0, PP83, DOI 10.1007/978-1-4614-1013-3_4
   Jackie Clark P, 2010, EAR CANDLES CANDLING, V0, P0
   Kushnir NM, 2005, DEPTH REV ALLERGIC R, V0, P0
   Lisowska B, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0139206
   Lourenço EA, 2016, INT ARCH OTORHINOLAR, V20, P6, DOI 10.1055/s-0035-1564437
   Mackawan S, 2007, J BODYW MOV THER, V11, P9, DOI 10.1016/j.jbmt.2005.11.001
   Manuel AM, 2012, TROP BIOMED, V29, P360
   McDonald JL, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/591796
   Molina-Ortega F, 2014, MAN THER, V19, P0
   Nee RJ, 2006, PHYS THER SPORT, V7, P36, DOI 10.1016/j.ptsp.2005.10.002
   OConnor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061
   Packard KA, 2003, INT IMMUNOPHARMACOL, V3, P909, DOI 10.1016/S1567-5769(02)00235-7
   Petti Filomena Bangrazi, 2002, J TRADIT CHIN MED, V22, P104
   Pols DHJ, 2016, SCAND J PRIM HEALTH, V34, P143, DOI 10.3109/02813432.2016.1160629
   Prepageran N, 2014, ASIA PAC ALLERGY, V4, P142, DOI 10.5415/apallergy.2014.4.3.142
   Rafferty J, 2007, CAN FAM PHYSICIAN, V53, P2121
   Seidman MD, 2015, OTOLARYNG HEAD NECK, V152, PS1, DOI 10.1177/0194599814561600
   Sejari N, 2014, ARCH PHARM PRACT, V5, P144, DOI 10.4103/2045-080X.142048
   Sejari N, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-0988-1
   Shiue HS, 2008, J ALTERN COMPLEM MED, V14, P689, DOI 10.1089/acm.2007.0669
   Shiue HS, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1418-0
   Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, PS2, DOI 10.1067/mai.2001.115569
   Taylor MB, 2012, RHINOLOGY, V50, P139, DOI 10.4193/Rhino10.140
   Verhoef MJ, 2006, BMC COMPLEM ALTERN M, V6, P1
   Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, PS1, DOI 10.1016/j.jaci.2008.06.003
NR 37
TC 3
Z9 3
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 15
PY 2017
VL 96
IS 30
BP 
EP 
DI 10.1097/MD.0000000000007511
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA FB9SY
UT WOS:000406480500026
PM 28746195
DA 2026-01-16
ER

PT J
AU Chokshi, SK
   Ladas, EJ
   Taromina, K
   McDaniel, D
   Rooney, D
   Jin, ZZ
   Hsu, WC
   Kelly, KM
AF Chokshi, Sagar K.
   Ladas, Elena J.
   Taromina, Katherine
   McDaniel, Douglas
   Rooney, Diane
   Jin, Zhezhen
   Hsu, Wei-Chun
   Kelly, Kara M.
TI Predictors of acupuncture use among children and adolescents with cancer
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE acupuncture therapy; integrative medicine; pediatric oncology; supportive care
ID complementary therapy; alternative medicine; prevalence; symptoms; oncology; safety; care; distress; patient; adults
AB BackgroundEvidence for the application of acupuncture in pediatric oncology is limited. We investigated the acceptance of acupuncture and factors associated with its use among children and adolescents with cancer. MethodsNinety acupuncture-naive children receiving cancer treatment at Columbia University Medical Center (CUMC) provided consent/assent for participation. Participants could choose to receive or refuse integrative services offered at CUMC. Symptoms were collected for a 6-month period with the Memorial Symptom Assessment Scale (MSAS). Acute and delayed adverse events among participants who received acupuncture were recorded. ResultsFifty-four percent of the participants elected to receive acupuncture. In total, 252 acupuncture sessions were administered with a median of four sessions per patient (range 1-13 sessions). Pain (56%), nausea (51%), lack of energy (50%), and irritability (43%) were the most frequently reported symptoms in the whole cohort. Determinants of acupuncture use included older age and ethnicity. Acupuncture was more likely than other integrative modalities to be used for gastrointestinal and constitutional symptoms including drowsiness (odds ratio [OR], 3.34; 95% confidence interval [CI], 1.98-5.66; P < 0.0001), lack of energy (OR, 3.23; 95% CI, 1.78-5.87; P = 0.0001), and pain (OR, 2.63; 95% CI, 1.46-4.72; P = 0.001). Adverse events were reported by 3% of the participants. There was no increased incidence of adverse events in children with thrombocytopenia (P = 0.189) or neutropenia (P = 0.497). ConclusionOur results highlight the potential use of acupuncture as a safe, adjunctive therapy for symptom management within existing supportive care regimens in pediatric oncology and potential areas to focus research initiatives.
C1 [Chokshi, Sagar K.] Cooper Univ Hosp, Dept Obstet & Gynecol, Camden, NJ USA.
   [Ladas, Elena J.; Taromina, Katherine; McDaniel, Douglas; Rooney, Diane; Kelly, Kara M.] Columbia Univ, Med Ctr, Div Pediat Hematol Oncol & Stem Cell Transplant, New York, NY USA.
   [Ladas, Elena J.] Columbia Univ, Med Ctr, Inst Human Nutr, New York, NY USA.
   [Jin, Zhezhen] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA.
   [Hsu, Wei-Chun] Cornell Univ, Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY 10021 USA.
C3 Cooper University Hospital; Columbia University; Columbia University; Columbia University; Cornell University; Weill Cornell Medicine
RP Chokshi, SK (corresponding author), 3 Cooper Plaza,Suite 221, Camden, NJ 08103 USA.
EM chokshi-sagar@cooperhealth.edu
CR Adams D, 2011, PEDIATRICS, V128, PE1575, DOI 10.1542/peds.2011-1091
   Unknown -, 2002, ACUPUNCTURE REV ANAL, V0, P0
   Baker JN, 2008, PEDIATR CLIN N AM, V55, P223, DOI 10.1016/j.pcl.2007.10.011
   Barnes PM, 2008, STAT NCFH COMPLEMENT, V0, P0
   Bishop FL, 2010, PEDIATRICS, V125, P768, DOI 10.1542/peds.2009-1775
   Black Lindsey I, 2015, NATL HEALTH STAT REPORT, V0, P1
   Bleyer WA, 2002, MED PEDIATR ONCOL, V38, P1, DOI 10.1002/mpo.1257
   Bluebond-Langner M, 2007, J CLIN ONCOL, V25, P2414, DOI 10.1200/JCO.2006.08.7759
   Brett J, 2015, CLEAN NEEDLE TECHNIQ, V0, P0
   Chao MT, 2006, J ALTERN COMPLEM MED, V12, P719, DOI 10.1089/acm.2006.12.719
   Cohen Andrea J, 2005, INTEGR CANCER THER, V4, P131, DOI 10.1177/1534735405276419
   Collins JJ, 2000, J PAIN SYMPTOM MANAG, V19, P363, DOI 10.1016/S0885-3924(00)00127-5
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Dyson GJ, 2012, SUPPORT CARE CANCER, V20, P75, DOI 10.1007/s00520-010-1059-7
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Freyer DR, 2013, PEDIATR BLOOD CANCER, V60, P1055, DOI 10.1002/pbc.24431
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   Graham RE, 2005, J NATL MED ASSOC, V97, P535
   Hedstrom Mariann, 2003, J PEDIATR ONCOL NURS, V20, P120
   Herman PM, 2012, BMJ OPEN, V2, P0, DOI 10.1136/bmjopen-2012-001046
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Kelly Kara M, 2009, HEMATOLOGY AM SOC HEMATOL EDUC PROGRAM, V0, PP307, DOI 10.1182/asheducation-2009.1.307
   Kelly KM, 2000, J PEDIAT HEMATOL ONC, V22, P412, DOI 10.1097/00043426-200009000-00005
   Kemper KJ, 2000, PEDIATRICS, V105, P941
   Ladas EJ, 2006, J PEDIAT HEMATOL ONC, V28, P601, DOI 10.1097/01.mph.0000212989.26317.52
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Laengler A, 2008, EUR J CANCER, V44, P2233, DOI 10.1016/j.ejca.2008.07.020
   Martel D, 2005, PEDIATR BLOOD CANCER, V44, P660, DOI 10.1002/pbc.20205
   McDaniel D, 2016, MERIDIANS J ACUPUNCT, V3, P1
   Micozzi MarcS, 2006, FUNDAMENTALS COMPLEM, V0, P0
   Raith W, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/739414
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Söllner W, 2000, CANCER-AM CANCER SOC, V89, P873, DOI 10.1002/1097-0142(20000815)89:4<873::AID-CNCR21>3.0.CO;2-K
   White A, 2001, ACUPUNCT MED, V19, P84
   Wolfe J, 2015, J CLIN ONCOL, V33, P1928, DOI 10.1200/JCO.2014.59.1222
   Zhukovsky DS, 2015, CANCER-AM CANCER SOC, V121, P4080, DOI 10.1002/cncr.29597
NR 39
TC 25
Z9 29
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUL 15
PY 2017
VL 64
IS 7
BP 
EP 
DI 10.1002/pbc.26424
PG 7
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA EV8KE
UT WOS:000402028300034
PM 28176457
DA 2026-01-16
ER

PT J
AU Choi, J
   Jeon, C
   Lee, JH
   Jang, JU
   Quan, FS
   Lee, K
   Kim, W
   Kim, SK
AF Choi, Jiho
   Jeon, Changhoon
   Lee, Ji Hwan
   Jang, Jo Ung
   Quan, Fu Shi
   Lee, Kyungjin
   Kim, Woojin
   Kim, Sun Kwang
TI Suppressive Effects of Bee Venom Acupuncture on Paclitaxel-Induced Neuropathic Pain in Rats: Mediation by Spinal α2-Adrenergic Receptor
SO TOXINS
LA English
DT Article
DE bee venom acupuncture; chemotherapy-induced neuropathic pain; paclitaxel
ID complete freunds-adjuvant; peripheral neuropathy; acupoint stimulation; controlled-trial; cold allodynia; formalin test; model; apipuncture; electroacupuncture; chemotherapy
AB Paclitaxel, a chemotherapy drug for solid tumors, induces peripheral painful neuropathy. Bee venom acupuncture (BVA) has been reported to have potent analgesic effects, which are known to be mediated by activation of spinal -adrenergic receptor. Here, we investigated the effect of BVA on mechanical hyperalgesia and spinal neuronal hyperexcitation induced by paclitaxel. The role of spinal -adrenergic receptor subtypes in the analgesic effect of BVA was also observed. Administration of paclitaxel (total 8 mg/kg, intraperitoneal) on four alternate days (days 0, 2, 4, and 6) induced significant mechanical hyperalgesic signs, measured using a von Frey filament. BVA (1 mg/kg, ST36) relieved this mechanical hyperalgesia for at least two hours, and suppressed the hyperexcitation in spinal wide dynamic range neurons evoked by press or pinch stimulation. Both melittin (0.5 mg/kg, ST36) and phospholipase A2 (0.12 mg/kg, ST36) were shown to play an important part in this analgesic effect of the BVA, as they significantly attenuated the pain. Intrathecal pretreatment with the (2)-adrenergic receptor antagonist (idazoxan, 50 mu g), but not (1)-adrenergic receptor antagonist (prazosin, 30 mu g), blocked the analgesic effect of BVA. These results suggest that BVA has potent suppressive effects against paclitaxel-induced neuropathic pain, which were mediated by spinal (2)-adrenergic receptor.
C1 [Choi, Jiho; Jeon, Changhoon; Kim, Woojin; Kim, Sun Kwang] Kyung Hee Univ, Coll Korean Med, Dept Physiol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Lee, Ji Hwan; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Jang, Jo Ung; Kim, Woojin; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept East West Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Quan, Fu Shi] Kyung Hee Univ, Sch Med, Dept Med Zool, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Lee, Kyungjin] Kyung Hee Univ, Coll Korean Med, Dept Herbol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Kim, W; Kim, SK (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Physiol, 26 Kyungheedae Ro, Seoul 02447, South Korea.; Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.; Kim, W; Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept East West Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM cyanical@hotmail.com; cjmystars44@gmail.com; mibdna@khu.ac.kr; powerfox032@naver.com; fsquan@khu.ac.kr; niceday@khu.ac.kr; wjkim@khu.ac.kr; skkim77@khu.ac.kr
FU Korea Institute of Oriental Medicine [Y16113]; Kyung Hee University College of Korean Medicine; society of immune and pain
CR Argyriou AA, 2008, CRIT REV ONCOL HEMAT, V66, P218, DOI 10.1016/j.critrevonc.2008.01.008
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5
   Cata JP, 2006, NEUROSCIENCE, V138, P329, DOI 10.1016/j.neuroscience.2005.11.009
   Chen J, 2010, PROG NEUROBIOL, V92, P151, DOI 10.1016/j.pneurobio.2010.06.006
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Choi S, 2017, J PHYSIOL SCI, V67, P431, DOI 10.1007/s12576-016-0505-9
   Covens A, 2002, GYNECOL ONCOL, V85, P71, DOI 10.1006/gyno.2001.6552
   EZE OBL, 2016, J PHARM CHEM BIOL SCI, V4, P48
   Flatters SJL, 2006, NEUROSCI LETT, V397, P219, DOI 10.1016/j.neulet.2005.12.013
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580
   Gim GT, 2011, BRAIN RES BULL, V86, P403, DOI 10.1016/j.brainresbull.2011.09.010
   Goffin J, 2010, J THORAC ONCOL, V5, P260, DOI 10.1097/JTO.0b013e3181c6f035
   JONES SL, 1991, PROG BRAIN RES, V88, P381
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kim HW, 2003, J VET MED SCI, V65, P349, DOI 10.1292/jvms.65.349
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   Koh PS, 2013, J SHOULDER ELB SURG, V22, P1053, DOI 10.1016/j.jse.2012.10.045
   Kwon YB, 2000, ACUPUNCTURE ELECTRO, V25, P27, DOI 10.3727/036012900816356235
   Kwon YB, 2004, MOL CELLS, V17, P329
   Kwon YB, 2001, AM J CHINESE MED, V29, P187, DOI 10.1142/S0192415X01000228
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Kwon YB, 2006, NEUROSCI RES, V55, P197, DOI 10.1016/j.neures.2006.03.003
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-471
   Lee JJ, 2006, J CLIN ONCOL, V24, P1633, DOI 10.1200/JCO.2005.04.0543
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Li D, 2015, TOXINS, V7, P2422, DOI 10.3390/toxins7072422
   Li JH, 2010, AM J CHINESE MED, V38, P1039, DOI 10.1142/S0192415X10008457
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/369324
   Lin L, 2017, BIOMED PHARMACOTHER, V90, P921, DOI 10.1016/j.biopha.2017.04.055
   Ling B, 2008, NEUROPHARMACOLOGY, V55, P724, DOI 10.1016/j.neuropharm.2008.06.007
   Liu WC, 2004, NEUROREPORT, V15, P1937, DOI 10.1097/00001756-200408260-00021
   Ormseth MJ, 2011, PATIENT PREFER ADHER, V5, P343, DOI 10.2147/PPA.S16358
   Park JW, 2012, INTEGR CANCER THER, V11, P166, DOI 10.1177/1534735411413265
   Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Serpell MG, 2002, PAIN, V99, P557, DOI 10.1016/S0304-3959(02)00255-5
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Sparano J A, 2000, CLIN BREAST CANCER, V1, P32, DOI 10.3816/CBC.2000.n.002
   Vinik AI, 2013, DIABETES METAB SYNDR, V6, P57, DOI 10.2147/DMSO.S24825
   WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045
   Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004
   Yoon H, 2015, BIOL PHARM BULL, V38, P710, DOI 10.1248/bpb.b14-00797
   Yoon J, 2012, J ACUPUNCT MERIDIAN, V5, P156, DOI 10.1016/j.jams.2012.05.003
   Yoon SY, 2009, J PAIN, V10, P253, DOI 10.1016/j.jpain.2008.09.002
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 48
TC 40
Z9 42
U1 1
U2 13
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6651
EI 
J9 TOXINS
JI Toxins
PD NOV 15
PY 2017
VL 9
IS 11
BP 
EP 
DI 10.3390/toxins9110351
PG 12
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA FO2FI
UT WOS:000416589800016
DA 2026-01-16
ER

PT J
AU Chen, L
   Lin, CC
   Huang, TW
   Kuan, YC
   Huang, YH
   Chen, HC
   Kao, CY
   Su, CM
   Tam, KW
AF Chen, Lawrence
   Lin, Chao-Chun
   Huang, Tsai-Wei
   Kuan, Yi-Chun
   Huang, Yao-Hsien
   Chen, Hung-Chou
   Kao, Chun-Yu
   Su, Chih-Ming
   Tam, Ka-Wai
TI Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with
SO Breast (Edinburgh, Scotland)
LA English
DT Review
DE Acupuncture; Aromatase inhibitor-induced arthralgia; Breast cancer; Meta-analysis
AB PURPOSE: Aromatase inhibitor (AI)-induced arthralgia (AIA) is a common side  effect that may lead to premature discontinuation of effective hormonal therapy  in patients with breast cancer. Acupuncture may relieve joint pain in patients  with AIA. We conducted a meta-analysis of randomized controlled trials (RCTs) to  evaluate the effectiveness of acupuncture in pain relief in AIA. METHODS: The  PubMed, Embase, Cochrane Library, and Scopus databases and the ClinicalTrials.gov  registry were searched for studies published before February 2017. Individual  effect sizes were standardized, and a meta-analysis was conducted to calculate  the pooled effect size by using a random effect model. Pain was assessed using  the Brief Pain Inventory (BPI) and Western Ontario and McMaster Universities  Osteoarthritis Index (WOMAC) at 3-4, 6-8, and 12 weeks. Secondary outcomes  included disability level, upper extremity function, physical performance, and  quality of life. RESULTS: Five trials involving 181 patients were reviewed.  Significant pain reduction was observed after 6-8 weeks of acupuncture treatment.  Patients receiving acupuncture showed a significant decrease in the BPI worst  pain score (weighted mean difference [WMD]: -3.81, 95% confidence interval  [CI]: -5.15 to -2.47) and the WOMAC pain score (WMD: -130.77, 95% CI: -230.31  to -31.22) after 6-8 weeks of treatment. One of the 4 trials reported 18 minor  adverse events in 8 patients during 398 intervention episodes. CONCLUSION:  Acupuncture is a safe and viable nonpharmacologic treatment that may relieve  joint pain in patients with AIA. Additional studies involving a higher number of  RCTs are warranted.
C1 Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
   Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
   Department of Nursing, College of Medicine and Nursing, HungKuang University, Taichung, Taiwan.
   Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
   Department of Neurology, School of Medicine, Taipei MedicalUniversity, Taipei, Taiwan.
   Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
   Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
   Department of Physical Medicine andRehabilitation, Shuang Ho Hospital, Taipei Medical University, New Taipei City,Taiwan
   Department of Physical Medicine and Rehabilitation, School of Medicine,College of Medicine, Taipei Medical University, Taipei, Taiwan.
   Division of Pediatric Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
   Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
   Division of General Surgery,Department of Surgery, School of Medicine, College of Medicine, Taipei MedicalUniversity, Taipei, Taiwan.
   Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
   Division of General Surgery, Department ofSurgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan;Division of General Surgery, Department of Surgery, School of Medicine, Collegeof Medicine, Taipei Medical University, Taipei, Taiwan
   Cochrane Taiwan, TaipeiMedical University, Taipei, Taiwan.
EM kelvintam@h.tmu.edu.tw
NR 0
TC 0
SN 1532-308
EI 
J9 Breast
PD APR 7
PY 2017
VL 33
IS 
BP 132
EP 138
DI 10.1016/j.breast.2017.03.015
PG 6
WC Acupuncture Therapy; methods; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; adverse effects; Aromatase Inhibitors; adverse effects; Arthralgia; chemically induced; Breast Neoplasms; drug therapy; Female; Humans; Middle Aged; Pain Measurement; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:28384564
PM 28384564
DA 2017-04-07
ER

PT J
AU Asadpour, R
   Kessel, KA
   Bruckner, T
   Sertel, S
   Combs, SE
AF Asadpour, Rebecca
   Kessel, Kerstin A
   Bruckner, Tom
   Sertel, Serkan
   Combs, Stephanie E
TI Randomized study exploring the combination of radiotherapy with two types of
SO Trials
LA English
DT Journal Article
DE Acupuncture; Fatigue; Quality of life (QOL); Radiotherapy; Sham-controlled trial
AB BACKGROUND: Adverse effects such as fatigue, pain, erythema, nausea and vomiting  are commonly known in patients undergoing irradiation (RT) alone or in  combination with chemotherapy (RCHT). Patients suffering from these symptoms are  limited in their daily life and their quality of life (QOL) is often reduced. As  addressed in several trials, acupuncture can cause amelioration of these specific  disorders. Especially for pain symptoms, several groups have shown efficacy of  acupuncture. To what extent the difference between traditional acupuncture (verum  acupuncture) and false acupuncture (sham acupuncture) is in reducing side effects  and improvement of QOL is not clear. METHODS/DESIGN: ROSETTA is a prospective  randomized phase II trial (version 1.0) to examine the efficacy of traditional  acupuncture in patients with RT-related side effects. In the experimental (verum)  arm (n = 37) an experienced acupuncture-trained person will treat dedicated  acupuncture points. In the control (sham) arm (n = 37) sham acupuncture will be  performed to provide a blinded comparison of results. DISCUSSION: This is the  first randomized prospective trial to evaluate the effect of traditional  acupuncture on RT-related side effects such as fatigue and QOL. TRIAL  REGISTRATION: ClinicalTrials.gov, NCT02674646 . Registered on 8 December 2015.
C1 Department of Radiation Oncology, Technische Universität München (TUM), Klinikum rechts der Isar, Ismaninger Straße 22, 81675, Munich, Germany.
   Department of Radiation Oncology, Technische Universität München (TUM), Klinikum rechts der Isar, Ismaninger Straße 22, 81675, Munich, Germany.
   Department of Radiation Sciences (DRS), Institute of Innovative Radiotherapy 
   Department of Medical Biometry, Institute of Medical Biometry and Informatics (IMBI), Universität Heidelberg, Im Neuenheimer Feld 305, 69120, Heidelberg,Germany.
   Praxisgemeinschaft Prof. Sertel & Dr. Passerino , Rottstrasse 39, 67061, Ludwigshafen am Rhein, Germany.
   Department of Otorhinolaryngology, Head & Neck Surgery, University of Heidelberg, 
   Department of 325 Otorhinolaryngology, Head and Neck Surgery, University Hospital CHUV, 326 Bâtiment hospitalier, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
   Department of Radiation Oncology, Technische Universität München (TUM), Klinikum rechts der Isar, Ismaninger Straße 22, 81675, Munich, Germany.stephanie.combs@tum.de.
   Department of Radiation Sciences (DRS), Institute of Innovative Radiotherapy 
   Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany. stephanie.combs@tum.de.
NR 0
TC 0
SN 1745-621
EI 
J9 Trials
PD AUG 31
PY 2017
VL 18
IS 1
BP 398
EP 398
DI 10.1186/s13063-017-2139-5
PG 0
WC Acupuncture Points; Acupuncture Therapy; adverse effects; Fatigue; etiology; Germany; Humans; Neoplasms; diagnosis; Prospective Studies; Quality of Life; Radiotherapy; adverse effects; Surveys and Questionnaires; Time Factors; Treatment Outcome
UT PubMed:28851420
PM 28851420
DA 2017-08-31
ER

PT J
AU Enblom, A
   Johnsson, A
AF Enblom, Anna
   Johnsson, Anna
TI Type and frequency of side effects during PC6 acupuncture: observations from
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE Acupuncture; Adverse Events; Clinical Trials; Complementary Medicine; Physiotherapy
AB BACKGROUND: Many therapists practise PC6 acupuncture for emesis (nausea and  vomiting) during pregnancy, different cancer therapies, palliative care, after  surgery, or to induce relaxing effects in general. Knowledge of side effects is  central to shared decision-making. AIM: To describe the type and frequency of  side effects and the level of needle-induced pain during PC6 acupuncture.  METHODS: We included 1298 PC6 acupuncture treatments, delivered to 221  participants (77% women, mean age 52.5, range 18-91 years). The subjects had  received genuine PC6 acupuncture, in one of two previous randomised controlled  trials, aimed at inducing antiemetic (n=100, with 100 providing data on side  effects and 94 on needle-induced pain, respectively) or relaxing (n=121, with 120  providing data) effects. Side effects during and after the acupuncture treatments  were registered in structured treatment protocols and study diaries. RESULTS: No  serious complications occurred. Side effects during the acupuncture sessions  included minor bleeding in 5.0%, tiredness in 4.9%, numbness in 4.5% and  dizziness in 1.4% of the 1298 treatments. After treatment, the mean proportions  of participants reporting side effects each week were: tiredness 25.8%; feeling  cold 17.8%; dizziness 9.7%; sweating 9.3%; haematoma 8.8%; and soreness at the  needling sites 4.3%. Participants perceived the needling to be not painful (47.4%  of participants), or mildly (39.1%), moderately (11.6%) or very painful (1.4%).  CONCLUSIONS: Few side effects occurred and those that did were mild. Nearly 90%  found PC6 acupuncture to be not painful or only mildly painful. Healthcare  professionals may consider the observed levels of side effects when informing  patients about side effects of PC6 acupuncture.
C1 Region of Östergötland and Department of Medical and Health Sciences, Division of Physiotherapy, Linköping University, Sweden.
   Department of Oncology, Skåne University Hospital, and Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD DEC 10
PY 2017
VL 35
IS 6
BP 421
EP 429
DI 10.1136/acupmed-2016-011270
PG 8
WC Acupuncture Points; Acupuncture Therapy; adverse effects; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Pain; etiology; Patient Satisfaction; Postoperative Nausea and Vomiting; prevention & control; Symptom Assessment; Young Adult
UT PubMed:29222203
PM 29222203
DA 2017-12-10
ER

PT J
AU Garcia, MK
   Cohen, L
   Spano, M
   Spelman, A
   Hashmi, Y
   Chaoul, A
   Wei, Q
   Lopez, G
AF Garcia, M Kay
   Cohen, Lorenzo
   Spano, Michael
   Spelman, Amy
   Hashmi, Yousra
   Chaoul, Alejandro
   Wei, Qi
   Lopez, Gabriel
TI Inpatient Acupuncture at a Major Cancer Center.
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; cancer; inpatient; integrative medicine; oncology
AB BACKGROUND: Use of complementary and integrative therapies is increasing among  cancer patients, but data regarding the impact treatments such as acupuncture  have in an inpatient oncology setting are limited. METHODS: Patients who received  acupuncture in an inpatient hospital environment between December 2014 and  December 2015 were asked to complete a modified Edmonton Symptom Assessment Scale  (ESAS; 0-10 scale) before and after each visit. Pre- and post-treatment scores  were examined for each symptom using paired t tests. RESULTS: A total of 172  inpatients were treated with acupuncture in their hospital beds (257 visits).  Thirty percent (n = 51) received at least one additional follow-up treatment  (mean visits/patient = 1.5). Completion rate of the modified ESAS after  acupuncture was 42%. The most common reasons for not completing the  post-treatment ESAS were "patient too drowsy" or "patient fell asleep" (72%). For  patients who reported a baseline symptom score ≥1, the greatest improvements  (mean change ± SD) after acupuncture on the initial visit were found for pain  (-1.8 ± 2.2; n = 69; P < .0001), nausea (-1.2 ± 1.9; n = 30; P < .001), anxiety  (-0.8 ± 1.8; n = 36; P = .01), drowsiness (-0.6 ± 1.8; n = 57; P = .02), and  fatigue (-0.4 ± 1.1; n = 67; P = .008). For patients who received at least one  follow-up visit, significant improvement from baseline was found for sleep  disturbance (-2.5 ± 4.4; n = 17; P = .03), anxiety (-2.4 ± 1.7; n = 9; P = .002),  pain (-2.3 ± 2.7; n = 20; P = .001), and drowsiness (-2.0 ± 2.6; n = 16; P =  .008). CONCLUSIONS: Patients who received inpatient acupuncture at a major cancer  center experienced significant improvement after treatment for pain, sleep  disturbance, anxiety, drowsiness, nausea, and fatigue.
C1 1 The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
   1 The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
   1 The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
   1 The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
   1 The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
   1 The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
   1 The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
   1 The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD JAN 5
PY 2017
VL 17
IS 1
BP 148
EP 152
DI 10.1177/1534735416685403
PG 4
WC Acupuncture Therapy; Adolescent; Adult; Aged; Aged, 80 and over; Female; Hospitalization; Humans; Male; Middle Aged; Neoplasms; complications; Young Adult
UT PubMed:28050924
PM 28050924
DA 2017-01-05
ER

PT J
AU Mazzei, LG
   Bergamaschi, CD
   Silva, MT
   Lopes, LC
AF Mazzei, Lauren Giustti
   Bergamaschi, Cristiane de Cassia
   Silva, Marcus Tolentino
   Lopes, Luciane Cruz
TI Use of IMMPACT domains in clinical trials of acupuncture for chronic pain: a protocol for a methodological survey
SO BMJ OPEN
LA English
DT Article
ID cost
AB Introduction Pain is one of the most common and most debilitating complaints among patients. It affects the individual, their relationship with friends and family, their ability to function at work, and their sociability. Acupuncture is one of the therapeutic resources for managing chronic pain. Given the variability of outcome measures in controlled randomised clinical trials on non-oncologicchronic pain (CRCT-NOCP), the Initiative in Methods, Measurements and Pain Assessment in Clinical Trials (IMMPACT) recommends six domains to be covered in evaluating the effectiveness of treatments for chronic pain. Objective To check whether the methodological quality of outcome reporting in published trials has used IMMPACT recommendations in measuring CRCT-NOCP outcomes when acupuncture was used as a treatment. Method This is a methodological study. We will systematically search for eligible studies in specific databases with a defined strategy. We will use the MeSHterms of 'acupuncture', 'chronic pain' and similar terms, without restrictions on idiom. Eligible studies will include those which are randomised and chose NOCP patients to be treated with acupuncture or control (sham acupuncture or no acupuncture), recruited after September 2004, with >= 100 patients. The measured outcomes are to be the presence of outcome domains recommended by IMMPACT, domains reported by the patient or clinician, tools used to measure such domains, as well as other features of the studies. We shall conduct a regression analysis to explore factors which can be associated with the presence of outcome domains according to IMMPACT recommendations. Ethics and dissemination This survey will be submitted for presentation at congresses and for publication in a scientific journal. The findings obtained in this study will allow us to measure the quality of the evidence and provide greater transparency in decisions regarding the use of acupuncture as a viable alternative to managing chronic pain.
C1 [Mazzei, Lauren Giustti; Bergamaschi, Cristiane de Cassia; Silva, Marcus Tolentino; Lopes, Luciane Cruz] Univ Sorocaba, Dept Pharmaceut Sci, Grad Program, Sao Paulo, Brazil.
C3 Universidade de Sorocaba
RP Lopes, LC (corresponding author), Univ Sorocaba, Dept Pharmaceut Sci, Grad Program, Sao Paulo, Brazil.
EM luslopes@terra.com.br
CR Akl EA, 2012, J CLIN EPIDEMIOL, V65, P262, DOI 10.1016/j.jclinepi.2011.04.015
   Unknown -, 2013, MANAGEMENT OF CHRONIC PAIN: A NATIONAL CLINICAL GUIDELINE, V0, P0
   Unknown -, 2013, NO TITLE CAPTURED, V0, P0
   Azevedo LF, 2016, EUR J HEALTH ECON, V17, P87, DOI 10.1007/s10198-014-0659-4
   Santos CMD, 2007, REV LAT-AM ENFERM, V15, P508, DOI 10.1590/S0104-11692007000300023
   Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012
   Dworkin RH, 2010, PAIN, V149, P177, DOI 10.1016/j.pain.2010.02.018
   Guerriere DN, 2010, CAN J ANAESTH, V57, P549, DOI 10.1007/s12630-010-9306-4
   Higgins J, 2011, COCHRANE COLLABORATI, V0, P0
   National Guideline, 2011, PAIN, V0, P0
   OMdl Salud, 2013, ESTR OMS MED TRAD 20, V0, P0
   Ontario CPSO, 2000, EV BAS REC MED MAN C, V0, P0
   Rasu RS, 2014, J MANAG CARE SPEC PH, V20, P921, DOI 10.18553/jmcp.2014.20.9.921
   Rosenquist RW, 2010, ANESTHESIOLOGY, V112, P810, DOI 10.1097/ALN.0b013e3181c43103
   Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
NR 18
TC 1
Z9 1
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD SEP 15
PY 2017
VL 7
IS 9
BP 
EP 
DI 10.1136/bmjopen-2016-014904
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA FJ3RY
UT WOS:000412650700030
PM 28963280
DA 2026-01-16
ER

PT J
AU Xu, Y
   Zhao, WL
   Li, T
   Zhao, Y
   Bu, HE
   Song, SL
AF Xu, Yang
   Zhao, Wenli
   Li, Te
   Zhao, Ye
   Bu, Huaien
   Song, Shilin
TI Effects of acupuncture for the treatment of endometriosis-related pain: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID pelvic pain; ca-125; women; surgery; quality; cancer; life
AB Background Endometriosis is a multifactorial, oestrogen-dependent, inflammatory, gynaecological condition that can result in long-lasting visceral pelvic pain and infertility. Acupuncture could be an effective treatment for endometriosis and may relieve pain. Our aim in the present study was to determine the effectiveness of acupuncture as a treatment for endometriosis-related pain. Methods In December 2016, six databases were searched for randomised controlled trials that determined the effectiveness of acupuncture in the treatment of endometriosis-related pain. Ultimately, 10 studies involving 589 patients were included. The main outcomes assessed were variation in pain level, variation in peripheral blood CA-125 level, and clinical effective rate. All analyses were performed using comprehensive meta-analysis statistical software. Results Of the 10 studies included, only one pilot study used a placebo control and assessed blinding; the rest used various controls (medications and herbs), which were impossible to blind. The sample sizes were small in all studies, ranging from 8 to 36 patients per arm. The mean difference (MD) in pain reduction (pre-minus post-interventional pain level D measured on a 0-10-point scale) between the acupuncture and control groups was 1.36 (95% confidence intervals [ CI] = 1.01-1.72, P<0.0001). Acupuncture had a positive effect on peripheral blood CA-125 levels, as compared with the control groups (MD = 5.9, 95% CI = 1.56-10.25, P = 0.008). Similarly, the effect of acupuncture on clinical effective rate was positive, as compared with the control groups (odds ratio = 2.07; 95% CI = 1.24-3.44, P = 0.005). Conclusions Few randomised, blinded clinical trials have addressed the efficacy of acupuncture in treating endometriosis-related pain. Nonetheless, the current literature suggests that acupuncture reduces pain and serum CA-125 levels, regardless of the control intervention used. To confirm these findings, additional, blinded studies with proper controls and adequate sample sizes are needed.
C1 [Xu, Yang] Tianjin Acad Integrat Med, Nankai Hosp, Dept Gynecol & Obstet, Tianjin, Peoples R China.
   [Zhao, Wenli] Tianjin Univ Tradit Chinese Med, Grad Sch, Tianjin, Peoples R China.
   [Zhao, Wenli] Tianjin Acad Integrat Med, Nankai Hosp, Dept Neurol, Tianjin, Peoples R China.
   [Li, Te] Tianjin Hearing Impairment Specialist Hosp, Dept Chinese Med, Tianjin, Peoples R China.
   [Zhao, Ye] Univ Florida, Dept Chem Engn, Gainesville, FL 32611 USA.
   [Bu, Huaien] Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, Dept Publ Hlth, Tianjin, Peoples R China.
   [Song, Shilin] Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Lab Anat, Tianjin, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; State University System of Florida; University of Florida; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine
RP Bu, HE (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, Dept Publ Hlth, Tianjin, Peoples R China.; Song, SL (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Lab Anat, Tianjin, Peoples R China.
EM buhuaien@163.com; haiguagua@163.com
CR Abbott JA, 2003, HUM REPROD, V18, P1922, DOI 10.1093/humrep/deg275
   Ahn SH, 2016, FERTIL STERIL, V106, P1420, DOI 10.1016/j.fertnstert.2016.07.005
   Amaral Vivian Ferreira do, 2006, SAO PAULO MED. J., V124, P223
   Amer S, 2008, OBSTET. GYNAECOL. REPROD. MED, V18, P126
   ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   Unknown -, 2015, NO TITLE CAPTURED, V0, P0
   BARBIERI RL, 1986, FERTIL STERIL, V45, P630
   Brawn J, 2014, HUM REPROD UPDATE, V20, P737, DOI 10.1093/humupd/dmu025
   Chen GX, 2014, THESIS, V0, P16
   Chen Ming, 2010, ZHONGGUO ZHEN JIU, V30, P725
   Chen QX, 2015, THESIS, V0, P16
   CHEN S, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/609594
   Cheng YM, 2002, OBSTET GYNECOL, V99, P375, DOI 10.1016/S0029-7844(01)01731-8
   DIZEREGA GS, 1980, FERTIL STERIL, V33, P649
   EISERMANN J, 1988, FERTIL STERIL, V50, P573
   Fedele L, 2004, AM J OBSTET GYNECOL, V190, P1020, DOI 10.1016/j.ajog.2003.10.698
   Ferrero S, 2005, FERTIL STERIL, V83, P573, DOI 10.1016/j.fertnstert.2004.07.973
   Higgins J, 2011, COCHRANE COLLABORATI, V0, P0
   Hui KK, 2006, INTEGR CANCER THER, V5, P56, DOI 10.1177/1534735405286109
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   JACOBS I, 1988, LANCET, V1, P889
   Johnston MF, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep236
   Kaludjerovic J, 2012, J NUTR METAB, V2012, P0, DOI 10.1155/2012/837901
   Kennedy S, 2005, HUM REPROD, V20, P2698, DOI 10.1093/humrep/dei135
   Liu YX, 2003, XIN ZHONG YI, V35, P55
   Liu YY, 2009, HUBEI J TRADITIONAL, V31, P53
   Lund I, 2016, J PAIN RES, V9, P157, DOI 10.2147/JPR.S55580
   Ma Jie, 2008, ZHEN CI YAN JIU, V33, P235
   Miller JD, 2000, AM J OBSTET GYNECOL, V182, P1483, DOI 10.1067/mob.2000.106846
   Scheerer C, 2016, ARCH GYNECOL OBSTET, V294, P657, DOI 10.1007/s00404-016-4142-6
   Staud R, 2006, EXPERT REV NEUROTHER, V6, P661, DOI 10.1586/14737175.6.5.661
   Sun Yuan-Zheng, 2006, ZHONGGUO ZHEN JIU, V26, P863
   Tian LY, 2016, CLIN J TRAD CHIN MED, V0, P670
   Tian X, 2014, ALTERN THER HEALTH M, V20, P33
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Vercellini P, 2009, HUM REPROD UPDATE, V15, P177, DOI 10.1093/humupd/dmn062
   Wang M, 1991, ZHONGGUO ZHONG XI YI, V11, P0
   Wayne PM, 2008, J PEDIATR ADOL GYNEC, V21, P247, DOI 10.1016/j.jpag.2007.07.008
   Wieser F, 2007, HUM REPROD UPDATE, V13, P487, DOI 10.1093/humupd/dmm015
   Wu JX, 2013, J EMERG TRADIT CHIN, V0, P1947
   Xiang Dong-Fang, 2011, ZHONGGUO ZHEN JIU, V31, P113
   Yan Hong, 2008, ZHONGGUO ZHEN JIU, V28, P579
   Zhang Xinxin, 2015, ZHONGGUO ZHEN JIU, V35, P323
   Zhen R, 2009, YI XUE LI LUN YU SHI, V22, P571
   Zhu XS, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007864.pub2
NR 46
TC 52
Z9 62
U1 2
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD OCT 27
PY 2017
VL 12
IS 10
BP 
EP 
DI 10.1371/journal.pone.0186616
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FK9WD
UT WOS:000413861200014
PM 29077705
DA 2026-01-16
ER

PT J
AU Zhou, J
   Fang, L
   Wu, WY
   He, F
   Zhang, XL
   Zhou, X
   Xiong, ZJ
AF Zhou, J
   Fang, L
   Wu, W Y
   He, F
   Zhang, X L
   Zhou, X
   Xiong, Z J
TI The effect of acupuncture on chemotherapy-associated gastrointestinal symptoms in
SO Current oncology (Toronto, Ont.)
LA English
DT Journal Article
DE Acupuncture; chemotherapy; gastric cancer; gastrointestinal symptoms; quality of life
AB BACKGROUND: Gastrointestinal (gi) symptoms are the most notable side effects of  chemotherapeutic drugs; such symptoms are currently treated with drugs. In the  present study, we investigated the effect of acupuncture on gi symptoms induced  by chemotherapy in patients with advanced gastric cancer. METHODS: A cohort of 56  patients was randomly divided into an experimental group and a control group. All  patients received combination chemotherapy with oxaliplatin-paclitaxel. Patients  in the experimental group received 30 minutes of acupuncture therapy daily for 2  weeks. The frequency and duration of nausea, vomiting, abdominal pain, and  diarrhea, the average days and costs of hospitalization, and quality-of-life  scores were compared between the groups. RESULTS: Nausea was sustained for 32 ± 5  minutes and 11 ± 3 minutes daily in the control and experimental groups  respectively (p < 0.05). On average, vomiting occurred 2 ± 1 times daily in the  experimental group and 4 ± 1 times daily in the control group (p < 0.05).  Abdominal pain persisted for 7 ± 2 minutes and 16 ± 5 minutes daily in the  experimental and control groups respectively (p < 0.05). On average, diarrhea  occurred 1 ± 1 times daily in the experimental group and 3 ± 1 times daily in the  control group (p < 0.05). The average quality-of-life score was higher in the  experimental group than in the control group (p < 0.05). No adverse events were  observed for the patients receiving acupuncture. CONCLUSIONS: Acupuncture, a safe  technique, could significantly reduce gi symptoms induced by chemotherapy and  enhance quality of life in patients with advanced gastric cancer.
C1 Department of Chemotherapy, Sichuan Cancer Hospital, and.
   Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P.R.C.
   Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P.R.C.
   Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P.R.C.
   Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P.R.C.
   Department of Chemotherapy, Sichuan Cancer Hospital, and.
   Department of Chemotherapy, Sichuan Cancer Hospital, and.
NR 0
TC 0
SN 1718-772
EI 1198-005
J9 Curr Oncol
PD MAR 9
PY 2017
VL 24
IS 1
BP e1
EP e5
DI 10.3747/co.24.3296
PG 1
UT PubMed:28270726
PM 28270726
DA 2017-03-09
ER

PT J
AU Liu, YH
   Ye, Y
   Zheng, JB
   Wang, XQ
   Zhang, Y
   Lin, HS
AF Liu, Yi-Hua
   Ye, Yang
   Zheng, Jia-Bin
   Wang, Xue-Qian
   Zhang, Ying
   Lin, Hong-Sheng
TI Acupuncture for enhancing early recovery of bowel function in cancer Protocol for a systematic review
SO MEDICINE
LA English
DT Review
DE acupuncture; bowel function; cancer; POI; protocol; systematic review
ID prolonged postoperative ileus; quality-of-life; electroacupuncture; mechanisms; promotes; surgery; care
AB Background: Cancer patients undergoing surgical procedure often suffer from bowel dysfunction and postoperative ileus (POI). Cancer management for early recovery of bowel function is still a challenging topic. Acupuncture has been commonly used in a variety of gastrointestinal diseases. The aim of this study is to evaluate the effects of acupuncture therapy to reduce the duration of POI and enhance bowel function in cancer patients. Methods: We will systematically screen all randomized controlled trials (RCTs) published through electronically and hand searching. The following search engines including Medline, EMBASE, Cochrane CENTRAL, the Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, VIP Information, Wanfang Data, one Japanese database (Japan Science and Technology Information Aggregator, Electronic) and 2 Korean Medical Databases (Korean Studies Information, and Data Base Periodical Information Academic) will be retrieved. Supplementary sources will be searched including gray literature, conference proceedings, and potential identified publications. Two reviewers will independently conduct the trial inclusion, data extraction and assess the quality of studies. The time to first passing flatus and time to first bowel motion will be assessed as the primary outcomes. Adverse effects, time to first bowel sound, visual analog scale (VAS) pain score, hospital stay, and postoperative analgesic requirement will be measured as secondary outcomes. Methodological quality will be evaluated according to the Cochrane risk of bias. Details of interventions will be assessed by the Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA) checklist. All analyses will be applied by RevMan (version 5.3) and StataSE (version 12). Ethics and Dissemination: This systematic review will provide up-to-date information on acupuncture therapy for early recovery of bowel function in cancer patients. This review does not require ethical approval and will be reported in a peer-reviewed journal and presented at a relevant conference.
C1 [Liu, Yi-Hua; Ye, Yang; Zheng, Jia-Bin; Wang, Xue-Qian] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China.
   [Liu, Yi-Hua; Ye, Yang; Zheng, Jia-Bin; Wang, Xue-Qian; Zhang, Ying; Lin, Hong-Sheng] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Oncol, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Guang'anmen Hospital, CACMS; China Academy of Chinese Medical Sciences
RP Lin, HS (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China.
EM drlinhongsheng_@126.com
FU State Administration of Traditional Chinese Medicine of the People's Republic of China [201307006]; International S&T Cooperation Program Office of China [2013DFA32540]
CR Artinyan A, 2008, WORLD J SURG, V32, P1495, DOI 10.1007/s00268-008-9491-2
   Asgeirsson T, 2010, J AM COLL SURGEONS, V210, P228, DOI 10.1016/j.jamcollsurg.2009.09.028
   Bauer AJ, 2004, NEUROGASTROENT MOTIL, V16, P54, DOI 10.1111/j.1743-3150.2004.00558.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fang JF, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep39801
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   2011, 1900, V343, V0, PPD5928, DOI 10.1136/BMJ.D5928
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kehlet H, 2008, NAT CLIN PRACT GASTR, V5, P552, DOI 10.1038/ncpgasthep1230
   Kehlet H, 2008, LANCET, V371, P791, DOI 10.1016/S0140-6736(08)60357-8
   Kronberg U, 2011, ANN SURG, V253, P78, DOI 10.1097/SLA.0b013e3181fcb83e
   Langenhoff BS, 2001, BJS-BRIT J SURG, V88, P643, DOI 10.1046/j.1365-2168.2001.01755.x
   Li H, 2015, WORLD J GASTROENTERO, V21, P8304, DOI 10.3748/wjg.v21.i27.8304
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Luo D, 2008, DIGEST DIS SCI, V53, P689, DOI 10.1007/s10620-007-9929-7
   Lv JQ, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-153
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Miller ND, 2014, ACUPUNCT MED, V32, P139, DOI 10.1136/acupmed-2013-010465
   Neuman HB, 2007, ANN SURG ONCOL, V14, P1727, DOI 10.1245/s10434-006-9283-6
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Person B, 2006, CURR PROB SURG, V43, P6, DOI 10.1067/j.cpsurg.2005.10.003
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tada H, 2003, DIGEST DIS SCI, V48, P59, DOI 10.1023/A:1021730314068
   van Bree SHW, 2014, ANN SURG, V259, P708, DOI 10.1097/SLA.0b013e318293ee55
   van Bree SHW, 2012, NAT REV GASTRO HEPAT, V9, P675, DOI 10.1038/nrgastro.2012.134
   Vather R, 2014, CLIN EXP PHARMACOL P, V41, P358, DOI 10.1111/1440-1681.12220
   Vather R, 2013, J GASTROINTEST SURG, V17, P962, DOI 10.1007/s11605-013-2148-y
   Wang CP, 2008, J ALTERN COMPLEM MED, V14, P833, DOI 10.1089/acm.2008.0107
   Yin JY, 2010, AM J PHYSIOL-GASTR L, V298, PG563, DOI 10.1152/ajpgi.00252.2009
NR 33
TC 2
Z9 2
U1 0
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR 15
PY 2017
VL 96
IS 17
BP 
EP 
DI 10.1097/MD.0000000000006644
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA ET6ZL
UT WOS:000400442700012
PM 28445263
DA 2026-01-16
ER

PT J
AU Asmussen, S
   Przkora, R
   Maybauer, DM
   Fraser, JF
   Sanfilippo, F
   Jennings, K
   Adamzik, M
   Maybauer, MO
AF Asmussen, Sven
   Przkora, Rene
   Maybauer, Dirk M
   Fraser, John F
   Sanfilippo, Filippo
   Jennings, Kristofer
   Adamzik, Michael
   Maybauer, Marc O
TI Meta-Analysis of Electroacupuncture in Cardiac Anesthesia and Intensive Care.
SO Journal of intensive care medicine
LA English
DT Journal Article
DE anesthetic drugs; cytokines; immune response; systematic review; transcutaneous electrical acupoint stimulation
AB BACKGROUND: Acupuncture treatment has been employed in China for over 2500 years  and it is used worldwide as analgesia in acute and chronic pain. Acupuncture is  also used in general anesthesia (GA). The aim of this systematic review and  meta-analysis was to assess the efficacy of electroacupuncture (EA) in addition  to GA in patients undergoing cardiac surgery. METHODS: We searched 3 databases  (Pubmed, Cochrane Library, and Web of Science-from 1965 until January 31, 2017)  for randomized controlled trials (RCTs) including patients undergoing cardiac  surgery and receiving GA alone or GA + EA. As primary outcomes, we investigated  the association between GA + EA approach and the dosage of intraoperative  anesthetic drugs administered, the duration of mechanical ventilation (MV), the  postoperative dose of vasoactive drugs, the length of intensive care unit (ICU)  and hospital stay, and the levels of troponin I and cytokines. RESULTS: The  initial search yielded 477 citations, but only 7 prospective RCTs enrolling a  total of 321 patients were included. The use of GA + EA reduced the dosage of  intraoperative anesthetic drugs (P < .05), leading to shorter MV time (P < .01)  and ICU stay (P < .05) as well as reduced postoperative dose of vasoactive drugs  (P < .001). In addition, significantly lower levels of troponin I (P < .01) and  tumor necrosis factor α (P < .01) were observed. CONCLUSION: The complementary  use of EA for open-heart surgery reduces the duration of MV and ICU stay, blunts  the inflammatory response, and might have protective effects on the heart. Our  findings stimulate future RCT to provide definitive recommendations.
C1 1 Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
   2 Departments of Anesthesiology and Epidemiology and Biostatistics, The 
   3 Critical Care Research Group, Prince Charles Hospital, The University of Queensland, Brisbane, Queensland, Australia.
   2 Departments of Anesthesiology and Epidemiology and Biostatistics, The University of Texas Medical Branch, Galveston, TX, USA.
   4 Department of Anesthesiology, College of Medicine, University of Florida, 
   2 Departments of Anesthesiology and Epidemiology and Biostatistics, The University of Texas Medical Branch, Galveston, TX, USA.
   5 Department of Cardiothoracic Anaesthesia and Critical Care, St George's 
   3 Critical Care Research Group, Prince Charles Hospital, The University of Queensland, Brisbane, Queensland, Australia.
   6 Department of Anesthesia and Intensive Care, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy.
   7 Department of Anaesthesiology and Intensive Care, Philipps University, Marburg, 
   2 Departments of Anesthesiology and Epidemiology and Biostatistics, The University of Texas Medical Branch, Galveston, TX, USA.
   1 Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
   2 Departments of Anesthesiology and Epidemiology and Biostatistics, The University of Texas Medical Branch, Galveston, TX, USA.
   3 Critical Care Research Group, Prince Charles Hospital, The University of 
   5 Department of Cardiothoracic Anaesthesia and Critical Care, St George's Hospital, London, UK.
   8 Cardiothoracic Anaesthesia and Intensive Care, Central Manchester University
NR 0
TC 0
SN 1525-148
EI 
J9 J Intensive Care Med
PD JUN 2
PY 2017
VL 34
IS 8
BP 652
EP 661
DI 10.1177/0885066617708558
PG 9
WC Anesthesia, Cardiac Procedures; methods; Anesthesia, General; Cardiac Surgical Procedures; Critical Care; Electroacupuncture; Humans; Outcome Assessment, Health Care; Perioperative Care; methods
UT PubMed:28569130
PM 28569130
DA 2017-06-02
ER

PT J
AU Greenlee, H
   DuPont-Reyes, MJ
   Balneaves, LG
   Carlson, LE
   Cohen, MR
   Deng, G
   Johnson, JA
   Mumber, M
   Seely, D
   Zick, SM
   Boyce, LM
   Tripathy, D
AF Greenlee, Heather
   DuPont-Reyes, Melissa J.
   Balneaves, Lynda G.
   Carlson, Linda E.
   Cohen, Misha R.
   Deng, Gary
   Johnson, Jillian A.
   Mumber, Matthew
   Seely, Dugald
   Zick, Suzanna M.
   Boyce, Lindsay M.
   Tripathy, Debu
TI Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment
SO CA-A CANCER JOURNAL FOR CLINICIANS
LA English
DT Review
DE acupressure; acupuncture; breast cancer; complementary therapies; integrative medicine; integrative oncology; massage; meditation; music therapy; stressmanagement; yoga
ID quality-of-life; chemotherapy-induced nausea; randomized controlled-trial; stress-management intervention; manual lymphatic drainage; placebo-controlled trial; induced peripheral neuropathy; cognitive-behavioral therapy; expressive group-therapy; double-blind trial
AB Patients with breast cancer commonly use complementary and integrative therapies as supportive care during cancer treatment and to manage treatment-related side effects. However, evidence supporting the use of such therapies in the oncology setting is limited. This report provides updated clinical practice guidelines from the Society for Integrative Oncology on the use of integrative therapies for specific clinical indications during and after breast cancer treatment, including anxiety/stress, depression/mood disorders, fatigue, quality of life/physical functioning, chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced peripheral neuropathy, pain, and sleep disturbance. Clinical practice guidelines are based on a systematic literature review from 1990 through 2015. Music therapy, meditation, stress management, and yoga are recommended for anxiety/stress reduction. Meditation, relaxation, yoga, massage, and music therapy are recommended for depression/mood disorders. Meditation and yoga are recommended to improve quality of life. Acupressure and acupuncture are recommended for reducing chemotherapy-induced nausea and vomiting. Acetyl-L-carnitine is not recommended to prevent chemotherapy-induced peripheral neuropathy due to a possibility of harm. No strong evidence supports the use of ingested dietary supplements to manage breast cancer treatment-related side effects. In summary, there is a growing body of evidence supporting the use of integrative therapies, especially mind-body therapies, as effective supportive care strategies during breast cancer treatment. Many integrative practices, however, remain understudied, with insufficient evidence to be definitively recommended or avoided. (C) 2017 American Cancer Society.
C1 [Greenlee, Heather; DuPont-Reyes, Melissa J.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, 722 West 168th St,Seventh Fl, New York, NY 10032 USA.
   [Greenlee, Heather] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
   [Balneaves, Lynda G.] Rady Fac Hlth Sci, Coll Nursing, Winnipeg, MB, Canada.
   [Carlson, Linda E.] Univ Calgary, Dept Oncol, Calgary, AB, Canada.
   [Cohen, Misha R.] Calif Inst Integral Studies, Amer Coll Tradit Chinese Med, San Francisco, CA USA.
   [Cohen, Misha R.] Chicken Soup Chinese Med, San Francisco, CA USA.
   [Deng, Gary] Mem Sloan Kettering Canc Ctr, Integrat Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Johnson, Jillian A.] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA.
   [Mumber, Matthew] Harbin Clin, Rome, GA USA.
   [Seely, Dugald] Ottawa Integrat Canc Ctr, Ottawa, ON, Canada.
   [Seely, Dugald] Canadian Coll Naturopath Med, Res, Toronto, ON, Canada.
   [Zick, Suzanna M.] Univ Michigan, Dept Family Med, Michigan Med, Ann Arbor, MI 48109 USA.
   [Zick, Suzanna M.] Univ Michigan, Sch Publ Hlth, Dept Nutr Sci, Ann Arbor, MI 48109 USA.
   [Boyce, Lindsay M.] Mem Sloan Kettering Canc Ctr, Mem Sloan Kettering Lib, 1275 York Ave, New York, NY 10021 USA.
   [Tripathy, Debu] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA.
C3 Columbia University; Columbia University; University of Calgary; Memorial Sloan Kettering Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center
RP Greenlee, H (corresponding author), Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, 722 West 168th St,Seventh Fl, New York, NY 10032 USA.
EM hg2120@columbia.edu
FU National Cancer Institute [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672] Funding Source: Medline
CR Adamsen L, 2009, BMJ-BRIT MED J, V339, P0, DOI 10.1136/bmj.b3410
   Ancoli-Israel S, 2012, SUPPORT CARE CANCER, V20, P1211, DOI 10.1007/s00520-011-1203-z
   Andersen BL, 2014, J CLIN ONCOL, V32, P1605, DOI 10.1200/JCO.2013.52.4611
   Andersen BL, 2004, J CLIN ONCOL, V22, P3570, DOI 10.1200/JCO.2004.06.030
   Andersen L, 2000, ACTA ONCOL, V39, P399, DOI 10.1080/028418600750013186
   Andersen SR, 2013, ACTA ONCOL, V52, P336, DOI 10.3109/0284186X.2012.745948
   Unknown -, 2007, FOOD NUTR PHYS ACT P, V0, P0
   Unknown -, 2013, J COMPL INTEGR MED, V0, P0
   Unknown -, 2007, CANC CARE WHOLE PATI, V0, P0
   Unknown -, 2011, EVID BASED COMPLEMEN, V0, P0
   Unknown -, 2011, CLIN PRACTICE GUIDEL, V0, P0, DOI DOI 10.17226/13058
   Ansari M, 2013, IRAN J MED SCI, V38, P293
   Antoni MH, 2001, HEALTH PSYCHOL, V20, P20, DOI 10.1037/0278-6133.20.1.20
   Antoni MH, 2006, J CONSULT CLIN PSYCH, V74, P1143, DOI 10.1037/0022-006X.74.6.1152
   ARATHUZIK D, 1994, CANCER NURS, V17, P207
   Argyriou AA, 2006, J PAIN SYMPTOM MANAG, V32, P237, DOI 10.1016/j.jpainsymman.2006.03.013
   Arslan M, 2015, CLIN J ONCOL NURS, V19, PE92, DOI 10.1188/15.CJON.E92-E97
   Baker Barbara S, 2012, COMPLEMENT THER CLIN PRACT, V18, P182, DOI 10.1016/j.ctcp.2012.03.002
   Balk Judith, 2009, J SOC INTEGR ONCOL, V7, P4
   Balzarini A, 2000, BR HOMEOPATH J, V89, P8, DOI 10.1054/homp.1999.0328
   Banasik J, 2011, J AM ACAD NURSE PRAC, V23, P135, DOI 10.1111/j.1745-7599.2010.00573.x
   Banerjee B, 2007, INTEGR CANCER THER, V6, P242, DOI 10.1177/1534735407306214
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bardwell WA, 2008, PSYCHO-ONCOLOGY, V17, P9, DOI 10.1002/pon.1192
   Barton DL, 2013, JNCI-J NATL CANCER I, V105, P1230, DOI 10.1093/jnci/djt181
   Barton DL, 2013, SUPPORT CARE CANCER, V21, P1185, DOI 10.1007/s00520-012-1647-9
   Barton DL, 2010, SUPPORT CARE CANCER, V18, P179, DOI 10.1007/s00520-009-0642-2
   Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495
   Beith JM, 2012, MED ACUPUNCT, V24, P241, DOI 10.1089/acu.2012.0876
   Belmonte R, 2012, CLIN REHABIL, V26, P607, DOI 10.1177/0269215511427414
   Berger AM, 2010, J NATL COMPR CANC NE, V8, P904, DOI 10.6004/jnccn.2010.0067
   Billhult A, 2007, J ALTERN COMPLEM MED, V13, P53, DOI 10.1089/acm.2006.6049
   Binns-Turner Pamela G, 2011, AANA J, V79, P0
   Björneklett HG, 2012, ACTA ONCOL, V51, P198, DOI 10.3109/0284186X.2011.610352
   Boehm K, 2014, ALTERNAT MED, V2014, P0
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Bond K, 2009, PSYCHOL RELIG SPIRIT, V1, P129, DOI 10.1037/a0015736
   Boon Heather S, 2007, BMC WOMENS HEALTH, V7, P4, DOI 10.1186/1472-6874-7-4
   Booth Christopher M, 2007, J SUPPORT ONCOL, V5, P374
   Bourgeois JF, 2008, SKIN RES TECHNOL, V14, P71, DOI 10.1111/j.1600-0846.2007.00263.x
   Bower JE, 2006, CANCER-AM CANCER SOC, V106, P751, DOI 10.1002/cncr.21671
   Bower JE, 2014, J CLIN ONCOL, V32, P1840, DOI 10.1200/JCO.2013.53.4495
   Bower JE, 2012, CANCER-AM CANCER SOC, V118, P3766, DOI 10.1002/cncr.26702
   Bozzetti F, 1997, NUTRITION, V13, P748, DOI 10.1016/S0899-9007(97)83038-9
   Bright-Gbebry M, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-30
   Brintzenhofe-Szoc KM, 2009, PSYCHOSOMATICS, V50, P383, DOI 10.1176/appi.psy.50.4.383
   Brisbois TD, 2011, ANN ONCOL, V22, P2086, DOI 10.1093/annonc/mdq727
   Buffart LM, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-559
   Bulfone T, 2009, HOLIST NURS PRACT, V23, P238, DOI 10.1097/HNP.0b013e3181aeceee
   Burns DS, 2001, J MUSIC THER, V38, P51, DOI 10.1093/jmt/38.1.51
   Bussing A, 2000, MISTLETOE GENUS VISC, V0, P0
   Butler LD, 2009, HEALTH PSYCHOL, V28, P579, DOI 10.1037/a0016124
   Campo RA, 2013, INTEGR CANCER THER, V12, P464, DOI 10.1177/1534735413485418
   Carlotto A, 2013, PHARMACOECONOMICS, V31, P753, DOI 10.1007/s40273-013-0081-2
   Carlson LE, 2001, SUPPORT CARE CANCER, V9, P112, DOI 10.1007/s005200000206
   Carlson LE, 2013, J CLIN ONCOL, V31, P3119, DOI 10.1200/JCO.2012.47.5210
   Carpenter JS, 2002, CANCER NURS, V25, P104, DOI 10.1097/00002820-200204000-00005
   Carson JW, 2009, SUPPORT CARE CANCER, V17, P1301, DOI 10.1007/s00520-009-0587-5
   Chandwani KD, 2014, J CLIN ONCOL, V32, P1058, DOI 10.1200/JCO.2012.48.2752
   Chandwani Kavita D, 2010, J SOC INTEGR ONCOL, V8, P43
   Chen Z, 2013, CANCER-AM CANCER SOC, V119, P1690, DOI 10.1002/cncr.27904
   Cimprich B, 2003, CANCER NURS, V26, P284, DOI 10.1097/00002820-200308000-00005
   Cluzan RV, 2004, LYMPHOLOGY, V37, P47
   Cluzan RV, 1996, LYMPHOLOGY, V29, P29
   Coelho HF, 2008, INT J CLIN PRACT, V62, P325, DOI 10.1111/j.1742-1241.2007.01553.x
   Cohen MR, 2015, THE NEW CHINESE MEDICINE HANDBOOK: AN INNOVATIVE GUIDE TO INTEGRATING EASTERN WISDOM WITH WESTERN PRACTICE FOR MODERN HEALING, V0, P0
   Collins Kimberly B, 2004, J AM ACAD NURSE PRACT, V16, P76
   Cramer H, 2012, CURR ONCOL, V19, PE343, DOI 10.3747/co.19.1016
   Cramer H, 2015, CANCER-AM CANCER SOC, V121, P2175, DOI 10.1002/cncr.29330
   Cramer H, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0075515
   Cramer H, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-412
   Crane-Okada R, 2012, CANCER NURS, V35, PE1, DOI 10.1097/NCC.0b013e3182280f73
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Culos-Reed SN, 2006, PSYCHO-ONCOLOGY, V15, P891, DOI 10.1002/pon.1021
   Culos-Reed SN, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/642576
   Danhauer SC, 2009, PSYCHO-ONCOLOGY, V18, P360, DOI 10.1002/pon.1503
   Dayes IS, 2013, J CLIN ONCOL, V31, P3758, DOI 10.1200/JCO.2012.45.7192
   Campos MPD, 2011, J ALTERN COMPLEM MED, V17, P505, DOI 10.1089/acm.2010.0571
   Fede ABD, 2007, AM J CLIN ONCOL-CANC, V30, P432, DOI 10.1097/COC.0b013e31804b40d9
   Delanian S, 2003, J CLIN ONCOL, V21, P2545, DOI 10.1200/JCO.2003.06.064
   Demiralp M, 2010, J CLIN NURS, V19, P1073, DOI 10.1111/j.1365-2702.2009.03037.x
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Derry HM, 2015, PSYCHO-ONCOLOGY, V24, P958, DOI 10.1002/pon.3707
   Devoogdt N, 2011, BMJ-BRIT MED J, V343, P0
   Dhruva A, 2012, J ALTERN COMPLEM MED, V18, P473, DOI 10.1089/acm.2011.0555
   Dibble S L, 2000, ONCOL NURS FORUM, V27, P41
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   Dodds SE, 2015, SUPPORT CARE CANCER, V23, P3599, DOI 10.1007/s00520-015-2888-1
   Duijts SFA, 2011, PSYCHO-ONCOLOGY, V20, P115, DOI 10.1002/pon.1728
   DUNDEE JW, 1987, LANCET, V1, P1083
   DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508
   Dyer J, 2013, COMPLEMENT THER CLIN, V19, P139, DOI 10.1016/j.ctcp.2013.03.002
   Dyer Jeannie, 2008, COMPLEMENT THER CLIN PRACT, V14, P273, DOI 10.1016/j.ctcp.2008.02.003
   El-Deeb AM, 2011, J ANESTH, V25, P698, DOI 10.1007/s00540-011-1198-0
   Elkins G, 2008, J CLIN ONCOL, V26, P5022, DOI 10.1200/JCO.2008.16.6389
   Enomoto TM, 2005, AM J SURG, V189, P627, DOI 10.1016/j.amjsurg.2005.02.001
   Ernst E, 2003, RHEUMATOLOGY, V42, P1101, DOI 10.1093/rheumatology/keg306
   Eskelinen M, 2011, ANTICANCER RES, V31, P1801
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Fabi A, 2003, SUPPORT CARE CANCER, V11, P156, DOI 10.1007/s00520-002-0427-3
   Faller H, 2013, J CLIN ONCOL, V31, P782, DOI 10.1200/JCO.2011.40.8922
   Fernández-Lao C, 2012, EUR J CANCER CARE, V21, P233, DOI 10.1111/j.1365-2354.2011.01306.x
   FitzHenry F, 2014, INTEGR CANCER THER, V13, P105, DOI 10.1177/1534735413503545
   Foley E, 2010, J CONSULT CLIN PSYCH, V78, P72, DOI 10.1037/a0017566
   Frank LS, 2007, PAIN MED, V8, P419, DOI 10.1111/j.1526-4637.2006.00256.x
   Frass M, 2015, COMPLEMENT THER MED, V23, P309, DOI 10.1016/j.ctim.2015.03.004
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Frisk J, 2012, SUPPORT CARE CANCER, V20, P715, DOI 10.1007/s00520-011-1134-8
   Galway K, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007064.pub2
   Gan TJ, 2004, ANESTH ANALG, V99, P1070, DOI 10.1213/01.ANE.0000130355.91214.9E
   Ganz PA, 1998, J CLIN ONCOL, V16, P501, DOI 10.1200/JCO.1998.16.2.501
   Ganz PA, 2003, J CLIN ONCOL, V21, P4027, DOI 10.1200/JCO.2003.08.097
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Garssen B, 2013, PSYCHO-ONCOLOGY, V22, P572, DOI 10.1002/pon.3034
   Gaston-Johansson F, 2000, CANCER NURS, V23, P277, DOI 10.1097/00002820-200008000-00004
   Gecsedi Renee A, 2002, CLIN J ONCOL NURS, V6, P52
   Genç F, 2015, PALLIAT SUPPORT CARE, V13, P275, DOI 10.1017/S1478951514000248
   Ghoreishi Z, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-355
   Goerling U, 2014, ONCOLOGY-BASEL, V87, P114, DOI 10.1159/000362818
   Gosselin TK, 2010, ONCOL NURS FORUM, V37, P619, DOI 10.1188/10.ONF.619-626
   Gothard L, 2004, RADIOTHER ONCOL, V73, P133, DOI 10.1016/j.radonc.2004.09.013
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018
   Greenlee H, 2016, J CLIN ONCOL, V34, P3133, DOI 10.1200/JCO.2016.66.4391
   Greenlee Heather, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP346, DOI 10.1093/jncimonographs/lgu041
   Greenlee H, 2014, BMC CANCER, V14, P0, DOI 10.1186/1471-2407-14-382
   Greenlee H, 2009, BREAST CANCER RES TR, V117, P653, DOI 10.1007/s10549-009-0315-3
   Gudenkauf LM, 2015, J CONSULT CLIN PSYCH, V83, P677, DOI 10.1037/ccp0000020
   Guetin S, 2013, DEMENTIA-LONDON, V12, P619, DOI 10.1177/1471301212438290
   Gurdal SO, 2012, LYMPHAT RES BIOL, V10, P129, DOI 10.1089/lrb.2012.0002
   Hanai A, 2016, BREAST CANCER RES TR, V155, P99, DOI 10.1007/s10549-015-3652-4
   Hanser Suzanne B, 2006, J SOC INTEGR ONCOL, V4, P116, DOI 10.2310/7200.2006.014
   Harder H, 2015, EUR J INTEGR MED, V7, P202, DOI 10.1016/j.eujim.2015.02.002
   Heggie S, 2002, CANCER NURS, V25, P442, DOI 10.1097/00002820-200212000-00007
   Henderson VP, 2013, INTEGR CANCER THER, V12, P404, DOI 10.1177/1534735412473640
   Henderson V, 2012, BREAST CANCER RES TR, V131, P99, DOI 10.1007/s10549-011-1738-1
   Hernandez-Reif M, 2004, J PSYCHOSOM RES, V57, P45, DOI 10.1016/S0022-3999(03)00500-2
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hershman DL, 2013, J CLIN ONCOL, V31, P2627, DOI 10.1200/JCO.2012.44.8738
   Hervik J, 2010, INT J WOMENS HEALTH, V2, P319, DOI 10.2147/IJWH.S12809
   Hesketh PJ, 2016, J CLIN ONCOL, V34, P381, DOI 10.1200/JCO.2015.64.3635
   Hidderley Margaret, 2004, EUR J ONCOL NURS, V8, P61, DOI 10.1016/j.ejon.2003.09.003
   Hoffman CJ, 2012, J CLIN ONCOL, V30, P1335, DOI 10.1200/JCO.2010.34.0331
   Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555
   Hoge EA, 2013, J CLIN PSYCHIAT, V74, P786, DOI 10.4088/JCP.12m08083
   Horneber MA, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003297.pub2
   Hou WH, 2010, J CLIN PSYCHIAT, V71, P894, DOI 10.4088/JCP.09r05009blu
   Huang C-J, 2015, EVID-BASED COMPL ALT, V2015, P0
   Iyengar BKS, 2005, LIGHT ON PRANAYAMA: THE YOGIC ART OF BREATHING, V0, P0
   Jacobs J, 2005, J ALTERN COMPLEM MED, V11, P21, DOI 10.1089/acm.2005.11.21
   Jacobsen PB, 2013, PSYCHO-ONCOLOGY, V22, P1229, DOI 10.1002/pon.3122
   Jacobson G, 2013, INT J RADIAT ONCOL, V85, P604, DOI 10.1016/j.ijrobp.2012.06.042
   Jacobson JS, 2001, J CLIN ONCOL, V19, P2739, DOI 10.1200/JCO.2001.19.10.2739
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jain S, 2012, CANCER-AM CANCER SOC, V118, P777, DOI 10.1002/cncr.26345
   Jensen JM, 2011, STRAHLENTHER ONKOL, V187, P378, DOI 10.1007/s00066-011-2224-8
   Jo SH, 2013, KOREAN CIRC J, V43, P174, DOI 10.4070/kcj.2013.43.3.174
   John GM, 2016, J CANCER SURVIV, V10, P850, DOI 10.1007/s11764-016-0530-y
   Johnston MF, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-49
   Jordan K, 2015, ANN ONCOL, V26, P1081, DOI 10.1093/annonc/mdv138
   Kabat-Zin Jon, 1990, FULL CATASTROPHE LIV, V0, P0
   KABATZINN J, 1992, AM J PSYCHIAT, V149, P936
   Kiecolt-Glaser JK, 2014, J CLIN ONCOL, V32, P1040, DOI 10.1200/JCO.2013.51.8860
   Kieviet-Stijnen A, 2008, PATIENT EDUC COUNS, V72, P436, DOI 10.1016/j.pec.2008.05.015
   Kim YH, 2013, COMPLEMENT THER MED, V21, P379, DOI 10.1016/j.ctim.2013.06.005
   Kirkwood G, 2005, BRIT J SPORT MED, V39, P884, DOI 10.1136/bjsm.2005.018069
   Kirova YM, 2011, RADIOTHER ONCOL, V100, P205, DOI 10.1016/j.radonc.2011.05.014
   Kissane DW, 2007, PSYCHO-ONCOL, V16, P277, DOI 10.1002/pon.1185
   Klainin-Yobas P, 2015, AGING MENT HEALTH, V19, P1043, DOI 10.1080/13607863.2014.997191
   Kluetz Paul G, 2016, AM SOC CLIN ONCOL EDUC BOOK, V35, P67, DOI 10.14694/EDBK_159514
   Kovacic T, 2011, INTEGR CANCER THER, V10, P16, DOI 10.1177/1534735410387418
   Krohn M, 2011, SUPPORT CARE CANCER, V19, P1303, DOI 10.1007/s00520-010-0946-2
   Kunos CA, 2014, BREAST J, V20, P679, DOI 10.1111/tbj.12348
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Kwon JH, 2016, CANCER NURS, V39, P61, DOI 10.1097/NCC.0000000000000243
   Lechner Suzanne C, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP315, DOI 10.1093/jncimonographs/lgu032
   Lee J, 2008, J PAIN SYMPTOM MANAG, V36, P529, DOI 10.1016/j.jpainsymman.2007.10.019
   Lee Jiyeon, 2010, ONCOL NURS FORUM, V37, PE419, DOI 10.1188/10.ONF.E419-E425
   Lee MS, 2011, ANN ONCOL, V22, P1459, DOI 10.1093/annonc/mdr147
   Lee S, 2013, CHIN J INTEGR MED, V19, P277, DOI 10.1007/s11655-013-1425-7
   Lengacher CA, 2015, PSYCHO-ONCOLOGY, V24, P424, DOI 10.1002/pon.3603
   Lengacher CA, 2012, J HOLIST NURS, V30, P170, DOI 10.1177/0898010111435949
   Lengacher CA, 2009, PSYCHO-ONCOLOGY, V18, P1261, DOI 10.1002/pon.1529
   Lerman R, 2012, ANN SURG ONCOL, V19, P373, DOI 10.1245/s10434-011-2051-2
   Lesser Glenn J, 2013, J SUPPORT ONCOL, V11, P31
   Li XM, 2012, J ADV NURS, V68, P1145, DOI 10.1111/j.1365-2648.2011.05824.x
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   Lindley C M, 1992, BR J CANCER SUPPL, V19, P0
   Link AR, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/301549
   Listing M, 2010, ARCH WOMEN MENT HLTH, V13, P165, DOI 10.1007/s00737-009-0143-9
   Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508
   Littman AJ, 2012, SUPPORT CARE CANCER, V20, P267, DOI 10.1007/s00520-010-1066-8
   Liu CJ, 2008, J CLIN NURS, V17, P2539, DOI 10.1111/j.1365-2702.2008.02296.x
   Loi CXA, 2012, J PSYCHOSOC ONCOL, V30, P57, DOI 10.1080/07347332.2011.633981
   Lomas T, 2015, MINDFULNESS, V6, P848, DOI 10.1007/s12671-014-0329-8
   Loprinzi CL, 2005, CANCER-AM CANCER SOC, V104, P176, DOI 10.1002/cncr.21107
   Loudon A, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-214
   Lua PL, 2015, COMPLEMENT THER MED, V23, P396, DOI 10.1016/j.ctim.2015.03.009
   MacGregor CA, 2005, EUR J CANCER, V41, P708, DOI 10.1016/j.ejca.2005.01.005
   Magnusson M, 2009, EUR J CANCER, V45, P2488, DOI 10.1016/j.ejca.2009.05.015
   Maher J, 2012, SUPPORT CARE CANCER, V20, P3079, DOI 10.1007/s00520-012-1433-8
   MAICHE AG, 1991, ACTA ONCOL, V30, P395
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Maratos AS, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004517.pub2
   Marshall-McKenna R, 2014, EUR J PHYSIOTHER, V16, P58, DOI 10.3109/21679169.2013.872184
   Marvibaigi M, 2014, BIOMED RES INT-UK, V2014, P0, DOI 10.1155/2014/785479
   Matchim Yaowarat, 2011, ONCOL NURS FORUM, V38, PE61, DOI 10.1188/11.ONF.E61-E71
   Matsuno RK, 2012, J WOMENS HEALTH, V21, P1252, DOI 10.1089/jwh.2012.3698
   McNeely ML, 2004, BREAST CANCER RES TR, V86, P95, DOI 10.1023/B:BREA.0000032978.67677.9f
   Melchart D, 2006, SUPPORT CARE CANCER, V14, P878, DOI 10.1007/s00520-006-0028-7
   Milbury K, 2013, PSYCHO-ONCOLOGY, V22, P2354, DOI 10.1002/pon.3296
   MILLER JJ, 1995, GEN HOSP PSYCHIAT, V17, P192, DOI 10.1016/0163-8343(95)00025-M
   Minton O, 2008, BREAST CANCER RES TR, V112, P5, DOI 10.1007/s10549-007-9831-1
   Miranda VD, 2009, J ALTERN COMPLEM MED, V15, P431, DOI 10.1089/acm.2008.0324
   Moadel AB, 2007, J CLIN ONCOL, V25, P4387, DOI 10.1200/JCO.2006.06.6027
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Molassiotis A, 2013, HEALTH TECHNOL ASSES, V17, P0, DOI 10.3310/hta17260
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2002, SUPPORT CARE CANCER, V10, P237, DOI 10.1007/s00520-001-0329-9
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Montazeri A, 2008, BMC CANCER, V8, P0, DOI 10.1186/1471-2407-8-330
   Montgomery GH, 2002, INT J CLIN EXP HYP, V50, P17, DOI 10.1080/00207140208410088
   Montgomery GH, 2007, JNCI-J NATL CANCER I, V99, P1304, DOI 10.1093/jnci/djm106
   Montgomery GH, 2014, J CLIN ONCOL, V32, P557, DOI 10.1200/JCO.2013.49.3437
   Montgomery GH, 2009, HEALTH PSYCHOL, V28, P317, DOI 10.1037/a0013582
   Monti DA, 2012, STRESS HEALTH, V28, P397, DOI 10.1002/smi.2470
   Moolenaar M, 2006, ACTA ONCOL, V45, P623, DOI 10.1080/02841860600781799
   Moradian S, 2015, EUR J ONCOL NURS, V19, P282, DOI 10.1016/j.ejon.2014.10.016
   Muñoz GH, 2003, MATURITAS, V44, PS59, DOI 10.1016/S0378-5122(02)00349-3
   Musial F, 2011, FORSCH KOMPLEMENTMED, V18, P192, DOI 10.1159/000330714
   Mustian KM, 2013, J CLIN ONCOL, V31, P3233, DOI 10.1200/JCO.2012.43.7707
   Mustian KM, 2011, INTEGR CANCER THER, V10, P27, DOI 10.1177/1534735410397044
   Mustian KM, 2004, SUPPORT CARE CANCER, V12, P871, DOI 10.1007/s00520-004-0682-6
   Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081
   Nedstrand E, 2005, CLIMACTERIC, V8, P243, DOI 10.1080/13697130500118050
   Nidich SI, 2009, INTEGR CANCER THER, V8, P228, DOI 10.1177/1534735409343000
   Nilsson Ulrica, 2008, AORN J, V87, P780, DOI 10.1016/j.aorn.2007.09.013
   Noguchi N, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/704619
   Noroozinia Heydar, 2013, ACTA MED IRAN, V51, P163
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Oh B, 2012, SUPPORT CARE CANCER, V20, P1235, DOI 10.1007/s00520-011-1209-6
   Ollonen P, 2005, ANTICANCER RES, V25, P2527
   Omar MTA, 2011, J SURG RES, V165, P82, DOI 10.1016/j.jss.2010.03.050
   Ostermann T, 2009, BMC CANCER, V9, P0, DOI 10.1186/1471-2407-9-451
   Pace A, 2010, NEUROLOGY, V74, P762, DOI 10.1212/WNL.0b013e3181d5279e
   Pan YQ, 2014, INT J CLIN ONCOL, V19, P829, DOI 10.1007/s10147-013-0635-5
   Panahi Y, 2014, PHYTOTHER RES, V28, P1461, DOI 10.1002/ptr.5149
   Panahi Y, 2012, INTEGR CANCER THER, V11, P204, DOI 10.1177/1534735411433201
   Park ER, 2013, BREAST, V22, P799, DOI 10.1016/j.breast.2013.02.012
   Paskett ED, 2007, CANCER EPIDEM BIOMAR, V16, P775, DOI 10.1158/1055-9965.EPI-06-0168
   Pérol D, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-603
   Peterson DE, 2007, CANCER, V109, P322, DOI 10.1002/cncr.22384
   Phillips KM, 2008, PSYCHOSOM MED, V70, P1044, DOI 10.1097/PSY.0b013e318186fb27
   Piet J, 2012, J CONSULT CLIN PSYCH, V80, P1007, DOI 10.1037/a0028329
   Pilkington K, 2005, J AFFECT DISORDERS, V89, P13, DOI 10.1016/j.jad.2005.08.013
   Pinnix C, 2012, INT J RADIAT ONCOL, V83, P1089, DOI 10.1016/j.ijrobp.2011.09.021
   Pommier P, 2004, J CLIN ONCOL, V22, P1447, DOI 10.1200/JCO.2004.07.063
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   Potter PJ, 2007, J HOLIST NURS, V25, P238, DOI 10.1177/0898010107301618
   Pruthi Sandhya, 2012, GLOB ADV HEALTH MED, V1, P30, DOI 10.7453/gahmj.2012.1.5.010
   Pruthi S, 2012, MENOPAUSE, V19, P48, DOI 10.1097/gme.0b013e318223b021
   Pyszel A, 2006, LYMPHOLOGY, V39, P185
   Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068
   Raghavendra RM, 2007, EUR J CANCER CARE, V16, P462, DOI 10.1111/j.1365-2354.2006.00739.x
   Raghavendra RM, 2009, INTEGR CANCER THER, V8, P37, DOI 10.1177/1534735409331456
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Rao MR, 2009, COMPLEMENT THER MED, V17, P1, DOI 10.1016/j.ctim.2008.05.005
   Rao RM, 2015, INDIAN J PALLIAT CAR, V21, P174, DOI 10.4103/0973-1075.156486
   Rashid A, 2010, MD ANDERSON MANUAL P, V0, P271
   Rastelli AL, 2011, BREAST CANCER RES TR, V129, P107, DOI 10.1007/s10549-011-1644-6
   Reis Debra, 2013, ONCOL NURS FORUM, V40, PE374, DOI 10.1188/13.ONF.E374-E381
   Richardson M A, 1997, ALTERN THER HEALTH MED, V3, P62
   Ridner SH, 2005, SUPPORT CARE CANCER, V13, P904, DOI 10.1007/s00520-005-0810-y
   Ridner SH, 2013, ONCOL NURS FORUM, V40, P383, DOI 10.1188/13.ONF.383-393
   Rissanen R, 2014, ACTA ONCOL, V53, P1221, DOI 10.3109/0284186X.2014.923935
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Robb KA, 2007, J PAIN SYMPTOM MANAG, V33, P410, DOI 10.1016/j.jpainsymman.2006.09.020
   Robins JLW, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/372908
   Rocha T, 2014, ATLANTIC, V0, P25
   Rock CL, 2012, CA-CANCER J CLIN, V62, P243, DOI 10.3322/caac.21142
   Roffe L, 2005, PSYCHO-ONCOLOGY, V14, P607, DOI 10.1002/pon.889
   Roila F, 2014, J CLIN ONCOL, V32, P101, DOI 10.1200/JCO.2013.51.4547
   Rojas C, 2014, EUR J PHARMACOL, V722, P26, DOI 10.1016/j.ejphar.2013.08.049
   Roscoe JA, 2005, J PAIN SYMPTOM MANAG, V29, P376, DOI 10.1016/j.jpainsymman.2004.07.007
   Roscoe Joseph A, 2005, INTEGR CANCER THER, V4, P8, DOI 10.1177/1534735404273726
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Rubio I, 2013, JPEN-PARENTER ENTER, V37, P623, DOI 10.1177/0148607112474994
   Runowicz CD, 2016, J CLIN ONCOL, V34, P611, DOI 10.1200/JCO.2015.64.3809
   Rusy LM, 2002, ANESTHESIOLOGY, V96, P300, DOI 10.1097/00000542-200202000-00013
   Ryan JL, 2013, RADIAT RES, V180, P34, DOI 10.1667/RR3255.1
   Ryan JL, 2012, SUPPORT CARE CANCER, V20, P1479, DOI 10.1007/s00520-011-1236-3
   Sadja J, 2013, EXPLORE-NY, V9, P232, DOI 10.1016/j.explore.2013.04.005
   Sandel SL, 2005, CANCER NURS, V28, P301
   Araújo MDS, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/676984
   Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895
   Schmidt ME, 2015, INT J CANCER, V137, P471, DOI 10.1002/ijc.29383
   Schmitz KH, 2010, MED SCI SPORT EXER, V42, P1409, DOI 10.1249/MSS.0b013e3181e0c112
   Schnur JB, 2008, ANESTH ANALG, V106, P440, DOI 10.1213/ane.0b013e31815edb13
   Schnur JB, 2009, J CLIN PSYCHOL, V65, P443, DOI 10.1002/jclp.20559
   Semiglasov VF, 2004, ANTICANCER RES, V24, P1293
   Semiglazov VF, 2006, ANTICANCER RES, V26, P1519
   Shapiro D, 2007, EVID-BASED COMPL ALT, V4, P493, DOI 10.1093/ecam/nel114
   Shapiro SL, 2003, J PSYCHOSOM RES, V54, P85, DOI 10.1016/S0022-3999(02)00546-9
   Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006
   Sharp L, 2013, EUR J ONCOL NURS, V17, P429, DOI 10.1016/j.ejon.2012.11.003
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Shen YH, 2015, CANCER-AM CANCER SOC, V121, P84, DOI 10.1002/cncr.28973
   Shennan C, 2011, PSYCHO-ONCOLOGY, V20, P681, DOI 10.1002/pon.1819
   Shoma A, 2010, CURR CLIN PHARMACOL, V5, P251, DOI 10.2174/157488410793352021
   Siedentopf F, 2013, GEBURTSH FRAUENHEILK, V73, P311, DOI 10.1055/s-0032-1328438
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Smith KB, 2009, PSYCHO-ONCOLOGY, V18, P465, DOI 10.1002/pon.1411
   Song QH, 2013, INT J CLIN EXP MED, V6, P979
   Spahn G, 2013, INTEGR CANCER THER, V12, P291, DOI 10.1177/1534735413492727
   Speca M, 2000, PSYCHOSOM MED, V62, P613, DOI 10.1097/00006842-200009000-00004
   Sprod LK, 2012, J CANCER SURVIV, V6, P146, DOI 10.1007/s11764-011-0205-7
   Stagl JM, 2015, CANCER-AM CANCER SOC, V121, P1873, DOI 10.1002/cncr.29076
   Steindorf K, 2014, ANN ONCOL, V25, P2237, DOI 10.1093/annonc/mdu374
   Stephenson N L, 2000, ONCOL NURS FORUM, V27, P67
   Stone P, 2000, ANN ONCOL, V11, P971, DOI 10.1023/A:1008318932641
   Tamagawa R, 2015, MINDFULNESS, V6, P1201, DOI 10.1007/s12671-014-0381-4
   Tanyi RA, 2011, INT J PSYCHIAT MED, V42, P151, DOI 10.2190/PM.42.2.d
   Targ EF, 2002, GEN HOSP PSYCHIAT, V24, P238, DOI 10.1016/S0163-8343(02)00191-3
   Taso CJ, 2014, J NURS RES, V22, P155, DOI 10.1097/jnr.0000000000000044
   Teasdale JD, 2000, J CONSULT CLIN PSYCH, V68, P615, DOI 10.1037//0022-006X.68.4.615
   Nunes DFT, 2007, J PSYCHOSOM RES, V63, P647, DOI 10.1016/j.jpsychores.2007.07.004
   Thompson EA, 2005, J ALTERN COMPLEM MED, V11, P13, DOI 10.1089/acm.2005.11.13
   Thyme Karin Egberg, 2009, PALLIAT SUPPORT CARE, V7, P87, DOI 10.1017/S147895150900011X
   Togni S, 2015, EUR REV MED PHARMACO, V19, P1338
   TRIJSBURG RW, 1992, PSYCHOSOM MED, V54, P489, DOI 10.1097/00006842-199207000-00011
   Tröger W, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/430518
   Trögerl W, 2009, BREAST CANCER-BASIC, V3, P35
   Uebelacker LA, 2010, J PSYCHIATR PRACT, V16, P22, DOI 10.1097/01.pra.0000367775.88388.96
   Vadiraja HS, 2009, COMPLEMENT THER MED, V17, P274, DOI 10.1016/j.ctim.2009.06.004
   Valadares F, 2013, INDIAN J PHARMACOL, V45, P217, DOI 10.4103/0253-7613.111894
   Valentine A, 2011, MD ANDERSON MANUAL P, V0, P271
   van der Lee ML, 2012, PSYCHO-ONCOLOGY, V21, P264, DOI 10.1002/pon.1890
   Van Patten CL, 2002, J CLIN ONCOL, V20, P1449, DOI 10.1200/JCO.20.6.1449
   Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0
   Victorson D, 2007, HANDBOOK OF CANCER SURVIVORSHIP, V0, PP79, DOI 10.1007/978-0-387-34562-8_6
   Vincent A, 2014, CLIMACTRIC, V8, P690
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Walker LG, 1999, BRIT J CANCER, V80, P262, DOI 10.1038/sj.bjc.6690349
   Walsh R, 2006, AM PSYCHOL, V61, P227, DOI 10.1037/0003-066X.61.3.227
   Wang XQ, 2010, J NEUROSURG ANESTH, V22, P128, DOI 10.1097/ANA.0b013e3181c9fbde
   Weitzner MA, 1997, SUPPORT CARE CANCER, V5, P241, DOI 10.1007/s005200050067
   Wheat J, 2006, JOURNAL OF THE AUSTRALIAN TRADITIONAL MEDICINE SOCIETY, V12, P135
   White PF, 2002, ANESTHESIOLOGY, V97, P1075, DOI 10.1097/00000542-200211000-00008
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wilkinson SM, 2007, J CLIN ONCOL, V25, P532, DOI 10.1200/JCO.2006.08.9987
   Williams AF, 2002, EUR J CANCER CARE, V11, P254, DOI 10.1046/j.1365-2354.2002.00312.x
   Williams MS, 1996, INT J RADIAT ONCOL, V36, P345, DOI 10.1016/S0360-3016(96)00320-3
   Witt CM, 2016, BREAST, V28, P37, DOI 10.1016/j.breast.2016.04.012
   Witt CM, 2015, BREAST CANCER RES TR, V149, P449, DOI 10.1007/s10549-014-3249-3
   Woolery A, 2004, ALTERN THER HEALTH M, V10, P60
   Würtzen H, 2013, EUR J CANCER, V49, P1365, DOI 10.1016/j.ejca.2012.10.030
   Wyatt G, 2012, ONCOL NURS FORUM, V39, P568, DOI 10.1188/12.ONF.568-577
   Yaal-Hahoshen N, 2011, ONCOLOGIST, V16, P1197, DOI 10.1634/theoncologist.2011-0150
   Yang B, 2007, CHIN J INTEGR MED, V13, P37, DOI 10.1007/s11655-007-0037-5
   Yang Yan, 2009, ZHONGGUO ZHEN JIU, V29, P955
   Yilmaz Seher Gurdil, 2015, ASIAN PAC J CANCER PREV, V16, P217, DOI 10.7314/apjcp.2015.16.1.217
   Yoo HJ, 2005, SUPPORT CARE CANCER, V13, P826, DOI 10.1007/s00520-005-0806-7
   Younge JO, 2015, EUR J PREV CARDIOL, V22, P1385, DOI 10.1177/2047487314549927
   Zainal NZ, 2013, PSYCHO-ONCOLOGY, V22, P1457, DOI 10.1002/pon.3171
   Zavotsky Kathleen Evanovich, 2014, CLIN J ONCOL NURS, V18, PE45, DOI 10.1188/14.CJON.E45-E49
   Zernicke KA, 2014, PSYCHOSOM MED, V76, P257, DOI 10.1097/PSY.0000000000000053
   Zhang He, 2014, ZHONGGUO ZHEN JIU, V34, P273
   Zhao H, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/809614
   Zhou KN, 2011, CHINESE MED J-PEKING, V124, P2321, DOI 10.3760/cma.j.issn.0366-6999.2011.15.014
   Zhou KN, 2015, EUR J ONCOL NURS, V19, P54, DOI 10.1016/j.ejon.2014.07.010
   Zhuang SR, 2012, BRIT J NUTR, V107, P712, DOI 10.1017/S000711451100345X
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/142913
   Zindel V, 2012, MINDFULNESS BASED CO, V0, P0
NR 379
TC 560
Z9 658
U1 23
U2 422
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-9235
EI 1542-4863
J9 CA-CANCER J CLIN
JI CA-Cancer J. Clin.
PD MAY-JUN 15
PY 2017
VL 67
IS 3
BP 195
EP 232
DI 10.3322/caac.21397
PG 38
WC Oncology
SC Oncology
GA EU3OC
UT WOS:000400939900004
PM 28436999
DA 2026-01-16
ER

PT J
AU Arif, F
   Haroon, SF
   Balagamwala, MA
AF Arif, Fizzah
   Haroon, Syeda Fizzah
   Balagamwala, Marium Aon
TI Implementation of Acupuncture Therapy in the Care of Patients with Breast Cancer.
SO Journal of acupuncture and meridian studies
LA English
DT Letter
C1 Dow Medical College, Dow University of Health and Sciences, Karachi, Pakistan. 
   Dow Medical College, Dow University of Health and Sciences, Karachi, Pakistan.
   Dow Medical College, Dow University of Health and Sciences, Karachi, Pakistan.
EM aarif.fizzah@gmail.com
NR 0
TC 0
SN 2093-815
EI 
J9 J Acupunct Meridian Stud
PD JUL 18
PY 2017
VL 10
IS 3
BP 155
EP 156
DI 10.1016/j.jams.2017.02.001
PG 1
WC Acupuncture Therapy; Antineoplastic Agents; adverse effects; Breast Neoplasms; drug therapy; Female; Humans; Nausea; etiology; Pain, Postoperative; therapy; Quality of Life; Vomiting; etiology
UT PubMed:28712473
PM 28712473
DA 2017-07-18
ER

PT J
AU Chokshi, SK
   Ladas, EJ
   Taromina, K
   McDaniel, D
   Rooney, D
   Jin, Z
   Hsu, WC
   Kelly, KM
AF Chokshi, Sagar K
   Ladas, Elena J
   Taromina, Katherine
   McDaniel, Douglas
   Rooney, Diane
   Jin, Zhezhen
   Hsu, Wei-Chun
   Kelly, Kara M
TI Predictors of acupuncture use among children and adolescents with cancer.
SO Pediatric blood & cancer
LA English
DT Journal Article
DE acupuncture therapy; integrative medicine; pediatric oncology; supportive care
AB BACKGROUND: Evidence for the application of acupuncture in pediatric oncology is  limited. We investigated the acceptance of acupuncture and factors associated  with its use among children and adolescents with cancer. METHODS: Ninety  acupuncture-naïve children receiving cancer treatment at Columbia University  Medical Center (CUMC) provided consent/assent for participation. Participants  could choose to receive or refuse integrative services offered at CUMC. Symptoms  were collected for a 6-month period with the Memorial Symptom Assessment Scale  (MSAS). Acute and delayed adverse events among participants who received  acupuncture were recorded. RESULTS: Fifty-four percent of the participants  elected to receive acupuncture. In total, 252 acupuncture sessions were  administered with a median of four sessions per patient (range 1-13 sessions).  Pain (56%), nausea (51%), lack of energy (50%), and irritability (43%) were the  most frequently reported symptoms in the whole cohort. Determinants of  acupuncture use included older age and ethnicity. Acupuncture was more likely  than other integrative modalities to be used for gastrointestinal and  constitutional symptoms including drowsiness (odds ratio [OR], 3.34; 95%  confidence interval [CI], 1.98-5.66; P < 0.0001), lack of energy (OR, 3.23; 95%  CI, 1.78-5.87; P = 0.0001), and pain (OR, 2.63; 95% CI, 1.46-4.72; P = 0.001).  Adverse events were reported by 3% of the participants. There was no increased  incidence of adverse events in children with thrombocytopenia (P = 0.189) or  neutropenia (P = 0.497). CONCLUSION: Our results highlight the potential use of  acupuncture as a safe, adjunctive therapy for symptom management within existing  supportive care regimens in pediatric oncology and potential areas to focus  research initiatives.
C1 Department of Obstetrics and Gynecology, Cooper University Hospital, Camden, New Jersey.
   Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Columbia University Medical Center, New York, New York.
   Institute of Human Nutrition, Columbia University Medical Center, New York, New 
   Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Columbia University Medical Center, New York, New York.
   Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Columbia University Medical Center, New York, New York.
   Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Columbia University Medical Center, New York, New York.
   Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York.
   Department of Healthcare Policy and Research, Weill Cornell Medical College, Cornell University, New York, New York.
   Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Columbia University Medical Center, New York, New York.
NR 0
TC 0
SN 1545-501
EI 
J9 Pediatr Blood Cancer
PD FEB 9
PY 2017
VL 64
IS 7
BP 
EP 
DI 10.1002/pbc.26424
PG 0
WC Acupuncture Therapy; psychology; Adolescent; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasms; therapy; Patient Acceptance of Health Care; psychology; Prospective Studies; Young Adult
UT PubMed:28176457
PM 28176457
DA 2017-02-09
ER

PT J
AU Strauss, I
   Berger, A
   Ben Moshe, S
   Arad, M
   Hochberg, U
   Gonen, T
   Tellem, R
AF Strauss, Ido
   Berger, Assaf
   Ben Moshe, Shlomit
   Arad, Michal
   Hochberg, Uri
   Gonen, Tal
   Tellem, Rotem
TI Double Anterior Stereotactic Cingulotomy for Intractable Oncological Pain
SO STEREOTACTIC AND FUNCTIONAL NEUROSURGERY
LA English
DT Article
DE Cingulotomy; Cognitive function; Intractable pain; Metastatic disease; Oncology; Pain relief; Palliative care
ID cancer-related pain; prevalence; perception; signature
AB Background: Stereotactic anterior cingulotomy has been used in the treatment of patients suffering from refractory oncological pain due to its effects on pain perception. However, the optimal targets as well as suitable candidates and outcome measures have not been well defined. We report our initial experience in the ablation of 2 cingulotomy targets on each side and the use of the Brief Pain Inventory (BPI) as a perioperative assessment tool. Methods: A retrospective review of all patients who underwent stereotactic anterior cingulotomy in our Department between November 2015 and February 2017 was performed. All patients had advanced metastatic cancer with limited prognosis and suffered from intractable oncological pain. Results: Thirteen patients (10 women and 3 men) underwent 14 cingulotomy procedures. Their mean age was 54 +/- 14 years. All patients reported substantial pain relief immediately after the operation. Out of the 6 preoperatively bedridden patients, 3 started ambulating shortly after. At the 1-month follow-up, the mean preoperative Visual Analogue Scale score decreased from 9 +/- 0.9 to 4 +/- 2.7 (p = 0.003). Mean BPI pain severity and interference scores decreased from levels of 29 +/- 4 and 55 +/- 12 to 16 +/- 12 (p = 0.028) and 37 +/- 15 (p = 0.043), respectively. During the 1- and 3-month follow-up visits, 9/11 patients (82%) and 5/7 patients (71%) available for follow-up reported substantial pain relief. No patient reported worsening of pain during the study period. Neuropsychological analyses of 6 patients showed stable cognitive functions with a mild nonsignificant decline in focused attention and executive functions. Adverse events included transient confusion or mild apathy in 5 patients (38%) lasting 1-4 weeks. Conclusions: Our initial experience indicates that double stereotactic cingulotomy is safe and effective in alleviating refractory oncological pain. (c) 2018 S. Karger AG, Basel.
C1 [Strauss, Ido; Berger, Assaf; Ben Moshe, Shlomit; Gonen, Tal] Tel Aviv Univ, Tel Aviv Med Ctr, Dept Neurosurg, Tel Aviv, Israel.
   [Arad, Michal; Tellem, Rotem] Tel Aviv Univ, Palliat Care Serv, Tel Aviv Med Ctr, Tel Aviv, Israel.
   [Hochberg, Uri] Tel Aviv Univ, Inst Pain Med, Tel Aviv Med Ctr, Tel Aviv, Israel.
   [Gonen, Tal] Tel Aviv Univ, Funct Brain Ctr, Tel Aviv Med Ctr, Tel Aviv, Israel.
   [Strauss, Ido] Tel Aviv Univ, Neuromodulat Unit, Tel Aviv Med Ctr, Div Neurosurg, Tel Aviv, Israel.
   [Strauss, Ido; Berger, Assaf; Arad, Michal; Hochberg, Uri; Gonen, Tal; Tellem, Rotem] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine
RP Strauss, I (corresponding author), Tel Aviv Univ, Div Neurosurg, Tel Aviv Sourasky Med Ctr, 6 Weizmann St, IL-6423906 Tel Aviv, Israel.
EM idos@tlvmc.gov.il
CR Apkarian AV, 2008, CURR OPIN NEUROBIOL, V18, P464, DOI 10.1016/j.conb.2008.09.012
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1
   Cosgrove GR, 2003, NEUROSURG CLIN N AM, V14, P225, DOI 10.1016/S1042-3680(02)00115-8
   Dwolatzky Tzvi, 2003, BMC GERIATR, V3, P4, DOI 10.1186/1471-2318-3-4
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fallon M, 2015, OXFORD TXB PALLIATIV, V0, P525
   Harsh V, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0331-1
   Patel NV, 2015, OPER NEUROSURG, V11, P17, DOI 10.1227/NEU.0000000000000581
   Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6
   PILLAY PK, 1992, STEREOT FUNCT NEUROS, V59, P33, DOI 10.1159/000098914
   Raslan AM, 2008, NEUROSURGERY, V63, P226, DOI 10.1227/01.neu.0000317397.16089.f5
   Raslan AM, 2011, J NEUROSURG, V114, P155, DOI 10.3171/2010.6.JNS10119
   Russo JF, 2015, NEUROSURG FOCUS, V38, P0, DOI 10.3171/2015.3.FOCUS1543
   Sharim J, 2016, PAIN PHYSICIAN, V19, P537, DOI 10.36076/ppj/2016.19.537
   Sheth SA, 2013, J NEUROSURG, V118, P491, DOI 10.3171/2012.11.JNS12389
   Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Viswanathan A, 2013, NEUROSURG FOCUS, V35, P0, DOI 10.3171/2013.6.FOCUS13236
   Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471
   Yen CP, 2009, J CLIN NEUROSCI, V16, P214, DOI 10.1016/j.jocn.2008.04.008
   Yen CP, 2005, J CLIN NEUROSCI, V12, P886, DOI 10.1016/j.jocn.2004.11.018
NR 22
TC 32
Z9 35
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1011-6125
EI 1423-0372
J9 STEREOT FUNCT NEUROS
JI Stereotact. Funct. Neurosurg.
PD JUN 15
PY 2017
VL 95
IS 6
BP 400
EP 408
DI 10.1159/000484613
PG 9
WC Neurosciences; Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA FX6TQ
UT WOS:000426220600006
PM 29316566
DA 2026-01-16
ER

PT J
AU Steinhorn, DM
   Din, J
   Johnson, A
AF Steinhorn, David M.
   Din, Jana
   Johnson, Angela
TI Healing, spirituality and integrative medicine
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Review
DE Suffering; spiritual healing; complementary medicine; shamanism; acupuncture
ID alternative medicine; symptom management; palliative care; herbal medicine; pastoral care; cancer care; complementary; therapy; acupuncture; safety
AB Spirituality plays a prominent role in the lives of most palliative patients whether or not they formally adhere to a specific religion and belief. As a result, the palliative care team is frequently called upon to support families who are experiencing their "dark night of the soul" and struggling to make sense of their lives during a healthcare crisis. While conventional religious practices provide a source of comfort and guidance for many of our patients, a significant number of our patients do not have a strong religious community to which to turn. Over the last two decades, more people in Western countries identify themselves as spiritual but not religious and do not belong to an organized faith community. For those patients who express a strong spiritual connection or sense of 'something greater' or 'a higher power', encouraging the exploration of those feelings and beliefs through chaplains, clergypersons, or members of the interdisciplinary palliative care team can help provide context, meaning and purpose in their lives impacted by serious illness. One of the goals of effective palliative care is the facilitation of personal growth and psychological resilience in dealing with one's health challenges. Integrative medicine, also referred to as complementary and alternative medicine, provides a set of tools and philosophies intended to enhance wellness and a sense of wellbeing. Many of the modalities are derived from disciplines such as massage, acupuncture, Rei Ki, aromatherapy, and dietary supplements. The use of integrative medicine in North America is widespread and frequently not shared with one's clinician due to many patients' concerns that clinicians will disapprove of the patient's use of them. In addition to its efficacy in reducing symptoms commonly experienced by patients receiving palliative care (e.g., nausea, pain, depression, and existential suffering), integrative medicine offers non-verbal, non-cognitive avenues for many to achieve a peaceful and calm inner state. The calm state often achieved during integrative medicine treatments is similar to that seen during deep prayer or meditation. In such a transcendent or non-ordinary state of consciousness, many people experience new insights or understanding of their lives and choices they must make. Thus, integrative approaches facilitate patients attaining greater self-awareness and may meet their spiritual needs without the religious overtones that accompany traditional prayer. In so doing, patients may gain greater insight and find inner peace through simple, non-verbal approaches.
C1 [Steinhorn, David M.] Childrens Natl Med Ctr, PANDA Palliat Care Program, Washington, DC 20010 USA.
   [Din, Jana] Tao Ctr Healing, Sacramento, CA USA.
   [Johnson, Angela] Rush Presbyterian St Lukes Med Ctr, Canc Integrat Med Program, Chicago, IL USA.
C3 Children's National Health System; Rush University
RP Steinhorn, DM (corresponding author), Childrens Natl Med Ctr, Pediat, 111 Michigan Ave NW, Washington, DC 20010 USA.; Steinhorn, DM (corresponding author), Childrens Natl Med Ctr, PANDA Palliat Care Program, Div Crit Care, 111 Michigan Ave NW, Washington, DC 20010 USA.
EM dsteinhorn@childrensnational.org
CR Agdal R, 2011, FORSCH KOMPLEMENTMED, V18, P146, DOI 10.1159/000329316
   Alcorn R, 2010, HEALING STORIES MY J, V0, P0
   Alsanad SM, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1372-x
   Unknown -, 2013, FULL CATASTROPHE LIV, V0, P0
   Unknown -, 2015, TRENDS USE COMPLEMEN, V0, P0
   Barnes Patricia M, 2004, ADV DATA, V0, P1
   Barrie-Anthony S, 2014, ATLANTIC, V0, P0
   Ben-Arye E, 2016, CANCER-AM CANCER SOC, V122, P598, DOI 10.1002/cncr.29796
   Blumberg A, 2016, HUFFINGTON POST, V0, P0
   Botha Elmarie, 2015, JBI DATABASE SYSTEM REV IMPLEMENT REP, V13, P21, DOI 10.11124/jbisrir-2015-2380
   Braden G, 2008, THE DIVINE MATRIX: BRIDGING TIME, V0, P0
   Burden B, 2005, INT J PALLIAT NURS, V11, P248, DOI 10.12968/ijpn.2005.11.5.248
   Carey LB, 2015, J RELIG HEALTH, V54, P1772, DOI 10.1007/s10943-014-9938-8
   Carson C, 2013, SPIRITED MED SHAMANI, V0, P0
   CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104
   Chang KH, 2011, BMC CANCER, V11, P0, DOI 10.1186/1471-2407-11-196
   Chung VCH, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002793
   Conrad AC, 2014, J CANCER RES CLIN, V140, P1229, DOI 10.1007/s00432-014-1656-9
   de Aguiar PR, 2016, J RELIG HLTH, V0, P0
   Duncan G, 2000, J MED PHILOS, V25, P485, DOI 10.1076/0360-5310(200008)25:4;1-A;FT485
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Fadiman A, 1997, SPIRIT CATCHES YOU Y, V0, P0
   Falkensteiner Maria, 2011, ISRN NURS, V2011, P929868, DOI 10.5402/2011/929868
   Gouveia LO, 2009, SPINE, V34, PE405, DOI 10.1097/BRS.0b013e3181a16d63
   Grant SJ, 2012, BMC PUBLIC HEALTH, V12, P0, DOI 10.1186/1471-2458-12-299
   Harding SR, 2008, J HEALTH CARE CHAPL, V14, P99, DOI 10.1080/08854720802129067
   Isaac KS, 2016, J RELIG HEALTH, V55, P1065, DOI 10.1007/s10943-016-0190-2
   Jeuland J, 2017, J PALLIAT MED, V20, P502, DOI 10.1089/jpm.2016.0308
   Johnson A, 2012, OXFORD TXB PALLIATIV, V0, P0
   Jou J, 2016, JAMA INTERN MED, V176, P545, DOI 10.1001/jamainternmed.2015.8593
   Kemper KJ, 2016, AUTHENTIC HEALING, V0, P0
   Koenig HG, 2008, MED RELIG HLTH, V0, P0
   Koenig Harold G, 2012, ISRN PSYCHIATRY, V2012, P278730, DOI 10.5402/2012/278730
   Koenig HG, 2012, HANDBOOK OF RELIGION AND HEALTH (2ND EDITION), V0, P0
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Loquai C, 2016, MED ONCOL, V33, P0, DOI 10.1007/s12032-016-0764-6
   Luzzatto RM, 2009, WAY GOD DERECH HASHE, V0, P0
   Maschi D, 2016, AM MAY BE GETTING LE, V0, P0
   NG JY, 2016, BMC COMPLEM ALTERN M, V16, P0
   PDQ Integrative Alternative and Complementary Therapies Editorial BoardMedicinal Mushrooms, 2002, PDQ CANC INF SUMM, V0, P0
   Proserpio T, 2011, TUMORI, V97, P666, DOI 10.1700/989.10729
   Puchalski C, 2009, J PALLIAT MED, V12, P885, DOI 10.1089/jpm.2009.0142
   Roberts L, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000368.pub3
   Shin ES, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009873.pub3
   Singh D, 2012, CRIT REV FOOD SCI, V52, P876, DOI 10.1080/10408398.2010.512426
   Uhlig T, 2012, BEST PRACT RES CL RH, V26, P387, DOI 10.1016/j.berh.2012.05.006
   Weber SR, 2012, J RELIG HEALTH, V51, P72, DOI 10.1007/s10943-011-9541-1
   Weeks L, 2014, OPEN MED-WARSAW, V8, P0
NR 51
TC 62
Z9 80
U1 1
U2 54
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD JUL 15
PY 2017
VL 6
IS 3
BP 237
EP 247
DI 10.21037/apm.2017.05.01
PG 11
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA FC5TC
UT WOS:000406903600007
PM 28595441
DA 2026-01-16
ER

PT J
AU Yeh, CH
   Lin, WC
   Kwai-Ping, Suen L
   Park, NJ
   Wood, LJ
   van, Londen GJ
   Howard, Bovbjerg D
AF Yeh, Chao Hsing
   Lin, Wei-Chun
   Kwai-Ping Suen, Lorna
   Park, Na-Jin
   Wood, Lisa J
   van Londen, G J
   Howard Bovbjerg, Dana
TI Auricular Point Acupressure to Manage Aromatase Inhibitor-Induced Arthralgia in
SO Oncology nursing forum
LA English
DT Journal Article
DE acupressure; aromatase inhibitor–induced arthralgia; breast cancer survivors
AB PURPOSE/OBJECTIVES: To assess the feasibility of auricular point acupressure to  manage aromatase inhibitor-induced arthralgia. . DESIGN: Wait list control  design. . SETTING: Outpatient clinics and oncology center. . SAMPLE: 20 women  with aromatase inhibitor-induced arthralgia. . METHODS: After baseline data were  collected, participants waited one month before they received acupressure once  per week for four weeks at a convenient time. The baseline data served as the  control comparison. Self-reported measures and blood samples were obtained at  baseline, at preintervention, weekly during the intervention, and at  post-intervention. . MAIN RESEARCH VARIABLES: The primary outcomes included pain  intensity, pain interference, stiffness, and physical function. Inflammatory  cytokines and chemokines were tested. . FINDINGS: After the four-week  intervention, participants reported decreases in worst pain and pain  interference, and improvements in physical function, cancer-related symptom  severity, and interference. The proinflammatory cytokines and chemokines  displayed a trend of a mean percentage reduction. The anti-inflammatory cytokine  interleukin-13 increased from pre- to postintervention. . CONCLUSIONS: Auricular  point acupressure is feasible and may be effective in managing arthralgia in  breast cancer survivors. . IMPLICATIONS FOR NURSING: Nurses can administer  acupressure in clinical settings, which could enhance the management of aromatase  inhibitor-induced arthralgia and contribute to a shift from traditional  disease-based biomedical models to a broader, integrative, medical paradigm for  managing aromatase inhibitor-induced arthralgia.
C1 School of Nursing, University of Pittsburgh, Pennsylvania.
   University of Pittsburgh.
   Hong Kong Polytechnic University.
   University of Pittsburgh.
   MGH Institute of Health Professions.
   University of Pittsburgh.
   University of Pittsburgh Cancer Institute and Hillman Cancer Center.
NR 0
TC 0
SN 1538-068
EI 
J9 Oncol Nurs Forum
PD JUN 21
PY 2017
VL 44
IS 4
BP 476
EP 487
DI 10.1188/17.ONF.476-487
PG 11
WC Acupressure; Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; adverse effects; Arthralgia; chemically induced; Breast Neoplasms; drug therapy; Cancer Survivors; Female; Humans; Middle Aged; Pain Management; methods; Pilot Projects; Quality of Life; Treatment Outcome
UT PubMed:28632237
PM 28632237
DA 2017-06-21
ER

PT J
AU Ben-Horin, I
   Kahan, P
   Ryvo, L
   Inbar, M
   Lev-Ari, S
   Geva, R
AF Ben-Horin, Idan
   Kahan, Peretz
   Ryvo, Larisa
   Inbar, Moshe
   Lev-Ari, Shahar
   Geva, Ravit
TI Acupuncture and Reflexology for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE peripheral neuropathy; breast cancer; acupuncture; reflexology; chemotherapy
ID quality-of-life; management; therapy; pain
AB Background: Treatment of chemotherapy-induced peripheral neuropathy (CIPN), which affects approximately 30% to 40% of patients treated with neuropathy-causing agents, is mainly symptomatic. Currently available interventions are of little benefit. Study Design: This study was conducted as a retrospective analysis of the efficacy of acupuncture and reflexology in alleviating CIPN in breast cancer patients. Methods: Medical records of 30 consecutive breast cancer patients who received both chemotherapy and treatment for CIPN according to our Acupuncture and Reflexology Treatment for Neuropathy (ART-N) protocol between 2011 and 2012 were reviewed. Symptom severity was rated at baseline, during, and after treatment. Results: The records of 30 breast cancer patients who had been concomitantly treated with chemotherapy and ART-N for CIPN were retrieved. Two records were incomplete, leaving a total of 28 patients who were enrolled into the study. Twenty patients (71%) had sensory neuropathy, 7 (25%) had motor neuropathy, and 1 (4%) had both sensory and motor neuropathy. Only 2 (10%) of the 20 patients with grades 1 to 2 neuropathy still reported symptoms at 12 months since starting the ART-N protocol. All 8 patients who presented with grades 3 to 4 neuropathy were symptom-free at the 12-month evaluation. Overall, 26 patients (93%) had complete resolution of CIPN symptoms. Conclusion: The results of this study demonstrated that a joint protocol of acupuncture and reflexology has a potential to improve symptoms of CIPN in breast cancer patients. The protocol should be validated on a larger cohort with a control group. It also warrants testing as a preventive intervention.
C1 [Ben-Horin, Idan; Kahan, Peretz; Ryvo, Larisa; Inbar, Moshe; Lev-Ari, Shahar; Geva, Ravit] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center
RP Ben-Horin, I (corresponding author), Tel Aviv Sourasky Med Ctr, Div Oncol, 6 Weizman St, IL-6423906 Tel Aviv, Israel.
EM idanbh@tlvmc.gov.il
CR Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Cavaletti G, 2010, NAT REV NEUROL, V6, P657, DOI 10.1038/nrneurol.2010.160
   Chaudhry V, 2003, NEUROLOGY, V60, P337, DOI 10.1212/01.WNL.0000043691.53710.53
   Cunningham JE, 2011, SUPPORT CARE CANCER, V19, P1473, DOI 10.1007/s00520-011-1231-8
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   Kuroi K, 2008, JPN J CLIN ONCOL, V38, P748, DOI 10.1093/jjco/hyn100
   Lee JJ, 2006, J CLIN ONCOL, V24, P1633, DOI 10.1200/JCO.2005.04.0543
   Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Park R, 2015, CANCER NURS, V38, P239, DOI 10.1097/NCC.0000000000000181
   Quasthoff S, 2002, J NEUROL, V249, P9, DOI 10.1007/PL00007853
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Stubblefield MD, 2009, J NATL COMPR CANC NE, V7, PS1, DOI 10.6004/jnccn.2009.0078
   Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Yang XY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/319734
NR 25
TC 32
Z9 38
U1 1
U2 27
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD SEP 15
PY 2017
VL 16
IS 3
BP 258
EP 262
DI 10.1177/1534735417690254
PG 5
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA FE0SL
UT WOS:000407929900002
PM 28150504
DA 2026-01-16
ER

PT J
AU Sharif, Nia H
   Pahlevan, Sharif S
   Yaghoobzadeh, A
   Yeoh, KK
   Goudarzian, AH
   Soleimani, MA
   Jamali, S
AF Sharif Nia, Hamid
   Pahlevan Sharif, Saeed
   Yaghoobzadeh, Ameneh
   Yeoh, Ken Kyid
   Goudarzian, Amir Hossein
   Soleimani, Mohammad Ali
   Jamali, Saman
TI Effect of acupressure on pain in Iranian leukemia patients: A randomized
SO International journal of nursing practice
LA English
DT Journal Article
DE Iran; acupressure; cancer; leukemia; nursing; pain
AB Nonpharmacological methods of pain relief such as acupressure are becoming  increasingly popular worldwide. Practitioners often claim that such methods are  highly effective and less invasive than analgesic drugs, but available empirical  evidence is largely inconclusive. This study aimed to test the hypothesis that,  postacupressure intervention, the amount of pain experienced by sampled leukemia  patients, who received acupressure in addition to standard care, will reduce  substantially compared to patients who received only routine treatment. This  controlled trial was undertaken with hospitalized leukemia patients between  February and June 2015. Our primary sample consisted of 100 participants who were  randomly allocated to 2 groups. One (intervention) group underwent 12 acupressure  sessions in addition to standard treatment while the control group received no  intervention apart from being given the standard treatment for leukemia. The  visual analogue scale was used to measure the levels of pain experienced. No  significant differences were found between the 2 groups across 12 interventions.  However, each group reported significantly different pain level changes before  and after each intervention, suggested that the acupressure method was effective  in reducing pain in the short term. Nurses are able to apply this complementary  therapy alongside other procedures to manage these patients' pain. It is  recommended that further studies be conducted to better understand the specific  conditions under which acupressure can provide effective pain relief.
C1 School of Nursing and Midwifery Amol, Mazandaran University of Medical Sciences, Sari, Iran.
   Taylor's Business School, Subang Jaya, Malaysia.
   Tehran University of Medical Sciences, Tehran, Iran.
   Nottingham University Business School, University of Nottingham Malaysia Campus, Semenyih, Selangor Darul Ehsan, Malaysia.
   Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
   Social Determinants of Health Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
   Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
NR 0
TC 0
SN 1440-172
EI 
J9 Int J Nurs Pract
PD JAN 7
PY 2017
VL 23
IS 2
BP 
EP 
DI 10.1111/ijn.12513
PG 0
WC Acupressure; Adult; Cancer Pain; diagnosis; Female; Humans; Iran; Leukemia; complications; Male; Middle Aged; Pain Measurement; Single-Blind Method
UT PubMed:28058748
PM 28058748
DA 2017-01-07
ER

PT J
AU Domnick, M
   Domnick, M
   Wiebelitz, KR
   Beer, AM
AF Domnick, Martin
   Domnick, Manju
   Wiebelitz, Karl-Ruediger
   Beer, Andre-Michael
TI Evaluation of the Effectiveness of a Multimodal Complementary Medicine Program for Improving the Quality of Life of Cancer Patients during Adjuvant Radiotherapy and/or Chemotherapy or Outpatient Aftercare
SO ONCOLOGY
LA English
DT Article
DE Complementary therapy; Integrative oncology; Quality of life; Entity spanning; Multimodal
ID breast-cancer; integrative oncology; mistletoe extract; induced nausea; acupuncture; fatigue; pain; therapy; acupressure; meditation
AB Objectives: Evidence for complementary therapies as important strategies to relieve cancer treatment-associated symptoms is increasing. Mostly, these complementary therapies start at the end of adjuvant treatments, resulting in a long delay until the well-being of patients is addressed. Further, long distances between the rehabilitation center and the patients' residence hinder patients' compliance. Methods: The multimodal outpatient LOTUS Care Cure Project (LCCP) was tested in a randomized controlled trial including patients of various cancer entities and stages while on adjuvant chemotherapy and/or radiotherapy or outpatient aftercare. The intervention group received the LCCP additionally to the conventional treatment (LCCP group, n = 50). The control group (CG) was split into 2 groups, with (CG1, n = 33) and without (CG2, n = 17) weekly talks. The primary endpoint was quality of life (QoL) after 3 months. Results: In the LCCP group, QoL significantly improved after 3 months compared to CG2 (p = 0.022) but not compared to CG1. Other parameters showing a significant improvement were cognitive (p < 0.05, vs. CG1 and CG2) and social function (p < 0.05, vs. CG2). Conclusions: This pilot study describes a multimodal outpatient complementary therapy program conducted in parallel with conventional therapies and its potential to significantly improve QoL and reduce treatment-associated side effects. To substantiate these data, multicenter trials are needed. (C) 2017 S. Karger AG, Basel
C1 [Domnick, Martin; Domnick, Manju] Praxisklin & Internist Gemeinschaftspraxis Domnic, Josefstr 14-16, DE-45699 Herten, Germany.
   [Wiebelitz, Karl-Ruediger] Kreiskrankenhaus Prignitz Gemeinnutzige GmbH, Klin Kinder & Jugendmed, Prignitz, Germany.
   [Beer, Andre-Michael] Katholisches Klinikum Bochum, Klin Naturheilkunde Klin Blankenstein, Bochum, Germany.
C3 Ruhr University Bochum
RP Domnick, M (corresponding author), Praxisklin & Internist Gemeinschaftspraxis Domnic, Josefstr 14-16, DE-45699 Herten, Germany.
EM m.m.domnick@praxis-klinik-domnick.de
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Bar-Sela G, 2013, EUR J CANCER, V49, P1058, DOI 10.1016/j.ejca.2012.11.007
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004
   Ben-Arye E, 2015, CLIN NUTR, V34, P1215, DOI 10.1016/j.clnu.2014.12.011
   Ben-Arye E, 2015, SUPPORT CARE CANCER, V23, P3411, DOI 10.1007/s00520-015-2690-0
   Carlson Linda E, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP308, DOI 10.1093/jncimonographs/lgu034
   Cassileth B, 2006, ONCOLOGY-NY, V20, P1302
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Collins Kimberly B, 2004, J AM ACAD NURSE PRACT, V16, P76
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Dobos GJ, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-539
   Fayer P, 2001, EORTC QLQ C30 SCORIN, Vthird, P0
   Frass M, 2015, COMPLEMENT THER MED, V23, P309, DOI 10.1016/j.ctim.2015.03.004
   Geissner E, 1995, REHABILITATION (STUTTG), V34, P0
   Hautzinger M, 1994, BECK-DEPRESSIONS-INVENTAR (BDI), V0, P0
   Horneber M, 2012, DTSCH ARZTEBL INT, V109, P161, DOI 10.3238/arztebl.2012.0161
   International Agency for Research on Cancer, 2014, WORLD CANC REPORT 20, V0, P0
   KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3
   KABATZINN J, 1992, AM J PSYCHIAT, V149, P936
   Klafke N, 2016, SUPPORT CARE CANCER, V24, P2341, DOI 10.1007/s00520-015-3038-5
   Lenartz D, 1996, ANTICANCER RES, V16, P3799
   McKeon C, 2015, ACUPUNCT MED, V33, P277, DOI 10.1136/acupmed-2015-010781
   Melchart D, 2006, SUPPORT CARE CANCER, V14, P878, DOI 10.1007/s00520-006-0028-7
   Mohammadzadeh M, 2013, INTEGR CANCER THER, V12, P496, DOI 10.1177/1534735413485417
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Piao BK, 2004, ANTICANCER RES, V24, P303
   Running A, 2012, CURR PAIN HEADACHE R, V16, P325, DOI 10.1007/s11916-012-0275-x
   Schumacher K, 2003, ANTICANCER RES, V23, P5081
   Senf B, 2010, SUPPORT CARE CANCER, V18, P957, DOI 10.1007/s00520-010-0850-9
   Sharabi IS, 2016, SUPPORT CARE CANCER, V24, P4345, DOI 10.1007/s00520-016-3274-3
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Spahn G, 2013, INTEGR CANCER THER, V12, P291, DOI 10.1177/1534735413492727
   Sudarshan M, 2013, COMPLEMENT THER CLIN, V19, P227, DOI 10.1016/j.ctcp.2013.06.004
   Weze Clare, 2004, EUR J ONCOL NURS, V8, P40, DOI 10.1016/j.ejon.2003.10.004
   Witt CM, 2015, BREAST CANCER RES TR, V149, P449, DOI 10.1007/s10549-014-3249-3
NR 35
TC 8
Z9 11
U1 1
U2 17
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-2414
EI 1423-0232
J9 ONCOLOGY-BASEL
JI Oncology
PD JUN 15
PY 2017
VL 93
IS 2
BP 83
EP 91
DI 10.1159/000468939
PG 9
WC Oncology
SC Oncology
GA FC1KM
UT WOS:000406596000002
PM 28472802
DA 2026-01-16
ER

PT J
AU Zhou, J
   Fang, L
   Wu, WY
   He, F
   Zhang, XL
   Zhou, X
   Xiong, ZJ
AF Zhou, J.
   Fang, L.
   Wu, W. Y.
   He, F.
   Zhang, X. L.
   Zhou, X.
   Xiong, Z. J.
TI The effect of acupuncture on chemotherapy-associated gastrointestinal symptoms in gastric cancer
SO CURRENT ONCOLOGY
LA English
DT Article
DE Acupuncture; gastric cancer; chemotherapy; gastrointestinal symptoms; quality of life
ID quality-of-life; clinical-practice guidelines; adjuvant chemotherapy; persian version; whoqol-100; trials; thrombocytopenia; metaanalysis; prevention; therapy
AB Background Gastrointestinal (GI) symptoms are the most notable side effects of chemotherapeutic drugs; such symptoms are currently treated with drugs. In the present study, we investigated the effect of acupuncture on GI symptoms induced by chemotherapy in patients with advanced gastric cancer. Methods A cohort of 56 patients was randomly divided into an experimental group and a control group. All patients received combination chemotherapy with oxaliplatin-paclitaxel. Patients in the experimental group received 30 minutes of acupuncture therapy daily for 2 weeks. The frequency and duration of nausea, vomiting, abdominal pain, and diarrhea, the average days and costs of hospitalization, and quality-of-life scores were compared between the groups. Results Nausea was sustained for 32 +/- 5 minutes and 11 +/- 3 minutes daily in the control and experimental groups respectively (p < 0.05). On average, vomiting occurred 2 +/- 1 times daily in the experimental group and 4 +/- 1 times daily in the control group (p < 0.05). Abdominal pain persisted for 7 +/- 2 minutes and 16 +/- 5 minutes daily in the experimental and control groups respectively (p < 0.05). On average, diarrhea occurred 1 +/- 1 times daily in the experimental group and 3 +/- 1 times daily in the control group (p < 0.05). The average quality-of-life score was higher in the experimental group than in the control group (p < 0.05). No adverse events were observed for the patients receiving acupuncture. Conclusions Acupuncture, a safe technique, could significantly reduce GI symptoms induced by chemotherapy and enhance quality of life in patients with advanced gastric cancer.
C1 [Fang, L.; Wu, W. Y.; He, F.; Zhang, X. L.] Chengdu Med Coll, Dept Gastroenterol, Affiliated Hosp 1, 238 Baoguang Rd, Chengdu, Sichuan, Peoples R China.
   [Zhou, J.; Zhou, X.; Xiong, Z. J.] Chengdu Med Coll, Dept Chemotherapy, Sichuan Canc Hosp, Chengdu, Sichuan, Peoples R China.
C3 Chengdu Medical College; Chengdu Medical College
RP Fang, L (corresponding author), Chengdu Med Coll, Dept Gastroenterol, Affiliated Hosp 1, 238 Baoguang Rd, Chengdu, Sichuan, Peoples R China.
EM fangzjt521@163.com
FU Science and Technology Department of Sichuan Province [2011JYZ034, 2016JY0115]; Health Department of Sichuan Province [120035]; Academy of Finland (AKA) [120035] Funding Source: Academy of Finland (AKA)
CR Avvisati G, 2003, CRIT REV ONCOL HEMAT, V48, PS13, DOI 10.1016/j.critrevonc.2003.04.001
   Cazzorla C, 2012, MOL GENET METAB, V106, P25, DOI 10.1016/j.ymgme.2012.02.008
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Cui X, 2016, BIOMED RES INT, V2016, P0
   Cybularz PA, 2015, MED ACUPUNCT, V27, P224, DOI 10.1089/acu.2015.1099
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Karimlou M, 2011, ARCH IRAN MED, V14, P281, DOI 0011144/AIM.0011
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Li MK, 2015, NEURAL REGEN RES, V10, P1997, DOI 10.4103/1673-5374.172318
   Marrelli D, 2015, WORLD J GASTROENTERO, V21, P7954, DOI 10.3748/wjg.v21.i26.7954
   Min C, 2014, ONCOLOGY-BASEL, V86, P79, DOI 10.1159/000354641
   Paoletti X, 2010, JAMA-J AM MED ASSOC, V303, P1729, DOI 10.1001/jama.2010.534
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252
   Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908
   Schiffer CA, 2001, J CLIN ONCOL, V19, P1519, DOI 10.1200/JCO.2001.19.5.1519
   Siegel R, 2013, CA-CANCER J CLIN, V2013, P6311
   Thompson LMA, 2015, J ACUPUNCT MERIDIAN, V8, P127, DOI 10.1016/j.jams.2015.04.002
   Waddell T, 2014, EJSO-EUR J SURG ONC, V40, P584, DOI 10.1016/j.ejso.2013.09.020
   Wan CH, 2011, INT J NURS STUD, V48, P1080, DOI 10.1016/j.ijnurstu.2011.02.012
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Wu Y, 2016, J ZHEJIANG UNIV-SC B, V17, P169, DOI 10.1631/jzus.B1500301
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Yazdani K, 2015, IRAN J PUBLIC HEALTH, V44, P522
NR 24
TC 32
Z9 42
U1 1
U2 27
PU MULTIMED INC
PI TORONTO
PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA
SN 1198-0052
EI 
J9 CURR ONCOL
JI Curr. Oncol.
PD FEB 15
PY 2017
VL 24
IS 1
BP E1
EP E5
DI 10.3747/co.24.3296
PG 5
WC Oncology
SC Oncology
GA EM9TV
UT WOS:000395654900001
PM 28270726
DA 2026-01-16
ER

PT J
AU Strauss, I
   Berger, A
   Arad, M
   Hochberg, U
   Tellem, R
AF Strauss, Ido
   Berger, Assaf
   Arad, Michal
   Hochberg, Uri
   Tellem, Rotem
TI O-Arm-Guided Percutaneous Radiofrequency Cordotomy
SO STEREOTACTIC AND FUNCTIONAL NEUROSURGERY
LA English
DT Article
DE Pain; Percutaneous cordotomy; O-Arm intraoperative imaging system
ID cancer pain; cervical cordotomy; management
AB Background: Pain is often one of the most debilitating symptoms in patients with advanced oncological disease. Patients with localized pain due to malignancy refractory to medical treatment can benefit from selective percutaneous cordotomy that disconnects the ascending pain fibers in the spinothalamic tract. Objectives: Over the past year, we have been performing percutaneous radiofrequency cordotomy with the use of the O-Arm intraoperative imaging system that allows both 2D fluoroscopy and 3D reconstructed computerized tomography imaging. We present our experience using this technique, focusing on technical nuances and complications. Methods: A retrospective analysis was conducted of all patients who underwent percutaneous cordotomy between March 2016 and March 2017. Results: Nineteen patients underwent percutaneous cordotomy procedures. Two patients developed intraoperative delirium and were unable to tolerate the procedure. In 16 out of 17 completed procedures, we achieved excellent immediate pain relief (94%). At 1 month after operation, 15 of the 17 (88%) patients were pain free, and at 3 months 5 out of 5 patients available for follow-up were still free of their original pain. Mirror pain developed in 6 of the 17 patients (35%), but was mild in 4 of these cases and controlled with medications. We experienced 1 serious complication (6%) of ipsilateral hemiparesis. Conclusion: Percutaneous cordotomy using the O-Arm is safe and effective in the treatment of intractable oncological pain. (c) 2018 S. Karger AG, Basel.
C1 [Strauss, Ido; Berger, Assaf] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurosurg, 6 Weizmann St, IL-6423906 Tel Aviv, Israel.
   [Arad, Michal; Tellem, Rotem] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Palliat Care Serv, Tel Aviv, Israel.
   [Hochberg, Uri] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Inst Pain Med, Tel Aviv, Israel.
   [Strauss, Ido] Tel Aviv Sourasky Med Ctr, Neuromodulat Unit, Tel Aviv, Israel.
   [Strauss, Ido; Berger, Assaf; Tellem, Rotem] Tel Aviv Sourasky Med Ctr, Sackler Sch Med, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center
RP Strauss, I (corresponding author), Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurosurg, 6 Weizmann St, IL-6423906 Tel Aviv, Israel.
EM idos@tlvmc.gov.il
CR Bain E, 2013, J PALLIAT MED, V16, P901, DOI 10.1089/jpm.2013.0027
   Bellini M, 2016, ANAESTH INTENSIVE TH, V48, P197, DOI 10.5603/AIT.a2014.0070
   Collins KL, 2013, NEUROSURGERY, V72, P27, DOI 10.1227/NEU.0b013e31827415e7
   Crul Ben J P, 2005, J HEADACHE PAIN, V6, P24, DOI 10.1007/s10194-005-0145-6
   France BD, 2014, BMJ SUPPORT PALLIAT, V4, P19, DOI 10.1136/bmjspcare-2013-000508
   Harsh V, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0331-1
   Higaki N, 2015, NEUROSURGERY, V76, P249, DOI 10.1227/NEU.0000000000000593
   Honey CR, 2014, J PALLIAT MED, V17, P624, DOI 10.1089/jpm.2013.0664
   KANPOLAT Y, 1993, ACTA NEUROCHIR, V123, P92, DOI 10.1007/BF01476292
   Kanpolat Y, 2009, NEUROSURGERY, V64, PS187, DOI 10.1227/01.NEU.0000335645.67282.03
   Lordon Stephen P, 2002, CURR PAIN HEADACHE REP, V6, P202, DOI 10.1007/s11916-002-0036-3
   Nagaro T, 2001, J NEUROSURG, V95, P425, DOI 10.3171/jns.2001.95.3.0425
   Raslan AM, 2008, NEUROSURGERY, V63, P226, DOI 10.1227/01.neu.0000317397.16089.f5
   Raslan AM, 2011, J NEUROSURG, V114, P155, DOI 10.3171/2010.6.JNS10119
   Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233
   Vayne-Bossert P, 2016, SUPPORT CARE CANCER, V24, P1429, DOI 10.1007/s00520-015-3047-4
   Zhang J, 2009, J X-RAY SCI TECHNOL, V17, P305, DOI 10.3233/XST-2009-0231
NR 17
TC 17
Z9 17
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1011-6125
EI 1423-0372
J9 STEREOT FUNCT NEUROS
JI Stereotact. Funct. Neurosurg.
PD JUN 15
PY 2017
VL 95
IS 6
BP 409
EP 416
DI 10.1159/000484614
PG 8
WC Neurosciences; Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA FX6TQ
UT WOS:000426220600007
PM 29316547
DA 2026-01-16
ER

PT J
AU Xia, B
   Xie, Y
   Hu, S
   Xu, T
   Tong, P
AF Xia, Bingjiang
   Xie, Yiping
   Hu, Songfeng
   Xu, Taotao
   Tong, Peijian
TI Effect of Auricular Point Acupressure on Axial Neck Pain After Anterior Cervical
SO Pain medicine (Malden, Mass.)
LA English
DT Journal Article
DE Anterior Cervical Discectomy and Fusion; Auricular Point Acupressure; Axial Neck Pain
AB OBJECTIVES: To evaluate the effect of auricular point acupressure (APA) on axial  neck pain after anterior cervical discectomy and fusion (ACDF) surgery. DESIGN: A  prospective randomized controlled trial was performed. SUBJECTS AND SETTING:  Twenty-nine participants were randomly divided into two groups, real or sham APA.  Participants were enrolled from Shaoxing Hospital of Traditional Chinese  Medicine, affiliated with Zhejiang Chinese Medical University. METHODS: Eligible  participants received a four-week real or sham APA treatment according to their  assigned groups. The clinical outcomes were assessed by the criteria of Hosono et  al., the Brief Pain Inventory Short Form (BPI), and the 36-item Short Form Health  Survey (SF-36). In addition, plasma interleukin (IL)-1β, IL-6, and tumor necrosis  factor (TNF)-α were analyzed. RESULTS: Patients with severe or moderate axial  neck pain accounted for 28.6% and 35.7% in the real APA group at the end of  treatment and one-month follow-up. BPI scores were decreased in the real APA  group at the end of treatment and one-month follow-up. The total mean score of  SF-36 was improved in the real APA group and significantly higher than in the  sham APA group. Additional, the levels of IL-1β, IL-6, and TNF-α were decreased  in the real APA group. CONCLUSIONS: The findings supported the therapeutic effect  of APA treatment on axial neck pain after ACDF surgery, and they exert the  possible therapeutic effect on downregulating the levels of plasma IL-1β, IL-6,  and TNF-α.
C1 Shaoxing Hospital of Traditional Chinese Medicine (TCM), affiliated with Zhejiang Chinese Medical University, Shaoxing, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
   Research Department of Spine and Joint in Shaoxing, Shaoxing, Zhejiang, China.
   Shangyu Hospital of TCM, Shaoxing, Zhejiang, China.
   Shaoxing Hospital of Traditional Chinese Medicine (TCM), affiliated with Zhejiang Chinese Medical University, Shaoxing, Zhejiang, China.
   Research Department of Spine and Joint in Shaoxing, Shaoxing, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
NR 0
TC 0
SN 1526-463
EI 
J9 Pain Med
PD MAY 16
PY 2017
VL 19
IS 1
BP 193
EP 201
DI 10.1093/pm/pnx112
PG 8
WC Acupressure; methods; Adult; Aged; Cervical Vertebrae; Diskectomy; adverse effects; Female; Humans; Male; Middle Aged; Neck Pain; therapy; Pain, Postoperative; therapy; Patient Satisfaction; Spinal Fusion; adverse effects; Treatment Outcome
UT PubMed:28505292
PM 28505292
DA 2017-05-16
ER

PT J
AU Eccleston, C
   Fisher, E
   Thomas, KH
   Hearn, L
   Derry, S
   Stannard, C
   Knaggs, R
   Moore, RA
AF Eccleston, Christopher
   Fisher, Emma
   Thomas, Kyla H.
   Hearn, Leslie
   Derry, Sheena
   Stannard, Cathy
   Knaggs, Roger
   Moore, R. Andrew
TI Interventions for the reduction of prescribed opioid use in chronic non-cancer pain
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Analgesics, Opioid [*administration & dosage]; Chronic Pain [drug therapy; etiology; *therapy]; Cognitive Therapy [*methods]; Drug Tolerance; Electroacupuncture [*methods]; Observational Studies as Topic; Randomized Controlled Trials as Topic; Therapy, Computer-Assisted [methods]; Humans
ID low-back-pain; treatment outcm; extended-release; analgesic medication; united-states; older-adults; double-blind; efficacy; rehabilitation; withdrawal
AB Background This is the first update of the original Cochrane Review published in 2013. The conclusions of this review have not changed from the 2013 publication. People with chronic non-cancer pain who are prescribed and are taking opioids can have a history of long-term, high-dose opioid use without effective pain relief. In those without good pain relief, reduction of prescribed opioid dose may be the desired and shared goal of both patient and clinician. Simple, unsupervised reduction of opioid use is clinically challenging, and very difficult to achieve and maintain. Objectives To investigate the effectiveness of different methods designed to achieve reduction or cessation of prescribed opioid use for the management of chronic non-cancer pain in adults compared to controls. Search methods For this update we searched CENTRAL, MEDLINE, and Embase in January 2017, as well as bibliographies and citation searches of included studies. We also searched one trial registry for ongoing trials. Selection criteria Included studies had to be randomised controlled trials comparing opioid users receiving an intervention with a control group receiving treatment as usual, active control, or placebo. The aim of the study had to include a treatment goal of dose reduction or cessation of opioid medication. Data collection and analysis Two review authors independently extracted data and assessed risk of bias. We sought data relating to prescribed opioid use, adverse events of opioid reduction, pain, and psychological and physical function. We planned to assess the certainty of the evidence using the GRADE approach, however, due to the heterogeneity of studies, we were unable to combine outcomes in a meta-analysis and therefore we did not assess the evidence with GRADE. Main results Three studies are new to this update, resulting in five included studies in total (278 participants). Participants were primarily women (mean age 49.63 years, SD = 11.74) with different chronic pain conditions. We judged the studies too heterogeneous to pool data in a meta-analysis, so we have summarised the results from each study qualitatively. The studies included acupuncture, mindfulness, and cognitive behavioral therapy interventions aimed at reducing opioid consumption, misuse of opioids, or maintenance of chronic pain management treatments. We found mixed results from the studies. Three of the five studies reported opioid consumption at posttreatment and follow-up. Two studies that delivered 'Mindfulness-Oriented Recovery Enhancement' or 'Therapeutic Interactive Voice Response' found a significant difference between groups at post-treatment and follow-up in opioid consumption. The remaining study found reduction in opioid consumption in both treatment and control groups, and between-group differences were not significant. Three studies reported adverse events related to the study and two studies did not have study-related adverse events. We also found mixed findings for pain intensity and physical functioning. The interventions did not show between-group differences for psychological functioning across all studies. Overall, the risk of bias was mixed across studies. All studies included sample sizes of fewer than 100 and so we judged all studies as high risk of bias for that category. Authors' conclusions There is no evidence for the efficacy or safety of methods for reducing prescribed opioid use in chronic pain. There is a small number of randomised controlled trials investigating opioid reduction, which means our conclusions are limited regarding the benefit of psychological, pharmacological, or other types of interventions for people with chronic pain trying to reduce their opioid consumption. The findings to date are mixed: there were reductions in opioid consumption after intervention, and often in control groups too.
C1 [Eccleston, Christopher] Univ Bath, Ctr Pain Res, Bath, Avon, England.
   [Fisher, Emma] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA.
   [Thomas, Kyla H.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
   [Hearn, Leslie; Derry, Sheena; Moore, R. Andrew] Univ Oxford, Pain Res, Nuffield Div Anaesthet, Oxford, England.
   [Hearn, Leslie; Derry, Sheena; Moore, R. Andrew] Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Div Anaesthet, Oxford, England.
   [Stannard, Cathy] Frenchay Hosp, Macmillan Ctr, Pain Clin, Bristol, Avon, England.
   [Knaggs, Roger] Univ Nottingham, Sch Pharm, Nottingham, England.
C3 University of Bath; Seattle Children's Hospital; University of Bristol; University of Oxford; University of Oxford; University of Nottingham
RP Eccleston, C (corresponding author), Univ Bath, Ctr Pain Res, Bath, Avon, England.
EM papas@bath.ac.uk
FU Oxford Pain Relief Trust, UK; Academy of Medical Sciences (AMS) [AMS-SGCL12-Thomas] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/G012067/1] Funding Source: researchfish; National Institute for Health Research [CL-2013-25-003, 13/89/29] Funding Source: researchfish; EPSRC [EP/G012067/1] Funding Source: UKRI
CR Amato L, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005031.pub4
   Unknown -, 2019, OP THER GUID ADH REP, V0, P0
   Atluri S, 2012, PAIN PHYSICIAN, V15, P0
   Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411
   Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Braden JB, 2010, ARCH INTERN MED, V170, P1425, DOI 10.1001/archinternmed.2010.273
   Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559
   Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008
   Crisostomo RA, 2008, AM J PHYS MED REHAB, V87, P527, DOI 10.1097/PHM.0b013e31817c124f
   Darchuk KM, 2010, PAIN MED, V11, P1352, DOI 10.1111/j.1526-4637.2010.00937.x
   Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464
   Franklin GM, 2012, AM J IND MED, V55, P325, DOI 10.1002/ajim.21998
   Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528
   Gallagher AM, 2009, CLIN THER, V31, P1707, DOI 10.1016/j.clinthera.2009.08.022
   Garland EL, 2014, J CONSULT CLIN PSYCH, V82, P448, DOI 10.1037/a0035798
   Gowing L, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002022.pub3
   Gowing L, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002021.pub3
   Guy GP Jr, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4
   Hale ME, 2007, J PAIN, V8, P175, DOI 10.1016/j.jpain.2006.09.011
   Higgins JP, 2011, COCHRANE HDB SYSTEMA, V0, P0, DOI DOI 10.1007/S12119-019-09598-3
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hooten WM, 2007, PAIN MED, V8, P8, DOI 10.1111/j.1526-4637.2007.00253.x
   Hooten WM, 2009, ANESTH ANALG, V108, P308, DOI 10.1213/ane.0b013e31818c7b99
   Jamison RN, 2010, PAIN, V150, P390, DOI 10.1016/j.pain.2010.02.033
   Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019
   Krymchantowski AV, 2003, CEPHALALGIA, V23, P982, DOI 10.1046/j.1468-2982.2003.00648.x
   Manchikanti L, 2012, PAIN PHYSICIAN, V15, P0
   Miller M, 2011, J AM GERIATR SOC, V59, P430, DOI 10.1111/j.1532-5415.2011.03318.x
   Moore RA, 2012, PAIN, V153, P265, DOI 10.1016/j.pain.2011.10.004
   Moore RA, 2005, ARTHRITIS RES THER, V7, PR1046, DOI 10.1186/ar1782
   Moore RA, 2014, PAIN PRACT, V14, P79, DOI 10.1111/papr.12050
   Morasco BJ, 2010, PAIN, V151, P625, DOI 10.1016/j.pain.2010.08.002
   Naylor MR, 2008, PAIN, V134, P335, DOI 10.1016/j.pain.2007.11.001
   Naylor MR, 2010, J PAIN, V11, P1410, DOI 10.1016/j.jpain.2010.03.019
   Noble M, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006605.pub2
   Paulozzi Leonard J, 2011, MORBIDITY AND MORTALITY WEEKLY REPORT, V60, P1487
   Potter JS, 2010, J SUBST ABUSE TREAT, V38, PS80, DOI 10.1016/j.jsat.2009.12.007
   Roland CL, 2011, POSTGRAD MED, V123, P148, DOI 10.3810/pgm.2011.07.2314
   Siegfried N, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003362.pub2
   Solomon DH, 2010, ARCH INTERN MED, V170, P1968, DOI 10.1001/archinternmed.2010.391
   Stannard C, 2012, BRIT J PAIN, V6, P7, DOI 10.1177/2049463712439131
   Steiner DJ, 2011, J PAIN SYMPTOM MANAG, V42, P903, DOI 10.1016/j.jpainsymman.2011.04.006
   Sullivan MD, 2017, J PAIN, V18, P308, DOI 10.1016/j.jpain.2016.11.003
   Sullivan MD, 2010, PAIN, V150, P332, DOI 10.1016/j.pain.2010.05.020
   Townsend CO, 2008, PAIN, V140, P177, DOI 10.1016/j.pain.2008.08.005
   Weinstein SM, 2006, CLIN THER, V28, P86, DOI 10.1016/j.clinthera.2006.01.010
   Windmill J, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010323.pub2
   Zheng Z, 2008, EUR J PAIN, V12, P671, DOI 10.1016/j.ejpain.2007.10.003
NR 56
TC 122
Z9 131
U1 1
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PD JUN 15
PY 2017
VL 0
IS 11
BP 
EP 
DI 10.1002/14651858.CD010323.pub3
PG 35
WC Medicine, General & Internal
SC General & Internal Medicine
GA FO6NV
UT WOS:000416982300065
PM 29130474
DA 2026-01-16
ER

PT J
AU Lam, TY
   Lu, LM
   Ling, WM
   Lin, LZ
AF Lam, To-Yi
   Lu, Li-Ming
   Ling, Wai-Man
   Lin, Li-Zhu
TI A pilot randomized controlled trial of acupuncture at the Si Guan Xue for cancer
SO BMC complementary and alternative medicine
LA English
DT Journal Article
DE Acupuncture; Cancer pain; Randomized controlled trial; Si guan Xue
AB BACKGROUND: Pain is a common symptom in cancer patients. Acupuncture is a  suggested treatment for a wide range of clinical conditions, usually for its  beneficial effects on pain control. Si guan xue (the four points) have been  widely used in clinical practice, and has shown that it is highly effective,  effective in obtaining qi, shows strong acupuncture stimulation, and is simple to  manipulate and safe to use. Therefore, the aim of this study is to test the  protocol and safety of acupuncture at the si guan xue in the management of cancer  pain. METHODS: This is a single-blind, randomized controlled pilot trial. 42  patients with moderate to severe cancer pain were randomly assigned to three  different arms with seven sessions of treatment; that is, treatment arm 1 (the si  guan xue arm, n = 14), treatment arm 2 (the si guan xue plus commonly used  acupoints arm, n = 14) and the control arm (the commonly used acupoints arm  n = 14). Primary outcomes included acupuncture relieving cancer pain, and  patients' subjective improvement as measured by the Patient Global Impression of  Change (PGIC). Secondary outcomes included the scores of the European  Organization for Research and Treatment of Cancer Quality of Life  Questionnaire-Core 30 (EORTC QLQ-C30) and Karnofsky's Performance Status (KPS).  RESULTS: The analysis showed that the cancer pain reduction in treatment arm 2  was most prominent on day 5 when compared with the control arm (P<0.05). There  was no difference in the scores of PGIC, EORTC QLQ-C30 or KPS among the three  groups (P>0.05). Furthermore, no serious adverse events were observed.  CONCLUSIONS: These results indicate that acupuncture at the si guan xue plus  commonly used acupoints tends to be effective in reducing cancer pain. However,  the sample size was small, and a future multi-centre study with a larger sample  size is warranted. TRIAL REGISTRATION: ChiCTR-IOR-15007471 (Retroactively  registered on 28 NOV 2015).
C1 Department of Oncology, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
   The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
   Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Road, Chai Wan, Hong Kong.
   Department of Oncology, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. lizhulin903@139.com.
NR 0
TC 0
SN 1472-688
EI 
J9 BMC Complement Altern Med
PD JUN 28
PY 2017
VL 17
IS 1
BP 335
EP 335
DI 10.1186/s12906-017-1838-5
PG 0
WC Acupuncture Analgesia; Acupuncture Points; Acupuncture Therapy; Adult; Aged; Aged, 80 and over; Cancer Pain; therapy; Female; Humans; Male; Middle Aged; Pilot Projects; Single-Blind Method; Treatment Outcome
UT PubMed:28651642
PM 28651642
DA 2017-06-28
ER

PT J
AU Mohanty, S
   Shrestha, RL
AF Mohanty, Sriloy
   Shrestha, Rabin Lal
TI Effect of Electroacupuncture Rehabilitation in Transverse Myelitis: A Case
SO Journal of acupuncture and meridian studies
LA English
DT Journal Article
DE acupuncture; rehabilitation; transverse myelitis; yoga
AB A 32-year-old male diagnosed with transverse myelitis in 2013 came to our clinic  in 2015 with complaints of paraplegia, sensory disturbances, pain, exertional  dyspnea, poor quality of sleep, emotional instability, and depression. This was a  recurrent attack that had been exacerbated by post-traumatic stress. Owing to  pain and functional disabilities, he was struggling to actively participate in  the treatment modalities offered at our center. A modified protocol of  electroacupuncture was planned for a period of 21 days, every day, with each  session lasting for 30 minutes. Assessments based on the brief version of World  Health Organization Brief Quality of Life (WHO Brief QOL) questionnaire,  Pittsburgh sleep quality index, visual analog scale, and a disease-specific  physical examination showed momentous improvement in functional health status as  well as mental well-being. The quality of life showed significant improvement  particularly in the physical and psychological dimensions of WHO Brief QOL. The  patient reported a reduction in pain, dyspnea, and fatigue accompanied by an  improvement in the quality of sleep and mood. This case report suggests that  acupuncture can play a vital role in amelioration of symptoms, thereby improving  the health status in patients with transverse myelitis.
C1 Division of Yoga and Life Sciences, Swami Vivekananda Yoga Anusandhana Samsthana, Bengaluru, Karnataka, India. 
   SDM College of Naturopathy and Yogic Sciences, Ujire, Karnataka, India.
EM sriloy21@gmail.com
NR 0
TC 0
SN 2093-815
EI 
J9 J Acupunct Meridian Stud
PD SEP 12
PY 2017
VL 10
IS 4
BP 286
EP 289
DI 10.1016/j.jams.2017.06.005
PG 3
WC Adult; Electroacupuncture; Heart Rate; Humans; Male; Myelitis, Transverse; rehabilitation; Yoga
UT PubMed:28889845
PM 28889845
DA 2017-09-12
ER

PT J
AU Sarradon-Eck, A
   Bouhnik, AD
   Rey, D
   Bendiane, MK
   Huiart, L
   Peretti-Watel, P
AF Sarradon-Eck, Aline
   Bouhnik, Anne-Deborah
   Rey, Dominique
   Bendiane, Marc-Karim
   Huiart, Laetitia
   Peretti-Watel, Patrick
TI Use of non-conventional medicine two years after cancer diagnosis in France: evidence from the VICAN survey
SO JOURNAL OF CANCER SURVIVORSHIP
LA English
DT Article
DE Complementary and alternative medicine; Integrative medicine; Cancer survivors; Cohort study; Coping; France
ID quality-of-life; alternative medicine; breast-cancer; complementary/alternative medicine; united-states; health-care; therapy use; long-term; women; prevalence
AB The purpose of this study was to assess the use of non-conventional medicine (NCM) in a representative sample of French patients 2 years after cancer diagnosis. The study was based on data obtained in the VICAN survey (2012) on a representative sample of 4349 patients 2 years after cancer diagnosis. Self-reported data were collected at telephone interviews with patients. The questionnaire addressed the various types of non-conventional treatments used at the time of the survey. Among the participants, 16.4% reported that they used NCM, and 45.3% of this group had not used NCM before cancer diagnosis (new NCM users). Commonly, NCMs used were homeopathy (64.0%), acupuncture (22.1%), osteopathy (15.1%), herbal medicine (8.1%), diets (7.3%) and energy therapies (5.8%). NCM use was found to be significantly associated with younger age, female gender and a higher education level. Previous NCM use was significantly associated with having a managerial occupation and an expected 5-year survival rate ae<yen>80% at diagnosis; recent NCM use was associated with cancer progression since diagnosis, impaired quality of life and higher pain reports. This is the first study on NCM use 2 years after cancer diagnosis in France. In nearly half of the NCM users, cancer diagnosis was one of the main factors which incited patients to use NCM. Apart from the NCM users' socioeconomic profile, the present results show that impaired health was a decisive factor: opting for unconventional approaches was therefore a pragmatic response to needs which conventional medicine fails to meet during the course of the disease. Better information of patients and caregivers is needed to allow access to these therapies to a larger population of survivors.
C1 [Sarradon-Eck, Aline; Bouhnik, Anne-Deborah; Rey, Dominique; Bendiane, Marc-Karim; Huiart, Laetitia; Peretti-Watel, Patrick] Aix Marseille Univ, INSERM, IRD, SESSTIM,Econ & Social Sci Appl Hlth & Anal Med In, Marseille, France.
   [Sarradon-Eck, Aline] SESSTIM, Inst Paoli Calmettes, Marseille, France.
   [Rey, Dominique; Bendiane, Marc-Karim; Peretti-Watel, Patrick] ORS PACA, Southeastern Hlth Reg Observ, Marseille, France.
   [Huiart, Laetitia] CHU Reunion, Unite Soutien Methodol, St Denis, Reunion, France.
   [Huiart, Laetitia] CHU Reunion, INSERM, CIC 1410, St Pierre, Reunion, France.
C3 Aix-Marseille Universite; Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Aix-Marseille Universite; CHU Reunion; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Reunion
RP Sarradon-Eck, A (corresponding author), Aix Marseille Univ, INSERM, IRD, SESSTIM,Econ & Social Sci Appl Hlth & Anal Med In, Marseille, France.; Sarradon-Eck, A (corresponding author), SESSTIM, Inst Paoli Calmettes, Marseille, France.
EM aline.sarradon@inserm.fr
FU National Institute of Cancer (INCa) [05-2011]
CR Adler SR, 1999, MED ANTHROPOL Q, V13, P214, DOI 10.1525/maq.1999.13.2.214
   Unknown -, 2015, TRENDS USE COMPLEMEN, V0, P0
   Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Baider L, 2003, CRIT REV ONCOL HEMAT, V46, P5, DOI 10.1016/S1040-8428(02)00134-8
   Balneaves LG, 2007, SUPPORT CARE CANCER, V15, P973, DOI 10.1007/s00520-007-0282-3
   Bartmann JA, 1996, J APPL GERONTOL, V15, P376, DOI 10.1177/073346489601500307
   Baum M, 2006, EUR J CANCER, V42, P1711, DOI 10.1016/j.ejca.2006.02.019
   Bauml J, 2014, SUPPORT CARE CANCER, V22, P2465, DOI 10.1007/s00520-014-2220-5
   Bauml JM, 2015, CANCER-AM CANCER SOC, V121, P2431, DOI 10.1002/cncr.29173
   Begot, 2010, MED PARALLELES CANC, V0, P0
   Boon H, 2000, J CLIN ONCOL, V18, P2515, DOI 10.1200/JCO.2000.18.13.2515
   Bouhassira D, 2005, PAIN, V114, P29, DOI 10.1016/j.pain.2004.12.010
   Bouhnik AD, 2006, JAIDS-J ACQ IMM DEF, V42, P597, DOI 10.1097/01.qai.0000221674.76327.d7
   Bouhnik AD, 2015, BMJ OPEN, V5, P0, DOI 10.1136/bmjopen-2014-005971
   Burdine JN, 2000, HEALTH SERV RES, V35, P885
   Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206
   Bury M, 1982, SOCIOL HEALTH ILLN, V4, P167, DOI 10.1111/1467-9566.ep11339939
   Carlsson M, 2001, CANCER NURS, V24, P395, DOI 10.1097/00002820-200110000-00012
   CASSILETH BR, 1986, CANCER INVEST, V4, P591, DOI 10.3109/07357908609039837
   Chan JM, 2005, UROLOGY, V66, P1223, DOI 10.1016/j.urology.2005.06.003
   Chrystal K, 2003, NZ MED J, V116, P1168
   Cohen P, 2016, CANC PLURALISME THER, V0, P0
   Crocetti E, 1998, EUR J CANCER, V34, P324, DOI 10.1016/S0959-8049(97)10043-0
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Edwards GV, 2014, ASIA-PAC J CLIN ONCO, V10, P346, DOI 10.1111/ajco.12203
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Elziere P, 1986, SCI SOC SANTE, V4, P39, DOI 10.3406/sosan.1986.1033
   Ernst E, 2000, B WORLD HEALTH ORGAN, V78, P252
   Ganz PA, 2002, JNCI-J NATL CANCER I, V94, P39
   Gözüm S, 2003, CANCER NURS, V26, P230
   Groenvold M, 1997, J CLIN EPIDEMIOL, V50, P441, DOI 10.1016/S0895-4356(96)00428-3
   HACK TF, 1994, SOC SCI MED, V39, P279, DOI 10.1016/0277-9536(94)90336-0
   HOLLAND JC, 1982, CA-CANCER J CLIN, V32, P10, DOI 10.3322/canjclin.32.1.10
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Horner MJ, 2009, SEER CANC STAT REV, V1975-2006, P0
   Huiart L, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0081677
   Hunter D, 2014, SUPPORT CARE CANCER, V22, P1571, DOI 10.1007/s00520-014-2120-8
   Hyodo I, 2005, J CLIN ONCOL, V23, P2645, DOI 10.1200/JCO.2005.04.126
   Kelner M, 1997, SOC SCI MED, V45, P203, DOI 10.1016/S0277-9536(96)00334-6
   Kersnik J, 2000, SCHWEIZ MED WSCHR, V130, P390
   Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011
   Kim SG, 2007, J CLIN ONCOL, V25, P5267, DOI 10.1200/JCO.2007.11.9651
   Lanoe JL, 2005, ETUDES RESULTATS, V436, P1
   Laplantine F, 1987, LES MEDECINES PARALLELES, V0, P0
   Le Corroller-Soriano AG, 2011, EUR J CANCER CARE, V20, P132, DOI 10.1111/j.1365-2354.2009.01160.x
   Lee MM, 2000, JNCI-J NATL CANCER I, V92, P42, DOI 10.1093/jnci/92.1.42
   Maskarinec G, 2001, CANCER PRACT, V9, P183, DOI 10.1046/j.1523-5394.2001.94006.x
   McGregor KJ, 1996, SOC SCI MED, V43, P1317, DOI 10.1016/0277-9536(95)00405-X
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Montbriand MJ, 1998, CANCER NURS, V21, P36, DOI 10.1097/00002820-199802000-00005
   Morris KT, 2000, AM J SURG, V179, P407, DOI 10.1016/S0002-9610(00)00358-5
   *NAT CTR COMPL ALT, 2000, EXP HOR HEALTHC 5 YE, V0, P0
   Navo MA, 2004, J CLIN ONCOL, V22, P671, DOI 10.1200/JCO.2004.04.162
   Pedersen CG, 2009, EUR J CANCER, V45, P3172, DOI 10.1016/j.ejca.2009.09.005
   Portenoy R, 2006, CURR MED RES OPIN, V22, P1555, DOI 10.1185/030079906X115702
   Préau M, 2007, AIDS, V21, PS19, DOI 10.1097/01.aids.0000255081.24105.d7
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6
   Simon L, 2007, B CANCER, V94, P483
   Smith PJ, 2014, ASIA-PAC J CLIN ONCO, V10, P1, DOI 10.1111/ajco.12115
   Söllner W, 2000, CANCER-AM CANCER SOC, V89, P873, DOI 10.1002/1097-0142(20000815)89:4<873::AID-CNCR21>3.0.CO;2-K
   Thomas-Schoemann A, 2011, B CANCER, V98, P645, DOI 10.1684/bdc.2011.1375
   Träger-Maury S, 2007, B CANCER, V94, P1017
   Truant T, 1999, PATIENT EDUC COUNS, V38, P131, DOI 10.1016/S0738-3991(99)00060-9
   Tuppin P, 2010, REV EPIDEMIOL SANTE, V58, P286, DOI 10.1016/j.respe.2010.04.005
   Vincent C, 1996, BRIT J CLIN PSYCHOL, V35, P37, DOI 10.1111/j.2044-8260.1996.tb01160.x
   YATES PM, 1993, SOCIOL HEALTH ILL, V15, P199, DOI 10.1111/1467-9566.ep11346886
   Zaloznik A J, 1994, CANCER PRACT, V2, P19
NR 69
TC 13
Z9 13
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1932-2259
EI 1932-2267
J9 J CANCER SURVIV
JI J. Cancer Surviv.-Res. Pract.
PD AUG 15
PY 2017
VL 11
IS 4
BP 421
EP 430
DI 10.1007/s11764-017-0599-y
PG 10
WC Oncology; Social Sciences, Biomedical
SC Oncology; Biomedical Social Sciences
GA FA0EM
UT WOS:000405104100001
PM 28150122
DA 2026-01-16
ER

PT J
AU Shalom-Sharabi, I
   Samuels, N
   Lavie, O
   Lev, E
   Keinan-Boker, L
   Schiff, E
   Ben-Arye, E
AF Shalom-Sharabi, Ilanit
   Samuels, Noah
   Lavie, Ofer
   Lev, Efraim
   Keinan-Boker, Lital
   Schiff, Elad
   Ben-Arye, Eran
TI Effect of a patient-tailored integrative medicine program on gastro-intestinal concerns and quality of life in patients with breast and gynecologic cancer
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Integrative medicine; Breast cancer; Complementary medicine; Chemotherapy; Quality of life; Supportive care
ID randomized controlled-trial; complementary medicine; induced nausea; oncology; chemotherapy; acupuncture; outcm; israel; care; prevention
AB This study was conducted to assess the impact of a patient-tailored complementary/integrative medicine (CIM) program on gastro-intestinal (GI) symptoms and other concerns in female patients with breast/gynecological cancer undergoing chemotherapy. Patients with breast/gynecological cancer reporting GI-related concerns were referred to an integrative physician (IP) consultation. The treatment group included patients agreeing to attend the consultation; controls those who did not. The Edmonton Symptom Assessment Scale (ESAS) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) were administered at baseline and at 6 weeks. Adherence to integrative care (AIC) was defined as attending 4 CIM treatments, with 30 days between each session. Of 496 patients approached, 289 reported GI-related concerns. Optimal assessment at baseline and 6 weeks was achieved in 117 patients in the treatment arm, with 86 adhering to the CIM program (AIC subgroup); and in 89 of controls. EORTC scores improved more significantly in the treatment arm for appetite (P = 0.018), fatigue (P = 0.026), cognitive functioning (P < 0.001) and emotional functioning (P = 0.002); and ESAS scores for pain (P = 0.038), anxiety (P = 0.016), and sleep (P = 0.001). EORTC scores improved more significantly in the AIC group for global health status/QOL (P = 0.041), physical functioning (P = 0.004), role functioning (P = 0.011), appetite (P = 0.019), and fatigue (P = 0.001); and ESAS scores for pain (P = 0.048), fatigue (P = 0.011), drowsiness (P = 0.035), and appetite (P = 0.002). The integration of CIM may improve chemotherapy-related GI and other QOL-related concerns in patients with breast and gynecological cancer, with greater benefit observed in adherent patients.
C1 [Shalom-Sharabi, Ilanit; Samuels, Noah; Ben-Arye, Eran] Clalit Hlth Serv, Oncol Serv, Integrat Oncol Program, Haifa, Israel.
   [Shalom-Sharabi, Ilanit; Samuels, Noah; Ben-Arye, Eran] Clalit Hlth Serv, Lin Med Ctr, Haifa, Israel.
   [Samuels, Noah] Sheba Med Ctr, Inst Oncol, Tal Ctr Integrat Oncol, Tel Hashomer, Israel.
   [Lavie, Ofer] Carmel Hosp, Dept Obstet & Gynecol, Gynecol Oncol Serv, Haifa, Israel.
   [Lev, Efraim] Univ Haifa, Dept Eretz Israel Studies, Haifa, Israel.
   [Keinan-Boker, Lital] Univ Haifa, Sch Publ Hlth, Fac Social Welf & Hlth Sci, Haifa, Israel.
   [Keinan-Boker, Lital] Israel Minist Hlth, Israel Ctr Dis Control, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Dept Internal Med, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Integrat Med Serv, Haifa, Israel.
   [Ben-Arye, Eran] Technion Israel Inst Technol, Dept Family Med, Fac Med, Complementary & Tradit Med Unit, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Haifa, Israel.
C3 Clalit Health Services; Clalit Health Services; Chaim Sheba Medical Center; Tel Aviv University; Clalit Health Services; Carmel Medical Center; University of Haifa; University of Haifa; Ministry of Health - Israel; Bnai Zion Medical Center; Bnai Zion Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Oncol Serv, Integrat Oncol Program, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Lin Med Ctr, Haifa, Israel.; Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Dept Family Med, Fac Med, Complementary & Tradit Med Unit, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Haifa, Israel.
EM eranben@netvision.net.il
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Ben-Arye E, 2015, CLIN NUTR, V34, P1215, DOI 10.1016/j.clnu.2014.12.011
   Ben-Arye E, 2015, SUPPORT CARE CANCER, V23, P3411, DOI 10.1007/s00520-015-2690-0
   Ben-Arye E, 2015, J PAIN SYMPTOM MANAG, V49, P871, DOI 10.1016/j.jpainsymman.2014.09.014
   Ben-Arye E, 2013, MED ONCOL, V30, P0, DOI 10.1007/s12032-013-0511-1
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Bruera E, 1991, J PALLIAT CARE, V7, P6
   Keshet Y, 2015, PSYCHO-ONCOLOGY, V24, P169, DOI 10.1002/pon.3621
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Minchom A, 2016, EUR J CANCER, V61, P102, DOI 10.1016/j.ejca.2016.03.078
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Oldenmenger WH, 2013, J PAIN SYMPTOM MANAG, V45, P1083, DOI 10.1016/j.jpainsymman.2012.06.007
   Palmer JB, 2015, J CLIN ONCOL, V33, P3162, DOI 10.1200/JCO.2014.59.6049
   Pedersen CG, 2009, EUR J CANCER, V45, P3172, DOI 10.1016/j.ejca.2009.09.005
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Roila F, 2010, ANN ONCOL, V21, Pv232, DOI 10.1093/annonc/mdq194
   Sawada NO, 2010, CANCER NURS, V33, PE21, DOI 10.1097/NCC.0b013e3181d86739
   Sharabi IS, 2016, SUPPORT CARE CANCER, V24, P4345, DOI 10.1007/s00520-016-3274-3
   Weeks LC, 2013, CURR ONCOL, V20, PE289, DOI 10.3747/co.20.1378
   Witt CM, 2015, BREAST CANCER RES TR, V149, P449, DOI 10.1007/s10549-014-3249-3
NR 20
TC 30
Z9 32
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD JUL 15
PY 2017
VL 143
IS 7
BP 1243
EP 1254
DI 10.1007/s00432-017-2368-8
PG 12
WC Oncology
SC Oncology
GA EY8HQ
UT WOS:000404235900014
PM 28247032
DA 2026-01-16
ER

PT J
AU Eccleston, C
   Fisher, E
   Thomas, KH
   Hearn, L
   Derry, S
   Stannard, C
   Knaggs, R
   Moore, RA
AF Eccleston, Christopher
   Fisher, Emma
   Thomas, Kyla H
   Hearn, Leslie
   Derry, Sheena
   Stannard, Cathy
   Knaggs, Roger
   Moore, R Andrew
TI Interventions for the reduction of prescribed opioid use in chronic non-cancer
SO The Cochrane database of systematic reviews
LA English
DT Journal Article
AB BACKGROUND: This is the first update of the original Cochrane Review published in  2013. The conclusions of this review have not changed from the 2013 publication.  People with chronic non-cancer pain who are prescribed and are taking opioids can  have a history of long-term, high-dose opioid use without effective pain relief.  In those without good pain relief, reduction of prescribed opioid dose may be the  desired and shared goal of both patient and clinician. Simple, unsupervised  reduction of opioid use is clinically challenging, and very difficult to achieve  and maintain. OBJECTIVES: To investigate the effectiveness of different methods  designed to achieve reduction or cessation of prescribed opioid use for the  management of chronic non-cancer pain in adults compared to controls. SEARCH  METHODS: For this update we searched CENTRAL, MEDLINE, and Embase in January  2017, as well as bibliographies and citation searches of included studies. We  also searched one trial registry for ongoing trials. SELECTION CRITERIA: Included  studies had to be randomised controlled trials comparing opioid users receiving  an intervention with a control group receiving treatment as usual, active  control, or placebo. The aim of the study had to include a treatment goal of dose  reduction or cessation of opioid medication. DATA COLLECTION AND ANALYSIS: Two  review authors independently extracted data and assessed risk of bias. We sought  data relating to prescribed opioid use, adverse events of opioid reduction, pain,  and psychological and physical function. We planned to assess the certainty of  the evidence using the GRADE approach, however, due to the heterogeneity of  studies, we were unable to combine outcomes in a meta-analysis and therefore we  did not assess the evidence with GRADE. MAIN RESULTS: Three studies are new to  this update, resulting in five included studies in total (278 participants).  Participants were primarily women (mean age 49.63 years, SD = 11.74) with  different chronic pain conditions. We judged the studies too heterogeneous to  pool data in a meta-analysis, so we have summarised the results from each study  qualitatively. The studies included acupuncture, mindfulness, and cognitive  behavioral therapy interventions aimed at reducing opioid consumption, misuse of  opioids, or maintenance of chronic pain management treatments. We found mixed  results from the studies. Three of the five studies reported opioid consumption  at post-treatment and follow-up. Two studies that delivered 'Mindfulness-Oriented  Recovery Enhancement' or 'Therapeutic Interactive Voice Response' found a  significant difference between groups at post-treatment and follow-up in opioid  consumption. The remaining study found reduction in opioid consumption in both  treatment and control groups, and between-group differences were not significant.  Three studies reported adverse events related to the study and two studies did  not have study-related adverse events. We also found mixed findings for pain  intensity and physical functioning. The interventions did not show between-group  differences for psychological functioning across all studies. Overall, the risk  of bias was mixed across studies. All studies included sample sizes of fewer than  100 and so we judged all studies as high risk of bias for that category. AUTHORS'  CONCLUSIONS: There is no evidence for the efficacy or safety of methods for  reducing prescribed opioid use in chronic pain. There is a small number of  randomised controlled trials investigating opioid reduction, which means our  conclusions are limited regarding the benefit of psychological, pharmacological,  or other types of interventions for people with chronic pain trying to reduce  their opioid consumption. The findings to date are mixed: there were reductions  in opioid consumption after intervention, and often in control groups too.
C1 Centre for Pain Research, University of Bath, Claverton Down, Bath, UK.
NR 0
TC 0
SN 1469-493
EI 
J9 Cochrane Database Syst Rev
PD NOV 14
PY 2017
VL 11
IS 11
BP CD010323
EP CD010323
DI 10.1002/14651858.CD010323.pub3
PG 1
WC Analgesics, Opioid; administration & dosage; Chronic Pain; drug therapy; Cognitive Behavioral Therapy; methods; Drug Tolerance; Electroacupuncture; methods; Female; Humans; Male; Middle Aged; Mindfulness; Observational Studies as Topic; Randomized Controlled Trials as Topic; Therapy, Computer-Assisted; methods
UT PubMed:29130474
PM 29130474
DA 2017-11-14
ER

PT J
AU Shi, C
   Liu, Y
   Zhang, W
   Lei, Y
   Lu, C
   Sun, R
   Sun, Y
   Jiang, M
   Gu, X
   Ma, Z
AF Shi, Changxi
   Liu, Yue
   Zhang, Wei
   Lei, Yishan
   Lu, Cui'e
   Sun, Rao
   Sun, Yu'e
   Jiang, Ming
   Gu, Xiaoping
   Ma, Zhengliang
TI Intraoperative electroacupuncture relieves remifentanil-induced postoperative
SO Molecular pain
LA English
DT Journal Article
DE Electroacupuncture; glial cells; mitogen-activated protein kinases; postoperative hyperalgesia; proinflammatory cytokines; remifentanil-induced hyperalgesia
AB Background Accumulating studies have suggested that remifentanil, the widely-used  opioid analgesic in clinical anesthesia, can activate the pronociceptive systems  and enhance postoperative pain. Glial cells are thought to be implicated in  remifentanil-induced hyperalgesia. Electroacupuncture is a complementary therapy  to relieve various pain conditions with few side effects, and glial cells may be  involved in its antinociceptive effect. In this study, we investigated whether  intraoperative electroacupuncture could relieve remifentanil-induced  postoperative hyperalgesia by inhibiting the activation of spinal glial cells,  the production of spinal proinflammatory cytokines, and the activation of spinal  mitogen-activated protein kinases. Methods A rat model of remifentanil-induced  postoperative hyperalgesia was used in this study. Electroacupuncture during  surgery was conducted at bilateral Zusanli (ST36) acupoints. Behavior tests,  including mechanical allodynia and thermal hyperalgesia, were performed at  different time points. Astrocytic marker glial fibrillary acidic protein,  microglial marker Iba1, proinflammatory cytokines, and phosphorylated  mitogen-activated protein kinases in the spinal cord were detected by Western  blot and/or immunofluorescence. Results Mechanical allodynia and thermal  hyperalgesia were induced by both surgical incision and remifentanil infusion,  and remifentanil infusion significantly exaggerated and prolonged  incision-induced pronociceptive effects. Glial fibrillary acidic protein, Iba1,  proinflammatory cytokines (interleukin-1β and tumor necrosis factor-α), and  phosphorylated mitogen-activated protein kinases (p-p38, p-JNK, and p-ERK1/2)  were upregulated after surgical incision, remifentanil infusion, and especially  after their combination. Intraoperative electroacupuncture significantly  attenuated incision- and/or remifentanil-induced pronociceptive effects, spinal  glial activation, proinflammatory cytokine upregulation, and phosphorylated  mitogen-activated protein kinase upregulation. Conclusions Our study suggests  that remifentanil-induced postoperative hyperalgesia can be relieved by  intraoperative electroacupuncture via inhibiting the activation of spinal glial  cells, the upregulation of spinal proinflammatory cytokines, and the activation  of spinal mitogen-activated protein kinases.
C1 1 Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province, China.
   2 Department of Anesthesiology, Jiangsu Province Hospital on Integration of 
   3 Department of Anesthesiology, Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Province, China.
   3 Department of Anesthesiology, Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Province, China.
   3 Department of Anesthesiology, Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Province, China.
   3 Department of Anesthesiology, Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Province, China.
   3 Department of Anesthesiology, Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Province, China.
   3 Department of Anesthesiology, Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Province, China.
   3 Department of Anesthesiology, Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Province, China.
   3 Department of Anesthesiology, Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Province, China.
   3 Department of Anesthesiology, Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Province, China.
NR 0
TC 0
SN 1744-806
EI 
J9 Mol Pain
PD AUG 22
PY 2017
VL 13
IS 
BP 1744806917725636
EP 1744806917725636
DI 10.1177/1744806917725636
PG 1
WC Animals; Biomarkers; metabolism; Calcium-Binding Proteins; metabolism; Cytokines; metabolism; Electroacupuncture; Glial Fibrillary Acidic Protein; metabolism; Hyperalgesia; etiology; Inflammation Mediators; metabolism; Intraoperative Care; Male; Microfilament Proteins; metabolism; Mitogen-Activated Protein Kinases; metabolism; Neuroglia; metabolism; Pain, Postoperative; etiology; Phosphorylation; Piperidines; adverse effects; Rats, Sprague-Dawley; Remifentanil; Spinal Cord; pathology; Spinal Cord Dorsal Horn; metabolism; Up-Regulation
UT PubMed:28825338
PM 28825338
DA 2017-08-22
ER

PT J
AU Li, X
   Wang, R
   Shi, X
   Su, J
   Pan, Y
   Tian, J
   Yang, K
AF Li, Xiuxia
   Wang, Rong
   Shi, Xiue
   Su, Jinlong
   Pan, Yuanqing
   Tian, Jinhui
   Yang, Kehu
TI Reporting Characteristics and Quality of Systematic Reviews of Acupuncture
SO Pain practice : the official journal of World Institute of Pain
LA English
DT Review
DE acupuncture analgesia; characteristics; quality; systematic reviews
AB BACKGROUND: Evaluating the clinical efficacy of acupuncture analgesia with  systematic reviews (SRs) has attracted wide interest. OBJECTIVE: To collect a  sample of published SRs on acupuncture analgesia in PubMed and examine them in  terms of reporting characteristics and quality. METHODS: A search in PubMed was  performed in January 2016. All SRs on acupuncture analgesia were included. To  assess the quality of the SRs, AMSTAR tool and PRISMA Statements were used.  RESULTS: One hundred and nine SRs were included in our analysis, the yearly  number of publications ranging from 1 in 1997 to 15 in 2015. Only 17% of these  publications were Cochrane Systematic Reviews, and 94% were published in Science  Citation Index journals. The United Kingdom was the country with the higher  number of publications. Low back pain, headache, cancer pain, and labor pain were  the most reported diseases or phenotypes. Nearly 73% of these SRs conducted a  meta-analysis, 58% revealed positive results, 53% used RevMan software to analyze  data, and 44% used the Cochrane Risk of Bias Tool for quality assessment. Only a  few SRs assessed the likelihood of publication bias, reported details about the  protocol and the registration information, and performed additional analyses.  CONCLUSIONS: The quantity and the quality of SRs regarding acupuncture analgesia  have been promoted in recent years. More effort should be expended on the  assessment of publication bias, the provision of detailed information about the  protocol and the registration process, and the implementation of additional  analyses to improve the validity of the SRs.
C1 Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
   Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu 
   Gansu University of Chinese Medicine, Lanzhou, China.
   Department of Orthopedics, the General Hospital of PLA, Lanzhou, China.
   Rehabilitation Center Hospital of Gansu Province, Lanzhou, China.
   Pharmaceutical Center, Lanzhou University Second Hospital, Lanzhou, China.
   Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
   Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu 
   Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
   Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu 
   Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
   Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu
NR 0
TC 0
SN 1533-250
EI 
J9 Pain Pract
PD JAN 14
PY 2017
VL 17
IS 8
BP 1066
EP 1074
DI 10.1111/papr.12555
PG 8
WC Acupuncture Analgesia; Humans; PubMed; Publishing; standards; Review Literature as Topic
UT PubMed:28083991
PM 28083991
DA 2017-01-14
ER

PT J
AU Enblom, A
AF Enblom, Anna
TI Patients' and physiotherapists' belief in and use of acupuncture for cancer-related symptoms
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
ID chemotherapy-induced nausea; acustimulation wrist bands; breast-cancer; controlled-trial; hot flashes; acupressure; pain; prevention; electroacupuncture; multicenter
AB Background It is important to investigate attitudes to acupuncture, because therapists' and patients' expectations may affect the treatment outcome. Aim To explore the use of and belief in acupuncture among oncological physiotherapists and to explore patients' interest in receiving acupuncture during cancer therapy and their belief in its effectiveness. Methods 522 patients (80% female, mean age 67 years) reported on their interest in receiving acupuncture for nausea during radiotherapy treatment; a subgroup (n=198) additionally disclosed their belief in the effectiveness of acupuncture. 117 Swedish oncological physiotherapists (96% female, mean age 48 years) answered a questionnaire regarding their use of and belief in acupuncture. Results Of the patients initiating cancer therapy, 359 (69%) were interested in receiving acupuncture. The patients believed acupuncture to be effective for pain (79%), nausea (79%) and vasomotor symptoms (48%). Of the 117 physiotherapists, 66 (56%) practised acupuncture. Physiotherapists generally believed in the effectiveness of acupuncture. For pain, 89% believed that acupuncture was effective and 42% of them practised it. Similar responses were noted for chemotherapy-induced nausea (86% and 38%, respectively) and vasomotor symptoms (80% and 28%, respectively). Younger physiotherapists and patients were more likely to believe in the effectiveness of acupuncture compared with older ones. Conclusions More than two thirds of patients with cancer were interested in receiving acupuncture during therapy. Patients and oncological physiotherapists believed that acupuncture was effective for cancer pain, nausea and vasomotor symptoms. Further studies of acupuncture for cancer-related symptoms and of the effect of patients' and clinicians' therapeutic relationships, including treatment expectations, would be welcome.
C1 [Enblom, Anna] Linkoping Univ, Div Physiotherapy, Dept Med & Hlth Sci, Linkoping, Sweden.
C3 Linkoping University
RP Enblom, A (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, S-58183 Linkoping, Sweden.
EM anna.enblom@liu.se
FU Linkoping University; region of Ostergotland; Osher Center for Integrative Medicine, Karolinska Institute, Sweden
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2010, COCHRANE DATABASE SY, V0, P0
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P1
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   Enblom A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0014766
   Enblom A, 2009, SUPPORT CARE CANCER, V17, P23, DOI 10.1007/s00520-008-0445-x
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Frisk J, 2009, EUR UROL, V55, P156, DOI 10.1016/j.eururo.2008.02.002
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Kim KH, 2016, ACUPUNCT MED, V34, P248, DOI 10.1136/acupmed-2015-010941
   Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Lee I, 2017, ACUPUNCT MED, V35, P0, DOI 10.1136/acupmed-2016-011056
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Lu Weidong, 2005, SEMIN ONCOL NURS, V21, P190, DOI 10.1016/j.soncn.2005.04.008
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   McKeon C, 2015, ACUPUNCT MED, V33, P277, DOI 10.1136/acupmed-2015-010781
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Melchart D, 2006, SUPPORT CARE CANCER, V14, P878, DOI 10.1007/s00520-006-0028-7
   Meng ZQ, 2012, EUR J CANCER, V48, P1692, DOI 10.1016/j.ejca.2011.12.030
   Molassiotis A, 2013, HEALTH TECHNOL ASSES, V17, P0, DOI 10.3310/hta17260
   Norheim AJ, 1998, SOC SCI MED, V47, P519, DOI 10.1016/S0277-9536(98)00152-X
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Roscoe JA, 2005, J PAIN SYMPTOM MANAG, V29, P376, DOI 10.1016/j.jpainsymman.2004.07.007
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Roscoe JA, 2009, J PAIN SYMPTOM MANAG, V38, P381, DOI 10.1016/j.jpainsymman.2008.09.006
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Shen YH, 2015, CANCER-AM CANCER SOC, V121, P84, DOI 10.1002/cncr.28973
   Simcock R, 2013, ANN ONCOL, V24, P776, DOI 10.1093/annonc/mds515
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Xia YS, 2000, INT J CLIN ACUPUNCTU, V11, P145
NR 40
TC 19
Z9 20
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD AUG 15
PY 2017
VL 35
IS 4
BP 251
EP 258
DI 10.1136/acupmed-2015-011007
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA FE0JF
UT WOS:000407905900002
PM 28442462
DA 2026-01-16
ER

PT J
AU Lam, TY
   Lu, LM
   Ling, WM
   Lin, LZ
AF Lam, To-Yi
   Lu, Li-Ming
   Ling, Wai-Man
   Lin, Li-Zhu
TI A pilot randomized controlled trial of acupuncture at the Si Guan Xue for cancer pain
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Acupuncture; Si guan Xue; Cancer pain; Randomized controlled trial
AB Background: Pain is a common symptom in cancer patients. Acupuncture is a suggested treatment for a wide range of clinical conditions, usually for its beneficial effects on pain control. Si guan xue (the four points) have been widely used in clinical practice, and has shown that it is highly effective, effective in obtaining qi, shows strong acupuncture stimulation, and is simple to manipulate and safe to use. Therefore, the aim of this study is to test the protocol and safety of acupuncture at the si guan xue in the management of cancer pain. Methods: This is a single-blind, randomized controlled pilot trial. 42 patients with moderate to severe cancer pain were randomly assigned to three different arms with seven sessions of treatment; that is, treatment arm 1 (the si guan xue arm, n = 14), treatment arm 2 (the si guan xue plus commonly used acupoints arm, n = 14) and the control arm (the commonly used acupoints arm n = 14). Primary outcomes included acupuncture relieving cancer pain, and patients' subjective improvement as measured by the Patient Global Impression of Change (PGIC). Secondary outcomes included the scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Karnofsky's Performance Status (KPS). Results: The analysis showed that the cancer pain reduction in treatment arm 2 was most prominent on day 5 when compared with the control arm (P<0.05). There was no difference in the scores of PGIC, EORTC QLQ-C30 or KPS among the three groups (P>0.05). Furthermore, no serious adverse events were observed. Conclusions: These results indicate that acupuncture at the si guan xue plus commonly used acupoints tends to be effective in reducing cancer pain. However, the sample size was small, and a future multi-centre study with a larger sample size is warranted.
C1 [Lam, To-Yi; Lin, Li-Zhu] Guangzhou Univ Chinese Med, Dept Oncol, Guangzhou 510405, Guangdong, Peoples R China.
   [Lu, Li-Ming] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Guangzhou 510120, Guangdong, Peoples R China.
   [Ling, Wai-Man] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, 3 Lok Man Rd, Chaiwan, Hong Kong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Pamela Youde Nethersole Eastern Hospital
RP Lin, LZ (corresponding author), Guangzhou Univ Chinese Med, Dept Oncol, Guangzhou 510405, Guangdong, Peoples R China.
EM lizhulin903@139.com
CR Unknown -, 2005, CHIN J INTEGRATED TR, V0, P0
   Unknown -, 2000, CHINESE ACUPUNCTURE, V0, P0
   AUNG S, 1994, ACUPUNCT MED, V12, P37
   Bian R, 1995, J CHINESE MED, V36, P277
   Chen Guiping, 1996, CHINESE ACUPUNCTURE, V16, P9
   Chen H, 2008, J YUNNAN CHINESE MED, V29, P12
   Chen X, 1998, HUBEI J CHINESE MED, V5, P59
   Chen Y, 2001, J FUJIAN TRADITIONAL, V32, P12
   Cherny NI, 2000, CA-CANCER J CLIN, V50, P70, DOI 10.3322/canjclin.50.2.70
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Deng L, 1997, SHANXI CHINESE MED, V13, P42
   Dong J, 2010, J HENAN MED COLL, V22, P575
   Dong W, 1999, PRACTICAL J CHINESE, V15, P28
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Follwell M, 2009, J CLIN ONCOL, V27, P206, DOI 10.1200/JCO.2008.17.7568
   Gao XL, 2002, MOD NURS, V8, P588
   Gao Z, 1998, PRACTICAL J CHINESE, V11, P7
   Geng T, 2007, J INNER MONGOLIA TRA, V9, P49
   Geng T, 2007, INNER MONGOLIA TRADI, V9, P49
   JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870
   Jia YJ, 2008, CHINESE MED SHANXI, V29, P1103
   Jing H, 2005, J MED, V25, P34
   Jinhua X, 1999, SHANGHAI J ACUPUNCTU, V18, P21
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Karnofsky DA, 1949, EVALUATION CHEMOTHER, V0, P199
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Li Y, 2009, P INT AC SEM AC PAIN, V5, P355
   Liu Z, 2009, ESSENTIALS CHINESE M, V1, P284
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Ming X, 2006, PRACTICAL J CHINESE, V22, P300
   Mu Rong, 1995, CHINESE J INTEGRATED, V16, P611
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI 10.1371/journal.pmed.1000251
   Wang H, 2000, J HENAN TRADITIONAL, V15, P53
   Wang R, 2004, PHARM CARE RES, V4, P287
   Wu B, 1999, SHANGHAI J ACUPUNCTU, V18, P46
   Yin J, 2010, CULMINATION ACUPUNCT, V7, P47
   Yu D, 1998, CHINESE ACUPUNCTURE, V1, P17
   Zhang W, 2008, EMERGENCY CHINESE ME, V17, P543
NR 42
TC 14
Z9 23
U1 0
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD JUN 26
PY 2017
VL 17
IS 
BP 
EP 
DI 10.1186/s12906-017-1838-5
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA EY6RR
UT WOS:000404111400001
PM 28651642
DA 2026-01-16
ER

PT J
AU Chiu, HY
   Hsieh, YJ
   Tsai, PS
AF Chiu, H. Y.
   Hsieh, Y. J.
   Tsai, P. S.
TI Systematic review and meta-analysis of acupuncture to reduce cancer-related pain
SO EUROPEAN JOURNAL OF CANCER CARE
LA English
DT Review
DE acupuncture; cancer-related pain; meta-analysis
ID quality-of-life; neuropathic pain; controlled-trial; electroacupuncture; management; symptoms; bias; care
AB We conducted a systematic review and meta-analysis to evaluate the effects of acupuncture on malignancy-related, chemotherapy (CT)-or radiation therapy (RT)-induced, surgery-induced, and hormone therapy (HT)induced pain. Randomised controlled trials (RCTs) examining the effects of acupuncture on cancer-related pain were reached from the EMBASE, PubMed, PsycINFO, Cochrane Central Register of Controlled Trials, CINAHL, Airiti library, Taiwan Electrical Periodical Service, Wanfang Data (a Chinese database) and China Knowledge Resource Integrated Database from inception through June 2014. Heterogeneity, moderator analysis, publication bias and risk of bias associated with the included studies were examined. A total of 29 RCTs yielding 36 effect sizes were included. The overall effect of acupuncture on cancer-related pain was -0.45 [95% confidence interval (CI) = -0.63 to -0.26]. The subanalysis indicated that acupuncture relieved malignancy-related and surgery-induced pain [effect size (g) = -0.71, and -0.40; 95% CI = -0.94 to -0.48, and -0.69 to -0.10] but not CT-or RT-induced and HT-induced pain (g = -0.05, and -0.64, 95% CI = -0.33 to 0.24, and -1.55 to 0.27). Acupuncture is effective in relieving cancer-related pain, particularly malignancy-related and surgery-induced pain. Our findings suggest that acupuncture can be adopted as part of a multimodal approach for reducing cancer-related pain.
C1 [Chiu, H. Y.; Hsieh, Y. J.; Tsai, P. S.] Taipei Med Univ, Coll Nursing, Sch Nursing, 250 Wu Hsing St, Taipei 110, Taiwan.
C3 Taipei Medical University
RP Tsai, PS (corresponding author), Taipei Med Univ, Coll Nursing, Sch Nursing, 250 Wu Hsing St, Taipei 110, Taiwan.
EM ptsai@tmu.edu.tw
FU Ministry of Science and Technology, Taiwan [NSC 102-2628-B-038-004-MY3, MOST103-2314-B-038-068-MY2]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2010, LIAONING J TRAD CHINESE MED, V0, P0, DOI DOI 10.13192/J.LJTCM.2010.10.166.MIJP.061
   Unknown -, 2005, CHIN J INTEGRATED TR, V0, P0
   Unknown -, 2000, CHINESE ACUPUNCTURE, V0, P0
   Unknown -, 2000, ACUPUNCT RES, V0, P0
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Borenstein M, 2009, INTRODUCTION TO META-ANALYSIS, V0, P421
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P251
   Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9
   Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fallon MT, 2013, BRIT J ANAESTH, V111, P105, DOI 10.1093/bja/aet208
   Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574
   Grond S, 1996, PAIN, V64, P107, DOI 10.1016/0304-3959(95)00076-3
   Hammerschlag R, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/183910
   He Bi-mei, 2007, ZHONGGUO ZHEN JIU, V27, P369
   2011, 1900, V343, V0, PPD5928, DOI 10.1136/BMJ.D5928
   [Higgins JPTNoyes J Hannes K Booth A Harris J Harden A Popay J Pearson A Cargo M and Pantoja T on, 2015, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, V0, P0
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P149
   Kroenke K, 2010, J PAIN SYMPTOM MANAG, V40, P327, DOI 10.1016/j.jpainsymman.2009.12.023
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   LIN JG, 2012, EVID-BASED COMPL ALT, V2012, P0
   Liu J, 2001, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V21, P262
   Lu WD, 2012, MED ACUPUNCT, V24, P233, DOI 10.1089/acu.2012.0904
   Lundh A, 2008, BMC MED RES METHODOL, V8, P0, DOI 10.1186/1471-2288-8-22
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Nersesyan Hrachya, 2007, THER CLIN RISK MANAG, V3, P381
   Network NCC, 2014, NCCN CLIN PRACT GUID, V0, P0
   Oliveira KG, 2014, BMC CANCER, V14, P0, DOI 10.1186/1471-2407-14-39
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0
   Shekelle PG, 2005, ANN INTERN MED, V142, P1042, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00003
   Silberstein M, 2009, J THEOR BIOL, V261, P637, DOI 10.1016/j.jtbi.2009.09.008
   Song FJ, 2002, INT J EPIDEMIOL, V31, P88, DOI 10.1093/ije/31.1.88
   Vadalouca A, 2012, PAIN PRACT, V12, P219, DOI 10.1111/j.1533-2500.2011.00485.x
   Wilson DB, 2001, PRACTICAL META-ANALYSIS EFFECT SIZE CALCULATOR, V0, P0
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Yu Jian-ming, 2010, ZHEN CI YAN JIU, V35, P43
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou Y, 2007, J ACUPUNCT TUINA SCI, V5, P162, DOI 10.1007/s11726-007-0162-x
NR 64
TC 101
Z9 109
U1 0
U2 47
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-5423
EI 1365-2354
J9 EUR J CANCER CARE
JI Eur. J. Cancer Care
PD MAR 15
PY 2017
VL 26
IS 2
BP 
EP 
DI 10.1111/ecc.12457
PG 17
WC Oncology; Health Care Sciences & Services; Nursing; Rehabilitation
SC Oncology; Health Care Sciences & Services; Nursing; Rehabilitation
GA EO1KP
UT WOS:000396457700019
PM 26853524
DA 2026-01-16
ER

PT J
AU Shi, CX
   Liu, Y
   Zhang, W
   Lei, YS
   Lu, CE
   Sun, R
   Sun, YE
   Jiang, M
   Gu, XP
   Ma, ZL
AF Shi, Changxi
   Liu, Yue
   Zhang, Wei
   Lei, Yishan
   Lu, Cui'e
   Sun, Rao
   Sun, Yu'e
   Jiang, Ming
   Gu, Xiaoping
   Ma, Zhengliang
TI Intraoperative electroacupuncture relieves remifentanil-induced postoperative hyperalgesia via inhibiting spinal glial activation in rats
SO MOLECULAR PAIN
LA English
DT Article
DE Electroacupuncture; postoperative hyperalgesia; remifentanil-induced hyperalgesia; glial cells; proinflammatory cytokines; mitogen-activated protein kinases
ID opioid-induced hyperalgesia; receptor 2b subunit; cancer pain; tyrosine phosphorylation; intrathecal injection; neuropathic pain; model; cord; mechanisms; microglia
AB Background: Accumulating studies have suggested that remifentanil, the widely-used opioid analgesic in clinical anesthesia, can activate the pronociceptive systems and enhance postoperative pain. Glial cells are thought to be implicated in remifentanil-induced hyperalgesia. Electroacupuncture is a complementary therapy to relieve various pain conditions with few side effects, and glial cells may be involved in its antinociceptive effect. In this study, we investigated whether intraoperative electroacupuncture could relieve remifentanil-induced postoperative hyperalgesia by inhibiting the activation of spinal glial cells, the production of spinal proinflammatory cytokines, and the activation of spinal mitogen-activated protein kinases. Methods: A rat model of remifentanil-induced postoperative hyperalgesia was used in this study. Electroacupuncture during surgery was conducted at bilateral Zusanli (ST36) acupoints. Behavior tests, including mechanical allodynia and thermal hyperalgesia, were performed at different time points. Astrocytic marker glial fibrillary acidic protein, microglial marker Iba1, proinflammatory cytokines, and phosphorylated mitogen-activated protein kinases in the spinal cord were detected by Western blot and/or immunofluorescence. Results: Mechanical allodynia and thermal hyperalgesia were induced by both surgical incision and remifentanil infusion, and remifentanil infusion significantly exaggerated and prolonged incision-induced pronociceptive effects. Glial fibrillary acidic protein, Iba1, proinflammatory cytokines (interleukin-1 beta and tumor necrosis factor-alpha), and phosphorylated mitogen-activated protein kinases (p-p38, p-JNK, and p-ERK1/2) were upregulated after surgical incision, remifentanil infusion, and especially after their combination. Intraoperative electroacupuncture significantly attenuated incision- and/or remifentanil-induced pronociceptive effects, spinal glial activation, proinflammatory cytokine upregulation, and phosphorylated mitogen-activated protein kinase upregulation. Conclusions: Our study suggests that remifentanil-induced postoperative hyperalgesia can be relieved by intraoperative electroacupuncture via inhibiting the activation of spinal glial cells, the upregulation of spinal proinflammatory cytokines, and the activation of spinal mitogen-activated protein kinases.
C1 [Shi, Changxi] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, Nanjing, Jiangsu, Peoples R China.
   [Shi, Changxi] Nanjing Univ Chinese Med, Dept Anesthesiol, Jiangsu Prov Hosp Integrat Chinese & Western Med, Nanjing, Jiangsu, Peoples R China.
   [Liu, Yue; Zhang, Wei; Lei, Yishan; Lu, Cui'e; Sun, Rao; Sun, Yu'e; Jiang, Ming; Gu, Xiaoping; Ma, Zhengliang] Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Anesthesiol, Zhongshan Rd 321, Nanjing 210008, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University; Nanjing University of Chinese Medicine; Nanjing University
RP Ma, ZL (corresponding author), Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Anesthesiol, Zhongshan Rd 321, Nanjing 210008, Jiangsu, Peoples R China.
EM mazhengliang1964@nju.edu.cn
FU National Natural Science Foundation of China [81471129, 81671087, 81300950, 81300951, 81371207, 81171048, 81171047]; Department of Health of Jiangsu Province of China [XK201140, RC2011006]
CR Berta T, 2012, MOL PAIN, V8, P0, DOI 10.1186/1744-8069-8-18
   Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1
   Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038
   Cao JL, 2008, PAIN, V139, P617, DOI 10.1016/j.pain.2008.06.023
   Célérier E, 2006, ANESTHESIOLOGY, V104, P546
   Chernyak GV, 2005, ANESTHESIOLOGY, V102, P1031, DOI 10.1097/00000542-200505000-00024
   Clark AK, 2010, J NEUROSCI, V30, P573, DOI 10.1523/JNEUROSCI.3295-09.2010
   Derrode N, 2003, BRIT J ANAESTH, V91, P842, DOI 10.1093/bja/aeg263
   Drdla R, 2009, SCIENCE, V325, P207, DOI 10.1126/science.1171759
   Drdla-Schutting R, 2012, SCIENCE, V335, P235, DOI 10.1126/science.1211726
   Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137
   Grace PM, 2016, P NATL ACAD SCI USA, V113, PE3441, DOI 10.1073/pnas.1602070113
   Gu XP, 2009, MOL PAIN, V5, P0, DOI 10.1186/1744-8069-5-76
   Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161
   Hayashi Y, 2016, NAT COMMUN, V7, P0, DOI 10.1038/ncomms11697
   Heinl C, 2011, J NEUROSCI, V31, P16748, DOI 10.1523/JNEUROSCI.3491-11.2011
   Ishida R, 2012, ANESTH ANALG, V114, P224, DOI 10.1213/ANE.0b013e318237f678
   Ji RR, 2013, PAIN, V154, PS10, DOI 10.1016/j.pain.2013.06.022
   Ji RR, 2010, PAIN, V150, P377, DOI 10.1016/j.pain.2010.06.010
   Jiang M, 2015, PHARMACOL BIOCHEM BE, V134, P35, DOI 10.1016/j.pbb.2015.04.015
   Jo HR, 2011, KOREAN J ANESTHESIOL, V60, P198, DOI 10.4097/kjae.2011.61.2.166
   Johnson JL, 2014, TRANSL PSYCHIAT, V4, P0, DOI 10.1038/tp.2014.121
   Kailasam VK, 2016, NEUROSCI LETT, V624, P29, DOI 10.1016/j.neulet.2016.05.001
   Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008
   Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723
   Kim HNYR, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/643973
   Kim SH, 2015, AM J THER, V22, PE62, DOI 10.1097/MJT.0000000000000019
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Liang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/568273
   Lin JX, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0114948
   Lutz BM, 2015, MOL PAIN, V11, P0, DOI 10.1186/s12990-015-0030-5
   Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149
   Ruan JP, 2010, ANESTHESIOLOGY, V112, P1234, DOI 10.1097/ALN.0b013e3181d3e0df
   Sanna MD, 2015, PAIN, V156, P1265, DOI 10.1097/j.pain.0000000000000164
   Shan S, 2007, NEUROBIOL DIS, V26, P558, DOI 10.1016/j.nbd.2007.02.007
   Sun S, 2008, BRAIN RES BULL, V75, P83, DOI 10.1016/j.brainresbull.2007.07.027
   Sun Y, 2014, ANESTH ANALG, V118, P841, DOI 10.1213/ANE.0000000000000146
   Tang NM, 1997, PAIN, V71, P71, DOI 10.1016/S0304-3959(97)03341-1
   Wang ZY, 2009, FASEB J, V23, P2576, DOI 10.1096/fj.08-128348
   Watkins LR, 2009, TRENDS PHARMACOL SCI, V30, P581, DOI 10.1016/j.tips.2009.08.002
   Watkins LR, 2005, J INTERN MED, V257, P139, DOI 10.1111/j.1365-2796.2004.01443.x
   Wei F, 2008, J NEUROSCI, V28, P10482, DOI 10.1523/JNEUROSCI.3593-08.2008
   Wu LX, 2015, J CLIN ANESTH, V27, P311, DOI 10.1016/j.jclinane.2015.03.020
   Wu S Ly, 2016, EAST ASIAN ARCH PSYCHIATRY, V26, P70
   Xu J, 2016, ANESTH ANALG, V122, P882, DOI 10.1213/ANE.0000000000001097
   Zeng YJ, 2014, EVID-BASED COMPL ALT, V2014, P0
   Zhang LL, 2017, CLIN J PAIN, V33, P435, DOI 10.1097/AJP.0000000000000416
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang RX, 2005, PAIN, V118, P125, DOI 10.1016/j.pain.2005.08.001
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao Q, 2017, CELL MOL NEUROBIOL, V37, P643, DOI 10.1007/s10571-016-0401-0
   Zheng YG, 2012, BRAIN RES BULL, V87, P427, DOI 10.1016/j.brainresbull.2012.01.009
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 53
TC 14
Z9 15
U1 0
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1744-8069
EI 
J9 MOL PAIN
JI Mol. Pain
PD AUG 21
PY 2017
VL 13
IS 
BP 
EP 
DI 10.1177/1744806917725636
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA FE4UG
UT WOS:000408208200001
PM 28825338
DA 2026-01-16
ER

PT J
AU Butkovic, D
   Tot, OK
AF Butkovic, D
   Tot, O K
TI Laser acupuncture treatment of neuropathic pain in a boy with brain tumour.
SO Complementary therapies in medicine
LA English
DT Journal Article
DE Brain tumour; Laser acupuncture; Linezolid; Neuropathic pain; Paediatric
AB Neuropathic pain occurrence is associated with some cytostatic and antibiotics  use. Pharmacological therapy for the treatment of neuropathic pain is sometimes  unsuccessful, and complementary methods like acupuncture are included. In this  case report, a 14-year-old boy with cerebral tumour and neuropathic pain in his  feet after chemotherapy and linezolid use is presented. A complete cessation of  neuropathic pain symptoms like hyperalgesia and allodynia was accomplished after  laser acupuncture application.
C1 University of Osijek Medical School, Croatia
   Children's Hospital Zagreb, Paediatric Pain Clinic, Croatia. 
   University of Osijek Medical School, Croatia
   Clinical Hospital Centre Osijek, Department for Pain Therapy, Croatia.
EM diana.butkovic1@gmail.com
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD NOV 21
PY 2017
VL 35
IS 
BP 53
EP 56
DI 10.1016/j.ctim.2017.09.006
PG 3
WC Acupuncture Therapy; methods; Adolescent; Brain Neoplasms; complications; Humans; Hyperalgesia; therapy; Lasers; Male; Neuralgia; etiology
UT PubMed:29154067
PM 29154067
DA 2017-11-21
ER

PT J
AU Ledford, C
AF Ledford, Christopher
TI Spine Conditions: Mechanical and Inflammatory Low Back Pain.
SO FP essentials
LA English
DT Review
AB Mechanical low back pain (LBP) is an injury or derangement of an anatomic  structure in the low back. When evaluating patients with LBP, clinicians should  maintain clinical suspicion for vertebral fracture, cancer, and cauda equina  syndrome. Management includes patient education focused on exercise, massage, and  behavioral approaches such as cognitive behavioral therapy. Acupuncture can be an  effective alternative and specific herbal supplements may provide short-term pain  relief. The prognosis for patients with mechanical LBP is good. Inflammatory LBP  is pain resulting from a systemic inflammatory condition, often referred to as  axial spondyloarthritis. Ankylosing spondylitis is chronic inflammatory LBP  characterized by early onset (mean age 24 years), with a higher prevalence in  men. Five clinical parameters can help identify inflammatory LBP: improvement  with exercise, pain at night, insidious onset, onset at younger than 40 years,  and no improvement with rest. Management of inflammatory LBP typically includes  nonsteroidal anti-inflammatory drugs and structured exercise programs, with  emphasis on the involvement of a rheumatology subspecialist. Spondyloarthritis is  associated with other rheumatic or autoimmune conditions, including rheumatoid  arthritis, inflammatory bowel disease, and psoriasis. These should be considered  when evaluating patients with inflammatory LBP.
C1 Eglin Air Force Base Family Medicine Residency, 307 Boatner Rd, Eglin AFB, FL 32542.
NR 0
TC 0
SN 
EI 2159-300
J9 FP Essent
PD OCT 12
PY 2017
VL 461
IS 
BP 15
EP 20
DI 
PG 5
WC Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; therapeutic use; Back Injuries; diagnosis; Cognitive Behavioral Therapy; Exercise Therapy; Herbal Medicine; Humans; Low Back Pain; diagnosis; Pain Management; Physical Therapy Modalities; Prognosis; Spondylarthropathies; diagnosis
UT PubMed:29019640
PM 29019640
DA 2017-10-12
ER

PT J
AU Wei, HN
   Jiang, LP
   Xiong, B
   Zhou, S
   Yu, L
   Huang, YM
   Liu, DG
   Ling, W
   Song, XN
   Zhang, XX
   Zhao, HL
AF Wei, Han-Ning
   Jiang, Li-Ping
   Xiong, Bin
   Zhou, Si
   Yu, Lan
   Huang, Yan-Mei
   Liu, Dao-Guang
   Ling, Wei
   Song, Xin-Nan
   Zhang, Xiao-Xi
   Zhao, Hai-Lu
TI Characteristic patterns of normal meridian acupoint temperature
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Article
DE acupoint; medical college students; meridian; skin temperature; symmetry
ID randomized controlled-trial; low-back-pain; acupuncture; moxibustion; electroacupuncture; metaanalysis; stimulation; carcinoma; strength; stroke
AB Background: Body temperature is an important indicator of health and illness. However, a single temperature measurement is not always reliable. Such measurements can be made using meridians, which are energy channels with acupoints being the nodes. To date, there is no published reference of meridian acupoint temperatures applicable to human health, and there is no clear digitalized indicator that could be utilized to evaluate human health by way of meridian acupoints up to now. Methods: Our study recruited 100 healthy medical college students for the measurement of acupoint temperature. The temperatures of 135 acupoints of 14 main meridians were measured using infrared thermometers in order to provide a comprehensive body temperature reading of each study participant. (R)esults: The degree of the acupoint temperature consistently ranged from 34.88 degrees C to 36.14 degrees C. The gross thermograph was concentric, with high degree readings around the heart and low degree readings originating from the feet. The left and right body sides had significant correlation between the degrees of bilateral same name acupoint temperatures of 12 regular meridians (correlation coefficient, 0.367-0.985; p < 0.0001). There was also a significant correlation between the acupoint temperature for the governor vessel and the conception vessel (correlation coefficient, 0.083; p = 0.006). Conclusion: These findings indicate that meridian acupoint temperature is characterized by a consistently narrow range, as well as concentricity and symmetry in body temperature degree readings in college students. Meridian acupoint temperature may be a sensitive and valuable indicator to assist in the accurate evaluation of meridian and general human health, and the significance and changes of acupoint temperature in clinical conditions warrants future exploration. Copyright (C) 2017, the Chinese Medical Association. Published by Elsevier Taiwan LLC.
C1 [Wei, Han-Ning; Jiang, Li-Ping; Xiong, Bin; Zhou, Si; Yu, Lan; Huang, Yan-Mei; Liu, Dao-Guang; Ling, Wei; Song, Xin-Nan; Zhang, Xiao-Xi; Zhao, Hai-Lu] Guilin Med Univ, Fac Basic Med, Guangxi Lab Excellence, Ctr Syst Med, 109,North 2nd Huan Cheng Rd, Guilin 541004, Guangxi, Peoples R China.
C3 Guilin Medical University
RP Zhao, HL (corresponding author), Guilin Med Univ, Fac Basic Med, Guangxi Lab Excellence, Ctr Syst Med, 109,North 2nd Huan Cheng Rd, Guilin 541004, Guangxi, Peoples R China.
EM zhaohailu9@126.com
FU Program for Innovative Research Team of Guilin Medical University (PIRTGMU); National Natural Science Foundation of China [81270934]
CR Bahrami-Taghanaki H, 2014, ALTERN THER HEALTH M, V20, P13
   Beesley RC, 1989, PHYSIOLOGY, V0, P160
   Bin X, 2014, LIAONING CHIN TRADIT, V41, P1819
   Cai Guo-wei, 2013, ZHEN CI YAN JIU, V38, P488
   Chen RX, 2010, BMC COMPLEM ALTERN M, V10, P0, DOI 10.1186/1472-6882-10-32
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Chiu HY, 2016, OBSTET GYNECOL, V127, P507, DOI 10.1097/AOG.0000000000001268
   de Souza LL, 2016, J ACUPUNCT MERIDIAN, V9, P250, DOI 10.1016/j.jams.2016.07.004
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Farber JP, 1989, PHYSIOLOGY, V0, P112
   Fujiwara S, 2016, NEURORADIOLOGY, V58, P27, DOI 10.1007/s00234-015-1600-y
   Gao HM, 2013, NEURAL REGEN RES, V8, P2914, DOI 10.3969/j.issn.1673-5374.2013.31.004
   Houdas Y, 1982, HUMAN BODY TEMPERATU, V0, P33
   Hsiu H, 2013, MICROVASC RES, V89, P34, DOI 10.1016/j.mvr.2013.06.009
   Huang T, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/905852
   Jackson SM, 2012, DIFFERENTIAL DIAGNOS, V0, P785
   Jernigan DA, 2012, TOWNSEND LETT, V0, P0
   Kim JI, 2010, BMC CARDIOVASC DISOR, V10, P0, DOI 10.1186/1471-2261-10-33
   Lee DH, 2010, BMC GASTROENTEROL, V10, P0, DOI 10.1186/1471-230X-10-36
   Lee MS, 2005, AM J CHINESE MED, V33, P507, DOI 10.1142/S0192415X05003107
   Lee MS, 2010, AM J CHINESE MED, V38, P829, DOI 10.1142/S0192415X10008275
   Lee Myeong Soo, 2010, CHIN MED, V5, P28, DOI 10.1186/1749-8546-5-5
   Lee MS, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-130
   Lee MS, 2010, STROKE, V41, P817, DOI 10.1161/STROKEAHA.109.566851
   Liu H, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/932581
   MacPherson H, 2015, ANN INTERN MED, V163, P653, DOI 10.7326/M15-0667
   Mchale PA, 1989, PHYSIOLOGY, V0, P72
   Meng ZQ, 2012, EUR J CANCER, V48, P1692, DOI 10.1016/j.ejca.2011.12.030
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Raith W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/614210
   She Yan-Fen, 2012, ZHEN CI YAN JIU, V37, P145
   Shin KR, 2009, WESTERN J NURS RES, V31, P171, DOI 10.1177/0193945908323650
   Sui Y, 2012, OBES REV, V13, P409, DOI 10.1111/j.1467-789X.2011.00979.x
   Thies R, 1989, PHYSIOLOGY, V0, P26
   Wang GJ, 2012, J ALTERN COMPLEM MED, V18, P784, DOI 10.1089/acm.2011.0440
   Wang P, 2016, CHIN J INTEGR MED, V22, P532, DOI 10.1007/s11655-015-2157-7
   Wong YM, 2014, APPL PSYCHOPHYS BIOF, V39, P159, DOI 10.1007/s10484-014-9249-6
   Yang EJ, 2011, RHEUMATOL INT, V31, P725, DOI 10.1007/s00296-010-1364-y
   Zheng H, 2009, AM J CHINESE MED, V37, P35, DOI 10.1142/S0192415X09006631
   Zheng SX, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-323
   Zhou S, 2012, ARCH PHYS MED REHAB, V93, P50, DOI 10.1016/j.apmr.2011.08.010
NR 42
TC 8
Z9 8
U1 1
U2 30
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD JUL 15
PY 2017
VL 80
IS 7
BP 419
EP 426
DI 10.1016/j.jcma.2016.12.007
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA FA4XH
UT WOS:000405446500006
PM 28476445
DA 2026-01-16
ER

PT J
AU Oh, B
   Eade, T
   Kneebone, A
   Pavlakis, N
   Clarke, S
   Eslick, G
   River, J
   Back, M
AF Oh, Byeongsang
   Eade, Thomas
   Kneebone, Andrew
   Pavlakis, Nick
   Clarke, Stephen
   Eslick, Guy
   River, Jo
   Back, Michael
TI Factors affecting whether or not cancer patients consider using acupuncture
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
ID randomized controlled-trial; alternative medicine use; stage breast-cancer; complementary therapy; joint symptoms; hot flashes; management; women; physicians; chemotherapy
AB Objective To explore the factors associated with utilisation of an acupuncture service in a tertiary oncology setting in an Australian public hospital. Method Cancer patients attending oncology clinics at a university teaching hospital were invited to participate in the evaluation of acupuncture services from June 2014 to May 2015. Patients had a prior diagnosis of cancer (albeit at different stages) and were planning to receive, or were already receiving, systemic and/or radiation cancer treatment. Results The majority (81%) of participants indicated that they would consider the use of acupuncture during their cancer treatment. The most common reasons given for not considering acupuncture included adequate control of symptoms already with medical treatment, inconvenient clinic timing, and needle phobia. The main reasons given for considering acupuncture use included its perceived capability of reducing fatigue, boosting energy levels, improving immune function, and reducing pain and anxiety. Patients considering acupuncture use also demonstrated significantly higher levels of stress (p<0.001), anxiety and depression (p<0.001), fatigue (p<0.001), and lower global quality of life (p<0.01) compared to those who were not considering acupuncture. Conclusions The findings show that demand for acupuncture by cancer patients is high. A substantial proportion of cancer patients intend to use acupuncture to manage cancer and/or cancer treatment-related symptoms. Discussion with patients about acupuncture and other complementary therapies during the consultation may improve cancer care.
C1 [Oh, Byeongsang; Eade, Thomas; Kneebone, Andrew; Pavlakis, Nick; Clarke, Stephen; Back, Michael] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia.
   [Oh, Byeongsang; Eade, Thomas; Kneebone, Andrew; Pavlakis, Nick; Clarke, Stephen; Eslick, Guy; Back, Michael] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.
   [Oh, Byeongsang] Harvard Med Sch, Boston, MA USA.
   [River, Jo] Univ Sydney, Sydney Nursing Sch, Camperdown, NSW, Australia.
C3 University of Sydney; Royal North Shore Hospital; University of Sydney; Harvard University; Harvard Medical School; University of Sydney
RP Oh, B (corresponding author), Univ Sydney, Sydney Med Sch, Northern Sydney Canc Ctr, Royal North Shore Hosp, St Leonards, NSW 2065, Australia.
EM byeong.oh@sydney.edu.au
FU Northern Sydney Local Health District NSW; Dry July
CR Adams J, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-2
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2006, CANC AUSTR OV, V0, P0
   Unknown -, 2009, CANC FACTS FIG 2009, V0, P0
   Ashikaga T, 2002, SUPPORT CARE CANCER, V10, P542, DOI 10.1007/s00520-002-0356-1
   Begbie SD, 1996, MED J AUSTRALIA, V165, P545, DOI 10.5694/j.1326-5377.1996.tb138639.x
   Beith JM, 2011, MED ACUPUNCT, V23, P151, DOI 10.1089/acu.2011.0798
   Boon Heather S, 2007, BMC WOMENS HEALTH, V7, P4, DOI 10.1186/1472-6874-7-4
   Commonwealth of Australia, 2009, HLTH FUT ALL AUSTR F, V0, P0
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   de Valois BA, 2010, J ALTERN COMPLEM MED, V16, P1047, DOI 10.1089/acm.2009.0472
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Greenlee Heather, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP346, DOI 10.1093/jncimonographs/lgu041
   Halsey EJ, 2015, ACUPUNCT MED, V33, P188, DOI 10.1136/acupmed-2014-010735
   Highfield ES, 2003, COMPLEMENT THER MED, V11, P177, DOI 10.1016/S0965-2299(03)00069-4
   Kremser T, 2008, BREAST, V17, P387, DOI 10.1016/j.breast.2007.12.006
   Leng G, 1999, PALLIATIVE MED, V13, P163, DOI 10.1191/026921699676243035
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Mao JJ, 2012, J AM BOARD FAM MED, V25, P323, DOI 10.3122/jabfm.2012.03.110165
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Miller M, 1998, SUPPORT CARE CANCER, V6, P337, DOI 10.1007/s005200050175
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Morris KT, 2000, AM J SURG, V179, P407, DOI 10.1016/S0002-9610(00)00358-5
   National Institutes of Health, 2007, CAM BAS SEC CAM BAS, V0, P0
   Oh Byeongsang, 2010, J SOC INTEGR ONCOL, V8, P56
   Paltiel O, 2001, J CLIN ONCOL, V19, P2439, DOI 10.1200/JCO.2001.19.9.2439
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Saxe GA, 2008, INTEGR CANCER THER, V7, P122, DOI 10.1177/1534735408323081
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/710750
NR 37
TC 13
Z9 16
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD APR 15
PY 2017
VL 35
IS 2
BP 107
EP 113
DI 10.1136/acupmed-2016-011115
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA EV7OU
UT WOS:000401967300004
PM 27658799
DA 2026-01-16
ER

PT J
AU Lin, Y
   Yang, W
   Li, Y
   Li, Y
   Tong, Q
   Ma, W
   Li, Y
   Shen, W
AF Lin, Yufang
   Yang, Wei
   Li, Yajuan
   Li, Yin
   Tong, Qiuyu
   Ma, Wen
   Li, Yijing
   Shen, Weidong
TI [Mechanism of acupoint transcutaneous electric stimulation on analgesic
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupint transcutaneous electric stimulation; analgesic anesthesia; anorectal operation; immunity; stress
AB OBJECTIVE: To observe the regulatory effects of acupoint electric stimulation on  the analgesic substances and the relevant indices of nerve-immunity-endocrine  system in the patients undergoing general anesthesia anorectal operation.  METHODS: One hundred and fifty-six patients undergoing hemorrhoids and anal  fistula operation were randomized into three groups, 146 cases were included in  the analysis. In the No.1 group (48 cases), the conventional intravenous general  anesthesia was applied. In the No.2 group (50 cases), besides the conventional  intravenous general anesthesia, the acupoint transcutaneous electric stimulation  was combined at Neiguan (PC 6), Shenmen (HT 7), Shangliao (BL 31) and Ciliao (BL  32). operation in the No.2 and No.3 groups were lower apparently than that in the  No.1 group (P<0.05, P<0.01). CONCLUSIONS: During the general anesthesia anorectal  operation, the acupoint transcutaneous electric stimulation achieves analgesic  anesthesia through effectively promoting the release of body analgesic substance  and reducing the stress level in the operation. With the comprehensive acupoint  selection as Neiguan (PC 6) and Shenmen (HT 7) and the local acupoints, the  therapeutic effects are better in comparison with the simple selection of local  acupoints. In the No.3 group (48 cases), besides the conventional intravenous  general anesthesia, the acupoint transcutaneous electric stimulation was combined  at Shangliao (BL 31) and Ciliao (BL 32). The electric stimulation was maintained  till the end of operation. The patients' saliva was collected 0.5 h before  operation and 1 h after operation separately. The indices that reflect the body  pain regulation and nerve-immune-endocrine secretion were detected, such as  opiophin protein (OPI), secretory immunoglobulin A (SIgA), saliva amylase (sAA),  cortisol (Cor) and tumor necrosis factor α (TNF-α). The pain degree was observed  1 h after operation. RESULTS: In the No.2 group, OPI after operation was higher  than that before operation (P<0.05). The difference value of OPI in the No.2  group was higher apparently than that in the No.1 group and the No.3 group (both  P<0.05). SIgA after operation was higher than that before operation in the No.1  group (P<0.05). The difference values of SIgA, sAA, Cor in the No.2 group were  lower apparently than those in the No.1 group (P<0.05, P<0.01). TNF-αbefore and  after operation and its difference value among the groups were not significant  statistically (all P>0.05). The pain degrees in 1 h after.
C1 Shanghai University of TCM, Shanghai 201203, China.
   Department of Acupuncture and Moxibustion.
   Department of Proctology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203.
   Department of Acupuncture and Moxibustion.
   Department of Acupuncture and Moxibustion.
   Department of Acupuncture and Moxibustion.
   Department of Acupuncture and Moxibustion.
   Department of Acupuncture and Moxibustion.
   Department of Acupuncture and Moxibustion.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD DEC 13
PY 2017
VL 37
IS 7
BP 747
EP 752
DI 10.13703/j.0255-2930.2017.07.017
PG 5
WC Acupuncture Analgesia; Acupuncture Points; Anesthesia, General; Anesthesia, Intravenous; Electric Stimulation; Hemorrhoidectomy; methods; Humans; Rectal Fistula; surgery; Transcutaneous Electric Nerve Stimulation
UT PubMed:29231549
PM 29231549
DA 2017-12-13
ER

PT J
AU Han, XY
   Wang, LJ
   Shi, HF
   Zheng, GF
   He, JS
   Wu, WJ
   Shi, JM
   Wei, GQ
   Zheng, WY
   Sun, J
   Huang, H
   Cai, Z
AF Han, Xiaoyan
   Wang, Lijuan
   Shi, Hongfei
   Zheng, Gaofeng
   He, Jingsong
   Wu, Wenjun
   Shi, Jimin
   Wei, Guoqing
   Zheng, Weiyan
   Sun, Jie
   Huang, He
   Cai, Zhen
TI Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma
SO BMC CANCER
LA English
DT Article
DE Acupuncture; CIPN; Methylcobalamin; Multiple myeloma
ID electroacupuncture; pain; neurotoxicity; bortezomib; history
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) seriously affects the quality of life of patients with multiple myeloma (MM) as well as the response rate to chemotherapy. Acupuncture has a potential role in the treatment of CIPN, but at present there have been no randomized clinical research studies to analyze the effectiveness of acupuncture for the treatment of CIPN, particularly in MM patients. Methods: The MM patients (104 individuals) who met the inclusion criteria were randomly assigned into a solely methylcobalamin therapy group (500 mu g intramuscular methylcobalamin injections every other day for 20 days; ten injections) followed by 2 months of 500 mu g oral methylcobalamin administration, three times per day) and an acupuncture combined with methylcobalamin (Met + Acu) group (methylcobalamin used the same way as above accompanied by three cycles of acupuncture). Of the patients, 98 out of 104 completed the treatment and follow-ups. There were 49 patients in each group. The evaluating parameters included the visual analogue scale (VAS) pain score, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire scores, and electromyographic (EMG) nerve conduction velocity (NCV) determinations. We evaluated the changes of the parameters in each group before and after the therapies and made a comparison between the two groups. Results: After 84 days (three cycles) of therapy, the pain was significantly alleviated in both groups, with a significantly higher decrease in the acupuncture treated group (P < 0.01). The patients' daily activity evaluated by Fact/GOG-Ntx questionnaires significantly improved in the Met + Acu group (P < 0.001). The NCV in the Met + Acu group improved significantly while amelioration in the control group was not observed. Conclusions: The present study suggests that acupuncture combined with methylcobalamin in the treatment of CIPN showed a better outcome than methylcobalamin administration alone.
C1 [Han, Xiaoyan; Wang, Lijuan; Shi, Hongfei; Zheng, Gaofeng; He, Jingsong; Wu, Wenjun; Shi, Jimin; Wei, Guoqing; Zheng, Weiyan; Sun, Jie; Huang, He; Cai, Zhen] Zhejiang Univ, Sch Med, Dept Hematol,Affiliated Hosp 1, Multiple Myeloma Ctr,Bone Marrow Transplantat Ctr, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wang, Lijuan] Shandong Univ, Linyi Peoples Hosp, Hematol Lab, Dept Hematol, Linyi 276002, Peoples R China.
C3 Zhejiang University; Shandong University
RP Cai, Z (corresponding author), Zhejiang Univ, Sch Med, Dept Hematol,Affiliated Hosp 1, Multiple Myeloma Ctr,Bone Marrow Transplantat Ctr, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM caiz@zju.edu.cn
FU Administration of Traditional Chinese Medicine Science and Technology Program of Zhejiang Province [2010ZA057, 2014ZB060]; Science and Technology Project of the Health Department of Zhejiang Province [2013KYA071]; National Natural Science Foundation of China [81471532, 81402353]
CR Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X
   Ahn Andrew C, 2007, ACUPUNCT MED, V25, P11
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Argyriou AA, 2012, CRIT REV ONCOL HEMAT, V82, P51, DOI 10.1016/j.critrevonc.2011.04.012
   Bang SM, 2006, INT J HEMATOL, V83, P309, DOI 10.1532/IJH97.A30512
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Brunelli B, 2004, J NEUROL SCI, V218, P59, DOI 10.1016/j.jns.2003.10.013
   Cavaletti G, 2004, ANN ONCOL, V15, P1439, DOI 10.1093/annonc/mdh348
   Chauhan D, 2005, MOL CANCER THER, V4, P686, DOI 10.1158/1535-7163.MCT-04-0338
   Cheng X N, 1999, CHINESE ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dong ZQ, 2005, NEUROSCI LETT, V376, P143, DOI 10.1016/j.neulet.2004.11.044
   Galantino MLA, 1999, J ALTERN COMPLEM MED, V5, P135, DOI 10.1089/acm.1999.5.135
   Gao YH, 2013, NEUROCHEM RES, V38, P1467, DOI 10.1007/s11064-013-1047-7
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Huang HQ, 2007, INT J GYNECOL CANCER, V17, P387, DOI 10.1111/j.1525-1438.2007.00794.x
   HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8
   Jiang Hequn, 2006, J TRADIT CHIN MED, V26, P8
   Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524
   Litscher G, 2002, LASER MED SCI, V17, P19, DOI 10.1007/s10103-002-8262-9
   Minton O, 2007, J PAIN SYMPTOM MANAG, V33, P115, DOI 10.1016/j.jpainsymman.2006.09.011
   Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733
   Phillips KD, 2004, J ALTERN COMPLEM MED, V10, P449, DOI 10.1089/1075553041323678
   Postma TJ, 2000, ANN ONCOL, V11, P509, DOI 10.1023/A:1008345613594
   Richardson PG, 2006, J CLIN ONCOL, V24, P3113, DOI 10.1200/JCO.2005.04.7779
   Schröder S, 2007, EUR J NEUROL, V14, P276, DOI 10.1111/j.1468-1331.2006.01632.x
   Takayama S, 2012, EVID-BASED COMPL ALT, V2012, P0
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6
   Ulett GA, 1998, SOUTHERN MED J, V91, P1115, DOI 10.1097/00007611-199812000-00004
   Wang Yu-ping, 2005, ZHONGGUO ZHEN JIU, V25, P542
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Zhang C, 2010, J TRADIT CHIN MED, V30, P13, DOI 10.1016/S0254-6272(10)60003-9
   Zhang Zhang-Jin, 2012, EVID BASED COMPLEMENT ALTERNAT MED, V2012, P429412, DOI 10.1155/2012/429412
   Zhao Hui-ling, 2007, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V27, P312
   Zhao Jian-ling, 2008, ZHONGGUO ZHEN JIU, V28, P13
   Zhou YH, 2009, AM J CLIN ONCOL-CANC, V32, P319, DOI 10.1097/COC.0b013e318173a520
NR 36
TC 92
Z9 110
U1 1
U2 38
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 9
PY 2017
VL 17
IS 
BP 
EP 
DI 10.1186/s12885-016-3037-z
PG 7
WC Oncology
SC Oncology
GA EI2UD
UT WOS:000392343000001
PM 28068938
DA 2026-01-16
ER

PT J
AU Al-Atiyyat, N
   Obaid, A
AF Al-Atiyyat, Nijmeh
   Obaid, Abdullah
TI Management of peripheral neuropathy induced by chemotherapy in adults with
SO International journal of palliative nursing
LA English
DT Review
DE Antineoplastic drugs; Chemotherapy-induced peripheral neuropathy; Management; Sensory neurotoxicity
AB AIM: To identify which of the examined agents or modalities were effective in the  management of chemotherapy-induced peripheral neuropathy (CIPN). METHODS: PubMed,  CINAHL, Medline, Science Direct and Ovid databases were used to search keywords.  The literature search identified 59 potentially relevant studies; after removing  duplicates and reviewing titles a total of 26 articles were examined. In the end,  a total of 18 studies met the inclusion criteria. FINDINGS: The preliminary data  for using lafutidine, acupuncture and sweet bee venom pharmacopuncture indicate  that they may be useful in CIPN management. The use of duloxetine was effective  and supported as a management of CIPN; likewise the use of scrambler therapy  significantly decreased CIPN pain. However, the use of electroacupuncture and  topical amitriptyline and ketamine was not supported. CONCLUSION: The use of  duloxetine was effective in CIPN management. Further studies with larger sample  size are needed.
C1 Hashemite University, Faculty of Nursing.
   Pain Management Nurse, King Hussein Cancer Center, Hashemite University.
NR 0
TC 0
SN 
EI 1357-632
J9 Int J Palliat Nurs
PD JAN 31
PY 2017
VL 23
IS 1
BP 13
EP 17
DI 10.12968/ijpn.2017.23.1.13
PG 4
WC Adult; Antineoplastic Agents; adverse effects; Humans; Neoplasms; drug therapy; Peripheral Nervous System Diseases; chemically induced
UT PubMed:28132604
PM 28132604
DA 2017-01-31
ER

PT J
AU Lu, ZX
   Moody, J
   Marx, BL
   Hammerstrom, T
AF Lu, Zhaoxue
   Moody, Jennifer
   Marx, Benjamin L.
   Hammerstrom, Tracy
TI Treatment of Chemotherapy-Induced Peripheral Neuropathy in Integrative Oncology: A Survey of Acupuncture and Oriental Medicine Practitioners
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE acupuncture; chemotherapy-induced peripheral neuropathy; integrative oncology; neurological pain; neuropathic pain
ID symptom management; palliative care; cancer care; prevention; therapy; taxanes; trial
AB Objectives: Complementary and alternative medicine is increasingly integrated into cancer care. We sought detail on the treatment of chemotherapy-induced peripheral neuropathy (CIPN) with acupuncture and oriental medicine (AOM) by surveying practitioners at integrative oncology (IO) sites across the United States. Design: Online survey of licensed acupuncturists. Setting/Location: IO sites in the United States. Subjects: Fifteen licensed acupuncturists who completed the survey between February 2014 and June 2014. Outcome measures: Demographics, IO setting characteristics, AOM treatment characteristics, and practitioner-reported outcomes. Results: Respondents reported an average of 31.317.2 patients per week, and one-third (10.1 mean; 7.2 standard deviation [SD]) were treated for CIPN. Medical doctors (86.7%) were the most common providers with whom respondents worked. Traditional Chinese medicine style acupuncture was utilized by a majority of respondents (86.7%), and the most commonly used points were local, typically in the hands and feet, such as Ba Feng, Ba Xie, LV3, and LI4. In addition to acupuncture, nutritional advice was the most frequent auxiliary modality provided by respondents (85.7%). On average, respondents provided 12.75 +/- 4.17 treatments for CIPN patients, and a majority (53%) reported treating patients once per week. Timing of the treatments relative to chemotherapy infusion was evenly distributed between "1-2 days after infusion (60%), "at time of infusion (53.3%), and "1-2 days before infusion (46.7%). Sixty percent of respondents rated outcomes as moderately successful with moderate improvement seen. Conclusion: This survey provides detail regarding IO sites using acupuncture for CIPN as well as real-world treatment patterns, including common point combinations, visit characteristics, and practitioner-reported outcomes. This information contributes to the emerging evidence on the use of acupuncture to address unmet needs of CIPN patients, and supports the development of best practice guidelines for the treatment of CIPN with acupuncture in the IO setting.
C1 [Lu, Zhaoxue; Moody, Jennifer; Marx, Benjamin L.; Hammerstrom, Tracy] Oregon Coll Oriental Med, Portland, OR USA.
RP Marx, BL (corresponding author), Oregon Coll Oriental Med, Res Dept, 75 NW Couch St, Portland, OR 97209 USA.
EM bmarx@ocom.edu
CR Albers JW, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005228.pub4
   Unknown -, 2017, WHO | CANCER, V0, P0
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Ben-Arye E, 2016, COMPLEMENT THER MED, V29, P9, DOI 10.1016/j.ctim.2016.09.001
   Boon Heather S, 2007, BMC WOMENS HEALTH, V7, P4, DOI 10.1186/1472-6874-7-4
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Ewertz M, 2015, ACTA ONCOL, V54, P587, DOI 10.3109/0284186X.2014.995775
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Haddad NE, 2014, INTEGR CANCER THER, V13, P371, DOI 10.1177/1534735413520181
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hile ES, 2010, PHYS THER, V90, P1649, DOI 10.2522/ptj.20090405
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Javdan B, 2015, J ACUPUNCT MERIDIAN, V8, P115, DOI 10.1016/j.jams.2015.03.005
   KIM SY, 2016, EVID-BASED COMPL ALT, V2016, P0
   Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Ling WM, 2014, ONCOL NURS FORUM, V41, P581, DOI 10.1188/14.ONF.581-592
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Majithia N, 2016, SUPPORT CARE CANCER, V24, P1439, DOI 10.1007/s00520-015-3063-4
   Mao JJ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-7
   OSullivan EM, 2010, ACUPUNCT MED, V28, P191, DOI 10.1136/aim.2010.002733
   Paice Judith A, 2009, SEMIN ONCOL NURS, V25, PS8, DOI 10.1016/j.soncn.2009.03.013
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Rivera E, 2015, CANCER CHEMOTH PHARM, V75, P659, DOI 10.1007/s00280-014-2607-5
   Schloss J, 2016, ASIA-PAC J ONCOL NU, V3, P73, DOI 10.4103/2347-5625.170977
   Schneider BP, 2015, ADV EXP MED BIOL, V862, P77, DOI 10.1007/978-3-319-16366-6_6
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Tsuchiya M, 2007, ANESTH ANALG, V104, P301, DOI 10.1213/01.ane.0000230622.16367.fb
   Valentine-Davis B, 2015, MED ACUPUNCT, V27, P216, DOI 10.1089/acu.2015.1103
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Wong R, 2016, INTEGR CANCER THER, V15, P153, DOI 10.1177/1534735415627926
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
NR 39
TC 19
Z9 21
U1 1
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD DEC 15
PY 2017
VL 23
IS 12
BP 964
EP 970
DI 10.1089/acm.2017.0052
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA FQ6FZ
UT WOS:000418460500010
PM 28661695
DA 2026-01-16
ER

PT J
AU Yang, GS
   Kim, HJ
   Griffith, KA
   Zhu, SJ
   Dorsey, SG
   Renn, CL
AF Yang, Gee Su
   Kim, Hee Jun
   Griffith, Kathleen A.
   Zhu, Shijun
   Dorsey, Susan G.
   Renn, Cynthia L.
TI Interventions for the Treatment of Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors
SO CANCER NURSING
LA English
DT Article
DE Aromatase inhibitor; Arthralgia; Breast cancer; Intervention; Meta-analysis; Systematic review
ID adjuvant endocrine therapy; practice guideline update; musculoskeletal symptoms; joint symptoms; double-blind; postmenopausal women; american society; controlled trial; phase-ii; acupuncture
AB Background: Aromatase inhibitors (AIs) have been established as successful adjuvant therapy for breast cancer survivors. Unfortunately, nearly half of women taking AIs report joint pain, AI-associated arthralgia (AIA). Aromatase inhibitor-associated arthralgia often results in noncompliance, which could lead to cancer recurrence. Objective: The purpose of this study was to identify current pain management of AIA and to evaluate the study quality and effects of interventions. Methods: Nineteen articles published from 2000 to August 2015 were identified using PubMed, CINAHL, PsycINFO, Web of Science, and additional records. Study quality was evaluated by the Quality Assessment Tool for Quantitative Studies. Meta-analysis was used to obtain effect sizes of interventions on pain and subgroups. Results: Five types of interventions emerged: pharmacological approaches, acupuncture, nutritional supplementation, relaxation techniques, and physical exercise. Six studies were strong, 8 were moderate, and 5 were weak in quality. The overall effect size of the interventions on pain was large; pharmacological approaches, acupuncture, and relaxation techniques showed moderate to large effects on pain, whereas nutritional supplementation and physical exercise had no significant effects on it. Conclusion: The evidence was based on a body of research with moderate study quality. Although the overall effect of interventions is large, further investigation into the influence of nutrition and physical exercise is needed to better discern their potential for pain management. Implication for Practice: Oncology nurses may be able to implement such validated interventions as pain management modalities to mitigate the symptoms so that breast cancer survivors remain compliant with AIA therapy.
C1 [Yang, Gee Su; Kim, Hee Jun; Griffith, Kathleen A.; Dorsey, Susan G.; Renn, Cynthia L.] Univ Maryland, Sch Nursing, Dept Pain & Translat Symptom Sci, 655 W Lombard St, Baltimore, MD 21201 USA.
   [Zhu, Shijun] Univ Maryland, Sch Nursing, Dept Org Syst & Adult Hlth, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore
RP Renn, CL (corresponding author), Univ Maryland, Sch Nursing, Dept Pain & Translat Symptom Sci, 655 W Lombard St, Baltimore, MD 21201 USA.
EM renn@son.umaryland.edu
FU Oncology Nursing Society Foundation/Purdue Pharmaceuticals Trish Greene Pain Assessment and Management research grant
CR Arrow KJ, 1996, SCIENCE, V272, P221, DOI 10.1126/science.272.5259.221
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Borenstein M, 2009, INTRO METAANALYSIS, V0, P0
   Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Burstein HJ, 2007, J CLIN ONCOL, V25, P0, DOI 10.1200/JCO.2007.11.9529
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   Carlson KD, 1999, J APPL PSYCHOL, V84, P851, DOI 10.1037/0021-9010.84.6.851
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6
   DeNysschen CA, 2014, EUR J CANCER CARE, V23, P493, DOI 10.1111/ecc.12155
   Fields J, 2015, THESIS, V0, P0
   Fontein DBY, 2012, EJSO-EUR J SURG ONC, V38, P110, DOI 10.1016/j.ejso.2011.11.010
   Gaillard S, 2011, BREAST CANCER RES, V13, P0, DOI 10.1186/bcr2818
   Galantino ML, 2013, ALTERN THER HEALTH M, V19, P38
   Galantino ML, 2012, INTEGR CANCER THER, V11, P313, DOI 10.1177/1534735411413270
   Greenlee H, 2013, SUPPORT CARE CANCER, V21, P1077, DOI 10.1007/s00520-012-1628-z
   Henry NL, 2008, BREAST CANCER RES TR, V111, P365, DOI 10.1007/s10549-007-9774-6
   Henry NL, 2015, J CLIN ONCOL, V33, P1870, DOI 10.1200/JCO.2015.61.1004
   Henry NL, 2011, CANCER-AM CANCER SOC, V117, P5469, DOI 10.1002/cncr.26230
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Kubo M, 2012, ANTICANCER RES, V32, P2331
   Laroche F, 2014, J PAIN, V15, P293, DOI 10.1016/j.jpain.2013.11.004
   Liberati A, 2009, PLOS MED, V62, Pe1, DOI 10.1371/journal.pmed.1000100
   Lintermans A, 2011, STEROIDS, V76, P781, DOI 10.1016/j.steroids.2011.02.034
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Menas Pamela, 2012, J ONCOL PHARM PRACT, V18, P387, DOI 10.1177/1078155211434853
   Nabholtz Jean-Marc A, 2008, THER CLIN RISK MANAG, V4, P189
   Nevitt MC, 2001, ARTHRITIS RHEUM-US, V44, P811, DOI 10.1002/1529-0131(200104)44:4<811::AID-ANR137>3.0.CO;2-F
   Nyrop KA, 2014, J GERIATR ONCOL, V5, P148, DOI 10.1016/j.jgo.2013.12.002
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Rastelli AL, 2011, BREAST CANCER RES TR, V129, P107, DOI 10.1007/s10549-011-1644-6
   Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, V0, P1, DOI 10.1002/0470870168
   Thomas B H, 2004, WORLDVIEWS EVID BASED NURS, V1, P176, DOI 10.1111/j.1524-475X.2004.04006.x
   Turner RM, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0059202
   Zhang QY, 2010, AM J CLIN ONCOL-CANC, V33, P557, DOI 10.1097/COC.0b013e3181cae782
NR 42
TC 36
Z9 43
U1 0
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD JUL-AUG 15
PY 2017
VL 40
IS 4
BP E26
EP E41
DI 10.1097/NCC.0000000000000409
PG 16
WC Oncology; Nursing
SC Oncology; Nursing
GA EY2PP
UT WOS:000403811400003
PM 27333128
DA 2026-01-16
ER

PT J
AU Zhang, Y
   Li, A
   Xin, J
   Ren, K
   Berman, BM
   Lao, L
   Zhang, RX
AF Zhang, Y
   Li, A
   Xin, J
   Ren, K
   Berman, B M
   Lao, L
   Zhang, R-X
TI Electroacupuncture alleviates chemotherapy-induced pain through inhibiting
SO European journal of pain (London, England)
LA English
DT Journal Article
AB BACKGROUND: Current medical treatments for chemotherapy-induced pain (CIP) are  either ineffective or have adverse side effects. Acupuncture may alleviate CIP,  but its effectiveness against this condition has not been studied. Paclitaxel  causes neuropathic pain in cancer patients. METHODS: We evaluated the effects of  electroacupuncture (EA) on paclitaxel-induced CIP in a rat model. Paclitaxel  (2 mg/kg) or vehicle was injected (i.p.) on alternate days of 0-6. The resulting  pain was treated with 10 Hz/2 mA/0.4 ms pulse EA for 30 min at the equivalent of  human acupoint GB30 (Huantiao) once every other day between days 14 and 26. For  sham control, EA needles were inserted into GB30 without stimulation. Von Frey  filaments with bending forces of 2-8 g and 15 g were used to assess mechanical  allodynia and hyperalgesia, respectively, on day 13 and once every other day  between 14-26 days and then for 2-3 weeks after EA treatment. RESULTS: Compared  to sham control, EA significantly alleviated paclitaxel-induced mechanical  allodynia and hyperalgesia, as shown by less frequent withdrawal responses to the  filaments. The alleviation of allodynia/hyperalgesia lasted up to 3 weeks after  the EA treatment. EA significantly inhibited phosphorylation of Ca(2+)  /calmodulin-dependent protein kinase II (CaMKII) in the spinal cord. KN-93, a  selective inhibitor of p-CaMKII, inhibited mechanical allodynia/hyperalgesia and  p-CaMKII. 5-HT1A receptor antagonist blocked EA inhibition of  allodynia/hyperalgesia and p-CaMKII. CONCLUSIONS: Electroacupuncture activates  5-HT 1A receptors in the spinal cord and inhibits p-CaMKII to alleviate both  allodynia and hyperalgesia. The data support acupuncture/EA as a complementary  therapy for CIP. SIGNIFICANCE: Electroacupuncture (EA) activates spinal 5-HT1A  receptors to inhibit p-CaMKII to alleviate paclitaxel-induced pain.  Acupuncture/EA may be used as a complementary therapy for CIP.
C1 Department of Physiology, Shanxi Medical University, Taiyuan, China.
   Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, USA.
   Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, USA.
   Department of Neural and Pain Sciences, Dental School, University of Maryland, Baltimore, USA.
   Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, USA.
   Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, USA.
   Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, USA.
NR 0
TC 0
SN 1532-214
EI 1090-380
J9 Eur J Pain
PD OCT 17
PY 2017
VL 22
IS 4
BP 679
EP 690
DI 10.1002/ejp.1132
PG 11
WC Acupuncture Points; Animals; Antineoplastic Agents, Phytogenic; adverse effects; Calcium-Calmodulin-Dependent Protein Kinase Type 2; metabolism; Electroacupuncture; methods; Hyperalgesia; chemically induced; Male; Neuralgia; chemically induced; Paclitaxel; adverse effects; Phosphorylation; Rats; Rats, Sprague-Dawley; Spinal Cord; metabolism
UT PubMed:29034548
PM 29034548
DA 2017-10-17
ER

PT J
AU Krajewski, A
   Lech, G
   Makiewicz, M
   Kluciński, A
   Wojtasik, M
   Kozieł, S
   Słodkowski, M
AF Krajewski, Andrzej
   Lech, Gustaw
   Makiewicz, Marcin
   Kluciński, Andrzej
   Wojtasik, Monika
   Kozieł, Sławomir
   Słodkowski, Maciej
TI Infeasibility of endoscopic transmural drainage due to pancreatic pseudocyst wall
SO Polski przeglad chirurgiczny
LA English
DT Journal Article
DE calcifications in the pancreatic pseudocyst wall; endoscopic transmural drainage; postinflammatory pancreatic pseudocysts
AB Postinflammatory pancreatic pseudocysts are one of the most common complications  of acute pancreatitis. In most cases, pseudocysts self-absorb in the course of  treatment of pancreatitis. In some patients, pancreatic pseudocysts are  symptomatic and cause pain, problems with gastrointestinal transit, and other  complications. In such cases, drainage or resection should be performed. Among  the invasive methods, mini invasive procedures like endoscopic transmural  drainage through the wall of the stomach or duodenum play an important role. For  endoscopic transmural drainage, it is necessary that the cyst wall adheres to the  stomach or duodenum, making a visible impression. We present a very rare case of  infeasibility of endoscopic drainage of a postinflammatory pancreatic pseudocyst,  impressing the stomach, due to cyst wall calcifications. A 55-year-old man after  acute pancreatitis presented with a 1-year history of epigastric pain and was  admitted due to a postinflammatory pseudocyst in the body and tail of pancreas.  On admission, blood tests, including CA 19-9 and CEA, were normal. An ultrasound  examination revealed a 100-mm pseudocyst in the tail of pancreas, which was  confirmed on CT and EUS. Acoustic shadowing caused by cyst wall calcifications  made the cyst unavailable to ultrasound assessment and percutaneous drainage.  Gastroscopy revealed an impression on the stomach wall from the outside. The  patient was scheduled for endoscopic transmural drainage. After insufflation of  the stomach, a large mass protruding from the wall was observed. The stomach  mucosa was punctured with a cystotome needle knife, and the pancreatic cyst wall  was reached. Due to cyst wall calcifications, endoscopic drainage of the cyst was  unfeasible. Profuse submucosal bleeding at the puncture site was stopped by  placing clips. The patient was scheduled for open surgery, and distal  pancreatectomy with splenectomy was performed. The histopathological examination  confirmed the initial diagnosis of postinflammatory pancreatic pseudocyst.  Endoscopic transmural drainage is a highly effective procedure for treating  postinflammatory pancreatic pseudocysts. In some patents, especially with large  pseudocysts, pseudocysts with calcified walls, and cysts of primary origin,  resection should be performed.
C1 Warszawski Uniwersytet Medyczny Katedra i Klinika Chirurgii Ogólnej, Gastroenterologicznej i Onkologicznej.
   Warszawski Uniwersytet Medyczny Katedra i Klinika Chirurgii Ogólnej, Gastroenterologicznej i Onkologicznej.
   Warszawski Uniwersytet Medyczny Katedra i Klinika Chirurgii Ogólnej, Gastroenterologicznej i Onkologicznej.
   Warszawski Uniwersytet Medyczny Katedra i Klinika Chirurgii Ogólnej, Gastroenterologicznej i Onkologicznej.
   Warszawski Uniwersytet Medyczny Katedra i Klinika Chirurgii Ogólnej, Gastroenterologicznej i Onkologicznej.
   Warszawski Uniwersytet Medyczny Katedra i Klinika Chirurgii Ogólnej, Transplantacyjnej i Wątroby.
   Warszawski Uniwersytet Medyczny Katedra i Klinika Chirurgii Ogólnej, Gastroenterologicznej i Onkologicznej.
NR 0
TC 0
SN 2299-284
EI 
J9 Pol Przegl Chir
PD MAY 20
PY 2017
VL 89
IS 1
BP 63
EP 67
DI 10.5604/01.3001.0009.6006
PG 4
WC Calcinosis; etiology; Drainage; methods; Endoscopy; methods; Endoscopy, Digestive System; methods; Humans; Male; Middle Aged; Pancreatic Pseudocyst; surgery; Treatment Outcome
UT PubMed:28522785
PM 28522785
DA 2017-05-20
ER

PT J
AU Hou, L
   Xu, L
   Shi, Y
   Gu, F
AF Hou, Lili
   Xu, Lei
   Shi, Yan
   Gu, Fen
TI Effect of electric acupoint stimulation on gastrointestinal hormones and motility
SO Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
LA English
DT Journal Article
AB OBJECTIVE: To evaluate the effects of electric acupoint stimulation on  gastrointestinal hormones and motility among geriatric postoperative patients  with gastrointestinal tumors, and to explore an efficient and noninvasive method  for postoperative recovery of bowel functions. METHODS: Forty patients were  randomly and evenly assigned into a regular nursing care group (RNC) and an  acupoint electric stimulation group (AES). Patients in the RNC group received  regular nursing care and patients in the AES group received regular nursing care  plus electric stimulation of acupoints. The serum levels of gastrin (GAS),  motilin (MOT), and cholecystokinin (CCK), and an electrogastrogram (EGG) of all  the patients were evaluated on the first, third, and fifth day after surgery. The  time to first flatus after surgery and the number of patients with side effects  such as abdominal pain, abdominal distention, and diarrhea were recorded.  RESULTS: There were significant differences between the two groups in GAS, MOT,  EGG, time to first flatus, abdominal pain, abdominal distention, and diarrhea (P  < 0.05). CONCLUSION: Electric stimulation on acupoints could increase levels of  GAS and MOT, promote the recovery of gastrointestinal functions, and decrease  complications among postoperative senile patients with gastrointestinal tumors.
NR 0
TC 0
SN 2589-451
EI 
J9 J Tradit Chin Med
PD MAY 2
PY 2017
VL 36
IS 4
BP 450
EP 5
DI 10.1016/s0254-6272(16)30061-9
PG -445
WC Acupuncture Points; Aged; Aged, 80 and over; Electric Stimulation; Female; Gastrointestinal Diseases; etiology; Gastrointestinal Hormones; metabolism; Gastrointestinal Motility; Gastrointestinal Neoplasms; complications; Humans; Male; Middle Aged; Postoperative Complications; etiology
UT PubMed:28459508
PM 28459508
DA 2017-05-02
ER

PT J
AU Li, XX
   Wang, R
   Shi, XE
   Su, JL
   Pan, YQ
   Tian, JH
   Yang, KH
AF Li, Xiuxia
   Wang, Rong
   Shi, Xiue
   Su, Jinlong
   Pan, Yuanqing
   Tian, Jinhui
   Yang, Kehu
TI Reporting Characteristics and Quality of Systematic Reviews of Acupuncture Analgesia
SO PAIN PRACTICE
LA English
DT Review
DE acupuncture analgesia; systematic reviews; characteristics; quality
ID randomized controlled-trials; pain; metaanalysis; bias
AB Background: Evaluating the clinical efficacy of acupuncture analgesia with systematic reviews (SRs) has attracted wide interest. Objective: To collect a sample of published SRs on acupuncture analgesia in PubMed and examine them in terms of reporting characteristics and quality. Methods: A search in PubMed was performed in January 2016. All SRs on acupuncture analgesia were included. To assess the quality of the SRs, AMSTAR tool and PRISMA Statements were used. Results: One hundred and nine SRs were included in our analysis, the yearly number of publications ranging from 1 in 1997 to 15 in 2015. Only 17% of these publications were Cochrane Systematic Reviews, and 94% were published in Science Citation Index journals. The United Kingdom was the country with the higher number of publications. Low back pain, headache, cancer pain, and labor pain were the most reported diseases or phenotypes. Nearly 73% of these SRs conducted a meta-analysis, 58% revealed positive results, 53% used RevMan software to analyze data, and 44% used the Cochrane Risk of Bias Tool for quality assessment. Only a few SRs assessed the likelihood of publication bias, reported details about the protocol and the registration information, and performed additional analyses. Conclusions: The quantity and the quality of SRs regarding acupuncture analgesia have been promoted in recent years. More effort should be expended on the assessment of publication bias, the provision of detailed information about the protocol and the registration process, and the implementation of additional analyses to improve the validity of the SRs.
C1 [Li, Xiuxia; Pan, Yuanqing; Tian, Jinhui; Yang, Kehu] Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Gansu, Peoples R China.
   [Li, Xiuxia; Pan, Yuanqing; Tian, Jinhui; Yang, Kehu] Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Gansu, Peoples R China.
   [Wang, Rong] Gansu Univ Chinese Med, Lanzhou, Gansu, Peoples R China.
   [Wang, Rong] PLA, Dept Orthoped, Gen Hosp, Lanzhou, Gansu, Peoples R China.
   [Shi, Xiue] Rehabil Ctr Hosp Gansu Prov, Lanzhou, Gansu, Peoples R China.
   [Su, Jinlong] Lanzhou Univ, Pharmaceut Ctr, Hosp 2, Lanzhou, Gansu, Peoples R China.
C3 Lanzhou University; Gansu University of Chinese Medicine; Lanzhou University
RP Yang, KH (corresponding author), Lanzhou Univ, 199 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.
EM kehuyangebm2006@126.com
CR Unknown -, 1997, NIH CONSENS STATEMENT, V15, P1
   Berlin JA, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, V0, P35, DOI 10.1002/0470870168.ch3
   Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007
   Booth A, 2011, LANCET, V377, P108, DOI 10.1016/S0140-6736(10)60903-8
   Bücker B, 2008, GESUNDHEITSWESEN, V70, P559, DOI 10.1055/s-2008-1081505
   Cho YH, 2015, PAIN PRACT, V15, P279, DOI 10.1111/papr.12208
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   de Vries RBM, 2015, EVIDENCE-BASED PRECLINICAL MEDICINE, V2, P1, DOI 10.1002/ebm2.7
   Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004
   Fan AY, 2014, J INTEGR MED-JIM, V12, P390, DOI 10.1016/S2095-4964(14)60035-2
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011
   Higgins JP, 2011, COCHRANE HDB SYSTEMA, V0, P0, DOI DOI 10.1007/S12119-019-09598-3
   Hopewell S, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/bmj.c723
   Kung Jason, 2010, OPEN DENT J, V4, P84, DOI 10.2174/1874210601004020084
   Li XX, 2015, HEALTH POLICY, V119, P503, DOI 10.1016/j.healthpol.2014.09.002
   Liu DL, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0120911
   McKibbon KA, 2006, J AM MED INFORM ASSN, V13, P653, DOI 10.1197/jamia.M2087
   Mitchell Joyce A, 2003, AMIA ANNU SYMP PROC, V0, P460
   Moher D, 2015, SYST REV-LONDON, V4, P0, DOI 10.1186/s13643-015-0087-2
   Oomens MAEM, 2016, BRIT J ORAL MAX SURG, V54, P46, DOI 10.1016/j.bjoms.2015.10.021
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Plint AC, 2006, MED J AUSTRALIA, V185, P263, DOI 10.5694/j.1326-5377.2006.tb00557.x
   Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, V0, P1, DOI 10.1002/0470870168
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Shea BJ, 2007, BMC MED RES METHODOL, V7, P0, DOI 10.1186/1471-2288-7-10
   Shea BJ, 2009, J CLIN EPIDEMIOL, V62, P1013, DOI 10.1016/j.jclinepi.2008.10.009
   Shea BJ, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0001350
   Straus S, 2010, CAN MED ASSOC J, V182, P13, DOI 10.1503/cmaj.081849
   Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4
   World Health Organization, 2002, ACUPUNCTURE: REVIEW AND ANALYSIS OF REPORTS ON CONTROLLED CLINICAL TRIALS, V0, P0
NR 30
TC 9
Z9 12
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1530-7085
EI 1533-2500
J9 PAIN PRACT
JI Pain Pract.
PD NOV 15
PY 2017
VL 17
IS 8
BP 1066
EP 1074
DI 10.1111/papr.12555
PG 9
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA FM1BB
UT WOS:000414704300010
PM 28083991
DA 2026-01-16
ER

PT J
AU Chen, YF
   Tian, SA
   Tian, J
   Shu, S
AF Chen, Yingfan
   Tian, Sinan
   Tian, Jing
   Shu, Shi
TI Wrist-ankle acupuncture (WAA) for primary dysmenorrhea (PD) of young females: study protocol for a randomized controlled trial
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Wrist-ankle acupuncture (WAA); Primary dysmenorrheal (PD); Randomized controlled trial
ID management; cancer
AB Background: Primary dysmenorrhea (PD) is one of the most common health complaints all over the world, specifically among young females. Acupuncture has been employed to relieve the pain-based symptoms and to avoid the side effects of conventional medication, and wrist-ankle acupuncture (WAA) has confirmed analgesic efficacy for various types of pain. The aim of this study is to evaluate the immediate analgesia effect of WAA on PD of young females. Methods/design: This study will carry out a randomized parallel controlled single-blind trial to observe the immediate analgesia effect of WAA in PD of young females. Sixty participants who meet inclusion criteria will be recruited from September 2016 to September 2017 in Changhai hospital of China. They are randomly assigned to WAA therapy or sham acupuncture groups (30 patients for each group), and then receive real or sham acupuncture treatment, respectively. In this trial, the primary outcome measure is simple form of McGill pain questionnaire (SF-MPQ), while expectation and treatment credibility scale (ETCS), safety assessment, the COX menstrual symptom scale (CMSS), questionnaire about the feeling of being punctured are included in the secondary outcomes. Discussion: This trial will be the first study protocol designed to evaluate the immediate analgesia effect of WAA in PD of young females. The strengths in methodology, including rigorous randomized, sham-controlled, participants-blinded and assessors-blinded, will guarantee the quality of this study. WAA doesn't require any needling sensation, so nonpenetrating sham acupuncture can serve as an effective placebo intervention in this trial.
C1 [Chen, Yingfan; Tian, Sinan; Shu, Shi] Second Mil Med Univ, Changhai Hosp Tradit Chinese Med, 168 Changhai Rd, Shanghai, Peoples R China.
   [Tian, Jing] Second Mil Med Univ, Dept Nursing Sci, Shanghai, Peoples R China.
C3 Naval Medical University; Naval Medical University
RP Shu, S (corresponding author), Second Mil Med Univ, Changhai Hosp Tradit Chinese Med, 168 Changhai Rd, Shanghai, Peoples R China.
EM shushitcm@163.com
FU Incubation of Acupuncture and Tuina, Second Military Medical University
CR Dawood MY, 2006, OBSTET GYNECOL, V108, P428, DOI 10.1097/01.AOG.0000230214.26638.0c
   French L, 2005, AM FAM PHYSICIAN, V12, P85
   Gemma M, 2015, J INTEGR MED-JIM, V13, P99, DOI 10.1016/S2095-4964(15)60159-5
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P149
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P361
   Kennedy S, 1997, LANCET, V349, P1116, DOI 10.1016/S0140-6736(05)63018-8
   Lao HH, 1999, WRIST ANKLE ACUPUNCT, V0, P1
   Lefebvre G, 2005, J OBSTET GYNAECOL CA, V27, P1117
   Li B, 2014, ADV MATER SCI ENG, V2014, P0, DOI 10.1155/2014/510958
   Lin JG, 2012, AM J CHINESE MED, V40, P219, DOI 10.1142/S0192415X12500176
   Marra C, 2011, J ALTERN COMPLEM MED, V17, P239, DOI 10.1089/acm.2010.0256
   Nevatte T, 2013, ARCH WOMEN MENT HLTH, V16, P279, DOI 10.1007/s00737-013-0346-y
   Proctor M, 2006, BMJ-BRIT MED J, V332, P1134, DOI 10.1136/bmj.332.7550.1134
   Shu S, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-015-0910-z
   Su Jiang-tao, 2010, ZHONGGUO ZHEN JIU, V30, P617
   To M, 2015, J INTEGR MED-JIM, V13, P20, DOI 10.1016/S2095-4964(15)60153-4
   Wang ZF, 2016, CHINESE J ETHNOMEDIC, V24, P50
   Xia HU, 2005, CHINESE J INTEGRATED, V15, P131
   Yang J, 2007, NERVOUS DIS MENTAL H, V7, P371
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhang WY, 1998, BRIT J OBSTET GYNAEC, V105, P780, DOI 10.1111/j.1471-0528.1998.tb10210.x
   Zhang X, 2002, PRACTICAL WRIST-ANKLE ACUPUNCTURE THERAPY, V0, P0
   Zhou YL, 2017, CHINESE ACUPUNCTURE, V27, P923
   Zhu Z, 1998, J TRADIT CHIN MED, V18, P192
NR 24
TC 11
Z9 15
U1 1
U2 41
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6882
EI 
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD AUG 22
PY 2017
VL 17
IS 
BP 
EP 
DI 10.1186/s12906-017-1923-9
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA FE8KV
UT WOS:000408454900008
PM 28830511
DA 2026-01-16
ER

